,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"2021 ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORTIntroduction COVID-19 Response 2 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix Corporate Governance .","('Human_Rights_And_Community_Relations', 0.38421908020973206)","('Business_Model_Resilience', 0.14939868450164795)","('Management_Of_Legal_And_Regulatory_Framework', 0.08481030911207199)","('NON-ESG', 0.38421908020973206)","('NON-ESG', 0.14939868450164795)","('NON-ESG', 0.08481030911207199)"
Line 2,55 Business Ethics .,"('Business_Ethics', 0.9620211720466614)","('Competitive_Behavior', 0.0049340976402163506)","('Product_Quality_And_Safety', 0.003093132982030511)","(['Business Ethics'], 0.9620211720466614)","('NON-ESG', 0.0049340976402163506)","('NON-ESG', 0.003093132982030511)"
Line 3,56 Ethical Research .,"('Business_Ethics', 0.731757402420044)","('Competitive_Behavior', 0.11200570315122604)","('Human_Rights_And_Community_Relations', 0.013170741498470306)","(['Business Ethics'], 0.731757402420044)","('NON-ESG', 0.11200570315122604)","('NON-ESG', 0.013170741498470306)"
Line 4,58 Patient Safety and Product Quality .,"('Product_Quality_And_Safety', 0.787952184677124)","('Product_Design_And_Lifecycle_Management', 0.0894043892621994)","('Selling_Practices_And_Product_Labeling', 0.01737910322844982)","(['Product Quality & Recall Management'], 0.787952184677124)","('NON-ESG', 0.0894043892621994)","('NON-ESG', 0.01737910322844982)"
Line 5,60 Cybersecurity and Data Privacy .,"('Data_Security', 0.958641529083252)","('Customer_Privacy', 0.00473141809925437)","('Systemic_Risk_Management', 0.0032366709783673286)","([], 0.958641529083252)","('NON-ESG', 0.00473141809925437)","('NON-ESG', 0.0032366709783673286)"
Line 6,63 Government Affairs and Public Policy .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8252856731414795)","('Human_Rights_And_Community_Relations', 0.02404298633337021)","('Physical_Impacts_Of_Climate_Change', 0.01634337566792965)","([], 0.8252856731414795)","('NON-ESG', 0.02404298633337021)","('NON-ESG', 0.01634337566792965)"
Line 7,65 We value and welcome feedback from all stakeholders .,"('Human_Rights_And_Community_Relations', 0.2132856696844101)","('Business_Model_Resilience', 0.13091664016246796)","('Director_Removal', 0.12329157441854477)","('NON-ESG', 0.2132856696844101)","('NON-ESG', 0.13091664016246796)","('NON-ESG', 0.12329157441854477)"
Line 8,Please send comments or questions about this report to ESG@AMGEN .,"('Management_Of_Legal_And_Regulatory_Framework', 0.6909346580505371)","('Director_Removal', 0.03002968057990074)","('Business_Model_Resilience', 0.02857663668692112)","([], 0.6909346580505371)","('NON-ESG', 0.03002968057990074)","('NON-ESG', 0.02857663668692112)"
Line 9,"COMABOUT THIS REPORT This report describes our progress from January 1, 2021 to December 31, 2021 .","('Management_Of_Legal_And_Regulatory_Framework', 0.5338892936706543)","('Director_Removal', 0.08505465090274811)","('Business_Model_Resilience', 0.05951760709285736)","([], 0.5338892936706543)","('NON-ESG', 0.08505465090274811)","('NON-ESG', 0.05951760709285736)"
Line 10,"The content is informed by our ongoing monitoring of internal and external stakeholder perspectives, direct interactions with stakeholders, a review of relevant reporting standards and frameworks, and internal analyses of the alignment of environmental, social and governance (ESG) topics with our strategy, mission and values .","('Human_Rights_And_Community_Relations', 0.4554101824760437)","('Management_Of_Legal_And_Regulatory_Framework', 0.2982557713985443)","('Business_Model_Resilience', 0.03626449033617973)","('NON-ESG', 0.4554101824760437)","('NON-ESG', 0.2982557713985443)","('NON-ESG', 0.03626449033617973)"
Line 11,All of our worldwide business operations are included in this report unless otherwise stated .,"('Business_Model_Resilience', 0.6635045409202576)","('Director_Removal', 0.03663545474410057)","('Customer_Privacy', 0.03280235826969147)","(['Human Capital Development', 'Innovation Management'], 0.6635045409202576)","('NON-ESG', 0.03663545474410057)","('NON-ESG', 0.03280235826969147)"
Line 12,"Throughout this report, we also guide readers to additional sources of information online .","('Customer_Privacy', 0.23193930089473724)","('Selling_Practices_And_Product_Labeling', 0.1328439563512802)","('Management_Of_Legal_And_Regulatory_Framework', 0.12288545072078705)","('NON-ESG', 0.23193930089473724)","('NON-ESG', 0.1328439563512802)","('NON-ESG', 0.12288545072078705)"
Line 13,We have prepared this report in alignment with the Biopharma Investor ESG Communications Guidance (the Guidance) .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8198038339614868)","('Access_And_Affordability', 0.02180464193224907)","('GHG_Emissions', 0.021773550659418106)","([], 0.8198038339614868)","('NON-ESG', 0.02180464193224907)","('NON-ESG', 0.021773550659418106)"
Line 14,"Launched in 2020, the Guidance identifies high-priority ESG topics for the biopharmaceutical sector and recommends how to structure information and disclosures in a useful format for investors .","('Business_Model_Resilience', 0.3612896203994751)","('Systemic_Risk_Management', 0.18483814597129822)","('Management_Of_Legal_And_Regulatory_Framework', 0.07170673459768295)","('NON-ESG', 0.3612896203994751)","('NON-ESG', 0.18483814597129822)","('NON-ESG', 0.07170673459768295)"
Line 15,"The Guidance integrates components and principles of the Sustainability Accounting Standards Board (SASB) Biotechnology & Pharmaceuticals Sustainability Accounting Standard, as well as the Task Force on Climate-Related Financial Disclosures (TCFD) reporting standard .","('Physical_Impacts_Of_Climate_Change', 0.26945018768310547)","('Business_Model_Resilience', 0.17148089408874512)","('Management_Of_Legal_And_Regulatory_Framework', 0.15622051060199738)","('NON-ESG', 0.26945018768310547)","('NON-ESG', 0.17148089408874512)","('NON-ESG', 0.15622051060199738)"
Line 16,Our reporting also reflects our alignment with the United Nations (UN) Global Compact and Sustainable Development Goals .,"('Human_Rights_And_Community_Relations', 0.4052695631980896)","('Management_Of_Legal_And_Regulatory_Framework', 0.16294072568416595)","('Business_Model_Resilience', 0.10722425580024719)","('NON-ESG', 0.4052695631980896)","('NON-ESG', 0.16294072568416595)","('NON-ESG', 0.10722425580024719)"
Line 17,TABLE OF CONTENTS About This Report .,"('Management_Of_Legal_And_Regulatory_Framework', 0.4965973496437073)","('Access_And_Affordability', 0.05954146012663841)","('Systemic_Risk_Management', 0.05310665816068649)","('NON-ESG', 0.4965973496437073)","('NON-ESG', 0.05954146012663841)","('NON-ESG', 0.05310665816068649)"
Line 18,2 About Amgen .,"('Access_And_Affordability', 0.10059918463230133)","('Energy_Management', 0.0963796079158783)","('Supply_Chain_Management', 0.07611300051212311)","('NON-ESG', 0.10059918463230133)","('NON-ESG', 0.0963796079158783)","('NON-ESG', 0.07611300051212311)"
Line 19,3 Awards and Rankings .,"('Management_Of_Legal_And_Regulatory_Framework', 0.2971499264240265)","('Competitive_Behavior', 0.29644301533699036)","('Business_Ethics', 0.10857068747282028)","('NON-ESG', 0.2971499264240265)","('NON-ESG', 0.29644301533699036)","('NON-ESG', 0.10857068747282028)"
Line 20,5 Leadership Message .,"('Employee_Engagement_Inclusion_And_Diversity', 0.2948881983757019)","('Human_Rights_And_Community_Relations', 0.15417763590812683)","('Business_Model_Resilience', 0.12212120741605759)","('NON-ESG', 0.2948881983757019)","('NON-ESG', 0.15417763590812683)","('NON-ESG', 0.12212120741605759)"
Line 21,6 Our Approach to ESG .,"('Business_Model_Resilience', 0.5449113249778748)","('Systemic_Risk_Management', 0.082710400223732)","('Supply_Chain_Management', 0.04630681499838829)","(['Human Capital Development', 'Innovation Management'], 0.5449113249778748)","('NON-ESG', 0.082710400223732)","('NON-ESG', 0.04630681499838829)"
Line 22,7 .,"('Competitive_Behavior', 0.14777089655399323)","('Management_Of_Legal_And_Regulatory_Framework', 0.09013563394546509)","('Energy_Management', 0.08286081999540329)","('NON-ESG', 0.14777089655399323)","('NON-ESG', 0.09013563394546509)","('NON-ESG', 0.08286081999540329)"
Line 23,25 .,"('Competitive_Behavior', 0.1801666021347046)","('Management_Of_Legal_And_Regulatory_Framework', 0.0729958787560463)","('Product_Design_And_Lifecycle_Management', 0.06529480218887329)","('NON-ESG', 0.1801666021347046)","('NON-ESG', 0.0729958787560463)","('NON-ESG', 0.06529480218887329)"
Line 24,14 .,"('Business_Ethics', 0.12551529705524445)","('Management_Of_Legal_And_Regulatory_Framework', 0.11816366761922836)","('Competitive_Behavior', 0.1080261692404747)","('NON-ESG', 0.12551529705524445)","('NON-ESG', 0.11816366761922836)","('NON-ESG', 0.1080261692404747)"
Line 25,10 .,"('Competitive_Behavior', 0.1053069457411766)","('Management_Of_Legal_And_Regulatory_Framework', 0.09258180856704712)","('GHG_Emissions', 0.06819628924131393)","('NON-ESG', 0.1053069457411766)","('NON-ESG', 0.09258180856704712)","('NON-ESG', 0.06819628924131393)"
Line 26,2 .,"('Competitive_Behavior', 0.15795664489269257)","('Customer_Welfare', 0.10852150619029999)","('Energy_Management', 0.08616163581609726)","('NON-ESG', 0.15795664489269257)","('NON-ESG', 0.10852150619029999)","('NON-ESG', 0.08616163581609726)"
Line 27,44 .,"('Business_Ethics', 0.14719679951667786)","('Management_Of_Legal_And_Regulatory_Framework', 0.12647639214992523)","('Competitive_Behavior', 0.11806702613830566)","('NON-ESG', 0.14719679951667786)","('NON-ESG', 0.12647639214992523)","('NON-ESG', 0.11806702613830566)"
Line 28,53 .,"('Competitive_Behavior', 0.18988725543022156)","('Management_Of_Legal_And_Regulatory_Framework', 0.16341030597686768)","('Business_Ethics', 0.11578493565320969)","('NON-ESG', 0.18988725543022156)","('NON-ESG', 0.16341030597686768)","('NON-ESG', 0.11578493565320969)"
Line 29,66COVID-19 Response .,"('Critical_Incident_Risk_Management', 0.17165076732635498)","('Access_And_Affordability', 0.16536806523799896)","('Competitive_Behavior', 0.10752580314874649)","('NON-ESG', 0.17165076732635498)","('NON-ESG', 0.16536806523799896)","('NON-ESG', 0.10752580314874649)"
Line 30,11 Access to Medicines .,"('Access_And_Affordability', 0.6822006106376648)","('Product_Quality_And_Safety', 0.0314459428191185)","('Customer_Welfare', 0.03108365647494793)","(['Access to Healthcare'], 0.6822006106376648)","('NON-ESG', 0.0314459428191185)","('NON-ESG', 0.03108365647494793)"
Line 31,16 Health Equity .,"('Access_And_Affordability', 0.15938402712345123)","('Systemic_Risk_Management', 0.1523163914680481)","('Business_Model_Resilience', 0.09664151817560196)","('NON-ESG', 0.15938402712345123)","('NON-ESG', 0.1523163914680481)","('NON-ESG', 0.09664151817560196)"
Line 32,"20 Diversity, Inclusion and Belonging .","('Employee_Engagement_Inclusion_And_Diversity', 0.9714757800102234)","('Employee_Health_And_Safety', 0.0019893411081284285)","('Human_Rights_And_Community_Relations', 0.0019620549865067005)","(['Talent Attraction & Retention'], 0.9714757800102234)","('NON-ESG', 0.0019893411081284285)","('NON-ESG', 0.0019620549865067005)"
Line 33,27 Human Capital Management .,"('Business_Model_Resilience', 0.45675623416900635)","('Systemic_Risk_Management', 0.16311083734035492)","('Competitive_Behavior', 0.08858899027109146)","('NON-ESG', 0.45675623416900635)","('NON-ESG', 0.16311083734035492)","('NON-ESG', 0.08858899027109146)"
Line 34,33 Community Investment .,"('Human_Rights_And_Community_Relations', 0.8506908416748047)","('Business_Model_Resilience', 0.015261954627931118)","('Access_And_Affordability', 0.014575161039829254)","([], 0.8506908416748047)","('NON-ESG', 0.015261954627931118)","('NON-ESG', 0.014575161039829254)"
Line 35,.37 Responsible Sourcing .,"('Product_Design_And_Lifecycle_Management', 0.42586255073547363)","('Supply_Chain_Management', 0.3023562431335449)","('Customer_Welfare', 0.035387054085731506)","('NON-ESG', 0.42586255073547363)","('NON-ESG', 0.3023562431335449)","('NON-ESG', 0.035387054085731506)"
Line 36,42Environmental Sustainability .,"('Business_Model_Resilience', 0.47367018461227417)","('Supply_Chain_Management', 0.08862395584583282)","('Systemic_Risk_Management', 0.08190792053937912)","('NON-ESG', 0.47367018461227417)","('NON-ESG', 0.08862395584583282)","('NON-ESG', 0.08190792053937912)"
Line 37,46 UN Global Communications on Progress .,"('Human_Rights_And_Community_Relations', 0.5180169343948364)","('Management_Of_Legal_And_Regulatory_Framework', 0.08598058670759201)","('Access_And_Affordability', 0.06555096805095673)","([], 0.5180169343948364)","('NON-ESG', 0.08598058670759201)","('NON-ESG', 0.06555096805095673)"
Line 38,66 Company Performance Data .,"('Business_Model_Resilience', 0.3328304886817932)","('Systemic_Risk_Management', 0.23430177569389343)","('Supply_Chain_Management', 0.105998195707798)","('NON-ESG', 0.3328304886817932)","('NON-ESG', 0.23430177569389343)","('NON-ESG', 0.105998195707798)"
Line 39,67 SASB Index .,"('Systemic_Risk_Management', 0.5241439938545227)","('Data_Security', 0.07630105316638947)","('Management_Of_Legal_And_Regulatory_Framework', 0.06322160363197327)","([], 0.5241439938545227)","('NON-ESG', 0.07630105316638947)","('NON-ESG', 0.06322160363197327)"
Line 40,68 Forward-Looking Statements .,"('Customer_Privacy', 0.2851366400718689)","('Business_Model_Resilience', 0.21105274558067322)","('Data_Security', 0.09463287144899368)","('NON-ESG', 0.2851366400718689)","('NON-ESG', 0.21105274558067322)","('NON-ESG', 0.09463287144899368)"
Line 41,"74COVID-19 Response Healthy People Healthy SocietyHealthy Planet A Healthy AmgenIntroductionINTRODUCTION COVER IMAGES: (Right) Senior Associate Scientist Asha Kelley in the discovery research lab, Thousand Oaks, California.","('Employee_Engagement_Inclusion_And_Diversity', 0.21179337799549103)","('Employee_Health_And_Safety', 0.17759427428245544)","('Customer_Welfare', 0.10282013565301895)","('NON-ESG', 0.21179337799549103)","('NON-ESG', 0.17759427428245544)","('NON-ESG', 0.10282013565301895)"
Line 42,"(Far left) Induced Proximity Platform: the small molecule shown as green and blue balls (carbons and nitrogens) brings together a complex of four proteins (red, orange, beige and teal) that doesnt exist in nature.","('GHG_Emissions', 0.21720223128795624)","('Competitive_Behavior', 0.1487787663936615)","('Customer_Welfare', 0.14670424163341522)","('NON-ESG', 0.21720223128795624)","('NON-ESG', 0.1487787663936615)","('NON-ESG', 0.14670424163341522)"
Line 43,"This results in the enzymatic destruction of the teal protein, which is a cancer-driving protein.","('Customer_Welfare', 0.17464014887809753)","('GHG_Emissions', 0.1367565542459488)","('Ecological_Impacts', 0.10984506458044052)","('NON-ESG', 0.17464014887809753)","('NON-ESG', 0.1367565542459488)","('NON-ESG', 0.10984506458044052)"
Line 44,"Reference to our website is not intended to function as a hyperlink, and the information contained on our website is not intended to be part of this report .","('Customer_Privacy', 0.5686676502227783)","('Data_Security', 0.09012806415557861)","('Selling_Practices_And_Product_Labeling', 0.04876459389925003)","([], 0.5686676502227783)","('NON-ESG', 0.09012806415557861)","('NON-ESG', 0.04876459389925003)"
Line 45,"AppendixIntroduction COVID-19 Response 3 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve peoples lives .","('Employee_Health_And_Safety', 0.6672016978263855)","('Access_And_Affordability', 0.12420389801263809)","('Human_Rights_And_Community_Relations', 0.02486170455813408)","(['Health Outcome Contribution'], 0.6672016978263855)","('NON-ESG', 0.12420389801263809)","('NON-ESG', 0.02486170455813408)"
Line 46,"A biotechnology pioneer since 1980, Amgen has grown to be one of the worlds leading independent biotechnology companies, has reached millions of patients around the world with its medicines, and is developing a pipeline of innovative medicines .","('Customer_Welfare', 0.3455162048339844)","('Selling_Practices_And_Product_Labeling', 0.12821991741657257)","('Product_Design_And_Lifecycle_Management', 0.090078204870224)","('NON-ESG', 0.3455162048339844)","('NON-ESG', 0.12821991741657257)","('NON-ESG', 0.090078204870224)"
Line 47,"We focus our research in three therapeutic areas: inflammation, oncology, and general medicine.","('Customer_Welfare', 0.21539700031280518)","('Competitive_Behavior', 0.09389777481555939)","('Access_And_Affordability', 0.06401832401752472)","('NON-ESG', 0.21539700031280518)","('NON-ESG', 0.09389777481555939)","('NON-ESG', 0.06401832401752472)"
Line 48,Our medicines typically address diseases for which there are limited treatment options or provide a viable alternative to those treatments that are otherwise available .,"('Customer_Welfare', 0.24029791355133057)","('Selling_Practices_And_Product_Labeling', 0.19137640297412872)","('Access_And_Affordability', 0.13836467266082764)","('NON-ESG', 0.24029791355133057)","('NON-ESG', 0.19137640297412872)","('NON-ESG', 0.13836467266082764)"
Line 49,"Amgen is also a leader in developing and manufacturing biosimilars (medications that are biologically similar to existing biologic treatments), which have the potential to offer more affordable, life-altering treatment options .","('Customer_Welfare', 0.50809645652771)","('Selling_Practices_And_Product_Labeling', 0.22068457305431366)","('Product_Design_And_Lifecycle_Management', 0.041046060621738434)","([], 0.50809645652771)","('NON-ESG', 0.22068457305431366)","('NON-ESG', 0.041046060621738434)"
Line 50,"Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics.","('Employee_Health_And_Safety', 0.6726192235946655)","('Access_And_Affordability', 0.08884481340646744)","('Product_Quality_And_Safety', 0.04937715455889702)","(['Health Outcome Contribution'], 0.6726192235946655)","('NON-ESG', 0.08884481340646744)","('NON-ESG', 0.04937715455889702)"
Line 51,This approach begins by using tools such as advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.,"('Systemic_Risk_Management', 0.16537626087665558)","('Access_And_Affordability', 0.12107706069946289)","('Competitive_Behavior', 0.12005197256803513)","('NON-ESG', 0.16537626087665558)","('NON-ESG', 0.12107706069946289)","('NON-ESG', 0.12005197256803513)"
Line 52,"ABOUT AMGEN OUR BELIEF and the core of our strategy is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also help reduce the social and economic burden of disease on society today .","('Access_And_Affordability', 0.22733888030052185)","('Employee_Health_And_Safety', 0.0904545709490776)","('Systemic_Risk_Management', 0.07864627242088318)","('NON-ESG', 0.22733888030052185)","('NON-ESG', 0.0904545709490776)","('NON-ESG', 0.07864627242088318)"
Line 53,"Introduction COVID-19 Response 4 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix an environment that fosters inclusion, respect, individual responsibility, and values diversity .","('Employee_Engagement_Inclusion_And_Diversity', 0.9376974105834961)","('Human_Rights_And_Community_Relations', 0.014226625673472881)","('Employee_Health_And_Safety', 0.004402122460305691)","(['Talent Attraction & Retention'], 0.9376974105834961)","('NON-ESG', 0.014226625673472881)","('NON-ESG', 0.004402122460305691)"
Line 54,Trust is strengthened through personal initiative and by obtaining quality results rapidly .,"('Business_Ethics', 0.6386014223098755)","('Human_Rights_And_Community_Relations', 0.06339351832866669)","('Customer_Privacy', 0.05842530354857445)","(['Business Ethics'], 0.6386014223098755)","('NON-ESG', 0.06339351832866669)","('NON-ESG', 0.05842530354857445)"
Line 55,Ensure quality.,"('Product_Quality_And_Safety', 0.282471239566803)","('Product_Design_And_Lifecycle_Management', 0.1363895684480667)","('Business_Ethics', 0.06649692356586456)","('NON-ESG', 0.282471239566803)","('NON-ESG', 0.1363895684480667)","('NON-ESG', 0.06649692356586456)"
Line 56,Quality is a cornerstone of all of our activities .,"('Business_Ethics', 0.24675868451595306)","('Product_Quality_And_Safety', 0.1096888855099678)","('Business_Model_Resilience', 0.0670662596821785)","('NON-ESG', 0.24675868451595306)","('NON-ESG', 0.1096888855099678)","('NON-ESG', 0.0670662596821785)"
Line 57,"We seek the highest-quality information, decisions, and people .","('Customer_Privacy', 0.7398582696914673)","('Data_Security', 0.06127859279513359)","('Business_Ethics', 0.0431610643863678)","([], 0.7398582696914673)","('NON-ESG', 0.06127859279513359)","('NON-ESG', 0.0431610643863678)"
Line 58,We produce high-quality products and services .,"('Product_Design_And_Lifecycle_Management', 0.9503700733184814)","('Product_Quality_And_Safety', 0.0070302472449839115)","('Customer_Welfare', 0.004201172851026058)","([], 0.9503700733184814)","('NON-ESG', 0.0070302472449839115)","('NON-ESG', 0.004201172851026058)"
Line 59,Quality is woven into the fabric of everything we do .,"('Product_Design_And_Lifecycle_Management', 0.7795491218566895)","('Supply_Chain_Management', 0.02930356375873089)","('Business_Model_Resilience', 0.022558512166142464)","([], 0.7795491218566895)","('NON-ESG', 0.02930356375873089)","('NON-ESG', 0.022558512166142464)"
Line 60,Our website contains additional information about our approach to Quality and Patient Safety .,"('Product_Quality_And_Safety', 0.8333851099014282)","('Employee_Health_And_Safety', 0.023721184581518173)","('Product_Design_And_Lifecycle_Management', 0.01656743697822094)","(['Product Quality & Recall Management'], 0.8333851099014282)","('NON-ESG', 0.023721184581518173)","('NON-ESG', 0.01656743697822094)"
Line 61,Work in teams.,"('Employee_Engagement_Inclusion_And_Diversity', 0.23525257408618927)","('Employee_Health_And_Safety', 0.10700546205043793)","('Human_Rights_And_Community_Relations', 0.1030389592051506)","('NON-ESG', 0.23525257408618927)","('NON-ESG', 0.10700546205043793)","('NON-ESG', 0.1030389592051506)"
Line 62,Our teams work quickly to move scientific breakthroughs from the lab through the clinic to the marketplace and to support other aspects of our business .,"('Supply_Chain_Management', 0.1384081393480301)","('Access_And_Affordability', 0.11968500167131424)","('Customer_Welfare', 0.11051028966903687)","('NON-ESG', 0.1384081393480301)","('NON-ESG', 0.11968500167131424)","('NON-ESG', 0.11051028966903687)"
Line 63,"We believe that diverse teams working together generate the best decisions for patients, employees, and stockholders .","('Employee_Engagement_Inclusion_And_Diversity', 0.9484963417053223)","('Customer_Welfare', 0.00413392623886466)","('Competitive_Behavior', 0.004070343915373087)","(['Talent Attraction & Retention'], 0.9484963417053223)","('NON-ESG', 0.00413392623886466)","('NON-ESG', 0.004070343915373087)"
Line 64,"Our team structure provides opportunities for Amgen employees to affect the direction of the organization, to gain broader perspective about other functions within Amgen, and to reach their full potential .","('Employee_Engagement_Inclusion_And_Diversity', 0.6565641760826111)","('Business_Model_Resilience', 0.05836707353591919)","('Director_Removal', 0.033106908202171326)","(['Talent Attraction & Retention'], 0.6565641760826111)","('NON-ESG', 0.05836707353591919)","('NON-ESG', 0.033106908202171326)"
Line 65,"Collaborate, communicate, and be accountable.","('Business_Ethics', 0.21704156696796417)","('Management_Of_Legal_And_Regulatory_Framework', 0.19628961384296417)","('Human_Rights_And_Community_Relations', 0.10988574475049973)","('NON-ESG', 0.21704156696796417)","('NON-ESG', 0.19628961384296417)","('NON-ESG', 0.10988574475049973)"
Line 66,Leaders at Amgen seek input and involve key stakeholders in important decisions .,"('Management_Of_Legal_And_Regulatory_Framework', 0.5595341920852661)","('Director_Removal', 0.08863701671361923)","('Human_Rights_And_Community_Relations', 0.08832085877656937)","([], 0.5595341920852661)","('NON-ESG', 0.08863701671361923)","('NON-ESG', 0.08832085877656937)"
Line 67,"In gathering input, strong leaders will welcome diverse opinions, conflicting views, and open dialogue for serious consideration .","('Management_Of_Legal_And_Regulatory_Framework', 0.5279530882835388)","('Competitive_Behavior', 0.08117429912090302)","('Business_Ethics', 0.06489550322294235)","([], 0.5279530882835388)","('NON-ESG', 0.08117429912090302)","('NON-ESG', 0.06489550322294235)"
Line 68,They will clearly communicate decisions and rationale openly and in a timely manner .,"('Management_Of_Legal_And_Regulatory_Framework', 0.6827195286750793)","('Business_Ethics', 0.11364134401082993)","('Competitive_Behavior', 0.031698077917099)","([], 0.6827195286750793)","('NON-ESG', 0.11364134401082993)","('NON-ESG', 0.031698077917099)"
Line 69,"Once a decision is made, the leader and members of the team will all be accountable for the results and for implementing the decision rapidly .","('Management_Of_Legal_And_Regulatory_Framework', 0.2936849892139435)","('Director_Removal', 0.24301044642925262)","('Business_Model_Resilience', 0.06512259691953659)","('NON-ESG', 0.2936849892139435)","('NON-ESG', 0.24301044642925262)","('NON-ESG', 0.06512259691953659)"
Line 70,OUR VALUES Be science-based.,"('Human_Rights_And_Community_Relations', 0.3929673135280609)","('Employee_Engagement_Inclusion_And_Diversity', 0.13825350999832153)","('Business_Model_Resilience', 0.049597226083278656)","('NON-ESG', 0.3929673135280609)","('NON-ESG', 0.13825350999832153)","('NON-ESG', 0.049597226083278656)"
Line 71,"Our success depends on superior scientific innovation, integrity, and continuous improvement in all aspects of our business through the application of the scientific method .","('Competitive_Behavior', 0.3946698307991028)","('Business_Model_Resilience', 0.08757159858942032)","('Product_Design_And_Lifecycle_Management', 0.08670269697904587)","('NON-ESG', 0.3946698307991028)","('NON-ESG', 0.08757159858942032)","('NON-ESG', 0.08670269697904587)"
Line 72,"The scientific method is a multistep process that includes designing the right experiment, collecting and analyzing data, and rational decision-making .","('Competitive_Behavior', 0.6260502934455872)","('Management_Of_Legal_And_Regulatory_Framework', 0.09199494123458862)","('Ecological_Impacts', 0.028757130727171898)","([], 0.6260502934455872)","('NON-ESG', 0.09199494123458862)","('NON-ESG', 0.028757130727171898)"
Line 73,"It is not subjective or emotional, but rather a logical, open, reasoned process .","('Competitive_Behavior', 0.2751365900039673)","('Business_Ethics', 0.1991329789161682)","('Management_Of_Legal_And_Regulatory_Framework', 0.08798975497484207)","('NON-ESG', 0.2751365900039673)","('NON-ESG', 0.1991329789161682)","('NON-ESG', 0.08798975497484207)"
Line 74,Applying the scientific method in all parts of the organization is expected and highly valued .,"('Management_Of_Legal_And_Regulatory_Framework', 0.305671364068985)","('Ecological_Impacts', 0.12167588621377945)","('Access_And_Affordability', 0.1094331368803978)","('NON-ESG', 0.305671364068985)","('NON-ESG', 0.12167588621377945)","('NON-ESG', 0.1094331368803978)"
Line 75,Compete intensely and win.,"('Competitive_Behavior', 0.6190826296806335)","('Employee_Engagement_Inclusion_And_Diversity', 0.08343376219272614)","('Business_Model_Resilience', 0.035108521580696106)","([], 0.6190826296806335)","('NON-ESG', 0.08343376219272614)","('NON-ESG', 0.035108521580696106)"
Line 76,"We compete against time, past performance, and industry rivals to rapidly achieve high-quality results .","('Competitive_Behavior', 0.8483989238739014)","('Business_Model_Resilience', 0.03265100345015526)","('Systemic_Risk_Management', 0.026926662772893906)","([], 0.8483989238739014)","('NON-ESG', 0.03265100345015526)","('NON-ESG', 0.026926662772893906)"
Line 77,We cannot be lulled into complacency by previous achievements .,"('Competitive_Behavior', 0.7401442527770996)","('Systemic_Risk_Management', 0.03340873494744301)","('Business_Ethics', 0.026492075994610786)","([], 0.7401442527770996)","('NON-ESG', 0.03340873494744301)","('NON-ESG', 0.026492075994610786)"
Line 78,"Though we compete intensely, we maintain high ethical standards and demand integrity in our dealings with competitors, customers, partners, and each other .","('Business_Ethics', 0.8618552684783936)","('Competitive_Behavior', 0.05088169500231743)","('Product_Quality_And_Safety', 0.009482111781835556)","(['Business Ethics'], 0.8618552684783936)","('NON-ESG', 0.05088169500231743)","('NON-ESG', 0.009482111781835556)"
Line 79,"Create value for patients, employees, and stockholders.","('Competitive_Behavior', 0.4484656751155853)","('Business_Model_Resilience', 0.0903526097536087)","('Systemic_Risk_Management', 0.08865760266780853)","('NON-ESG', 0.4484656751155853)","('NON-ESG', 0.0903526097536087)","('NON-ESG', 0.08865760266780853)"
Line 80,We provide value by focusing on the needs of patients .,"('Access_And_Affordability', 0.7047336101531982)","('Human_Rights_And_Community_Relations', 0.05806126073002815)","('Product_Design_And_Lifecycle_Management', 0.030808530747890472)","(['Access to Healthcare'], 0.7047336101531982)","('NON-ESG', 0.05806126073002815)","('NON-ESG', 0.030808530747890472)"
Line 81,Amgen creates a work environment that provides opportunities for employees to reach their full potential .,"('Employee_Engagement_Inclusion_And_Diversity', 0.7707614898681641)","('Employee_Health_And_Safety', 0.05844593420624733)","('Human_Rights_And_Community_Relations', 0.031841080635786057)","(['Talent Attraction & Retention'], 0.7707614898681641)","('NON-ESG', 0.05844593420624733)","('NON-ESG', 0.031841080635786057)"
Line 82,"We strive to provide stockholders with superior long-term returns while balancing the needs of patients, employees, and stockholders .","('Competitive_Behavior', 0.5096215009689331)","('Employee_Engagement_Inclusion_And_Diversity', 0.09677321463823318)","('Systemic_Risk_Management', 0.07081227004528046)","([], 0.5096215009689331)","('NON-ESG', 0.09677321463823318)","('NON-ESG', 0.07081227004528046)"
Line 83,Be ethical.,"('Business_Ethics', 0.5157848000526428)","('Human_Rights_And_Community_Relations', 0.09461082518100739)","('Competitive_Behavior', 0.05606811121106148)","(['Business Ethics'], 0.5157848000526428)","('NON-ESG', 0.09461082518100739)","('NON-ESG', 0.05606811121106148)"
Line 84,"We are relentless in applying the highest ethical standards to our products, services, and communications .","('Business_Ethics', 0.7355712056159973)","('Product_Quality_And_Safety', 0.06842222064733505)","('Customer_Privacy', 0.027383854612708092)","(['Business Ethics'], 0.7355712056159973)","('NON-ESG', 0.06842222064733505)","('NON-ESG', 0.027383854612708092)"
Line 85,Trust and respect each other.,"('Business_Ethics', 0.4160095453262329)","('Customer_Privacy', 0.1068115234375)","('Human_Rights_And_Community_Relations', 0.07618395984172821)","('NON-ESG', 0.4160095453262329)","('NON-ESG', 0.1068115234375)","('NON-ESG', 0.07618395984172821)"
Line 86,"Every job at Amgen is important, and every Amgen employee is important .","('Employee_Health_And_Safety', 0.26111429929733276)","('Employee_Engagement_Inclusion_And_Diversity', 0.187909796833992)","('Human_Rights_And_Community_Relations', 0.08269789069890976)","('NON-ESG', 0.26111429929733276)","('NON-ESG', 0.187909796833992)","('NON-ESG', 0.08269789069890976)"
Line 87,"We attract diverse, capable, and committed people and provide AMGEN BY THE NUMBERS* 1980 Year Founded ~24,000 Employees$26B Total Revenues NASDAQStock Listing AMGNTicker Symbol$4.8B R&D InvestmentThousand Oaks, California Headquarters Number of Countries Where Products Are Sold: ~100 *As of December 31, 2021 .","('Employee_Engagement_Inclusion_And_Diversity', 0.5898298621177673)","('Product_Design_And_Lifecycle_Management', 0.10034683346748352)","('Business_Model_Resilience', 0.08104170858860016)","(['Talent Attraction & Retention'], 0.5898298621177673)","('NON-ESG', 0.10034683346748352)","('NON-ESG', 0.08104170858860016)"
Line 88,Amgen is also a member of the Dow Jones Industrial Average.,"('Systemic_Risk_Management', 0.5674459934234619)","('Business_Model_Resilience', 0.100447878241539)","('Competitive_Behavior', 0.0790024995803833)","([], 0.5674459934234619)","('NON-ESG', 0.100447878241539)","('NON-ESG', 0.0790024995803833)"
Line 89,"Introduction COVID-19 Response 5 | ENVIRONMENTAL, SOCIAL & GO VERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix 2021 AWARDS AND RANKINGS NEWSWEEK Amgen named to Newsweeks list of Americas Most Responsible Companies.","('Human_Rights_And_Community_Relations', 0.3505251705646515)","('Business_Model_Resilience', 0.08396371454000473)","('Employee_Engagement_Inclusion_And_Diversity', 0.07673438638448715)","('NON-ESG', 0.3505251705646515)","('NON-ESG', 0.08396371454000473)","('NON-ESG', 0.07673438638448715)"
Line 90,"AMERICAN HEART ASSOCIATION Amgen ranked as one of the leading companies in the United States for workplace health and wellness in the American Heart Associations Workplace Health Achievement Index, qualifying for Gold Recognition.","('Employee_Health_And_Safety', 0.801989734172821)","('Product_Quality_And_Safety', 0.033993132412433624)","('Employee_Engagement_Inclusion_And_Diversity', 0.025186171755194664)","(['Health Outcome Contribution'], 0.801989734172821)","('NON-ESG', 0.033993132412433624)","('NON-ESG', 0.025186171755194664)"
Line 91,BARRONS Barrons named Amgen to its 100 Most Sustainable Companies list.,"('Business_Model_Resilience', 0.3269660770893097)","('Product_Design_And_Lifecycle_Management', 0.21456199884414673)","('Supply_Chain_Management', 0.14063847064971924)","('NON-ESG', 0.3269660770893097)","('NON-ESG', 0.21456199884414673)","('NON-ESG', 0.14063847064971924)"
Line 92,DOW JONES SUSTAINABILITY INDEX Amgen ranked among the top biotech companies in corporate responsibility with its inclusion on the Dow Jones Sustainability Indices (DJSI) World Index for the eighth year in a row.,"('Business_Model_Resilience', 0.3176567256450653)","('Systemic_Risk_Management', 0.27312153577804565)","('Supply_Chain_Management', 0.0815608873963356)","('NON-ESG', 0.3176567256450653)","('NON-ESG', 0.27312153577804565)","('NON-ESG', 0.0815608873963356)"
Line 93,Amgen was also included on the DJSI North America Index for the ninth consecutive year.,"('Systemic_Risk_Management', 0.28765571117401123)","('Business_Model_Resilience', 0.26674365997314453)","('Supply_Chain_Management', 0.05691549926996231)","('NON-ESG', 0.28765571117401123)","('NON-ESG', 0.26674365997314453)","('NON-ESG', 0.05691549926996231)"
Line 94,JUST 100 LISTAmgen named to the list for the fourth consecutive year.,"('Systemic_Risk_Management', 0.16122080385684967)","('Management_Of_Legal_And_Regulatory_Framework', 0.15179817378520966)","('Business_Model_Resilience', 0.08161802589893341)","('NON-ESG', 0.16122080385684967)","('NON-ESG', 0.15179817378520966)","('NON-ESG', 0.08161802589893341)"
Line 95,"TRE S HAUTE QUALITE SOCIALE ET ENVIRONNEMENTALE (THQSE) Amgen is the first pharma company in France to receive the Silver Medal ranking in the THQSE award, given to companies committed to sustainable development and environmental health.","('Human_Rights_And_Community_Relations', 0.2990729808807373)","('Business_Model_Resilience', 0.1874828189611435)","('Ecological_Impacts', 0.0778445228934288)","('NON-ESG', 0.2990729808807373)","('NON-ESG', 0.1874828189611435)","('NON-ESG', 0.0778445228934288)"
Line 96,FORBES Ranked among Americas Best Employers for Diversity and ranked among Americas Best Employers for New Grads.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9724233150482178)","('Employee_Health_And_Safety', 0.0023615513928234577)","('Human_Rights_And_Community_Relations', 0.0021402526181191206)","(['Talent Attraction & Retention'], 0.9724233150482178)","('NON-ESG', 0.0023615513928234577)","('NON-ESG', 0.0021402526181191206)"
Line 97,"MILITARY FRIENDL Y EMPLOYER Amgen named a Military Friendly Employer, qualifying for Silver Recognition.","('Employee_Health_And_Safety', 0.33075737953186035)","('Labor_Practices', 0.11773029714822769)","('Customer_Privacy', 0.06659092009067535)","('NON-ESG', 0.33075737953186035)","('NON-ESG', 0.11773029714822769)","('NON-ESG', 0.06659092009067535)"
Line 98,BEST PLACES TO WORK CORPORATE EQUALITY INDEX Amgen earned a perfect score of 100% on the Corporate Equality Index for the fourth year in a row.,"('Business_Ethics', 0.4053487181663513)","('Competitive_Behavior', 0.2200363278388977)","('Labor_Practices', 0.08285906910896301)","('NON-ESG', 0.4053487181663513)","('NON-ESG', 0.2200363278388977)","('NON-ESG', 0.08285906910896301)"
Line 99,"Introduction COVID-19 Response 6 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix I am pleased to introduce Amgens latest Environmental, Social, and Governance (ESG) Report .","('Human_Rights_And_Community_Relations', 0.6533833146095276)","('Business_Model_Resilience', 0.058802757412195206)","('Ecological_Impacts', 0.050783272832632065)","([], 0.6533833146095276)","('NON-ESG', 0.058802757412195206)","('NON-ESG', 0.050783272832632065)"
Line 100,Amgens commitment to good ESG practices dates back to our founding more than four decades ago .,"('Business_Model_Resilience', 0.5960897207260132)","('Systemic_Risk_Management', 0.05784450098872185)","('Human_Rights_And_Community_Relations', 0.04313225299119949)","(['Human Capital Development', 'Innovation Management'], 0.5960897207260132)","('NON-ESG', 0.05784450098872185)","('NON-ESG', 0.04313225299119949)"
Line 101,"Throughout our history, Amgen has contributed to society in many ways most importantly by bringing innovative medicines to patients with serious disease, but also by supporting our employees and their families, contributing to the well-being of our local communities, and operating our business in an ethical, environmentally responsible, and socially inclusive manner .","('Human_Rights_And_Community_Relations', 0.8855985999107361)","('Access_And_Affordability', 0.029894083738327026)","('Employee_Health_And_Safety', 0.011172856204211712)","([], 0.8855985999107361)","('NON-ESG', 0.029894083738327026)","('NON-ESG', 0.011172856204211712)"
Line 102,"As you will learn from this report, Amgen has made considerable progress during the past year with our ESG performance .","('Business_Model_Resilience', 0.5593461990356445)","('Systemic_Risk_Management', 0.12900616228580475)","('Physical_Impacts_Of_Climate_Change', 0.04439285770058632)","(['Human Capital Development', 'Innovation Management'], 0.5593461990356445)","('NON-ESG', 0.12900616228580475)","('NON-ESG', 0.04439285770058632)"
Line 103,"On the environment, we announced our aspiration to achieve net zero carbon emissions in our operations by 2027, along with a 40% reduction in water use and a 75% reduction in waste disposed .1 We also announced plans for new manufacturing facilities in North Carolina and Ohio that will utilize cutting-edge technologies to be much more efficient and environmentally friendly than traditional plants .","('Waste_And_Hazardous_Materials_Management', 0.5139190554618835)","('Water_And_Wastewater_Management', 0.17606131732463837)","('Energy_Management', 0.09179934859275818)","([], 0.5139190554618835)","('NON-ESG', 0.17606131732463837)","('NON-ESG', 0.09179934859275818)"
Line 104,"Finally, renewable energy sources provided 79% of Amgens total electricity consumption in 2021, up from 41% in 2020 .","('Energy_Management', 0.9790340065956116)","('Management_Of_Legal_And_Regulatory_Framework', 0.00204620324075222)","('Water_And_Wastewater_Management', 0.0018647111719474196)","(['Operational Eco-Efficiency'], 0.9790340065956116)","('NON-ESG', 0.00204620324075222)","('NON-ESG', 0.0018647111719474196)"
Line 105,"In February 2022, Amgen issued its first-ever green bond, raising $750 million to support our 2027 environmental sustainability aspirations .","('Product_Design_And_Lifecycle_Management', 0.18629947304725647)","('Physical_Impacts_Of_Climate_Change', 0.12870585918426514)","('Ecological_Impacts', 0.12597152590751648)","('NON-ESG', 0.18629947304725647)","('NON-ESG', 0.12870585918426514)","('NON-ESG', 0.12597152590751648)"
Line 106,LEADERSHIP MESSAGE Robert A.,"('Employee_Engagement_Inclusion_And_Diversity', 0.40979790687561035)","('Director_Removal', 0.14548112452030182)","('Business_Model_Resilience', 0.06729038059711456)","('NON-ESG', 0.40979790687561035)","('NON-ESG', 0.14548112452030182)","('NON-ESG', 0.06729038059711456)"
Line 107,"Bradway, Chairman and Chief Executive Officer 1 Carbon neutrality goal refers to Scope 1 and 2 emissions .","('GHG_Emissions', 0.8825311064720154)","('Management_Of_Legal_And_Regulatory_Framework', 0.021646643057465553)","('Air_Quality', 0.018112706020474434)","(['Operational Eco-Efficiency'], 0.8825311064720154)","('NON-ESG', 0.021646643057465553)","('NON-ESG', 0.018112706020474434)"
Line 108,"Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline .","('Systemic_Risk_Management', 0.5973811149597168)","('Business_Model_Resilience', 0.22292457520961761)","('Competitive_Behavior', 0.0244595929980278)","([], 0.5973811149597168)","('NON-ESG', 0.22292457520961761)","('NON-ESG', 0.0244595929980278)"
Line 109,2 Measured against a 2019 baseline .,"('Energy_Management', 0.13604871928691864)","('GHG_Emissions', 0.12807801365852356)","('Management_Of_Legal_And_Regulatory_Framework', 0.1157727912068367)","('NON-ESG', 0.13604871928691864)","('NON-ESG', 0.12807801365852356)","('NON-ESG', 0.1157727912068367)"
Line 110,3 Valued at wholesale acquisition cost .,"('Competitive_Behavior', 0.4710952341556549)","('Energy_Management', 0.1667303889989853)","('Management_Of_Legal_And_Regulatory_Framework', 0.06143229454755783)","('NON-ESG', 0.4710952341556549)","('NON-ESG', 0.1667303889989853)","('NON-ESG', 0.06143229454755783)"
Line 111,"4 The Amgen Safety Net Foundation and The Amgen Foundation, Inc ., are separate legal entities entirely funded by Amgen .","('Management_Of_Legal_And_Regulatory_Framework', 0.5086749792098999)","('Ecological_Impacts', 0.05063175782561302)","('Director_Removal', 0.049494724720716476)","([], 0.5086749792098999)","('NON-ESG', 0.05063175782561302)","('NON-ESG', 0.049494724720716476)"
Line 112,"Turning to social performance, we continued our efforts to improve the diversity of our workforce, and we supplemented our traditional benefits by providing additional mental health resources to support our colleagues worldwide in this challenging time, including programs focused on the pressures facing communities of color .","('Employee_Engagement_Inclusion_And_Diversity', 0.9725660681724548)","('Employee_Health_And_Safety', 0.002522585215047002)","('Human_Rights_And_Community_Relations', 0.0024641333147883415)","(['Talent Attraction & Retention'], 0.9725660681724548)","('NON-ESG', 0.002522585215047002)","('NON-ESG', 0.0024641333147883415)"
Line 113,"Through our RISE (Representation in Clinical Research) Initiative, we continued working toward increasing the ethnic and racial diversity of participants in clinical trials of our investigational medicines .","('Employee_Engagement_Inclusion_And_Diversity', 0.9746422171592712)","('Employee_Health_And_Safety', 0.0019482770003378391)","('Human_Rights_And_Community_Relations', 0.0016402296023443341)","(['Talent Attraction & Retention'], 0.9746422171592712)","('NON-ESG', 0.0019482770003378391)","('NON-ESG', 0.0016402296023443341)"
Line 114,"Amgen is a founding sponsor of the OneTen coalition, a coalition of many of the worlds largest, best-known companies seeking to advance our shared goal of recruiting one million Black Americans into family-sustaining jobs over the next ten years, with a focus on people lacking traditional four-year college degrees .","('Employee_Engagement_Inclusion_And_Diversity', 0.9510190486907959)","('Labor_Practices', 0.004262213595211506)","('Employee_Health_And_Safety', 0.0039043775759637356)","(['Talent Attraction & Retention'], 0.9510190486907959)","('NON-ESG', 0.004262213595211506)","('NON-ESG', 0.0039043775759637356)"
Line 115,"In addition, Amgen pledged to double the amount of business we do with diverse suppliers in the United States and to triple our business with Black-owned suppliers by 2023 .2 To expand access to our treatments, some $2 .2 billion3 of our medicines were provided at no cost to uninsured or underinsured patients in the United States through the Amgen Safety Net Foundation,4 and Amgen provided 900,000 daily doses of our medicines at no cost in more than 20 low- and middle-income countries through our partnership with Direct Relief .","('Access_And_Affordability', 0.27316075563430786)","('Customer_Welfare', 0.1694425344467163)","('Selling_Practices_And_Product_Labeling', 0.09540300816297531)","('NON-ESG', 0.27316075563430786)","('NON-ESG', 0.1694425344467163)","('NON-ESG', 0.09540300816297531)"
Line 116,"In addition, Amgen pledged to double the amount of business we do with diverse suppliers in the United States and to triple our business with Black-owned suppliers by 2023 .2 To expand access to our treatments, some $2 .2 billion3 of our medicines were provided at no cost to uninsured or underinsured patients in the United States through the Amgen Safety Net Foundation,4 and Amgen provided 900,000 daily doses of our medicines at no cost in more than 20 low- and middle-income countries through our partnership with Direct Relief .","('Critical_Incident_Risk_Management', 0.3748443126678467)","('Employee_Health_And_Safety', 0.17722409963607788)","('Access_And_Affordability', 0.06871242076158524)","('NON-ESG', 0.3748443126678467)","('NON-ESG', 0.17722409963607788)","('NON-ESG', 0.06871242076158524)"
Line 117,"To inspire the next generation of innovators, in 2021 the Amgen Foundation4 supported science education programs that reached over 27 million students and educators worldwide, and it provided some $3 million to support racial and social justice initiatives, economic empowerment, and equal opportunity in education .","('Human_Rights_And_Community_Relations', 0.42279863357543945)","('Employee_Engagement_Inclusion_And_Diversity', 0.38333502411842346)","('Access_And_Affordability', 0.04926333576440811)","('NON-ESG', 0.42279863357543945)","('NON-ESG', 0.38333502411842346)","('NON-ESG', 0.04926333576440811)"
Line 118,"With respect to governance, Amgen has a diverse and independent Board of Directors, elected annually by a majority of our stockholders .","('Director_Removal', 0.7393742799758911)","('Management_Of_Legal_And_Regulatory_Framework', 0.03411783277988434)","('Employee_Engagement_Inclusion_And_Diversity', 0.02423468790948391)","(['Business Ethics'], 0.7393742799758911)","('NON-ESG', 0.03411783277988434)","('NON-ESG', 0.02423468790948391)"
Line 119,"Our lead independent director has robust and well-defined responsibilities, and only independent Board members serve on key committees .","('Director_Removal', 0.7546544075012207)","('Management_Of_Legal_And_Regulatory_Framework', 0.047297053039073944)","('Employee_Engagement_Inclusion_And_Diversity', 0.018351271748542786)","(['Business Ethics'], 0.7546544075012207)","('NON-ESG', 0.047297053039073944)","('NON-ESG', 0.018351271748542786)"
Line 120,"Amgen has adopted a number of practices that increase stockholders share of voice in our governance, including proxy access for director nominations and enabling stockholders to act by written consent and call special meetings .","('Director_Removal', 0.2344197928905487)","('Management_Of_Legal_And_Regulatory_Framework', 0.22335217893123627)","('Competitive_Behavior', 0.15751120448112488)","('NON-ESG', 0.2344197928905487)","('NON-ESG', 0.22335217893123627)","('NON-ESG', 0.15751120448112488)"
Line 121,"In 2021, we included ESG performance in our Company goals under our annual incentive compensation plan, and we are developing a wide range of external disclosuresincluding this reportto communicate frequently and transparently on our ESG performance .","('Systemic_Risk_Management', 0.34675461053848267)","('Business_Model_Resilience', 0.2147933542728424)","('Business_Ethics', 0.08946897089481354)","('NON-ESG', 0.34675461053848267)","('NON-ESG', 0.2147933542728424)","('NON-ESG', 0.08946897089481354)"
Line 122,I invite you to explore this report to learn more about Amgens ESG performance .,"('Business_Model_Resilience', 0.41083183884620667)","('Systemic_Risk_Management', 0.16217175126075745)","('Human_Rights_And_Community_Relations', 0.057281494140625)","('NON-ESG', 0.41083183884620667)","('NON-ESG', 0.16217175126075745)","('NON-ESG', 0.057281494140625)"
Line 123,We are pleased with our progress and eager to do more .,"('Business_Model_Resilience', 0.25593599677085876)","('Human_Rights_And_Community_Relations', 0.14021576941013336)","('Employee_Engagement_Inclusion_And_Diversity', 0.052787356078624725)","('NON-ESG', 0.25593599677085876)","('NON-ESG', 0.14021576941013336)","('NON-ESG', 0.052787356078624725)"
Line 124,"Throughout this report, you will see indicators of Amgens alignment with key components of the UN Sustainable Development Goals and the UN Global Compact.","('Human_Rights_And_Community_Relations', 0.3397606611251831)","('Management_Of_Legal_And_Regulatory_Framework', 0.30557456612586975)","('Ecological_Impacts', 0.06971652060747147)","('NON-ESG', 0.3397606611251831)","('NON-ESG', 0.30557456612586975)","('NON-ESG', 0.06971652060747147)"
Line 125,Amgen remains committed to its principles and to reporting on our progress in implementing them.,"('Human_Rights_And_Community_Relations', 0.5748119354248047)","('Management_Of_Legal_And_Regulatory_Framework', 0.12940174341201782)","('Business_Model_Resilience', 0.04942188784480095)","([], 0.5748119354248047)","('NON-ESG', 0.12940174341201782)","('NON-ESG', 0.04942188784480095)"
Line 126,"Introduction COVID-19 Response 7 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix OUR APPROACH TO ESG Amgens approach to corporate responsibility starts with our mission to serve patients and is executed through our ESG framework.","('Human_Rights_And_Community_Relations', 0.5013525485992432)","('Business_Model_Resilience', 0.12262129038572311)","('Employee_Engagement_Inclusion_And_Diversity', 0.05716158449649811)","([], 0.5013525485992432)","('NON-ESG', 0.12262129038572311)","('NON-ESG', 0.05716158449649811)"
Line 127,"include environmental sustainability; diversity, inclusion and belonging (DI&B); and access to medicines .","('Employee_Engagement_Inclusion_And_Diversity', 0.9706352949142456)","('Human_Rights_And_Community_Relations', 0.0026455288752913475)","('Employee_Health_And_Safety', 0.0024414602667093277)","(['Talent Attraction & Retention'], 0.9706352949142456)","('NON-ESG', 0.0026455288752913475)","('NON-ESG', 0.0024414602667093277)"
Line 128,"In 2022, oversight of DI&B shifted to the Boards Compensation and Management Development Committee, the committee that also provides oversight of our approach to human capital management .","('Management_Of_Legal_And_Regulatory_Framework', 0.2461804300546646)","('Business_Model_Resilience', 0.16811005771160126)","('Director_Removal', 0.15551963448524475)","('NON-ESG', 0.2461804300546646)","('NON-ESG', 0.16811005771160126)","('NON-ESG', 0.15551963448524475)"
Line 129,The Governance and Nominating Committee oversees the Companys corporate governance activities and Board membership .,"('Director_Removal', 0.3629250228404999)","('Management_Of_Legal_And_Regulatory_Framework', 0.3503436744213104)","('Business_Ethics', 0.0414079874753952)","('NON-ESG', 0.3629250228404999)","('NON-ESG', 0.3503436744213104)","('NON-ESG', 0.0414079874753952)"
Line 130,The Audit Committee provides oversight of our disclosure processes in support of our ESG reporting .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8643105030059814)","('Systemic_Risk_Management', 0.022536665201187134)","('Business_Ethics', 0.015883387997746468)","([], 0.8643105030059814)","('NON-ESG', 0.022536665201187134)","('NON-ESG', 0.015883387997746468)"
Line 131,Amgens executive management provides regular updates to the Board and its committees regarding the status and progress of the Companys ESG activities .,"('Director_Removal', 0.5293902158737183)","('Management_Of_Legal_And_Regulatory_Framework', 0.1457458883523941)","('Business_Model_Resilience', 0.05112825334072113)","(['Business Ethics'], 0.5293902158737183)","('NON-ESG', 0.1457458883523941)","('NON-ESG', 0.05112825334072113)"
Line 132,Our cross-functional executive-level ESG Council sets and reviews the Companys ESG strategy and programs .,"('Business_Model_Resilience', 0.29266512393951416)","('Management_Of_Legal_And_Regulatory_Framework', 0.16973648965358734)","('Director_Removal', 0.12517647445201874)","('NON-ESG', 0.29266512393951416)","('NON-ESG', 0.16973648965358734)","('NON-ESG', 0.12517647445201874)"
Line 133,The Council is chaired by the Senior Vice President of Corporate Affairs .,"('Management_Of_Legal_And_Regulatory_Framework', 0.36508482694625854)","('Director_Removal', 0.30938461422920227)","('Employee_Engagement_Inclusion_And_Diversity', 0.037884023040533066)","('NON-ESG', 0.36508482694625854)","('NON-ESG', 0.30938461422920227)","('NON-ESG', 0.037884023040533066)"
Line 134,"Four initiative steering committees (ISCs), each aligned with one of our four strategic pillars, support the ESG Council .","('Business_Model_Resilience', 0.301982045173645)","('Management_Of_Legal_And_Regulatory_Framework', 0.15762944519519806)","('Systemic_Risk_Management', 0.09531628340482712)","('NON-ESG', 0.301982045173645)","('NON-ESG', 0.15762944519519806)","('NON-ESG', 0.09531628340482712)"
Line 135,Each ISC coordinates the implementation of the strategy for its respective pillar and integrates our ESG strategy into the Company with the support of subject-matter-expert working teams .,"('Business_Model_Resilience', 0.6219086050987244)","('Management_Of_Legal_And_Regulatory_Framework', 0.0657658651471138)","('Systemic_Risk_Management', 0.049977753311395645)","(['Human Capital Development', 'Innovation Management'], 0.6219086050987244)","('NON-ESG', 0.0657658651471138)","('NON-ESG', 0.049977753311395645)"
Line 136,"ISC members identify emerging ESG issues that could impact Amgens business, employees, communities or stakeholders and, when appropriate, raise them with the ESG Council for discussion and analysis .","('Human_Rights_And_Community_Relations', 0.8878902792930603)","('Business_Model_Resilience', 0.013921933248639107)","('Ecological_Impacts', 0.01031873095780611)","([], 0.8878902792930603)","('NON-ESG', 0.013921933248639107)","('NON-ESG', 0.01031873095780611)"
Line 137,"Our ESG efforts are grounded in our mission to serve patients, from our endeavors to strengthen science education and inspire the next generation of scientists, to expanding access to our medicines and supporting efforts to strengthen healthcare systems to better serve patients in need worldwide while also pursuing a more environmentally sustainable business model .","('Access_And_Affordability', 0.8957887887954712)","('Critical_Incident_Risk_Management', 0.010116574354469776)","('Human_Rights_And_Community_Relations', 0.008941312320530415)","(['Access to Healthcare'], 0.8957887887954712)","('NON-ESG', 0.010116574354469776)","('NON-ESG', 0.008941312320530415)"
Line 138,"While our Company is very focused on the financial and data-driven metrics of our ESG programs, we also value the true human impact of our business, and strive for a strong culture of inclusion and belonging .","('Employee_Engagement_Inclusion_And_Diversity', 0.9236785173416138)","('Human_Rights_And_Community_Relations', 0.019989479333162308)","('Employee_Health_And_Safety', 0.0053420159965753555)","(['Talent Attraction & Retention'], 0.9236785173416138)","('NON-ESG', 0.019989479333162308)","('NON-ESG', 0.0053420159965753555)"
Line 139,"Amgens ESG Framework is built on four strategic pillars: Healthy People, Healthy Society, Healthy Planet, and A Healthy Amgen .","('Employee_Engagement_Inclusion_And_Diversity', 0.14583300054073334)","('Human_Rights_And_Community_Relations', 0.14412802457809448)","('Business_Model_Resilience', 0.10991666465997696)","('NON-ESG', 0.14583300054073334)","('NON-ESG', 0.14412802457809448)","('NON-ESG', 0.10991666465997696)"
Line 140,This framework facilitates our ability to address the interconnectivity of issues in a holistic way across our business and integrate these activities more close- ly with our long-term strategy .,"('Business_Model_Resilience', 0.702775776386261)","('Systemic_Risk_Management', 0.06860839575529099)","('Supply_Chain_Management', 0.033246081322431564)","(['Human Capital Development', 'Innovation Management'], 0.702775776386261)","('NON-ESG', 0.06860839575529099)","('NON-ESG', 0.033246081322431564)"
Line 141,"In 2021, to further integrate ESG across the organization, we added an ESG target to our Company-wide performance goals within our annual incentive compensation plan .","('Business_Model_Resilience', 0.4327583312988281)","('Systemic_Risk_Management', 0.2074125111103058)","('Competitive_Behavior', 0.060946010053157806)","('NON-ESG', 0.4327583312988281)","('NON-ESG', 0.2074125111103058)","('NON-ESG', 0.060946010053157806)"
Line 142,ESG GOVERNANCE The Amgen Board of Directors and its applicable committees oversee Amgens ESG strategy and activities .,"('Director_Removal', 0.5341833233833313)","('Management_Of_Legal_And_Regulatory_Framework', 0.130353182554245)","('Business_Model_Resilience', 0.052374109625816345)","(['Business Ethics'], 0.5341833233833313)","('NON-ESG', 0.130353182554245)","('NON-ESG', 0.052374109625816345)"
Line 143,The Corporate Responsibility and Compliance Committee (CRCC) assists the Board with oversight of Amgens activities in areas that Key Committees Initiative Steering CommitteeInitiative Steering CommitteeInitiative Steering CommitteeInitiative Steering Committee Working TeamsWorking TeamsWorking TeamsWorking TeamsAmgen Inc.,"('Management_Of_Legal_And_Regulatory_Framework', 0.7192920446395874)","('Business_Ethics', 0.07139168679714203)","('Director_Removal', 0.03526967018842697)","([], 0.7192920446395874)","('NON-ESG', 0.07139168679714203)","('NON-ESG', 0.03526967018842697)"
Line 144,"Board of Directors Oversees Amgens ESG Strategy and Activities ESG Council Sets and reviews the Companys ESG strategy and programsCorporate Responsibility & Compliance CommitteeCompensation & Management Development CommitteeGovernance & Nominating CommitteeAudit Committee Executive Management Provides the Board and its committees with updates on the Companys ESG strategy, performance, and priority areas Healthy PeopleHealthy SocietyHealthy PlanetA Healthy AmgenIntroduction COVID-19 Response 8 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix ESG FrameworkOUR We focus on removing barriers that limit equitable access to healthcare so that people can live their healthiest lives .","('Customer_Welfare', 0.1312880665063858)","('Business_Model_Resilience', 0.11742597818374634)","('Access_And_Affordability', 0.10908469557762146)","('NON-ESG', 0.1312880665063858)","('NON-ESG', 0.11742597818374634)","('NON-ESG', 0.10908469557762146)"
Line 145,"Board of Directors Oversees Amgens ESG Strategy and Activities ESG Council Sets and reviews the Companys ESG strategy and programsCorporate Responsibility & Compliance CommitteeCompensation & Management Development CommitteeGovernance & Nominating CommitteeAudit Committee Executive Management Provides the Board and its committees with updates on the Companys ESG strategy, performance, and priority areas Healthy PeopleHealthy SocietyHealthy PlanetA Healthy AmgenIntroduction COVID-19 Response 8 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix ESG FrameworkOUR We focus on removing barriers that limit equitable access to healthcare so that people can live their healthiest lives .","('Access_And_Affordability', 0.7916754484176636)","('Human_Rights_And_Community_Relations', 0.032887060195207596)","('Employee_Health_And_Safety', 0.03054998815059662)","(['Access to Healthcare'], 0.7916754484176636)","('NON-ESG', 0.032887060195207596)","('NON-ESG', 0.03054998815059662)"
Line 146,"Healthy PeopleKey Program ElementsHealth Equity Access to Medicines Corporate Philanthropy Ethical ResearchResponsible SourcingDiversity, Inclusion & BelongingEnvironmental SustainabilityGovernance Business EthicsWe work toward a more just society for our employees and the people we serve .","('Business_Ethics', 0.9078481793403625)","('Human_Rights_And_Community_Relations', 0.01395389810204506)","('Competitive_Behavior', 0.00909161102026701)","(['Business Ethics'], 0.9078481793403625)","('NON-ESG', 0.01395389810204506)","('NON-ESG', 0.00909161102026701)"
Line 147,Healthy Society We prioritize sustainability and aim to minimize our enviromental impact to preserve natural resources for generations to come .,"('Ecological_Impacts', 0.9772019982337952)","('GHG_Emissions', 0.002493428997695446)","('Product_Design_And_Lifecycle_Management', 0.0018068559002131224)","([], 0.9772019982337952)","('NON-ESG', 0.002493428997695446)","('NON-ESG', 0.0018068559002131224)"
Line 148,Healthy Planet We hold ourselves to high standards in our operations - working to ensure our culture and products reflect Amgen Values .,"('Product_Design_And_Lifecycle_Management', 0.8163067102432251)","('Product_Quality_And_Safety', 0.05209391936659813)","('Customer_Welfare', 0.025596966966986656)","([], 0.8163067102432251)","('NON-ESG', 0.05209391936659813)","('NON-ESG', 0.025596966966986656)"
Line 149,"A Healthy AmgenIDENTIFYING HIGH-PRIORITY ESG TOPICS Amgen uses a variety of analytical tools to identify, evolve, and monitor ESG topics, including: Periodic stakeholder perspective assessments, which analyze the perspectives of both internal and external stakeholders .","('Business_Model_Resilience', 0.36394527554512024)","('Human_Rights_And_Community_Relations', 0.17474104464054108)","('Systemic_Risk_Management', 0.09049609303474426)","('NON-ESG', 0.36394527554512024)","('NON-ESG', 0.17474104464054108)","('NON-ESG', 0.09049609303474426)"
Line 150,"Direct and indirect interactions with stakeholders, including investors, patients, healthcare professionals, and patient advocacy organizations .","('Access_And_Affordability', 0.4530133605003357)","('Human_Rights_And_Community_Relations', 0.2155618816614151)","('Employee_Health_And_Safety', 0.07488589733839035)","('NON-ESG', 0.4530133605003357)","('NON-ESG', 0.2155618816614151)","('NON-ESG', 0.07488589733839035)"
Line 151,"Review of the alignment and integration of ESG with Amgens strategy, mission, and values .","('Business_Model_Resilience', 0.7297800183296204)","('Employee_Engagement_Inclusion_And_Diversity', 0.039323143661022186)","('Human_Rights_And_Community_Relations', 0.030195478349924088)","(['Human Capital Development', 'Innovation Management'], 0.7297800183296204)","('NON-ESG', 0.039323143661022186)","('NON-ESG', 0.030195478349924088)"
Line 152,"We also review relevant ESG reporting standards and frameworks, such as the Biopharma Investor ESG Communication Guidance, SASB and TCFD .","('Management_Of_Legal_And_Regulatory_Framework', 0.6206786632537842)","('Systemic_Risk_Management', 0.05347447097301483)","('Product_Quality_And_Safety', 0.04761951044201851)","([], 0.6206786632537842)","('NON-ESG', 0.05347447097301483)","('NON-ESG', 0.04761951044201851)"
Line 153,"In 2021, Amgen conducted its most recent stakeholder perspective assessment .","('Human_Rights_And_Community_Relations', 0.25211355090141296)","('Management_Of_Legal_And_Regulatory_Framework', 0.1734485775232315)","('Business_Model_Resilience', 0.10715387761592865)","('NON-ESG', 0.25211355090141296)","('NON-ESG', 0.1734485775232315)","('NON-ESG', 0.10715387761592865)"
Line 154,"Using the results of this assessment, as well as the information gathered through stakeholder engagement and the other analytical tools and reviews described above, our current ESG priorities are shown to the right in relationship to the four strategic pillars .","('Business_Model_Resilience', 0.547391951084137)","('Human_Rights_And_Community_Relations', 0.15466231107711792)","('Systemic_Risk_Management', 0.04757443070411682)","(['Human Capital Development', 'Innovation Management'], 0.547391951084137)","('NON-ESG', 0.15466231107711792)","('NON-ESG', 0.04757443070411682)"
Line 155,"Introduction COVID-19 Response 9 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix The pursuit of good health and well-being is embedded in Amgens mission: to serve patients .","('Human_Rights_And_Community_Relations', 0.3740854561328888)","('Employee_Health_And_Safety', 0.15415236353874207)","('Access_And_Affordability', 0.14075614511966705)","('NON-ESG', 0.3740854561328888)","('NON-ESG', 0.15415236353874207)","('NON-ESG', 0.14075614511966705)"
Line 156,"We believe that discovering, developing, manufacturing, and delivering innovative therapeutics that address serious diseases will not only help patients, but also will help reduce the social and economic burdens of disease on society .","('Access_And_Affordability', 0.1806430071592331)","('Employee_Health_And_Safety', 0.13192850351333618)","('Systemic_Risk_Management', 0.09023556858301163)","('NON-ESG', 0.1806430071592331)","('NON-ESG', 0.13192850351333618)","('NON-ESG', 0.09023556858301163)"
Line 157,"We also support the health, wellness, and safety of our employees globally, and we work to ensure that our suppliers do the same .","('Employee_Health_And_Safety', 0.9620947241783142)","('Employee_Engagement_Inclusion_And_Diversity', 0.006365037057548761)","('Product_Quality_And_Safety', 0.0043670786544680595)","(['Health Outcome Contribution'], 0.9620947241783142)","('NON-ESG', 0.006365037057548761)","('NON-ESG', 0.0043670786544680595)"
Line 158,Expanded access to quality science education is at the heart of the Amgen Foundations activities .,"('Access_And_Affordability', 0.8709363341331482)","('Product_Quality_And_Safety', 0.01461685262620449)","('Ecological_Impacts', 0.011889668181538582)","(['Access to Healthcare'], 0.8709363341331482)","('NON-ESG', 0.01461685262620449)","('NON-ESG', 0.011889668181538582)"
Line 159,"Through programs and partnerships, the Amgen Foundation seeks to advance science education, including among low-income and disadvantaged students .","('Access_And_Affordability', 0.548000156879425)","('Employee_Engagement_Inclusion_And_Diversity', 0.1951388716697693)","('Human_Rights_And_Community_Relations', 0.05058867484331131)","(['Access to Healthcare'], 0.548000156879425)","('NON-ESG', 0.1951388716697693)","('NON-ESG', 0.05058867484331131)"
Line 160,"Since it started operating in 1991, the Amgen Foundation has committed over $200 million to support science education programming globally, and, with our partners, reached millions of students with high-quality science-based learning tools in the classroom and online .","('Access_And_Affordability', 0.7505308389663696)","('Employee_Engagement_Inclusion_And_Diversity', 0.033483535051345825)","('Customer_Welfare', 0.022822977975010872)","(['Access to Healthcare'], 0.7505308389663696)","('NON-ESG', 0.033483535051345825)","('NON-ESG', 0.022822977975010872)"
Line 161,Innovation is core to Amgens business .,"('Product_Design_And_Lifecycle_Management', 0.35990139842033386)","('Business_Model_Resilience', 0.30437514185905457)","('Supply_Chain_Management', 0.05129239335656166)","('NON-ESG', 0.35990139842033386)","('NON-ESG', 0.30437514185905457)","('NON-ESG', 0.05129239335656166)"
Line 162,"In addition to using innovation to develop pioneering medicines, Amgen applies innovation to our drug development operations and manufacturing processes .","('Competitive_Behavior', 0.35026001930236816)","('Product_Design_And_Lifecycle_Management', 0.20718957483768463)","('Customer_Welfare', 0.13177792727947235)","('NON-ESG', 0.35026001930236816)","('NON-ESG', 0.20718957483768463)","('NON-ESG', 0.13177792727947235)"
Line 163,The demonstrated environmental benefits of our next-generation biomanufacturing processes are one example of the value of our innovative approaches .,"('Product_Design_And_Lifecycle_Management', 0.8905426263809204)","('Supply_Chain_Management', 0.01916816458106041)","('Business_Model_Resilience', 0.013885763473808765)","([], 0.8905426263809204)","('NON-ESG', 0.01916816458106041)","('NON-ESG', 0.013885763473808765)"
Line 164,"We aim to achieve carbon neutrality in our operations, while reducing water usage (by 40%) and waste disposed (by 75%) by 2027 .5 We expect to make significant investments over time to achieve these aspirations, building on our past success .","('Waste_And_Hazardous_Materials_Management', 0.6743060350418091)","('Water_And_Wastewater_Management', 0.22903315722942352)","('Air_Quality', 0.012264003045856953)","([], 0.6743060350418091)","('NON-ESG', 0.22903315722942352)","('NON-ESG', 0.012264003045856953)"
Line 165,"In 2021, we worked to recycleand divert from landfills over 2,200 pounds of masks used by our employees and visitors to our sites .","('Waste_And_Hazardous_Materials_Management', 0.9479748606681824)","('Water_And_Wastewater_Management', 0.014281717129051685)","('Air_Quality', 0.00402110256254673)","([], 0.9479748606681824)","('NON-ESG', 0.014281717129051685)","('NON-ESG', 0.00402110256254673)"
Line 166,We also donate used lab equipment and office furniture to nonprofit organizations and educational institutions .,"('Waste_And_Hazardous_Materials_Management', 0.3262808620929718)","('Energy_Management', 0.09032349288463593)","('Access_And_Affordability', 0.07350355386734009)","('NON-ESG', 0.3262808620929718)","('NON-ESG', 0.09032349288463593)","('NON-ESG', 0.07350355386734009)"
Line 167,"Much of what Amgen accomplishes is through partnerships, sponsorships, and collaborations such as those with the nonprofit patient support organization Lazarex Cancer Foundation, medical assistance nongovernmental organization Direct Relief, OneTen, a nonprofit organization focused on closing the opportunity gap for Black talent in America, and the nonprofit educational organization Khan Academy .","('Employee_Engagement_Inclusion_And_Diversity', 0.9015054106712341)","('Access_And_Affordability', 0.01907353289425373)","('Product_Quality_And_Safety', 0.006415609270334244)","(['Talent Attraction & Retention'], 0.9015054106712341)","('NON-ESG', 0.01907353289425373)","('NON-ESG', 0.006415609270334244)"
Line 168,We remain focused on joining with diverse stakeholders to tackle significant challenges from climate change and health inequity to gender equality and education .,"('Employee_Engagement_Inclusion_And_Diversity', 0.48864251375198364)","('Human_Rights_And_Community_Relations', 0.20584706962108612)","('Access_And_Affordability', 0.12202206999063492)","('NON-ESG', 0.48864251375198364)","('NON-ESG', 0.20584706962108612)","('NON-ESG', 0.12202206999063492)"
Line 169,"ALIGNMENT WITH SUSTAINABLE DEVELOPMENT GOALS As a global biopharmaceutical company focused on improving human health and advancing science, we recognize the powerful role we can play in not only supporting, but contributing to the achievement of the United Nations (U.","('Access_And_Affordability', 0.25546392798423767)","('Product_Design_And_Lifecycle_Management', 0.1333802044391632)","('Employee_Health_And_Safety', 0.10167660564184189)","('NON-ESG', 0.25546392798423767)","('NON-ESG', 0.1333802044391632)","('NON-ESG', 0.10167660564184189)"
Line 170,N.) 17 Sustainable Development Goals.,"('Human_Rights_And_Community_Relations', 0.5589848756790161)","('Business_Model_Resilience', 0.0782502293586731)","('Ecological_Impacts', 0.05880988761782646)","([], 0.5589848756790161)","('NON-ESG', 0.0782502293586731)","('NON-ESG', 0.05880988761782646)"
Line 171,"Through our core business and investments by the Amgen Foundation, we believe we can most meaningfully contribute to the following five U.","('Business_Model_Resilience', 0.2694703936576843)","('Management_Of_Legal_And_Regulatory_Framework', 0.18591248989105225)","('Human_Rights_And_Community_Relations', 0.06621747463941574)","('NON-ESG', 0.2694703936576843)","('NON-ESG', 0.18591248989105225)","('NON-ESG', 0.06621747463941574)"
Line 172,N. goals.,"('Competitive_Behavior', 0.15344208478927612)","('Human_Rights_And_Community_Relations', 0.1315147876739502)","('Employee_Engagement_Inclusion_And_Diversity', 0.08276499062776566)","('NON-ESG', 0.15344208478927612)","('NON-ESG', 0.1315147876739502)","('NON-ESG', 0.08276499062776566)"
Line 173,5 Carbon neutrality goal refers to Scope 1 and 2 .,"('GHG_Emissions', 0.2047988474369049)","('Management_Of_Legal_And_Regulatory_Framework', 0.18167546391487122)","('Ecological_Impacts', 0.1428806334733963)","('NON-ESG', 0.2047988474369049)","('NON-ESG', 0.18167546391487122)","('NON-ESG', 0.1428806334733963)"
Line 174,"Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline .","('Systemic_Risk_Management', 0.5973811149597168)","('Business_Model_Resilience', 0.22292457520961761)","('Competitive_Behavior', 0.0244595929980278)","([], 0.5973811149597168)","('NON-ESG', 0.22292457520961761)","('NON-ESG', 0.0244595929980278)"
Line 175,"Introduction 10 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix COVID-19 Response COVID-19 RESPONSE As the pandemic continued in 2021, we remained vigilant in our efforts to protect employee health and safety and ensure ongoing supply of our medicines to patients worldwide.","('Employee_Health_And_Safety', 0.3534117043018341)","('Product_Quality_And_Safety', 0.24256210029125214)","('Access_And_Affordability', 0.12834997475147247)","('NON-ESG', 0.3534117043018341)","('NON-ESG', 0.24256210029125214)","('NON-ESG', 0.12834997475147247)"
Line 176,"Introduction COVID-19 Response 11 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix In the second year of the COVID-19 pandemic, we continued to monitor and counter risks to our staff, business and communities in which we operate.","('Human_Rights_And_Community_Relations', 0.723516047000885)","('Access_And_Affordability', 0.04173571243882179)","('Business_Model_Resilience', 0.03317726030945778)","([], 0.723516047000885)","('NON-ESG', 0.04173571243882179)","('NON-ESG', 0.03317726030945778)"
Line 177,"In addition, we are integrating key learnings into our ongoing pandemic preparedness planning.","('Critical_Incident_Risk_Management', 0.8132025003433228)","('Physical_Impacts_Of_Climate_Change', 0.06811708956956863)","('Air_Quality', 0.01762082427740097)","([], 0.8132025003433228)","('NON-ESG', 0.06811708956956863)","('NON-ESG', 0.01762082427740097)"
Line 178,"Using a science-based and data-driven approach, Amgen prioritized staff health and safety to help ensure business resilience and deliver on Amgens aspiration to serve every patient every time globally .","('Business_Model_Resilience', 0.8432775735855103)","('Product_Design_And_Lifecycle_Management', 0.023266226053237915)","('Supply_Chain_Management', 0.0146273672580719)","(['Human Capital Development', 'Innovation Management'], 0.8432775735855103)","('NON-ESG', 0.023266226053237915)","('NON-ESG', 0.0146273672580719)"
Line 179,"Ensuring Employee Health and Well-Being While many staff worked from home during 2021, we put in place additional measures to help ensure the safety of our employees and contractors working at our manufacturing and research sites who were vital to our ability to supply needed medicines to patients and advance new products and product candidates .","('Employee_Health_And_Safety', 0.8043830394744873)","('Product_Quality_And_Safety', 0.09865521639585495)","('Product_Design_And_Lifecycle_Management', 0.015927543863654137)","(['Health Outcome Contribution'], 0.8043830394744873)","('NON-ESG', 0.09865521639585495)","('NON-ESG', 0.015927543863654137)"
Line 180,We adjusted these measures as additional staff returned to offices when local conditions allowed .,"('Employee_Engagement_Inclusion_And_Diversity', 0.21122904121875763)","('Labor_Practices', 0.19513073563575745)","('Director_Removal', 0.183083176612854)","('NON-ESG', 0.21122904121875763)","('NON-ESG', 0.19513073563575745)","('NON-ESG', 0.183083176612854)"
Line 181,We required all U .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8325347304344177)","('Business_Ethics', 0.02696487121284008)","('Competitive_Behavior', 0.02307903580367565)","([], 0.8325347304344177)","('NON-ESG', 0.02696487121284008)","('NON-ESG', 0.02307903580367565)"
Line 182,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 183,"employees, contractors, and visitors to complete a digital daily wellness check before entering an Amgen site and implemented digital close-contact tracking devices at several of our major sites to quickly and efficiently identify exposure cases .","('Employee_Health_And_Safety', 0.6156588196754456)","('Labor_Practices', 0.07037191838026047)","('Product_Quality_And_Safety', 0.04548879340291023)","(['Health Outcome Contribution'], 0.6156588196754456)","('NON-ESG', 0.07037191838026047)","('NON-ESG', 0.04548879340291023)"
Line 184,"We also continued periodic testing at our offices in the United States, indoor masking, enhanced cleaning procedures and physical distancing .","('Product_Design_And_Lifecycle_Management', 0.23504677414894104)","('Employee_Health_And_Safety', 0.1699497550725937)","('Product_Quality_And_Safety', 0.1621340662240982)","('NON-ESG', 0.23504677414894104)","('NON-ESG', 0.1699497550725937)","('NON-ESG', 0.1621340662240982)"
Line 185,"COVID-19 RESPONSEIntroduction COVID-19 Response 12 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix As countries began to reopen in 2021, Amgen country leaders determined when and how their teams would return to the workplace in alignment with local guidelines .","('Human_Rights_And_Community_Relations', 0.6611331105232239)","('Employee_Engagement_Inclusion_And_Diversity', 0.06331423670053482)","('Business_Model_Resilience', 0.0350804328918457)","([], 0.6611331105232239)","('NON-ESG', 0.06331423670053482)","('NON-ESG', 0.0350804328918457)"
Line 186,"Moving forward, we will follow a new, more flexible workplace approach globally, based on lessons learned during the pandemic and employee feedback .","('Employee_Health_And_Safety', 0.4961265027523041)","('Access_And_Affordability', 0.07126106321811676)","('Critical_Incident_Risk_Management', 0.06714095920324326)","('NON-ESG', 0.4961265027523041)","('NON-ESG', 0.07126106321811676)","('NON-ESG', 0.06714095920324326)"
Line 187,Learn more about our new approach on page 34 .,"('Business_Model_Resilience', 0.18834646046161652)","('Competitive_Behavior', 0.11214327067136765)","('Systemic_Risk_Management', 0.11071515083312988)","('NON-ESG', 0.18834646046161652)","('NON-ESG', 0.11214327067136765)","('NON-ESG', 0.11071515083312988)"
Line 188,Supporting Patients and Healthcare Providers Clinical trials are a critical step in our development of new medicines .,"('Customer_Welfare', 0.2393757402896881)","('Access_And_Affordability', 0.13692668080329895)","('Selling_Practices_And_Product_Labeling', 0.06925690919160843)","('NON-ESG', 0.2393757402896881)","('NON-ESG', 0.13692668080329895)","('NON-ESG', 0.06925690919160843)"
Line 189,"Despite the challenges presented by COVID-19, we remain focused on supporting our active clinical sites in their providing of care to patients and in our provision of investigational drug supply .","('Access_And_Affordability', 0.3596532940864563)","('Customer_Welfare', 0.19513364136219025)","('Supply_Chain_Management', 0.054872777312994)","('NON-ESG', 0.3596532940864563)","('NON-ESG', 0.19513364136219025)","('NON-ESG', 0.054872777312994)"
Line 190,"Throughout the pandemic, Amgen Manufacturing operations have never stopped working to ensure the continued supply of our medicines to patients .","('Access_And_Affordability', 0.1274673193693161)","('Critical_Incident_Risk_Management', 0.12051604688167572)","('Supply_Chain_Management', 0.0868249163031578)","('NON-ESG', 0.1274673193693161)","('NON-ESG', 0.12051604688167572)","('NON-ESG', 0.0868249163031578)"
Line 191,"In addition, we have contributed our manufacturing expertise to the fight against COVID-19 .","('Product_Design_And_Lifecycle_Management', 0.3830702304840088)","('Supply_Chain_Management', 0.10798422992229462)","('Product_Quality_And_Safety', 0.107157863676548)","('NON-ESG', 0.3830702304840088)","('NON-ESG', 0.10798422992229462)","('NON-ESG', 0.107157863676548)"
Line 192,"Through a collaboration with Eli Lilly and Company, we are contributing to the production of their COVID-19 therapies, an effort that began in 2020 and continued in 2021 .","('Access_And_Affordability', 0.2562790811061859)","('Customer_Welfare', 0.1988999843597412)","('Selling_Practices_And_Product_Labeling', 0.08856319636106491)","('NON-ESG', 0.2562790811061859)","('NON-ESG', 0.1988999843597412)","('NON-ESG', 0.08856319636106491)"
Line 193,We also continued to provide healthcare professionals with the information they needed to prescribe our medicines appropriately .,"('Selling_Practices_And_Product_Labeling', 0.4065525531768799)","('Access_And_Affordability', 0.14599204063415527)","('Customer_Welfare', 0.130397766828537)","('NON-ESG', 0.4065525531768799)","('NON-ESG', 0.14599204063415527)","('NON-ESG', 0.130397766828537)"
Line 194,"While we leveraged new technologies and digital tools prior to COVID-19, the pandemic accelerated our efforts .","('Data_Security', 0.19382309913635254)","('Systemic_Risk_Management', 0.16373884677886963)","('Business_Model_Resilience', 0.12386012077331543)","('NON-ESG', 0.19382309913635254)","('NON-ESG', 0.16373884677886963)","('NON-ESG', 0.12386012077331543)"
Line 195,"For employees working from home in the United States and other countries, we continued to provide a monthly stipend for broadband Internet access along with an allowance to purchase necessary home-office equipment .","('Data_Security', 0.29426079988479614)","('Energy_Management', 0.2756156921386719)","('Management_Of_Legal_And_Regulatory_Framework', 0.07822724431753159)","('NON-ESG', 0.29426079988479614)","('NON-ESG', 0.2756156921386719)","('NON-ESG', 0.07822724431753159)"
Line 196,"We continued to make mental health resources available at no cost to all employees and their dependents, as well as education support, discounts on childcare and academic tutoring services, online learning resources, and additional Company-wide paid days off .","('Access_And_Affordability', 0.8950700163841248)","('Product_Quality_And_Safety', 0.012807684019207954)","('Employee_Health_And_Safety', 0.009345023892819881)","(['Access to Healthcare'], 0.8950700163841248)","('NON-ESG', 0.012807684019207954)","('NON-ESG', 0.009345023892819881)"
Line 197,And we provided managers with resilience training to help them assist their teams through this period of change .,"('Business_Model_Resilience', 0.9031864404678345)","('Physical_Impacts_Of_Climate_Change', 0.011613080278038979)","('Employee_Engagement_Inclusion_And_Diversity', 0.008216350339353085)","(['Human Capital Development', 'Innovation Management'], 0.9031864404678345)","('NON-ESG', 0.011613080278038979)","('NON-ESG', 0.008216350339353085)"
Line 198,"Employees have connected with each other through our Employee Resource Groups at an unprecedented rate over the pandemic, bolstering connectivity and embracing a culture of inclusion (read more on page 29) .","('Employee_Engagement_Inclusion_And_Diversity', 0.9588482975959778)","('Human_Rights_And_Community_Relations', 0.0061531951650977135)","('Employee_Health_And_Safety', 0.00488152913749218)","(['Talent Attraction & Retention'], 0.9588482975959778)","('NON-ESG', 0.0061531951650977135)","('NON-ESG', 0.00488152913749218)"
Line 199,"During the first half of 2021, as scientific evidence grew showing overwhelmingly that widespread vaccination was the most effective measure to protect communities from serious illness and limit the spread of COVID-19, we developed a dedicated COVID-19 vaccine internal webpage and education materials for staff and leaders to enhance greater awareness of the benefits of vaccines .","('Employee_Health_And_Safety', 0.7555466890335083)","('Product_Quality_And_Safety', 0.04879637062549591)","('Access_And_Affordability', 0.03762463480234146)","(['Health Outcome Contribution'], 0.7555466890335083)","('NON-ESG', 0.04879637062549591)","('NON-ESG', 0.03762463480234146)"
Line 200,We implemented a requirement for U .,"('Management_Of_Legal_And_Regulatory_Framework', 0.6737479567527771)","('Competitive_Behavior', 0.039131879806518555)","('Human_Rights_And_Community_Relations', 0.038710884749889374)","([], 0.6737479567527771)","('NON-ESG', 0.039131879806518555)","('NON-ESG', 0.038710884749889374)"
Line 201,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 202,"and Puerto Rico staff and certain contractors, particularly those working at our sites, to be fully vaccinated by November 1, 2021 .6 We strongly encouraged staff outside of the United States to receive the COVID-19 vaccination when it became available to them .","('Employee_Health_And_Safety', 0.3790660500526428)","('Access_And_Affordability', 0.13424184918403625)","('Product_Quality_And_Safety', 0.07128211110830307)","('NON-ESG', 0.3790660500526428)","('NON-ESG', 0.13424184918403625)","('NON-ESG', 0.07128211110830307)"
Line 203,"In 2021, Amgen hosted an on-site vaccination clinic at its largest manufacturing facility in Juncos, Puerto Rico, where more than 1,000 staff members received their first dose of the COVID-19 vaccine.","('Employee_Health_And_Safety', 0.49379709362983704)","('Product_Quality_And_Safety', 0.10902552306652069)","('Access_And_Affordability', 0.060747940093278885)","('NON-ESG', 0.49379709362983704)","('NON-ESG', 0.10902552306652069)","('NON-ESG', 0.060747940093278885)"
Line 204,"Despite the challenges of the pandemic, the site maintained full production capacity throughout 2020 and 2021.","('Energy_Management', 0.2730153799057007)","('Physical_Impacts_Of_Climate_Change', 0.17000626027584076)","('Supply_Chain_Management', 0.11398717015981674)","('NON-ESG', 0.2730153799057007)","('NON-ESG', 0.17000626027584076)","('NON-ESG', 0.11398717015981674)"
Line 205,COVID-19 RESPONSE 6 This vaccination requirement did not apply to staff who were unable to receive a COVID-19 vaccine because of qualifying medical or religious reasons .,"('Access_And_Affordability', 0.4295051395893097)","('Employee_Health_And_Safety', 0.15335404872894287)","('Product_Quality_And_Safety', 0.10087926685810089)","('NON-ESG', 0.4295051395893097)","('NON-ESG', 0.15335404872894287)","('NON-ESG', 0.10087926685810089)"
Line 206,"Introduction COVID-19 Response 13 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Healthy People Healthy Society Healthy Planet A Healthy Amgen Appendix Based on the data collected, deCODE completed studies of both humoral and cellular immunity against COVID-19, publishing results in two papers in the New England Journal of Medicine .","('Human_Rights_And_Community_Relations', 0.19822253286838531)","('Access_And_Affordability', 0.1825036108493805)","('Ecological_Impacts', 0.10995718836784363)","('NON-ESG', 0.19822253286838531)","('NON-ESG', 0.1825036108493805)","('NON-ESG', 0.10995718836784363)"
Line 207,"It also studied the long-term consequences of the virus, developing models for assessing the impact of vaccination against the COVID-19 virus and its spread among the unvaccinated .","('Physical_Impacts_Of_Climate_Change', 0.11475860327482224)","('Data_Security', 0.10950018465518951)","('Water_And_Wastewater_Management', 0.1083260104060173)","('NON-ESG', 0.11475860327482224)","('NON-ESG', 0.10950018465518951)","('NON-ESG', 0.1083260104060173)"
Line 208,"Helping Iceland Control COVID-19 Through Genetic Research As early as July 2020, world health officials were praising the efforts of Iceland in its control and prevention of COVID-19 .","('Customer_Welfare', 0.17616425454616547)","('Access_And_Affordability', 0.13768327236175537)","('Product_Quality_And_Safety', 0.10890263319015503)","('NON-ESG', 0.17616425454616547)","('NON-ESG', 0.13768327236175537)","('NON-ESG', 0.10890263319015503)"
Line 209,"Meanwhile, healthcare officials in the country itself were praising the contributions of Amgens subsidiary in Iceland, deCODE Genetics, for its support in helping them get ahead of the rapidly spreading virus .","('Systemic_Risk_Management', 0.1504237800836563)","('Physical_Impacts_Of_Climate_Change', 0.13803832232952118)","('Data_Security', 0.1046358272433281)","('NON-ESG', 0.1504237800836563)","('NON-ESG', 0.13803832232952118)","('NON-ESG', 0.1046358272433281)"
Line 210,"In 2020, researchers at deCODE began working with the Icelandic government to screen for COVID-19 among those who were asymptomatic and those diagnosed and symptomatic .","('Access_And_Affordability', 0.3789445757865906)","('Product_Quality_And_Safety', 0.09858180582523346)","('Employee_Engagement_Inclusion_And_Diversity', 0.0657816007733345)","('NON-ESG', 0.3789445757865906)","('NON-ESG', 0.09858180582523346)","('NON-ESG', 0.0657816007733345)"
Line 211,They then sequenced the virus from all diagnosed with COVID-19 and continued doing so throughout 2021 .,"('Systemic_Risk_Management', 0.10183379054069519)","('Access_And_Affordability', 0.10082561522722244)","('Ecological_Impacts', 0.090567946434021)","('NON-ESG', 0.10183379054069519)","('NON-ESG', 0.10082561522722244)","('NON-ESG', 0.090567946434021)"
Line 212,"To date, Iceland is the only country in the world where COVID-19 has been fully sequenced in all patients diagnosed with the virus .","('Access_And_Affordability', 0.09965213388204575)","('Selling_Practices_And_Product_Labeling', 0.08408612757921219)","('Customer_Welfare', 0.08016128093004227)","('NON-ESG', 0.09965213388204575)","('NON-ESG', 0.08408612757921219)","('NON-ESG', 0.08016128093004227)"
Line 213,"According to health officials, this large scale and early testing conducted by deCODE gave the country the information it needed to tailor its response to the pandemic .","('Critical_Incident_Risk_Management', 0.3872194290161133)","('Physical_Impacts_Of_Climate_Change', 0.14854449033737183)","('Air_Quality', 0.07149158418178558)","('NON-ESG', 0.3872194290161133)","('NON-ESG', 0.14854449033737183)","('NON-ESG', 0.07149158418178558)"
Line 214,"It is evident now that deCODEs screening gave us valuable insight into the situation, said Iunn Gararsdottir, Political Advisor to Icelandic Health Minister Svandis Svavarsdottir .7Supporting Communities During COVID-19 Building on our efforts in 2020 when Amgen and the Amgen Foundation committed up to $12 .5 million to support COVID-19 relief efforts, in 2021 the Amgen Foundation donated an additional $1 .25 million to organizations continuing to assist countries around the world .","('Human_Rights_And_Community_Relations', 0.2528682053089142)","('Management_Of_Legal_And_Regulatory_Framework', 0.22649434208869934)","('Access_And_Affordability', 0.20421631634235382)","('NON-ESG', 0.2528682053089142)","('NON-ESG', 0.22649434208869934)","('NON-ESG', 0.20421631634235382)"
Line 215,"Our support in 2021 included a $500,000 grant to Direct Relief, helping them provide portable oxygen concentrators to hard-hit India .","('Critical_Incident_Risk_Management', 0.7948006391525269)","('Access_And_Affordability', 0.053447019308805466)","('Employee_Health_And_Safety', 0.02668391726911068)","([], 0.7948006391525269)","('NON-ESG', 0.053447019308805466)","('NON-ESG', 0.02668391726911068)"
Line 216,"The Amgen Foundation also matched staff donations to Direct Relief, Project Hope, International Medical Corps, American India Foundation, CARE, Ekal Vidyalaya Foundation of USA, and Oxygen for India for COVID-19 relief and recovery efforts .","('Critical_Incident_Risk_Management', 0.44135233759880066)","('Access_And_Affordability', 0.22342552244663239)","('Human_Rights_And_Community_Relations', 0.0965963676571846)","('NON-ESG', 0.44135233759880066)","('NON-ESG', 0.22342552244663239)","('NON-ESG', 0.0965963676571846)"
Line 217,"In addition, Amgen donated COVID-19 testing equipment, consumables such as thermometers and gloves, and personal protective gear to those on the front line and at greatest risk .","('Employee_Health_And_Safety', 0.9192100763320923)","('Product_Design_And_Lifecycle_Management', 0.016933629289269447)","('Product_Quality_And_Safety', 0.009216985665261745)","(['Health Outcome Contribution'], 0.9192100763320923)","('NON-ESG', 0.016933629289269447)","('NON-ESG', 0.009216985665261745)"
Line 218,"MORE INFORMATION COVID-19 Response$1.25M donated to organizations assisting countries battling COVID-19 $500,000 grant to Direct Relief, helping them provide portable oxygen concentrators to hard-hit IndiaCOVID-19 RESPONSE 7 Controlling and Preventing Infection Spread in Iceland .14 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix Healthy People HEALTHY PEOPLE We focus on removing barriers that limit equitable access to healthcare so that people can live their healthiest lives.","('Access_And_Affordability', 0.46885761618614197)","('Employee_Health_And_Safety', 0.17811162769794464)","('Human_Rights_And_Community_Relations', 0.06157219782471657)","('NON-ESG', 0.46885761618614197)","('NON-ESG', 0.17811162769794464)","('NON-ESG', 0.06157219782471657)"
Line 219,"MORE INFORMATION COVID-19 Response$1.25M donated to organizations assisting countries battling COVID-19 $500,000 grant to Direct Relief, helping them provide portable oxygen concentrators to hard-hit IndiaCOVID-19 RESPONSE 7 Controlling and Preventing Infection Spread in Iceland .14 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix Healthy People HEALTHY PEOPLE We focus on removing barriers that limit equitable access to healthcare so that people can live their healthiest lives.","('Access_And_Affordability', 0.30895477533340454)","('Employee_Health_And_Safety', 0.23667988181114197)","('Product_Quality_And_Safety', 0.09918007254600525)","('NON-ESG', 0.30895477533340454)","('NON-ESG', 0.23667988181114197)","('NON-ESG', 0.09918007254600525)"
Line 220,"Provided approximately $2.2B* of Amgen medicines at no cost to uninsured or underinsured patients in the United States through the Amgen Safety Net FoundationProvided $147M* of Amgen medicines at no cost to underserved patients in more than 20 low- and middle-income countries since 2018Contributed $ 11.7M in funding to support health equity activities *Valued at wholesale acquisition cost .2021 HighlightsHealthy People 15 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix Our approach includes: Making our products more accessible through responsible pricing, patient support programs and targeted donation programs .","('Access_And_Affordability', 0.9093380570411682)","('Product_Quality_And_Safety', 0.011466516181826591)","('Customer_Welfare', 0.007141765672713518)","(['Access to Healthcare'], 0.9093380570411682)","('NON-ESG', 0.011466516181826591)","('NON-ESG', 0.007141765672713518)"
Line 221,"Provided approximately $2.2B* of Amgen medicines at no cost to uninsured or underinsured patients in the United States through the Amgen Safety Net FoundationProvided $147M* of Amgen medicines at no cost to underserved patients in more than 20 low- and middle-income countries since 2018Contributed $ 11.7M in funding to support health equity activities *Valued at wholesale acquisition cost .2021 HighlightsHealthy People 15 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix Our approach includes: Making our products more accessible through responsible pricing, patient support programs and targeted donation programs .","('Product_Design_And_Lifecycle_Management', 0.5900047421455383)","('Customer_Welfare', 0.1657804250717163)","('Selling_Practices_And_Product_Labeling', 0.06615278869867325)","([], 0.5900047421455383)","('NON-ESG', 0.1657804250717163)","('NON-ESG', 0.06615278869867325)"
Line 222,Addressing underlying social factors that can have a greater impact on health than clinical factors .,"('Human_Rights_And_Community_Relations', 0.8935278058052063)","('Business_Model_Resilience', 0.01336855161935091)","('Access_And_Affordability', 0.011193521320819855)","([], 0.8935278058052063)","('NON-ESG', 0.01336855161935091)","('NON-ESG', 0.011193521320819855)"
Line 223,"Working with partners to strengthen health systems and support health equity by Enhancing the knowledge, skills, and expertise of health workers to deliver proven, science-based care .","('Employee_Health_And_Safety', 0.7850930094718933)","('Access_And_Affordability', 0.06643429398536682)","('Customer_Welfare', 0.01638263836503029)","(['Health Outcome Contribution'], 0.7850930094718933)","('NON-ESG', 0.06643429398536682)","('NON-ESG', 0.01638263836503029)"
Line 224,"Supporting patients throughout their healthcare journey, from diagnosis and screening to treatment adherence .","('Access_And_Affordability', 0.8128719925880432)","('Employee_Health_And_Safety', 0.031117551028728485)","('Product_Quality_And_Safety', 0.02046757936477661)","(['Access to Healthcare'], 0.8128719925880432)","('NON-ESG', 0.031117551028728485)","('NON-ESG', 0.02046757936477661)"
Line 225,Educating patients and improving health literacy .,"('Access_And_Affordability', 0.8232365250587463)","('Employee_Health_And_Safety', 0.033895671367645264)","('Critical_Incident_Risk_Management', 0.023968379944562912)","(['Access to Healthcare'], 0.8232365250587463)","('NON-ESG', 0.033895671367645264)","('NON-ESG', 0.023968379944562912)"
Line 226,Increasing the representation of racial and ethnic minority patient populations in clinical trials .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9732349514961243)","('Employee_Health_And_Safety', 0.0021236625034362078)","('Human_Rights_And_Community_Relations', 0.0020865104161202908)","(['Talent Attraction & Retention'], 0.9732349514961243)","('NON-ESG', 0.0021236625034362078)","('NON-ESG', 0.0020865104161202908)"
Line 227,Strengthening community and care support systems that impact access to healthcare for underserved communities .,"('Access_And_Affordability', 0.946092963218689)","('Critical_Incident_Risk_Management', 0.005855016876012087)","('Human_Rights_And_Community_Relations', 0.004421664401888847)","(['Access to Healthcare'], 0.946092963218689)","('NON-ESG', 0.005855016876012087)","('NON-ESG', 0.004421664401888847)"
Line 228,"This section includes: For more than 40 years, Amgens commitment to science and innovation has helped patients live longer, healthier lives.","('Access_And_Affordability', 0.4835417568683624)","('Product_Design_And_Lifecycle_Management', 0.0774741917848587)","('Employee_Health_And_Safety', 0.07275136560201645)","('NON-ESG', 0.4835417568683624)","('NON-ESG', 0.0774741917848587)","('NON-ESG', 0.07275136560201645)"
Line 229,"We support initiatives to advance health equity so that more people can experience the benefits of science, including through improved access to life-saving medicines and care.","('Access_And_Affordability', 0.8712027072906494)","('Customer_Welfare', 0.013596129603683949)","('Product_Quality_And_Safety', 0.013293086551129818)","(['Access to Healthcare'], 0.8712027072906494)","('NON-ESG', 0.013596129603683949)","('NON-ESG', 0.013293086551129818)"
Line 230,"We use a portfolio of approaches to address challenges to access, working with governments, patient groups, civil society, and other partners.","('Access_And_Affordability', 0.8801237344741821)","('Human_Rights_And_Community_Relations', 0.02635285072028637)","('Critical_Incident_Risk_Management', 0.0077596199698746204)","(['Access to Healthcare'], 0.8801237344741821)","('NON-ESG', 0.02635285072028637)","('NON-ESG', 0.0077596199698746204)"
Line 231,"HEAL TH EQUITYACCESS TO MEDICINESHEALTHY PEOPLE AMBITION Our commitment to patients, science, and innovation motivates us to work to remove barriers that limit equitable access to high- quality medicine and healthcare .","('Access_And_Affordability', 0.6777470111846924)","('Customer_Welfare', 0.05470215529203415)","('Product_Quality_And_Safety', 0.03181279078125954)","(['Access to Healthcare'], 0.6777470111846924)","('NON-ESG', 0.05470215529203415)","('NON-ESG', 0.03181279078125954)"
Line 232,"These barriers are present around the world, but they vary significantly by geography and community, and tend to be particularly high in those communities that have been historically underserved .","('Access_And_Affordability', 0.9438847899436951)","('Human_Rights_And_Community_Relations', 0.0051905568689107895)","('Product_Quality_And_Safety', 0.004943741951137781)","(['Access to Healthcare'], 0.9438847899436951)","('NON-ESG', 0.0051905568689107895)","('NON-ESG', 0.004943741951137781)"
Line 233,"Healthy People 16 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix Patient Support Activities The Amgen Safety Net Foundation (ASNF)8 supports qualifying patients in the United States who might go without important medicines because of financial barriers .","('Access_And_Affordability', 0.30104249715805054)","('Product_Quality_And_Safety', 0.1611117422580719)","('Employee_Health_And_Safety', 0.11378137767314911)","('NON-ESG', 0.30104249715805054)","('NON-ESG', 0.1611117422580719)","('NON-ESG', 0.11378137767314911)"
Line 234,"In 2021, the commercial value of the Amgen medicines provided at no cost to uninsured or underinsured patients by ASNF was approximately $2 .2 billion .9 Outside of the United States, we continued to offer financial patient support programs in 20 middle-income countries designed to help clinically and financially eligible patients obtain the medicines they need while they await reimbursement .","('Access_And_Affordability', 0.7046025991439819)","('Customer_Welfare', 0.033483728766441345)","('Product_Quality_And_Safety', 0.030840860679745674)","(['Access to Healthcare'], 0.7046025991439819)","('NON-ESG', 0.033483728766441345)","('NON-ESG', 0.030840860679745674)"
Line 235,"These programs limit patient out-of-pocket costs for certain treatments, including for multiple myeloma, giant cell tumor of the bone, homozygous familial hypercholesterolemia, metastatic colorectal cancer, cancer-related bone complications, and acute lymphoblastic leukemia .","('Access_And_Affordability', 0.40644484758377075)","('Product_Quality_And_Safety', 0.0757639929652214)","('Employee_Health_And_Safety', 0.057305146008729935)","('NON-ESG', 0.40644484758377075)","('NON-ESG', 0.0757639929652214)","('NON-ESG', 0.057305146008729935)"
Line 236,"Working With Partners to Reach Patients In 2021, our longtime partner Direct Relief distributed Amgen products we donated to support underserved patients in more than 20 countries, from Haiti and India to Liberia and Syria .","('Access_And_Affordability', 0.9261921048164368)","('Energy_Management', 0.007965268567204475)","('Product_Quality_And_Safety', 0.007014803122729063)","(['Access to Healthcare'], 0.9261921048164368)","('NON-ESG', 0.007965268567204475)","('NON-ESG', 0.007014803122729063)"
Line 237,"In total, medicines donated provided more than 900,000 daily doses of treatment to patients .","('Access_And_Affordability', 0.2621808648109436)","('Customer_Welfare', 0.256071001291275)","('Selling_Practices_And_Product_Labeling', 0.08944933861494064)","('NON-ESG', 0.2621808648109436)","('NON-ESG', 0.256071001291275)","('NON-ESG', 0.08944933861494064)"
Line 238,"Our Approach to Responsible Pricing Every day, we work to discover, develop and deliver breakthrough medicines that make a difference to patients lives and address some of societys most serious diseases .","('Access_And_Affordability', 0.23390789330005646)","('Customer_Welfare', 0.16683679819107056)","('Selling_Practices_And_Product_Labeling', 0.13004820048809052)","('NON-ESG', 0.23390789330005646)","('NON-ESG', 0.16683679819107056)","('NON-ESG', 0.13004820048809052)"
Line 239,"Innovative medicines offer our best opportunity to effectively manage disease and contain long-term healthcare costs, which is why Amgen prices its medicines responsibly, partners with payers to align on value, and develops patient support programs to help ensure broad access to our novel therapies for appropriate patients .","('Access_And_Affordability', 0.38378408551216125)","('Customer_Welfare', 0.19361482560634613)","('Selling_Practices_And_Product_Labeling', 0.06591898202896118)","('NON-ESG', 0.38378408551216125)","('NON-ESG', 0.19361482560634613)","('NON-ESG', 0.06591898202896118)"
Line 240,Amgen understands that the cost of prescription medicines is a concern for many people .,"('Selling_Practices_And_Product_Labeling', 0.3327729105949402)","('Customer_Welfare', 0.1137094497680664)","('Energy_Management', 0.08949010819196701)","('NON-ESG', 0.3327729105949402)","('NON-ESG', 0.1137094497680664)","('NON-ESG', 0.08949010819196701)"
Line 241,We are committed to the responsible pricing of our medicines by considering their economic and social value and the clinical and economic burden of diseases .,"('Management_Of_Legal_And_Regulatory_Framework', 0.29703137278556824)","('Access_And_Affordability', 0.14733737707138062)","('Competitive_Behavior', 0.14389657974243164)","('NON-ESG', 0.29703137278556824)","('NON-ESG', 0.14733737707138062)","('NON-ESG', 0.14389657974243164)"
Line 242,"In each of the years since 2018, the average net price for Amgen medicines has declined .","('Selling_Practices_And_Product_Labeling', 0.13878431916236877)","('Systemic_Risk_Management', 0.1382756382226944)","('Competitive_Behavior', 0.1330992877483368)","('NON-ESG', 0.13878431916236877)","('NON-ESG', 0.1382756382226944)","('NON-ESG', 0.1330992877483368)"
Line 243,"In addition to responsible pricing, Amgen has implemented value-based contracting to help improve patient access to innovative medicines and offer stakeholders greater budget predictability .","('Access_And_Affordability', 0.40976035594940186)","('Customer_Welfare', 0.12657798826694489)","('Management_Of_Legal_And_Regulatory_Framework', 0.07144636660814285)","('NON-ESG', 0.40976035594940186)","('NON-ESG', 0.12657798826694489)","('NON-ESG', 0.07144636660814285)"
Line 244,"Also, our high-quality biosimilars are backed by four decades of biologics expertise and can potentially offer more affordable, life-altering treatment options that contribute to the sustainability of our healthcare system .","('Customer_Welfare', 0.3937040865421295)","('Access_And_Affordability', 0.14425092935562134)","('Product_Design_And_Lifecycle_Management', 0.08186344802379608)","('NON-ESG', 0.3937040865421295)","('NON-ESG', 0.14425092935562134)","('NON-ESG', 0.08186344802379608)"
Line 245,VALUE CREATION Providing access to our medicines is an extension of Amgens mission to serve patients.,"('Access_And_Affordability', 0.7384555339813232)","('Customer_Welfare', 0.04127156734466553)","('Selling_Practices_And_Product_Labeling', 0.02764817886054516)","(['Access to Healthcare'], 0.7384555339813232)","('NON-ESG', 0.04127156734466553)","('NON-ESG', 0.02764817886054516)"
Line 246,"Through our access to medicines programs, we work with partners to expand access to our medicines and support efforts to strengthen healthcare systems to better serve patients in need worldwide .","('Access_And_Affordability', 0.8725951313972473)","('Energy_Management', 0.012931427918374538)","('Customer_Welfare', 0.012671512551605701)","(['Access to Healthcare'], 0.8725951313972473)","('NON-ESG', 0.012931427918374538)","('NON-ESG', 0.012671512551605701)"
Line 247,"Amgens medicines make a difference for those facing serious illnesses, and together with partners and stakeholders, we are working to overcome access challenges and improve care capabilities through a multifaceted approach tailored to the unique aspects of biologic medicines.","('Access_And_Affordability', 0.5129862427711487)","('Product_Quality_And_Safety', 0.08452419936656952)","('Employee_Health_And_Safety', 0.0680101066827774)","(['Access to Healthcare'], 0.5129862427711487)","('NON-ESG', 0.08452419936656952)","('NON-ESG', 0.0680101066827774)"
Line 248,ACCESS TO MEDICINES 8 Amgen Safety Net Foundation is a separate legal entity funded solely by Amgen .,"('Product_Quality_And_Safety', 0.5317255854606628)","('Selling_Practices_And_Product_Labeling', 0.10888365656137466)","('Customer_Welfare', 0.08475527167320251)","(['Product Quality & Recall Management'], 0.5317255854606628)","('NON-ESG', 0.10888365656137466)","('NON-ESG', 0.08475527167320251)"
Line 249,9Valued at wholesale acquisition cost .,"('Competitive_Behavior', 0.27365797758102417)","('Energy_Management', 0.2437199503183365)","('Management_Of_Legal_And_Regulatory_Framework', 0.18777398765087128)","('NON-ESG', 0.27365797758102417)","('NON-ESG', 0.2437199503183365)","('NON-ESG', 0.18777398765087128)"
Line 250,"LEARN MORE ABOUT Amgens Approach to Responsible PricingHealthy People 17 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix Direct Relief is honored to partner with Amgen as we support the provision of innovative therapies to patients living in medically underserved areas that lack regular access to their required therapies, says D .","('Access_And_Affordability', 0.9404032826423645)","('Product_Quality_And_Safety', 0.00673202658072114)","('Human_Rights_And_Community_Relations', 0.0045126029290258884)","(['Access to Healthcare'], 0.9404032826423645)","('NON-ESG', 0.00673202658072114)","('NON-ESG', 0.0045126029290258884)"
Line 251,"Thomas Roane, Vice President, Corporate Engagement & Strategy at Direct Relief .","('Business_Model_Resilience', 0.5072134137153625)","('Human_Rights_And_Community_Relations', 0.09085611999034882)","('Management_Of_Legal_And_Regulatory_Framework', 0.04138152673840523)","(['Human Capital Development', 'Innovation Management'], 0.5072134137153625)","('NON-ESG', 0.09085611999034882)","('NON-ESG', 0.04138152673840523)"
Line 252,The Amgen donation enabled tens of thousands of underserved patients to access the medicines they required .,"('Access_And_Affordability', 0.9438601732254028)","('Critical_Incident_Risk_Management', 0.005510645918548107)","('Energy_Management', 0.004636381287127733)","(['Access to Healthcare'], 0.9438601732254028)","('NON-ESG', 0.005510645918548107)","('NON-ESG', 0.004636381287127733)"
Line 253,"In 2022, Amgen is partnering with Direct Relief to support a new global initiative to improve the health and lives of people suffering from breast cancer .","('Employee_Health_And_Safety', 0.5099231004714966)","('Access_And_Affordability', 0.22128523886203766)","('Employee_Engagement_Inclusion_And_Diversity', 0.043151240795850754)","(['Health Outcome Contribution'], 0.5099231004714966)","('NON-ESG', 0.22128523886203766)","('NON-ESG', 0.043151240795850754)"
Line 254,"The Comprehensive Breast Cancer Initiative seeks to expand access to breast cancer education and treatment, including Amgen medicines, for women living in less-developed countries .","('Access_And_Affordability', 0.44085484743118286)","('Employee_Health_And_Safety', 0.16290411353111267)","('Product_Quality_And_Safety', 0.06779122352600098)","('NON-ESG', 0.44085484743118286)","('NON-ESG', 0.16290411353111267)","('NON-ESG', 0.06779122352600098)"
Line 255,"It will also support investments in cancer care infrastructure and workforce, including in diagnosis, treatment, palliative care and supportive care .","('Access_And_Affordability', 0.8173354268074036)","('Employee_Health_And_Safety', 0.04756319522857666)","('Product_Quality_And_Safety', 0.01751384511590004)","(['Access to Healthcare'], 0.8173354268074036)","('NON-ESG', 0.04756319522857666)","('NON-ESG', 0.01751384511590004)"
Line 256,Amgen and Direct Relief will also work with the City Cancer Challenge Foundation in 2022 to advance access to cancer care through evidence-based decision-making .,"('Access_And_Affordability', 0.8317419290542603)","('Employee_Health_And_Safety', 0.025028973817825317)","('Product_Quality_And_Safety', 0.019329482689499855)","(['Access to Healthcare'], 0.8317419290542603)","('NON-ESG', 0.025028973817825317)","('NON-ESG', 0.019329482689499855)"
Line 257,"ACCESS TO MEDICINESExpanding Access to BLINCYTO to Those in Need In 2021, Amgen, together with St .","('Access_And_Affordability', 0.8664367198944092)","('Product_Quality_And_Safety', 0.012900435365736485)","('Human_Rights_And_Community_Relations', 0.010725396685302258)","(['Access to Healthcare'], 0.8664367198944092)","('NON-ESG', 0.012900435365736485)","('NON-ESG', 0.010725396685302258)"
Line 258,"Jude Childrens Hospital and Direct Relief, continued to expand the BLINCYTO Humanitarian Access Program (BHAP) .","('Access_And_Affordability', 0.8935415148735046)","('Critical_Incident_Risk_Management', 0.018315322697162628)","('Employee_Health_And_Safety', 0.009356583468616009)","(['Access to Healthcare'], 0.8935415148735046)","('NON-ESG', 0.018315322697162628)","('NON-ESG', 0.009356583468616009)"
Line 259,"Launched in 2020 in India, the program expanded in 2021 to an additional hospital in India treating pediatric cancer patients with B-cell precursor acute lymphoblastic leukemia (ALL) and to Pakistan .","('Access_And_Affordability', 0.6858860850334167)","('Employee_Health_And_Safety', 0.0391634926199913)","('Product_Quality_And_Safety', 0.03346612676978111)","(['Access to Healthcare'], 0.6858860850334167)","('NON-ESG', 0.0391634926199913)","('NON-ESG', 0.03346612676978111)"
Line 260,We expect to further expand this program in 2022 with the addition of a new hospital in Vietnam .,"('Access_And_Affordability', 0.5785287022590637)","('Critical_Incident_Risk_Management', 0.09210576117038727)","('Employee_Health_And_Safety', 0.05224697291851044)","(['Access to Healthcare'], 0.5785287022590637)","('NON-ESG', 0.09210576117038727)","('NON-ESG', 0.05224697291851044)"
Line 261,"ALL is the most common form of leukemia in children and, if left untreated, can be fatal within weeks .","('Employee_Health_And_Safety', 0.28508374094963074)","('Employee_Engagement_Inclusion_And_Diversity', 0.11758505553007126)","('Access_And_Affordability', 0.10522562265396118)","('NON-ESG', 0.28508374094963074)","('NON-ESG', 0.11758505553007126)","('NON-ESG', 0.10522562265396118)"
Line 262,"Under BHAP , carefully selected and qualified hospitals receive BLINCYTO at no cost, together with medical training and ongoing support of safe administration and patient care .","('Access_And_Affordability', 0.7746972441673279)","('Product_Quality_And_Safety', 0.03702661395072937)","('Employee_Health_And_Safety', 0.036674145609140396)","(['Access to Healthcare'], 0.7746972441673279)","('NON-ESG', 0.03702661395072937)","('NON-ESG', 0.036674145609140396)"
Line 263,"DARRYL SLEEP Chief Medical Officer at AmgenThe impact of a cancer like ALL is devastating for children and their families, and we hope that the access to BLINCYTO brings much needed hope to these patients as they continue their treatment .","('Access_And_Affordability', 0.6074585914611816)","('Employee_Health_And_Safety', 0.07182682305574417)","('Product_Quality_And_Safety', 0.050247084349393845)","(['Access to Healthcare'], 0.6074585914611816)","('NON-ESG', 0.07182682305574417)","('NON-ESG', 0.050247084349393845)"
Line 264,"WORKING WITH PARTNERS TO STRENGTHEN HEAL TH SYSTEMS AND ADVOCATE FOR BETTER CARE In addition to working with our partners to help expand access to our medicines, Amgen collaborates with advocacy groups to address the underlying barriers of access and improve health outcomes for patients around the world .","('Access_And_Affordability', 0.894275963306427)","('Product_Quality_And_Safety', 0.011508926749229431)","('Employee_Health_And_Safety', 0.008674276061356068)","(['Access to Healthcare'], 0.894275963306427)","('NON-ESG', 0.011508926749229431)","('NON-ESG', 0.008674276061356068)"
Line 265,Below are a few recent examples .,"('Systemic_Risk_Management', 0.25341373682022095)","('Business_Model_Resilience', 0.11613224446773529)","('Competitive_Behavior', 0.11357124894857407)","('NON-ESG', 0.25341373682022095)","('NON-ESG', 0.11613224446773529)","('NON-ESG', 0.11357124894857407)"
Line 266,"Building Resilient Health Systems in Europe COVID-19 disrupted healthcare systems around the world, making it difficult and, in some cases, even impossible for many people to access diagnostic services .","('Business_Model_Resilience', 0.7083947658538818)","('Supply_Chain_Management', 0.03718637302517891)","('Product_Design_And_Lifecycle_Management', 0.03277088329195976)","(['Human Capital Development', 'Innovation Management'], 0.7083947658538818)","('NON-ESG', 0.03718637302517891)","('NON-ESG', 0.03277088329195976)"
Line 267,"Delayed diagnosis can have life-threatening impacts on people living with cancer who, if not diagnosed promptly, may be unable to benefit from treatment .","('Access_And_Affordability', 0.3075108528137207)","('Employee_Health_And_Safety', 0.2899332642555237)","('Product_Quality_And_Safety', 0.0905490592122078)","('NON-ESG', 0.3075108528137207)","('NON-ESG', 0.2899332642555237)","('NON-ESG', 0.0905490592122078)"
Line 268,Cold storage for temperature sensitive therapies are staged at Direct Reliefs warehouse before being shipped.,"('Waste_And_Hazardous_Materials_Management', 0.36925411224365234)","('Energy_Management', 0.21739508211612701)","('Supply_Chain_Management', 0.08646366745233536)","('NON-ESG', 0.36925411224365234)","('NON-ESG', 0.21739508211612701)","('NON-ESG', 0.08646366745233536)"
Line 269,"(Lara Cooper/Direct Relief)Healthy People 18 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix ACCESS TO MEDICINES To help address this challenge, in 2021, Amgen sponsored two reports on the collateral impact of COVID-19 on cancer diagnosis in Europe .","('Access_And_Affordability', 0.5711222887039185)","('Human_Rights_And_Community_Relations', 0.0767521858215332)","('Customer_Welfare', 0.05085602030158043)","(['Access to Healthcare'], 0.5711222887039185)","('NON-ESG', 0.0767521858215332)","('NON-ESG', 0.05085602030158043)"
Line 270,"The reports included policy recommendations to help nations reduce wait times for cancer care caused by COVID-related delays, build more resilient healthcare systems, and better weather future crises .","('Business_Model_Resilience', 0.6989376544952393)","('Physical_Impacts_Of_Climate_Change', 0.04155593365430832)","('Access_And_Affordability', 0.029436195269227028)","(['Human Capital Development', 'Innovation Management'], 0.6989376544952393)","('NON-ESG', 0.04155593365430832)","('NON-ESG', 0.029436195269227028)"
Line 271,"In partnership with the European Cancer Organization, the UKs National Screening Committee, the European Cancer Patient Coalition, and other groups, IQVIA Institute for Human Data Science hosted webinars to share findings from the reports with more than 1,000 attendees in over 70 countries .","('Access_And_Affordability', 0.2956501543521881)","('Product_Quality_And_Safety', 0.08938323706388474)","('Management_Of_Legal_And_Regulatory_Framework', 0.0740814134478569)","('NON-ESG', 0.2956501543521881)","('NON-ESG', 0.08938323706388474)","('NON-ESG', 0.0740814134478569)"
Line 272,"There is a positive message from the pandemicif there is a will, there is a way .","('Physical_Impacts_Of_Climate_Change', 0.47183334827423096)","('Critical_Incident_Risk_Management', 0.1567201316356659)","('Air_Quality', 0.07360029220581055)","('NON-ESG', 0.47183334827423096)","('NON-ESG', 0.1567201316356659)","('NON-ESG', 0.07360029220581055)"
Line 273,"All the stakeholders have the possibility to act together and do something for better diagnosis and screening, said Alfonso Alguaron, a patient advocate in Spain, during the Cancer Wont Wait webinar .","('Access_And_Affordability', 0.2919575870037079)","('Employee_Health_And_Safety', 0.16299113631248474)","('Product_Quality_And_Safety', 0.08162727952003479)","('NON-ESG', 0.2919575870037079)","('NON-ESG', 0.16299113631248474)","('NON-ESG', 0.08162727952003479)"
Line 274,MORE INFORMATION Access to MedicinesElevating Awareness of the Risk of Osteoporosis in Mexico Many women may not know they are living with post- menopausal osteoporosis and are at risk of life-threatening bone fractures .,"('Employee_Health_And_Safety', 0.6792869567871094)","('Access_And_Affordability', 0.07278110831975937)","('Employee_Engagement_Inclusion_And_Diversity', 0.0411122664809227)","(['Health Outcome Contribution'], 0.6792869567871094)","('NON-ESG', 0.07278110831975937)","('NON-ESG', 0.0411122664809227)"
Line 275,"In Mexico, many are unaware of the condition, as screening is infrequent and not consistent across the country .","('Systemic_Risk_Management', 0.24884317815303802)","('Access_And_Affordability', 0.17191804945468903)","('Product_Quality_And_Safety', 0.07781197130680084)","('NON-ESG', 0.24884317815303802)","('NON-ESG', 0.17191804945468903)","('NON-ESG', 0.07781197130680084)"
Line 276,"READ THE REPORTS: Cancer Wont Wait Report Lung Cancer Wont Wait ReportWATCH THE WEBINARS: Cancer Wont Wait Webinar Lung Cancer Wont WaitSince 2019, Amgen has worked with medical societies, healthcare providers, and members of government to help elevate the visibility of osteoporosis as a public health issue and build consensus around screening, diagnosis, and treatment protocols, including for post-fracture and secondary prevention .","('Employee_Health_And_Safety', 0.6039589643478394)","('Access_And_Affordability', 0.051693569868803024)","('Product_Quality_And_Safety', 0.051415931433439255)","(['Health Outcome Contribution'], 0.6039589643478394)","('NON-ESG', 0.051693569868803024)","('NON-ESG', 0.051415931433439255)"
Line 277,"In 2021, these collaborative efforts reached a key milestone when seven leading medical societies reached agreement on osteoporosis detection and treatment practices .","('Access_And_Affordability', 0.20846976339817047)","('Customer_Welfare', 0.13035939633846283)","('Product_Quality_And_Safety', 0.12619303166866302)","('NON-ESG', 0.20846976339817047)","('NON-ESG', 0.13035939633846283)","('NON-ESG', 0.12619303166866302)"
Line 278,"With support from Amgen, their recommendations were presented in a special congressional forum of the Mexican Senate and published in a leading clinical journal .","('Management_Of_Legal_And_Regulatory_Framework', 0.5023223161697388)","('Access_And_Affordability', 0.08100195229053497)","('GHG_Emissions', 0.06536857783794403)","([], 0.5023223161697388)","('NON-ESG', 0.08100195229053497)","('NON-ESG', 0.06536857783794403)"
Line 279,"Following the agreement, Amgen sponsored workshops and a social media campaign called Unbreakable Together to help build awareness of the recommendations and new treatment protocols among authorities and healthcare providers in the country .","('Access_And_Affordability', 0.7688165307044983)","('Product_Quality_And_Safety', 0.032003119587898254)","('Employee_Health_And_Safety', 0.02860970050096512)","(['Access to Healthcare'], 0.7688165307044983)","('NON-ESG', 0.032003119587898254)","('NON-ESG', 0.02860970050096512)"
Line 280,"Helping Migraine Sufferers in Japan An estimated 8 .4 million patients in Japan suffer from migraines, with more than one million patients believed to be in need of treatment .","('Employee_Health_And_Safety', 0.1888701617717743)","('Business_Ethics', 0.1351989060640335)","('Product_Quality_And_Safety', 0.12821434438228607)","('NON-ESG', 0.1888701617717743)","('NON-ESG', 0.1351989060640335)","('NON-ESG', 0.12821434438228607)"
Line 281,One challenge many patients face is difficulty finding a headache specialist due to specialist shortages .,"('Employee_Health_And_Safety', 0.4364696443080902)","('Product_Quality_And_Safety', 0.11461441963911057)","('Access_And_Affordability', 0.10159251093864441)","('NON-ESG', 0.4364696443080902)","('NON-ESG', 0.11461441963911057)","('NON-ESG', 0.10159251093864441)"
Line 282,"In addition, many patients find it difficult to see a specialist due to work and caregiving responsibilities .","('Access_And_Affordability', 0.7588662505149841)","('Employee_Health_And_Safety', 0.0892452523112297)","('Critical_Incident_Risk_Management', 0.03189513459801674)","(['Access to Healthcare'], 0.7588662505149841)","('NON-ESG', 0.0892452523112297)","('NON-ESG', 0.03189513459801674)"
Line 283,"This challenge was compounded by COVID-19, which made face-to-face consultation even more difficult .","('Competitive_Behavior', 0.4185847043991089)","('Management_Of_Legal_And_Regulatory_Framework', 0.10851650685071945)","('Systemic_Risk_Management', 0.0763690173625946)","('NON-ESG', 0.4185847043991089)","('NON-ESG', 0.10851650685071945)","('NON-ESG', 0.0763690173625946)"
Line 284,"Partnering with MICIN, Amgen launched a pilot program to assess the usefulness of telemedicine for patients in Japan living with migraines .","('Employee_Health_And_Safety', 0.175299733877182)","('Product_Quality_And_Safety', 0.14528943598270416)","('Business_Ethics', 0.12382003664970398)","('NON-ESG', 0.175299733877182)","('NON-ESG', 0.14528943598270416)","('NON-ESG', 0.12382003664970398)"
Line 285,Findings from the pilot demonstrated that telemedicine can help patients manage their care .,"('Access_And_Affordability', 0.7226151823997498)","('Critical_Incident_Risk_Management', 0.05400754138827324)","('Employee_Health_And_Safety', 0.04440854489803314)","(['Access to Healthcare'], 0.7226151823997498)","('NON-ESG', 0.05400754138827324)","('NON-ESG', 0.04440854489803314)"
Line 286,Amgen is also working with the Japanese Headache Society to continue to support the needs of migraine patients .,"('Employee_Health_And_Safety', 0.26422902941703796)","('Product_Quality_And_Safety', 0.09900815039873123)","('Business_Ethics', 0.09406140446662903)","('NON-ESG', 0.26422902941703796)","('NON-ESG', 0.09900815039873123)","('NON-ESG', 0.09406140446662903)"
Line 287,ACCESS TO MEDICINES DATA 2019 2020 2021$1.4B*$1.5B*$2.2B*Amgen Safety Net Foundation Value of medicines provided at no cost to low-income patients in the United States through the Amgen Safety Net Foundation Direct Relief Value of medicines provided at no cost in low- and middle-income countries through Direct Relief from 2018 through 2021 $147M* *Valued at wholesale acquisition cost .,"('Access_And_Affordability', 0.2595575451850891)","('Product_Quality_And_Safety', 0.2155691236257553)","('Customer_Welfare', 0.1171206459403038)","('NON-ESG', 0.2595575451850891)","('NON-ESG', 0.2155691236257553)","('NON-ESG', 0.1171206459403038)"
Line 288,"Healthy People Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix 19 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021Introduction STRENGTHENING PEDIATRIC CANCER CARE IN TANZANIA The vial filled with a critical $500 cancer treatment for a sick child in Tanzania was delivered in what amounted to a picnic cooler stuffed with ice .","('Access_And_Affordability', 0.6168120503425598)","('Employee_Health_And_Safety', 0.13098874688148499)","('Product_Quality_And_Safety', 0.030816596001386642)","(['Access to Healthcare'], 0.6168120503425598)","('NON-ESG', 0.13098874688148499)","('NON-ESG', 0.030816596001386642)"
Line 289,It might as well have arrived empty .,"('Waste_And_Hazardous_Materials_Management', 0.21361401677131653)","('Competitive_Behavior', 0.09558427333831787)","('Product_Design_And_Lifecycle_Management', 0.06296830624341965)","('NON-ESG', 0.21361401677131653)","('NON-ESG', 0.09558427333831787)","('NON-ESG', 0.06296830624341965)"
Line 290,"The humid, subtropical climate had already taken its toll .","('Ecological_Impacts', 0.4227777123451233)","('Physical_Impacts_Of_Climate_Change', 0.18529078364372253)","('Business_Model_Resilience', 0.09391337633132935)","('NON-ESG', 0.4227777123451233)","('NON-ESG', 0.18529078364372253)","('NON-ESG', 0.09391337633132935)"
Line 291,Dr .,"('Management_Of_Legal_And_Regulatory_Framework', 0.124688521027565)","('Competitive_Behavior', 0.11675971746444702)","('Product_Quality_And_Safety', 0.09105435758829117)","('NON-ESG', 0.124688521027565)","('NON-ESG', 0.11675971746444702)","('NON-ESG', 0.09105435758829117)"
Line 292,"Trish Scanlan said the medicine, which must be kept at a temperature between 2 and 8 degrees Celsius, had arrived from Dar Es Salam in the loose, insecure package .","('Selling_Practices_And_Product_Labeling', 0.23785361647605896)","('Customer_Welfare', 0.19474247097969055)","('Waste_And_Hazardous_Materials_Management', 0.12636835873126984)","('NON-ESG', 0.23785361647605896)","('NON-ESG', 0.19474247097969055)","('NON-ESG', 0.12636835873126984)"
Line 293,"Over the hours on its journey, the medicine had warmed .","('Customer_Welfare', 0.19798143208026886)","('Access_And_Affordability', 0.12139500677585602)","('Waste_And_Hazardous_Materials_Management', 0.08344412595033646)","('NON-ESG', 0.19798143208026886)","('NON-ESG', 0.12139500677585602)","('NON-ESG', 0.08344412595033646)"
Line 294,It was useless .,"('Access_And_Affordability', 0.09389371424913406)","('Waste_And_Hazardous_Materials_Management', 0.0890999510884285)","('Product_Design_And_Lifecycle_Management', 0.06572814285755157)","('NON-ESG', 0.09389371424913406)","('NON-ESG', 0.0890999510884285)","('NON-ESG', 0.06572814285755157)"
Line 295,"An absolute disaster, Scanlan said .","('Critical_Incident_Risk_Management', 0.9351663589477539)","('Employee_Health_And_Safety', 0.010083415545523167)","('Physical_Impacts_Of_Climate_Change', 0.007071889005601406)","([], 0.9351663589477539)","('NON-ESG', 0.010083415545523167)","('NON-ESG', 0.007071889005601406)"
Line 296,It meant the cancer was getting a break in a child who needs that medicine now .,"('Access_And_Affordability', 0.30803006887435913)","('Employee_Health_And_Safety', 0.17087140679359436)","('Employee_Engagement_Inclusion_And_Diversity', 0.06055719777941704)","('NON-ESG', 0.30803006887435913)","('NON-ESG', 0.17087140679359436)","('NON-ESG', 0.06055719777941704)"
Line 297,"For Scanlan, director of the nonprofit childrens cancer charity Tumaini La Maisha, seeing medicine being wasted was too much .","('Access_And_Affordability', 0.6691489219665527)","('Employee_Health_And_Safety', 0.0372898131608963)","('Critical_Incident_Risk_Management', 0.032926786690950394)","(['Access to Healthcare'], 0.6691489219665527)","('NON-ESG', 0.0372898131608963)","('NON-ESG', 0.032926786690950394)"
Line 298,"In 2021, she found help through a California-based nonprofit, Direct Relief, and Amgen .","('Access_And_Affordability', 0.47090861201286316)","('Human_Rights_And_Community_Relations', 0.07407452166080475)","('Critical_Incident_Risk_Management', 0.07096432149410248)","('NON-ESG', 0.47090861201286316)","('NON-ESG', 0.07407452166080475)","('NON-ESG', 0.07096432149410248)"
Line 299,"Both stepped in, supporting Muhimbili National Hospital and Tumaini La Maisha with a cold room that cost nearly $20,000 that keeps medicines at the low temperatures needed .","('Employee_Health_And_Safety', 0.16782844066619873)","('Air_Quality', 0.14584271609783173)","('Critical_Incident_Risk_Management', 0.13873594999313354)","('NON-ESG', 0.16782844066619873)","('NON-ESG', 0.14584271609783173)","('NON-ESG', 0.13873594999313354)"
Line 300,"Direct Relief is also supplying Tumaini La Maisha with 50 thermal packages that can be reused for up to five years, while Amgen is donating $12 .5 million10 worth of oncology supportive care medicine .","('Access_And_Affordability', 0.7396719455718994)","('Customer_Welfare', 0.029766373336315155)","('Critical_Incident_Risk_Management', 0.02465999871492386)","(['Access to Healthcare'], 0.7396719455718994)","('NON-ESG', 0.029766373336315155)","('NON-ESG', 0.02465999871492386)"
Line 301,High-Tech Packages The thermal packages began arriving in Tanzania in April .,"('Product_Design_And_Lifecycle_Management', 0.7979002594947815)","('Energy_Management', 0.03428597003221512)","('Supply_Chain_Management', 0.02628353051841259)","([], 0.7979002594947815)","('NON-ESG', 0.03428597003221512)","('NON-ESG', 0.02628353051841259)"
Line 302,"Mike Wooten, Direct Relief cold chain specialist, said the boxes that will carry the cancer treatments are a mix of high-end data technology and old-school durability that shouldnt pose any problems for shipping medicine overnight in Tanzania .","('Customer_Welfare', 0.22509241104125977)","('Product_Quality_And_Safety', 0.1495024561882019)","('Access_And_Affordability', 0.09528688341379166)","('NON-ESG', 0.22509241104125977)","('NON-ESG', 0.1495024561882019)","('NON-ESG', 0.09528688341379166)"
Line 303,"Each package, about 8 liters, has a battery-operated data logger to keep track of the temperatures as the box is transported, to make sure the medications inside never go above the ideal temperatures .","('Energy_Management', 0.3054295778274536)","('Water_And_Wastewater_Management', 0.11742348968982697)","('Waste_And_Hazardous_Materials_Management', 0.07392027229070663)","('NON-ESG', 0.3054295778274536)","('NON-ESG', 0.11742348968982697)","('NON-ESG', 0.07392027229070663)"
Line 304,He said the packages are good for about 80 hours in worst-case weather .,"('Physical_Impacts_Of_Climate_Change', 0.5666646957397461)","('Business_Model_Resilience', 0.17828361690044403)","('Air_Quality', 0.02953176200389862)","([], 0.5666646957397461)","('NON-ESG', 0.17828361690044403)","('NON-ESG', 0.02953176200389862)"
Line 305,"Meanwhile, the cold storage unit will enable bulk purchases for medications without fears of spoiling .","('Waste_And_Hazardous_Materials_Management', 0.4000125527381897)","('Customer_Welfare', 0.11458848416805267)","('Product_Design_And_Lifecycle_Management', 0.08663336932659149)","('NON-ESG', 0.4000125527381897)","('NON-ESG', 0.11458848416805267)","('NON-ESG', 0.08663336932659149)"
Line 306,"The Work Scanlan said about 4,000 children in Tanzania will develop cancer each year, but less than a quarter of those currently seek care .","('Access_And_Affordability', 0.3646465241909027)","('Employee_Health_And_Safety', 0.22794222831726074)","('Product_Quality_And_Safety', 0.07931328564882278)","('NON-ESG', 0.3646465241909027)","('NON-ESG', 0.22794222831726074)","('NON-ESG', 0.07931328564882278)"
Line 307,She said the arrival of the cold chain supplies will allow more children to get life-saving treatment and spend less time in the hospitals .,"('Access_And_Affordability', 0.5000379085540771)","('Employee_Health_And_Safety', 0.21267013251781464)","('Critical_Incident_Risk_Management', 0.07430367171764374)","(['Access to Healthcare'], 0.5000379085540771)","('NON-ESG', 0.21267013251781464)","('NON-ESG', 0.07430367171764374)"
Line 308,"We can send boxes of chemo every week and look after the children in the peripheral areas, Scanlan said .","('Access_And_Affordability', 0.7880923748016357)","('Employee_Health_And_Safety', 0.04984363541007042)","('Critical_Incident_Risk_Management', 0.02586696669459343)","(['Access to Healthcare'], 0.7880923748016357)","('NON-ESG', 0.04984363541007042)","('NON-ESG', 0.02586696669459343)"
Line 309,That means the children have to spend far less time of their life in the hospital and can be at home with their family between treatments .,"('Access_And_Affordability', 0.7778382301330566)","('Employee_Health_And_Safety', 0.04965859651565552)","('Critical_Incident_Risk_Management', 0.02188306488096714)","(['Access to Healthcare'], 0.7778382301330566)","('NON-ESG', 0.04965859651565552)","('NON-ESG', 0.02188306488096714)"
Line 310,"As a cancer survivor herself, Scanlan knows the pain and struggle of the fight .","('Employee_Health_And_Safety', 0.5554384589195251)","('Human_Rights_And_Community_Relations', 0.0798477977514267)","('Access_And_Affordability', 0.059266772121191025)","(['Health Outcome Contribution'], 0.5554384589195251)","('NON-ESG', 0.0798477977514267)","('NON-ESG', 0.059266772121191025)"
Line 311,She said she wont be satisfied until the thousands of children suffering with cancer in Tanzania all have access to treatment .,"('Access_And_Affordability', 0.8245753645896912)","('Employee_Health_And_Safety', 0.029369009658694267)","('Product_Quality_And_Safety', 0.024808749556541443)","(['Access to Healthcare'], 0.8245753645896912)","('NON-ESG', 0.029369009658694267)","('NON-ESG', 0.024808749556541443)"
Line 312,Thats the work .,"('Business_Ethics', 0.22484557330608368)","('Competitive_Behavior', 0.07335207611322403)","('Labor_Practices', 0.07309907674789429)","('NON-ESG', 0.22484557330608368)","('NON-ESG', 0.07335207611322403)","('NON-ESG', 0.07309907674789429)"
Line 313,And the mission .,"('Business_Model_Resilience', 0.2206108421087265)","('Director_Removal', 0.09309475868940353)","('Human_Rights_And_Community_Relations', 0.09144232422113419)","('NON-ESG', 0.2206108421087265)","('NON-ESG', 0.09309475868940353)","('NON-ESG', 0.09144232422113419)"
Line 314,One child at a time .,"('Access_And_Affordability', 0.5272258520126343)","('Employee_Engagement_Inclusion_And_Diversity', 0.08398351818323135)","('Human_Rights_And_Community_Relations', 0.052177418023347855)","(['Access to Healthcare'], 0.5272258520126343)","('NON-ESG', 0.08398351818323135)","('NON-ESG', 0.052177418023347855)"
Line 315,MORE INFORMATION Access to Medicines 10 Valued at wholesale acquisition cost .,"('Selling_Practices_And_Product_Labeling', 0.16419337689876556)","('Access_And_Affordability', 0.14715565741062164)","('Customer_Welfare', 0.14428263902664185)","('NON-ESG', 0.16419337689876556)","('NON-ESG', 0.14715565741062164)","('NON-ESG', 0.14428263902664185)"
Line 316,"Healthy People 20 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix HEAL TH EQUITYThere are significant opportunities to improve the health of all people through understanding and addressing health disparities present in our communities, particularly in key therapeutic areas such as oncology, cardiovascular, and inflammation .","('Employee_Health_And_Safety', 0.6806577444076538)","('Access_And_Affordability', 0.05811137706041336)","('Employee_Engagement_Inclusion_And_Diversity', 0.042849667370319366)","(['Health Outcome Contribution'], 0.6806577444076538)","('NON-ESG', 0.05811137706041336)","('NON-ESG', 0.042849667370319366)"
Line 317,Improving health equity requires addressing both barriers to medical care and social determinants of health .,"('Access_And_Affordability', 0.7750160694122314)","('Human_Rights_And_Community_Relations', 0.05994846671819687)","('Employee_Health_And_Safety', 0.022360440343618393)","(['Access to Healthcare'], 0.7750160694122314)","('NON-ESG', 0.05994846671819687)","('NON-ESG', 0.022360440343618393)"
Line 318,"VALUE CREATION Addressing health disparities helps to expand access to solutions and improve health outcomes for people in underserved communities, while also allowing us to build new relationships and gain unique perspectives and understanding that will allow us to better meet the needs of such patients in the future .","('Access_And_Affordability', 0.9474152326583862)","('Critical_Incident_Risk_Management', 0.004851542413234711)","('Human_Rights_And_Community_Relations', 0.004433727823197842)","(['Access to Healthcare'], 0.9474152326583862)","('NON-ESG', 0.004851542413234711)","('NON-ESG', 0.004433727823197842)"
Line 319,OUR FOCUS AREAS OUR OBJECTIVESOUR VISION Advance policies and practices in support of achieving health equity so that all people have an opportunity to be as healthy as possible Representative product development Expand access to and participation in clinical trials and develop medicines to address unmet needs among historically underserved patientsComprehensive health education Improve health literacy and education among historically underserved patientsAccessible and inclusive healthcare Strengthen community and care support systems and access to medicines for historically underserved patientsAmgen is working to advance policies and practices in support of achieving health equity so that all people have an opportunity to maximize health outcomes .,"('Access_And_Affordability', 0.943773627281189)","('Product_Quality_And_Safety', 0.0052411314100027084)","('Critical_Incident_Risk_Management', 0.004801901988685131)","(['Access to Healthcare'], 0.943773627281189)","('NON-ESG', 0.0052411314100027084)","('NON-ESG', 0.004801901988685131)"
Line 320,OUR FOCUS AREAS OUR OBJECTIVESOUR VISION Advance policies and practices in support of achieving health equity so that all people have an opportunity to be as healthy as possible Representative product development Expand access to and participation in clinical trials and develop medicines to address unmet needs among historically underserved patientsComprehensive health education Improve health literacy and education among historically underserved patientsAccessible and inclusive healthcare Strengthen community and care support systems and access to medicines for historically underserved patientsAmgen is working to advance policies and practices in support of achieving health equity so that all people have an opportunity to maximize health outcomes .,"('Access_And_Affordability', 0.9443051218986511)","('Product_Quality_And_Safety', 0.005541246850043535)","('Human_Rights_And_Community_Relations', 0.004871595185250044)","(['Access to Healthcare'], 0.9443051218986511)","('NON-ESG', 0.005541246850043535)","('NON-ESG', 0.004871595185250044)"
Line 321,"This includes efforts to improve representation in clinical trials and provide comprehensive health education to underserved patients, as well as advocating for policies and programs that support accessible and inclusive healthcare and working with partners to give rise to underrepresented voices .","('Access_And_Affordability', 0.94605553150177)","('Critical_Incident_Risk_Management', 0.004999845754355192)","('Product_Quality_And_Safety', 0.0049889408983290195)","(['Access to Healthcare'], 0.94605553150177)","('NON-ESG', 0.004999845754355192)","('NON-ESG', 0.0049889408983290195)"
Line 322,"Healthy People 21 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix HEAL TH EQUITY SUMMIT FIVE KEY TAKEAWAYS TECHNOLOGY IS A TOOL and a challenge in addressing health disparities .","('Employee_Health_And_Safety', 0.3659230172634125)","('Employee_Engagement_Inclusion_And_Diversity', 0.1297355592250824)","('Human_Rights_And_Community_Relations', 0.11537034064531326)","('NON-ESG', 0.3659230172634125)","('NON-ESG', 0.1297355592250824)","('NON-ESG', 0.11537034064531326)"
Line 323,"PATIENT-CENTRIC, CUL TURALL Y SENSITIVE approach to care is critical .","('Access_And_Affordability', 0.7812621593475342)","('Employee_Health_And_Safety', 0.025478890165686607)","('Human_Rights_And_Community_Relations', 0.02301291562616825)","(['Access to Healthcare'], 0.7812621593475342)","('NON-ESG', 0.025478890165686607)","('NON-ESG', 0.02301291562616825)"
Line 324,COMMUNITY-BASED services form a foundation to address health inequities .,"('Access_And_Affordability', 0.4610033631324768)","('Critical_Incident_Risk_Management', 0.11115892976522446)","('Employee_Health_And_Safety', 0.06699686497449875)","('NON-ESG', 0.4610033631324768)","('NON-ESG', 0.11115892976522446)","('NON-ESG', 0.06699686497449875)"
Line 325,SOCIAL CARE & DIGNITY sit at the heart of health equity .,"('Human_Rights_And_Community_Relations', 0.7137437462806702)","('Access_And_Affordability', 0.1349160373210907)","('Employee_Engagement_Inclusion_And_Diversity', 0.015327580273151398)","([], 0.7137437462806702)","('NON-ESG', 0.1349160373210907)","('NON-ESG', 0.015327580273151398)"
Line 326,COVID-19 has brought years-old health equity issues to the forefront .,"('Access_And_Affordability', 0.5298975706100464)","('Human_Rights_And_Community_Relations', 0.0865989550948143)","('Employee_Engagement_Inclusion_And_Diversity', 0.05665527284145355)","(['Access to Healthcare'], 0.5298975706100464)","('NON-ESG', 0.0865989550948143)","('NON-ESG', 0.05665527284145355)"
Line 327,"Raising the Spotlight on Health Inequities In 2021, we partnered with a national health equity advisory group of state legislators from 16 U .","('Access_And_Affordability', 0.18429483473300934)","('Systemic_Risk_Management', 0.1495364010334015)","('Customer_Welfare', 0.06789140403270721)","('NON-ESG', 0.18429483473300934)","('NON-ESG', 0.1495364010334015)","('NON-ESG', 0.06789140403270721)"
Line 328,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 329,"states and four national caucuses of colorthe National Black Caucus of State Legislators, the National Hispanic Caucus of State Legislators, the National Asian Pacific American Caucus of State Legislators, and the National Caucus of Native American State Legislatorsto support bipartisan dialogue on health equity .","('Employee_Engagement_Inclusion_And_Diversity', 0.9584570527076721)","('Human_Rights_And_Community_Relations', 0.004448072984814644)","('Management_Of_Legal_And_Regulatory_Framework', 0.0029635345563292503)","(['Talent Attraction & Retention'], 0.9584570527076721)","('NON-ESG', 0.004448072984814644)","('NON-ESG', 0.0029635345563292503)"
Line 330,"Through a series of town hall discussions and educational resources, we are working to support policy change that will address barriers to care facing historically underrepresented communities .","('Access_And_Affordability', 0.776983380317688)","('Human_Rights_And_Community_Relations', 0.05611295625567436)","('Employee_Engagement_Inclusion_And_Diversity', 0.02754906564950943)","(['Access to Healthcare'], 0.776983380317688)","('NON-ESG', 0.05611295625567436)","('NON-ESG', 0.02754906564950943)"
Line 331,"Together we can work toward a country where your background, your ZIP code and your income do not determine whether you have access to quality affordable care, said Congressman Raul Ruiz, MD, U .","('Access_And_Affordability', 0.8423852324485779)","('Employee_Engagement_Inclusion_And_Diversity', 0.020641814917325974)","('Product_Quality_And_Safety', 0.015185304917395115)","(['Access to Healthcare'], 0.8423852324485779)","('NON-ESG', 0.020641814917325974)","('NON-ESG', 0.015185304917395115)"
Line 332,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 333,"Representative for Californias 36th Congressional District and Chair of the Congressional Hispanic Caucus, at the 2021 Amgen Health Equity Summit .","('Employee_Engagement_Inclusion_And_Diversity', 0.8936240673065186)","('Access_And_Affordability', 0.019256295636296272)","('Human_Rights_And_Community_Relations', 0.011455902829766273)","(['Talent Attraction & Retention'], 0.8936240673065186)","('NON-ESG', 0.019256295636296272)","('NON-ESG', 0.011455902829766273)"
Line 334,At our 8th Annual Health Equity Summit we focused on disrupting health disparities through partnership .,"('Employee_Health_And_Safety', 0.37971997261047363)","('Access_And_Affordability', 0.12678754329681396)","('Systemic_Risk_Management', 0.07244037836790085)","('NON-ESG', 0.37971997261047363)","('NON-ESG', 0.12678754329681396)","('NON-ESG', 0.07244037836790085)"
Line 335,"The virtual event included more than 500 participants from seven countries representing patient advocacy organizations, physician associations, medical institutions, academia, and the private sector .","('Access_And_Affordability', 0.227945476770401)","('Management_Of_Legal_And_Regulatory_Framework', 0.22658567130565643)","('Human_Rights_And_Community_Relations', 0.08456246554851532)","('NON-ESG', 0.227945476770401)","('NON-ESG', 0.22658567130565643)","('NON-ESG', 0.08456246554851532)"
Line 336,Discussions from the summit yielded five key takeaways .,"('Competitive_Behavior', 0.507881760597229)","('Management_Of_Legal_And_Regulatory_Framework', 0.10345330089330673)","('Business_Model_Resilience', 0.06058556213974953)","([], 0.507881760597229)","('NON-ESG', 0.10345330089330673)","('NON-ESG', 0.06058556213974953)"
Line 337,"HEAL TH EQUITYWorking to Increase Diversity and Improve Representation in Clinical Trials The underrepresentation of racial and ethnic minority patients in clinical trials contributes to the collection of incomplete or limited trial data, limited access to innovative treatment for vulnerable populations, and disparities in health outcomes .","('Employee_Engagement_Inclusion_And_Diversity', 0.9760640859603882)","('Employee_Health_And_Safety', 0.0018376965308561921)","('Human_Rights_And_Community_Relations', 0.001498704543337226)","(['Talent Attraction & Retention'], 0.9760640859603882)","('NON-ESG', 0.0018376965308561921)","('NON-ESG', 0.001498704543337226)"
Line 338,"Barriers to participation include mistrust, lack of awareness, logistical challenges such as transportation, and provider bias .","('Business_Ethics', 0.21519047021865845)","('Competitive_Behavior', 0.17025256156921387)","('Employee_Engagement_Inclusion_And_Diversity', 0.07465958595275879)","('NON-ESG', 0.21519047021865845)","('NON-ESG', 0.17025256156921387)","('NON-ESG', 0.07465958595275879)"
Line 339,Racial and ethnic minority groups have been underrepresented in clinical trials vs .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9734723567962646)","('Human_Rights_And_Community_Relations', 0.0019309958443045616)","('Employee_Health_And_Safety', 0.0018035321263596416)","(['Talent Attraction & Retention'], 0.9734723567962646)","('NON-ESG', 0.0019309958443045616)","('NON-ESG', 0.0018035321263596416)"
Line 340,the proportion of the general population that they represent .,"('Employee_Engagement_Inclusion_And_Diversity', 0.4736311435699463)","('Customer_Privacy', 0.0686369314789772)","('Human_Rights_And_Community_Relations', 0.06688988208770752)","('NON-ESG', 0.4736311435699463)","('NON-ESG', 0.0686369314789772)","('NON-ESG', 0.06688988208770752)"
Line 341,"Black Americans bear a disproportionate share of the cancer burden, having the highest death rate and the lowest survival rate of any racial or ethnic group in the U .","('Employee_Engagement_Inclusion_And_Diversity', 0.9272985458374023)","('Employee_Health_And_Safety', 0.0156780444085598)","('Human_Rights_And_Community_Relations', 0.006256722379475832)","(['Talent Attraction & Retention'], 0.9272985458374023)","('NON-ESG', 0.0156780444085598)","('NON-ESG', 0.006256722379475832)"
Line 342,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 343,for most cancers .,"('Access_And_Affordability', 0.14061032235622406)","('Ecological_Impacts', 0.10667603462934494)","('Customer_Welfare', 0.08502274751663208)","('NON-ESG', 0.14061032235622406)","('NON-ESG', 0.10667603462934494)","('NON-ESG', 0.08502274751663208)"
Line 344,Yet according to the U .,"('Management_Of_Legal_And_Regulatory_Framework', 0.2697475850582123)","('Competitive_Behavior', 0.10993119329214096)","('Human_Rights_And_Community_Relations', 0.10897009074687958)","('NON-ESG', 0.2697475850582123)","('NON-ESG', 0.10993119329214096)","('NON-ESG', 0.10897009074687958)"
Line 345,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 346,"Food and Drug Administration (FDA), in 2019 alone, of the participants in oncology trials, 73% were White, 18% were Asian, 4% were Black American and 5% were Hispanic .","('Employee_Engagement_Inclusion_And_Diversity', 0.951353907585144)","('Competitive_Behavior', 0.0034487328957766294)","('Water_And_Wastewater_Management', 0.0033199810422956944)","(['Talent Attraction & Retention'], 0.951353907585144)","('NON-ESG', 0.0034487328957766294)","('NON-ESG', 0.0033199810422956944)"
Line 347,"Black Americans are 30% more likely to die from heart disease than non-Hispanic Whites, but they make up only 2 .5% of cardiovascular disease clinical trials .","('Employee_Engagement_Inclusion_And_Diversity', 0.9078865051269531)","('Employee_Health_And_Safety', 0.013973197899758816)","('Customer_Privacy', 0.006156550720334053)","(['Talent Attraction & Retention'], 0.9078865051269531)","('NON-ESG', 0.013973197899758816)","('NON-ESG', 0.006156550720334053)"
Line 348,Black and Hispanic Americans patients suffer disproportionately from severe asthma .,"('Employee_Health_And_Safety', 0.6504155993461609)","('Employee_Engagement_Inclusion_And_Diversity', 0.15604686737060547)","('Access_And_Affordability', 0.042080096900463104)","(['Health Outcome Contribution'], 0.6504155993461609)","('NON-ESG', 0.15604686737060547)","('NON-ESG', 0.042080096900463104)"
Line 349,"However, they are often underrepresented within clinical trials of asthma therapies .","('Competitive_Behavior', 0.20468387007713318)","('Customer_Welfare', 0.1945302039384842)","('GHG_Emissions', 0.08123571425676346)","('NON-ESG', 0.20468387007713318)","('NON-ESG', 0.1945302039384842)","('NON-ESG', 0.08123571425676346)"
Line 350,"Amgen is working to improve the proportional representation of trial participants in clinical trials by addressing key systemic issues that deter people from participating in research, Healthy People 22 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix HEAL TH EQUITY especially those groups who have been historically excluded due to race, ethnicity, sex, age, and other factors .","('Employee_Engagement_Inclusion_And_Diversity', 0.9731812477111816)","('Human_Rights_And_Community_Relations', 0.002650088630616665)","('Employee_Health_And_Safety', 0.0018750661984086037)","(['Talent Attraction & Retention'], 0.9731812477111816)","('NON-ESG', 0.002650088630616665)","('NON-ESG', 0.0018750661984086037)"
Line 351,"Amgens Representation in Clinical Research team, also known as RISE, is working to address these barriers .","('Employee_Engagement_Inclusion_And_Diversity', 0.7443311214447021)","('Human_Rights_And_Community_Relations', 0.027233952656388283)","('Business_Ethics', 0.024580011144280434)","(['Talent Attraction & Retention'], 0.7443311214447021)","('NON-ESG', 0.027233952656388283)","('NON-ESG', 0.024580011144280434)"
Line 352,"In 2021, RISE led engagement with representatives of historically underserved and excluded communities through a series of product- agnostic community advisory boards .","('Access_And_Affordability', 0.944619357585907)","('Human_Rights_And_Community_Relations', 0.007276779506355524)","('Critical_Incident_Risk_Management', 0.004852782469242811)","(['Access to Healthcare'], 0.944619357585907)","('NON-ESG', 0.007276779506355524)","('NON-ESG', 0.004852782469242811)"
Line 353,"This helped us obtain insights and perspectives on best practices for engagement with these communities more broadly, with the goal of building long-term, sustainable relationships .","('Human_Rights_And_Community_Relations', 0.9430433511734009)","('Access_And_Affordability', 0.006189293228089809)","('Business_Model_Resilience', 0.004967707209289074)","([], 0.9430433511734009)","('NON-ESG', 0.006189293228089809)","('NON-ESG', 0.004967707209289074)"
Line 354,We will continue to seek guidance from key community advisors to help ensure that our efforts resonate with community needs and highlight community members voices .,"('Human_Rights_And_Community_Relations', 0.936372697353363)","('Employee_Engagement_Inclusion_And_Diversity', 0.010284914635121822)","('Access_And_Affordability', 0.0067796302028000355)","([], 0.936372697353363)","('NON-ESG', 0.010284914635121822)","('NON-ESG', 0.0067796302028000355)"
Line 355,"In 2021, we developed, with input from RISE, an enterprise-wide framework to strengthen our focus on enhancing diversity and representation in clinical trial participation across our portfolio .","('Employee_Engagement_Inclusion_And_Diversity', 0.9686292409896851)","('Competitive_Behavior', 0.002430272987112403)","('Employee_Health_And_Safety', 0.0020287081133574247)","(['Talent Attraction & Retention'], 0.9686292409896851)","('NON-ESG', 0.002430272987112403)","('NON-ESG', 0.0020287081133574247)"
Line 356,"In addition, we have developed diversity plans for multiple clinical studies that align with industry principles and FDA guidance for industry to enhance diversity in clinical trials and encourage inclusivity in medical product development .","('Employee_Engagement_Inclusion_And_Diversity', 0.9295670986175537)","('Competitive_Behavior', 0.00963528361171484)","('Business_Model_Resilience', 0.006655247416347265)","(['Talent Attraction & Retention'], 0.9295670986175537)","('NON-ESG', 0.00963528361171484)","('NON-ESG', 0.006655247416347265)"
Line 357,"In early 2022, Amgen announced its support for the CEO Roundtable on Cancer s new multiyear initiative Going for Gold .","('Management_Of_Legal_And_Regulatory_Framework', 0.47420382499694824)","('Business_Model_Resilience', 0.09259766340255737)","('Access_And_Affordability', 0.06654101610183716)","('NON-ESG', 0.47420382499694824)","('NON-ESG', 0.09259766340255737)","('NON-ESG', 0.06654101610183716)"
Line 358,"This initiative will work with Historically Black Colleges and Universities and Hispanic Serving Institutions to improve health equity, education, navigation, and access .","('Access_And_Affordability', 0.48955732583999634)","('Employee_Engagement_Inclusion_And_Diversity', 0.2808617651462555)","('Human_Rights_And_Community_Relations', 0.029671454802155495)","('NON-ESG', 0.48955732583999634)","('NON-ESG', 0.2808617651462555)","('NON-ESG', 0.029671454802155495)"
Line 359,"The program is expected to positively impact more than 20 million lives, especially among communities disproportionately affected by cancer .","('Access_And_Affordability', 0.5808738470077515)","('Employee_Health_And_Safety', 0.10102616250514984)","('Human_Rights_And_Community_Relations', 0.09156829863786697)","(['Access to Healthcare'], 0.5808738470077515)","('NON-ESG', 0.10102616250514984)","('NON-ESG', 0.09156829863786697)"
Line 360,"Through the initiative, universities can contribute to research efforts through the CEO Roundtables Project Data Sphere, which helps expand access to clinical trial research and offers an open-access digital platform for aggregating and analyzing data to advance health equity efforts .","('Access_And_Affordability', 0.2998271882534027)","('Management_Of_Legal_And_Regulatory_Framework', 0.14960943162441254)","('Competitive_Behavior', 0.10238154232501984)","('NON-ESG', 0.2998271882534027)","('NON-ESG', 0.14960943162441254)","('NON-ESG', 0.10238154232501984)"
Line 361,"Increasing Access to Oncology Trials for Underrepresented Communities Recent data from the FDA show that, of total participants in clinical trials for oncology products that led to approvals, just 4% were Black participants and 5% were Hispanic participants, despite the fact that, during this same period, 13 .4% of the U .","('Employee_Engagement_Inclusion_And_Diversity', 0.7775261998176575)","('Access_And_Affordability', 0.0538487546145916)","('Customer_Welfare', 0.026364311575889587)","(['Talent Attraction & Retention'], 0.7775261998176575)","('NON-ESG', 0.0538487546145916)","('NON-ESG', 0.026364311575889587)"
Line 362,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 363,"population was Black and 18 .1% was Hispanic .11 This is even though Black, Indigenous, and People of Color overall in the United States have both the highest death rates and shortest survival rates for most cancers .12 Amgen is investing in programs to increase scientific data with the goal of changing these numbers .","('Employee_Engagement_Inclusion_And_Diversity', 0.8364307284355164)","('Employee_Health_And_Safety', 0.04797141253948212)","('Access_And_Affordability', 0.018008548766374588)","(['Talent Attraction & Retention'], 0.8364307284355164)","('NON-ESG', 0.04797141253948212)","('NON-ESG', 0.018008548766374588)"
Line 364,"One way to contribute to this change is by bringing historically underrepresented patients into clinical trials conducted where they live, such as in community clinics where four THREE-YEAR PLAN / SIX PILLARSRISE is working to exceed industry standards for clinical trial diversity and representation and to help Amgen develop new medicines studied in participants who better reflect the populations impacted by certain diseases or conditions .","('Employee_Engagement_Inclusion_And_Diversity', 0.4331674873828888)","('Competitive_Behavior', 0.11744121462106705)","('Product_Quality_And_Safety', 0.06328066438436508)","('NON-ESG', 0.4331674873828888)","('NON-ESG', 0.11744121462106705)","('NON-ESG', 0.06328066438436508)"
Line 365,11 Oncology Leaders Take Action to Curb Lack of Diversity in Clinical Trials .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9539212584495544)","('Employee_Health_And_Safety', 0.0034489957615733147)","('Competitive_Behavior', 0.0031068429816514254)","(['Talent Attraction & Retention'], 0.9539212584495544)","('NON-ESG', 0.0034489957615733147)","('NON-ESG', 0.0031068429816514254)"
Line 366,12 Improving Diversity and Inclusion in Cancer Clinical Trials and Research .,"('Employee_Engagement_Inclusion_And_Diversity', 0.969366192817688)","('Employee_Health_And_Safety', 0.0024116134736686945)","('Human_Rights_And_Community_Relations', 0.0022601818200200796)","(['Talent Attraction & Retention'], 0.969366192817688)","('NON-ESG', 0.0024116134736686945)","('NON-ESG', 0.0022601818200200796)"
Line 367,"Evolve the way we design and run clinical trials, focusing on people who have been historically excluded from clinical researchPartner with clinical trial investigators who are representative of the participants they are aiming to recruitBring the research directly to the communities where people live and workChange how researchers communicate with patients, caregivers, and providersEnhance precision medicine awareness and improve genetic diversity in translational scienceCollaborate with national and community organizationsHealthy People 23 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix HEAL TH EQUITY fifths of cancer patients in the United States are treated .","('Employee_Engagement_Inclusion_And_Diversity', 0.8275666832923889)","('Access_And_Affordability', 0.027678782120347023)","('Customer_Welfare', 0.01652502827346325)","(['Talent Attraction & Retention'], 0.8275666832923889)","('NON-ESG', 0.027678782120347023)","('NON-ESG', 0.01652502827346325)"
Line 368,"Evolve the way we design and run clinical trials, focusing on people who have been historically excluded from clinical researchPartner with clinical trial investigators who are representative of the participants they are aiming to recruitBring the research directly to the communities where people live and workChange how researchers communicate with patients, caregivers, and providersEnhance precision medicine awareness and improve genetic diversity in translational scienceCollaborate with national and community organizationsHealthy People 23 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix HEAL TH EQUITY fifths of cancer patients in the United States are treated .","('Employee_Health_And_Safety', 0.26336246728897095)","('Access_And_Affordability', 0.2041255533695221)","('Employee_Engagement_Inclusion_And_Diversity', 0.08558087050914764)","('NON-ESG', 0.26336246728897095)","('NON-ESG', 0.2041255533695221)","('NON-ESG', 0.08558087050914764)"
Line 369,To reach these patientsmany of whom are from lower-income backgroundswe established the Amgen Community Oncology Research Collaborators program .,"('Access_And_Affordability', 0.6500147581100464)","('Employee_Engagement_Inclusion_And_Diversity', 0.10862600803375244)","('Customer_Welfare', 0.04059670865535736)","(['Access to Healthcare'], 0.6500147581100464)","('NON-ESG', 0.10862600803375244)","('NON-ESG', 0.04059670865535736)"
Line 370,This initiative makes it easier for community oncologists at more than 200 sites across the United States to refer their patients to studies of Amgens investigational cancer medicines .,"('Access_And_Affordability', 0.39206570386886597)","('Customer_Welfare', 0.12763755023479462)","('Product_Quality_And_Safety', 0.05329291522502899)","('NON-ESG', 0.39206570386886597)","('NON-ESG', 0.12763755023479462)","('NON-ESG', 0.05329291522502899)"
Line 371,"Since its inception in 2018, we have offered oncologists at sites participating in the program more than 65 new clinical trial opportunities for their patients, representing a 2,100% increase .","('Access_And_Affordability', 0.20942248404026031)","('Customer_Welfare', 0.1319631189107895)","('Competitive_Behavior', 0.11859464645385742)","('NON-ESG', 0.20942248404026031)","('NON-ESG', 0.1319631189107895)","('NON-ESG', 0.11859464645385742)"
Line 372,We are also supporting a study led by the Leukemia & Lymphoma Society and the University of Florida to develop and assess the effectiveness of a novel online training program designed to increase primary care providers understanding of cancer clinical trials and their capacity to encourage patients to inquire about clinical trials when making treatment decisions .,"('Access_And_Affordability', 0.1677623987197876)","('Customer_Welfare', 0.15510645508766174)","('GHG_Emissions', 0.07582155615091324)","('NON-ESG', 0.1677623987197876)","('NON-ESG', 0.15510645508766174)","('NON-ESG', 0.07582155615091324)"
Line 373,The study will include 400 providers who predominantly treat patients underrepresented in clinical trials .,"('Access_And_Affordability', 0.30050384998321533)","('Customer_Welfare', 0.09594213962554932)","('Competitive_Behavior', 0.08620671927928925)","('NON-ESG', 0.30050384998321533)","('NON-ESG', 0.09594213962554932)","('NON-ESG', 0.08620671927928925)"
Line 374,Study results are expected by early 2023 .,"('Management_Of_Legal_And_Regulatory_Framework', 0.27653324604034424)","('Business_Model_Resilience', 0.12437807023525238)","('Physical_Impacts_Of_Climate_Change', 0.10517334938049316)","('NON-ESG', 0.27653324604034424)","('NON-ESG', 0.12437807023525238)","('NON-ESG', 0.10517334938049316)"
Line 375,"Through support from Amgen, our longtime partner the Lazarex Cancer Foundation recently launched several innovative community-based Cancer Wellness HUBs in partnership with the University of Southern Californias Norris Comprehensive Cancer Center .","('Access_And_Affordability', 0.36259424686431885)","('Employee_Health_And_Safety', 0.2003360539674759)","('Product_Quality_And_Safety', 0.05757857859134674)","('NON-ESG', 0.36259424686431885)","('NON-ESG', 0.2003360539674759)","('NON-ESG', 0.05757857859134674)"
Line 376,These HUBs bring existing cancer education and awareness efforts directly to residents of underrepresented and vulnerable communities .,"('Access_And_Affordability', 0.6086950898170471)","('Human_Rights_And_Community_Relations', 0.20621873438358307)","('Employee_Engagement_Inclusion_And_Diversity', 0.03950779512524605)","(['Access to Healthcare'], 0.6086950898170471)","('NON-ESG', 0.20621873438358307)","('NON-ESG', 0.03950779512524605)"
Line 377,"This partnership is designed to provide residents of underserved communities with access to the latest available research, information about current clinical trials, technology, access to available lifestyle improvement programs, and opportunities to optimize health outcomes .","('Access_And_Affordability', 0.9431380033493042)","('Product_Quality_And_Safety', 0.006128459703177214)","('Critical_Incident_Risk_Management', 0.004598372615873814)","(['Access to Healthcare'], 0.9431380033493042)","('NON-ESG', 0.006128459703177214)","('NON-ESG', 0.004598372615873814)"
Line 378,"They also offer a safe space for residents to talk about health concerns, including disease prevention, survivorship, and end-of-life issues .","('Employee_Health_And_Safety', 0.7802367806434631)","('Critical_Incident_Risk_Management', 0.05795508623123169)","('Access_And_Affordability', 0.054803114384412766)","(['Health Outcome Contribution'], 0.7802367806434631)","('NON-ESG', 0.05795508623123169)","('NON-ESG', 0.054803114384412766)"
Line 379,One of the key goals of the HUBs is to connect patients to clinical trials .,"('Access_And_Affordability', 0.29750555753707886)","('Customer_Welfare', 0.12411242723464966)","('Business_Model_Resilience', 0.06609799712896347)","('NON-ESG', 0.29750555753707886)","('NON-ESG', 0.12411242723464966)","('NON-ESG', 0.06609799712896347)"
Line 380,"The Lazarex Cancer Foundation is helping raise awareness of the benefits of clinical trials for many here in Los Angeles, said Freddie Muse Jr ., a prostate cancer survivor and founder of The Mens Cancer Network in Los Angeles .","('Access_And_Affordability', 0.20929954946041107)","('Employee_Health_And_Safety', 0.12099146097898483)","('Product_Quality_And_Safety', 0.1038300096988678)","('NON-ESG', 0.20929954946041107)","('NON-ESG', 0.12099146097898483)","('NON-ESG', 0.1038300096988678)"
Line 381,"This is especially important for people of color, many of whom have concerns and misconceptions about trials based on historical incidents .","('Employee_Engagement_Inclusion_And_Diversity', 0.9654216766357422)","('Employee_Health_And_Safety', 0.00302126444876194)","('Competitive_Behavior', 0.0021269042044878006)","(['Talent Attraction & Retention'], 0.9654216766357422)","('NON-ESG', 0.00302126444876194)","('NON-ESG', 0.0021269042044878006)"
Line 382,"The Mens Cancer Network is working with Lazarex, to not only change mindsets, but to help our community navigate access to trials .","('Access_And_Affordability', 0.731539249420166)","('Customer_Welfare', 0.03260546922683716)","('Employee_Engagement_Inclusion_And_Diversity', 0.024754662066698074)","(['Access to Healthcare'], 0.731539249420166)","('NON-ESG', 0.03260546922683716)","('NON-ESG', 0.024754662066698074)"
Line 383,"Lazarex is helping our network get reimbursed for the costs associated with travel to and from clinical trials, lodging, and mealsseemingly small, but potentially significant, barriers to access for many .","('Access_And_Affordability', 0.70647132396698)","('Management_Of_Legal_And_Regulatory_Framework', 0.03388382866978645)","('Product_Quality_And_Safety', 0.030330616980791092)","(['Access to Healthcare'], 0.70647132396698)","('NON-ESG', 0.03388382866978645)","('NON-ESG', 0.030330616980791092)"
Line 384,Addressing Health Equity Through Comprehensive Health Education Historically underrepresented populations have lower rates of screening and diagnosis for many life-threatening conditionsfrom cancer and heart disease to osteoporosis and rheumatoid arthritis .,"('Employee_Health_And_Safety', 0.31954050064086914)","('Access_And_Affordability', 0.24936453998088837)","('Product_Quality_And_Safety', 0.10390181839466095)","('NON-ESG', 0.31954050064086914)","('NON-ESG', 0.24936453998088837)","('NON-ESG', 0.10390181839466095)"
Line 385,"Delays in diagnosis in some cases mean patients do not receive access to potentially life-saving treatments until it is too late, leading to higher mortality rates for underrepresented and underserved populations .","('Access_And_Affordability', 0.9460220336914062)","('Product_Quality_And_Safety', 0.005536773707717657)","('Critical_Incident_Risk_Management', 0.004708387888967991)","(['Access to Healthcare'], 0.9460220336914062)","('NON-ESG', 0.005536773707717657)","('NON-ESG', 0.004708387888967991)"
Line 386,One group at risk is Black women who have undergone treatment for breast cancer and may be at an increased risk for osteoporosis and bone fracture .,"('Employee_Health_And_Safety', 0.36890077590942383)","('Access_And_Affordability', 0.15272825956344604)","('Employee_Engagement_Inclusion_And_Diversity', 0.1492636501789093)","('NON-ESG', 0.36890077590942383)","('NON-ESG', 0.15272825956344604)","('NON-ESG', 0.1492636501789093)"
Line 387,"For the second year in a row, Amgen partnered with the Tigerlily Foundation to raise awareness among young women, women of color, and underserved communities regarding bone health and its impact specifically on breast cancer patients .","('Access_And_Affordability', 0.9377965331077576)","('Product_Quality_And_Safety', 0.00666247820481658)","('Human_Rights_And_Community_Relations', 0.005575121846050024)","(['Access to Healthcare'], 0.9377965331077576)","('NON-ESG', 0.00666247820481658)","('NON-ESG', 0.005575121846050024)"
Line 388,"Through education and multimedia efforts, the campaign reached more than six million people .","('Access_And_Affordability', 0.6624073386192322)","('Human_Rights_And_Community_Relations', 0.06212553754448891)","('Management_Of_Legal_And_Regulatory_Framework', 0.029858311638236046)","(['Access to Healthcare'], 0.6624073386192322)","('NON-ESG', 0.06212553754448891)","('NON-ESG', 0.029858311638236046)"
Line 389,"We are also working with TOUCH, the Black Breast Cancer Alliance, to help the Black breast cancer community advocate for the best healthcare possible .","('Employee_Health_And_Safety', 0.42068082094192505)","('Employee_Engagement_Inclusion_And_Diversity', 0.15629655122756958)","('Access_And_Affordability', 0.10831864923238754)","('NON-ESG', 0.42068082094192505)","('NON-ESG', 0.15629655122756958)","('NON-ESG', 0.10831864923238754)"
Line 390,"Amgen is supporting Touchs The Doctor is In: Bone Health Campaign, that includes a weekly web series, and a #LoveYourBones social media campaign to connect women to educational blogs, resources, and events featuring testimonials and tips for maintaining healthy bones .","('Employee_Health_And_Safety', 0.6514881253242493)","('Employee_Engagement_Inclusion_And_Diversity', 0.06952321529388428)","('Customer_Welfare', 0.036178357899188995)","(['Health Outcome Contribution'], 0.6514881253242493)","('NON-ESG', 0.06952321529388428)","('NON-ESG', 0.036178357899188995)"
Line 391,"Working to Raise Health Awareness Through Trusted Community Leaders Religious leaders are among the most trusted members of local communities, providing vital information on social services, education, and health to their congregations .","('Access_And_Affordability', 0.5119748115539551)","('Human_Rights_And_Community_Relations', 0.307895302772522)","('Employee_Health_And_Safety', 0.04014221206307411)","(['Access to Healthcare'], 0.5119748115539551)","('NON-ESG', 0.307895302772522)","('NON-ESG', 0.04014221206307411)"
Line 392,"We work with the Health Education Advocacy Learning (HEAL) collaborative, which partners with faith-based organizations to help make communities of color healthier .","('Access_And_Affordability', 0.4745287299156189)","('Employee_Engagement_Inclusion_And_Diversity', 0.25378015637397766)","('Human_Rights_And_Community_Relations', 0.05318794399499893)","('NON-ESG', 0.4745287299156189)","('NON-ESG', 0.25378015637397766)","('NON-ESG', 0.05318794399499893)"
Line 393,"Amgen is supporting a number of HEAL initiatives in Georgia, Ohio, Texas, and Maryland to raise awareness of diseases that disproportionately affect undeserved communities and people of color, including osteoporosis, Healthy People 24 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy Society Healthy Planet A Healthy Amgen Appendix lung cancer, prostate cancer, and multiple myeloma .","('Access_And_Affordability', 0.24893882870674133)","('Employee_Engagement_Inclusion_And_Diversity', 0.23772332072257996)","('Employee_Health_And_Safety', 0.17960992455482483)","('NON-ESG', 0.24893882870674133)","('NON-ESG', 0.23772332072257996)","('NON-ESG', 0.17960992455482483)"
Line 394,"The program includes information on risk factors, channels for accessing care, and seeks to raise awareness about participating in clinical trials for potential treatments .","('Access_And_Affordability', 0.3274061381816864)","('Customer_Welfare', 0.10472510010004044)","('Selling_Practices_And_Product_Labeling', 0.0653863251209259)","('NON-ESG', 0.3274061381816864)","('NON-ESG', 0.10472510010004044)","('NON-ESG', 0.0653863251209259)"
Line 395,"Our work with Amgen has put a spotlight on diseases that most people, including those from underrepresented communities, have cursory or no knowledge at all about symptoms, let alone available screenings or clinical trials, said Howard Mosby, who serves as one of the leaders of HEAL .","('Access_And_Affordability', 0.1736256629228592)","('Product_Quality_And_Safety', 0.13831540942192078)","('Customer_Welfare', 0.10325383394956589)","('NON-ESG', 0.1736256629228592)","('NON-ESG', 0.13831540942192078)","('NON-ESG', 0.10325383394956589)"
Line 396,"Amgen has proved through its work with us that it is not interested in checking off boxes, but wants to see the needle move as a result of education and policy change .","('Management_Of_Legal_And_Regulatory_Framework', 0.8516683578491211)","('Human_Rights_And_Community_Relations', 0.033290594816207886)","('Access_And_Affordability', 0.017153697088360786)","([], 0.8516683578491211)","('NON-ESG', 0.033290594816207886)","('NON-ESG', 0.017153697088360786)"
Line 397,Addressing Social Determinants of Health Recent data13 show that disparities in cardiovascular risk factors between Black and White adults in the United States may be largely attributable to social determinants of health .,"('Employee_Health_And_Safety', 0.7076364755630493)","('Employee_Engagement_Inclusion_And_Diversity', 0.07541554421186447)","('Access_And_Affordability', 0.03967898711562157)","(['Health Outcome Contribution'], 0.7076364755630493)","('NON-ESG', 0.07541554421186447)","('NON-ESG', 0.03967898711562157)"
Line 398,"To improve our understanding of this issue, Amgen partnered with Humana to conduct a study among patients who have been hospitalized for cardiovascular-related conditions .","('Employee_Health_And_Safety', 0.5007292628288269)","('Access_And_Affordability', 0.10654932260513306)","('Product_Quality_And_Safety', 0.061156515032052994)","(['Health Outcome Contribution'], 0.5007292628288269)","('NON-ESG', 0.10654932260513306)","('NON-ESG', 0.061156515032052994)"
Line 399,"Social determinants of health can have a greater impact on health outcomes than clinical factors, especially within underserved populations .","('Access_And_Affordability', 0.9364829659461975)","('Product_Quality_And_Safety', 0.00665509095415473)","('Employee_Health_And_Safety', 0.005905740894377232)","(['Access to Healthcare'], 0.9364829659461975)","('NON-ESG', 0.00665509095415473)","('NON-ESG', 0.005905740894377232)"
Line 400,"Barriers most often reported by respondents included food insecurity, financial strain, housing quality, and transportation barriers .","('Systemic_Risk_Management', 0.8297526836395264)","('Business_Ethics', 0.02775360830128193)","('Supply_Chain_Management', 0.02322787418961525)","([], 0.8297526836395264)","('NON-ESG', 0.02775360830128193)","('NON-ESG', 0.02322787418961525)"
Line 401,"In terms of the groups most likely to face social determinants of health barriers, 68% of White survey respondents reported no social needs, while more than half (54%) of Black survey respondents reported at least one social need .","('Human_Rights_And_Community_Relations', 0.642375111579895)","('Access_And_Affordability', 0.20559267699718475)","('Employee_Health_And_Safety', 0.025870798155665398)","([], 0.642375111579895)","('NON-ESG', 0.20559267699718475)","('NON-ESG', 0.025870798155665398)"
Line 402,"Amgen and Humana will use the findings to identify, implement, and evaluate potential interventions .","('Access_And_Affordability', 0.5666182041168213)","('Human_Rights_And_Community_Relations', 0.09147892147302628)","('Management_Of_Legal_And_Regulatory_Framework', 0.03678131476044655)","(['Access to Healthcare'], 0.5666182041168213)","('NON-ESG', 0.09147892147302628)","('NON-ESG', 0.03678131476044655)"
Line 403,"HEAL TH EQUITY 2021 PERFORMANCE DATA MORE INFORMATION 2021 Amgen Health Equity Summit 13 He J, Zhu Z, Bundy JD, Dorans KS, Chen J, Hamm LL .","('Systemic_Risk_Management', 0.33132100105285645)","('Management_Of_Legal_And_Regulatory_Framework', 0.18931187689304352)","('Business_Model_Resilience', 0.0915454551577568)","('NON-ESG', 0.33132100105285645)","('NON-ESG', 0.18931187689304352)","('NON-ESG', 0.0915454551577568)"
Line 404,"Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018 .","('Employee_Engagement_Inclusion_And_Diversity', 0.969244122505188)","('Human_Rights_And_Community_Relations', 0.0031451010145246983)","('Customer_Privacy', 0.0026046219281852245)","(['Talent Attraction & Retention'], 0.969244122505188)","('NON-ESG', 0.0031451010145246983)","('NON-ESG', 0.0026046219281852245)"
Line 405,JAMA.,"('Data_Security', 0.19058115780353546)","('Business_Ethics', 0.12321178615093231)","('Employee_Engagement_Inclusion_And_Diversity', 0.06833604723215103)","('NON-ESG', 0.19058115780353546)","('NON-ESG', 0.12321178615093231)","('NON-ESG', 0.06833604723215103)"
Line 406,2021;326(13):12861298 .,"('Management_Of_Legal_And_Regulatory_Framework', 0.7132358551025391)","('Competitive_Behavior', 0.04274039342999458)","('Systemic_Risk_Management', 0.03410891443490982)","([], 0.7132358551025391)","('NON-ESG', 0.04274039342999458)","('NON-ESG', 0.03410891443490982)"
Line 407,14 World Health Organization .,"('Access_And_Affordability', 0.3543994724750519)","('Human_Rights_And_Community_Relations', 0.10754141956567764)","('Product_Quality_And_Safety', 0.08176669478416443)","('NON-ESG', 0.3543994724750519)","('NON-ESG', 0.10754141956567764)","('NON-ESG', 0.08176669478416443)"
Line 408,15 Aetna CVS Health .,"('Systemic_Risk_Management', 0.20709609985351562)","('Product_Quality_And_Safety', 0.09514305740594864)","('Supply_Chain_Management', 0.08754818141460419)","('NON-ESG', 0.20709609985351562)","('NON-ESG', 0.09514305740594864)","('NON-ESG', 0.08754818141460419)"
Line 409,"Not addressing social determinants of health adds at least 5% to total health plan costs in the United States.15Social and economic factors drive an estimated 40% of health outcomes twice as influential as factors related to clinical care .14 $1 1.7M Funding contributed in support of advancing health equity activities60 Number of organizations funded82 Number of projects funded We also collaborated with our longtime partner the American Heart Association in 2021, launching a three-year grassroots program that will raise awareness of cardiovascular health and prevention strategies while engaging and supporting community members to create a culture of health .","('Access_And_Affordability', 0.7550753951072693)","('Employee_Health_And_Safety', 0.03962453454732895)","('Human_Rights_And_Community_Relations', 0.025224069133400917)","(['Access to Healthcare'], 0.7550753951072693)","('NON-ESG', 0.03962453454732895)","('NON-ESG', 0.025224069133400917)"
Line 410,"Not addressing social determinants of health adds at least 5% to total health plan costs in the United States.15Social and economic factors drive an estimated 40% of health outcomes twice as influential as factors related to clinical care .14 $1 1.7M Funding contributed in support of advancing health equity activities60 Number of organizations funded82 Number of projects funded We also collaborated with our longtime partner the American Heart Association in 2021, launching a three-year grassroots program that will raise awareness of cardiovascular health and prevention strategies while engaging and supporting community members to create a culture of health .","('Employee_Health_And_Safety', 0.7943775057792664)","('Access_And_Affordability', 0.0588097870349884)","('Critical_Incident_Risk_Management', 0.015601064078509808)","(['Health Outcome Contribution'], 0.7943775057792664)","('NON-ESG', 0.0588097870349884)","('NON-ESG', 0.015601064078509808)"
Line 411,"The platform, EmPOWERED to Serve, will provide healthy living lessons to underresourced communities in California, Florida, Indiana, Nevada, North Carolina, Ohio, Pennsylvania, and Texas .","('Access_And_Affordability', 0.7329647541046143)","('Employee_Health_And_Safety', 0.042673856019973755)","('Customer_Welfare', 0.026974406093358994)","(['Access to Healthcare'], 0.7329647541046143)","('NON-ESG', 0.042673856019973755)","('NON-ESG', 0.026974406093358994)"
Line 412,"The program accelerates innovative solutions to eliminate disparities in underresourced communities caused by social determinants of health by leveraging local health ambassadors to help spread awareness about heart disease, stroke and the importance of a healthy lifestyle .","('Human_Rights_And_Community_Relations', 0.32038185000419617)","('Employee_Health_And_Safety', 0.24110351502895355)","('Access_And_Affordability', 0.23812249302864075)","('NON-ESG', 0.32038185000419617)","('NON-ESG', 0.24110351502895355)","('NON-ESG', 0.23812249302864075)"
Line 413,"Beyond cardiovascular health, we are also exploring interventions to address barriers to care in other therapeutic areas, working with local community providers and other partners .","('Access_And_Affordability', 0.6721178889274597)","('Employee_Health_And_Safety', 0.09086838364601135)","('Human_Rights_And_Community_Relations', 0.03922807425260544)","(['Access to Healthcare'], 0.6721178889274597)","('NON-ESG', 0.09086838364601135)","('NON-ESG', 0.03922807425260544)"
Line 414,"For example, in 2021, we established a partnership with Findhelp .org, a community network referral program that helps people find financial assistance, food pantries, medical care, and other free or reduced-cost services in their local communities .","('Access_And_Affordability', 0.792799711227417)","('Human_Rights_And_Community_Relations', 0.0728486031293869)","('Energy_Management', 0.012053105048835278)","(['Access to Healthcare'], 0.792799711227417)","('NON-ESG', 0.0728486031293869)","('NON-ESG', 0.012053105048835278)"
Line 415,"25 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix Healthy Society HEALTHY SOCIETY We work toward a more just society for our employees and the people we serve.","('Human_Rights_And_Community_Relations', 0.8387551307678223)","('Employee_Engagement_Inclusion_And_Diversity', 0.02409379556775093)","('Business_Model_Resilience', 0.016023065894842148)","([], 0.8387551307678223)","('NON-ESG', 0.02409379556775093)","('NON-ESG', 0.016023065894842148)"
Line 416,"Announced a new, more FLEXIBLE WORKPLACE APPROACHThe Amgen Foundation reached more than 27M students and educators worldwide through its four core science education programsIn a staff listening survey, Leaders demonstrate a VISIBLE COMMITMENT TO DIVERSITY was rated as a top strength2021 HighlightsHealthy Society 26 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix AMBITION We value and are focused on doing our part to build a more just society, starting within our own workplace .","('Employee_Engagement_Inclusion_And_Diversity', 0.9675630331039429)","('Employee_Health_And_Safety', 0.0031676357612013817)","('Human_Rights_And_Community_Relations', 0.002708959858864546)","(['Talent Attraction & Retention'], 0.9675630331039429)","('NON-ESG', 0.0031676357612013817)","('NON-ESG', 0.002708959858864546)"
Line 417,"Announced a new, more FLEXIBLE WORKPLACE APPROACHThe Amgen Foundation reached more than 27M students and educators worldwide through its four core science education programsIn a staff listening survey, Leaders demonstrate a VISIBLE COMMITMENT TO DIVERSITY was rated as a top strength2021 HighlightsHealthy Society 26 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix AMBITION We value and are focused on doing our part to build a more just society, starting within our own workplace .","('Human_Rights_And_Community_Relations', 0.43345120549201965)","('Employee_Engagement_Inclusion_And_Diversity', 0.08547073602676392)","('Competitive_Behavior', 0.07260584831237793)","('NON-ESG', 0.43345120549201965)","('NON-ESG', 0.08547073602676392)","('NON-ESG', 0.07260584831237793)"
Line 418,"At Amgen, we are working to attract and retain a wide diversity of people from different backgrounds, cultures, educational experiences, and religions because we believe that a workforce that reflects the diversity of our customers and communities fosters innovation, which supports our ability to serve patients and their communities.","('Employee_Engagement_Inclusion_And_Diversity', 0.9727382659912109)","('Employee_Health_And_Safety', 0.0020685221534222364)","('Human_Rights_And_Community_Relations', 0.0019012867705896497)","(['Talent Attraction & Retention'], 0.9727382659912109)","('NON-ESG', 0.0020685221534222364)","('NON-ESG', 0.0019012867705896497)"
Line 419,"Attracting talent from diverse candidate pools and considering the full breadth of what an individuals background and experience can bring to a role at Amgen, while striving to eliminate potential bias from the decision-making process .","('Employee_Engagement_Inclusion_And_Diversity', 0.9647104740142822)","('Business_Model_Resilience', 0.0028635701164603233)","('Employee_Health_And_Safety', 0.0025281680282205343)","(['Talent Attraction & Retention'], 0.9647104740142822)","('NON-ESG', 0.0028635701164603233)","('NON-ESG', 0.0025281680282205343)"
Line 420,"Providing staff members with mentorship, sponsorship, and career development opportunities to help them achieve their fullest potential .","('Employee_Engagement_Inclusion_And_Diversity', 0.8079743385314941)","('Access_And_Affordability', 0.03507573902606964)","('Human_Rights_And_Community_Relations', 0.016128085553646088)","(['Talent Attraction & Retention'], 0.8079743385314941)","('NON-ESG', 0.03507573902606964)","('NON-ESG', 0.016128085553646088)"
Line 421,"Continuing to develop practices around pay, promotions, and performance management with a focus on enhancing equity throughout the organization .","('Labor_Practices', 0.8377072811126709)","('Business_Ethics', 0.027210712432861328)","('Competitive_Behavior', 0.02347119338810444)","([], 0.8377072811126709)","('NON-ESG', 0.027210712432861328)","('NON-ESG', 0.02347119338810444)"
Line 422,Emphasizing and working to respond to the personal well-being and mental health of our staff .,"('Employee_Health_And_Safety', 0.7184319496154785)","('Human_Rights_And_Community_Relations', 0.0870748907327652)","('Access_And_Affordability', 0.03811420500278473)","(['Health Outcome Contribution'], 0.7184319496154785)","('NON-ESG', 0.0870748907327652)","('NON-ESG', 0.03811420500278473)"
Line 423,"Endeavoring to create a work environment where each employee is able to bring their whole self to work, to have their voice heard, and to feel a sense of belonging .","('Employee_Engagement_Inclusion_And_Diversity', 0.5138249397277832)","('Employee_Health_And_Safety', 0.13887858390808105)","('Human_Rights_And_Community_Relations', 0.0848706066608429)","(['Talent Attraction & Retention'], 0.5138249397277832)","('NON-ESG', 0.13887858390808105)","('NON-ESG', 0.0848706066608429)"
Line 424,"HEALTHY SOCIETY Beyond Amgen, we are working with community leaders to explore and address deeply rooted barriers to economic prosperity, equity, and social justice, as well as expand economic opportunities within the communities in which we operate .","('Human_Rights_And_Community_Relations', 0.9607636332511902)","('Access_And_Affordability', 0.0050239237025380135)","('Employee_Engagement_Inclusion_And_Diversity', 0.0026671288069337606)","([], 0.9607636332511902)","('NON-ESG', 0.0050239237025380135)","('NON-ESG', 0.0026671288069337606)"
Line 425,"We are also working with teachers and other partners to reimagine science education, improve science literacy, and empower diverse thinkers .","('Employee_Engagement_Inclusion_And_Diversity', 0.8745651841163635)","('Access_And_Affordability', 0.0344448983669281)","('Customer_Welfare', 0.00886624027043581)","(['Talent Attraction & Retention'], 0.8745651841163635)","('NON-ESG', 0.0344448983669281)","('NON-ESG', 0.00886624027043581)"
Line 426,"And, we are engaging with diverse suppliers and supporting local communities through job creation with the potential for better wages .","('Human_Rights_And_Community_Relations', 0.3700046241283417)","('Labor_Practices', 0.18569685518741608)","('Employee_Engagement_Inclusion_And_Diversity', 0.15010857582092285)","('NON-ESG', 0.3700046241283417)","('NON-ESG', 0.18569685518741608)","('NON-ESG', 0.15010857582092285)"
Line 427,"This section includes: DIVERSITY , INCLUSION & BELONGING HUMAN CAPITAL MANAGEMENT COMMUNITY INVESTMENT RESPONSIBLE SOURCINGOUR STRATEGY INCLUDES: Healthy Society 27 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix We are on an ongoing journey to become a more diverse and inclusive organization that recruits, develops, and retains a workforce representative of the global communities we serve.","('Employee_Engagement_Inclusion_And_Diversity', 0.9615153670310974)","('Human_Rights_And_Community_Relations', 0.006922682281583548)","('Employee_Health_And_Safety', 0.0028075112495571375)","(['Talent Attraction & Retention'], 0.9615153670310974)","('NON-ESG', 0.006922682281583548)","('NON-ESG', 0.0028075112495571375)"
Line 428,"This journey requires deliberate and consistent action to address longstanding challenges and bring us to a better place, together.","('Human_Rights_And_Community_Relations', 0.6368128657341003)","('Business_Model_Resilience', 0.05918462947010994)","('Access_And_Affordability', 0.04432660713791847)","([], 0.6368128657341003)","('NON-ESG', 0.05918462947010994)","('NON-ESG', 0.04432660713791847)"
Line 429,"Beyond Amgen, we are engaging with business and other community leaders, government officials, and external partners who share our desire to promote social justice and equity.","('Human_Rights_And_Community_Relations', 0.9591925740242004)","('Access_And_Affordability', 0.0049398597329854965)","('Management_Of_Legal_And_Regulatory_Framework', 0.0029231312219053507)","([], 0.9591925740242004)","('NON-ESG', 0.0049398597329854965)","('NON-ESG', 0.0029231312219053507)"
Line 430,"DIVERSITY , INCLUSION & BELONGING GLOBAL Increase the representation and development of women in executive director and above roles .","('Employee_Engagement_Inclusion_And_Diversity', 0.9745294451713562)","('Employee_Health_And_Safety', 0.002251234371215105)","('Labor_Practices', 0.001930230762809515)","(['Talent Attraction & Retention'], 0.9745294451713562)","('NON-ESG', 0.002251234371215105)","('NON-ESG', 0.001930230762809515)"
Line 431,"UNITED STATES Increase the representation of Black people in science, technology, engineering, and mathematics- based roles .","('Employee_Engagement_Inclusion_And_Diversity', 0.9653846025466919)","('Human_Rights_And_Community_Relations', 0.0031317768152803183)","('Employee_Health_And_Safety', 0.003119934583082795)","(['Talent Attraction & Retention'], 0.9653846025466919)","('NON-ESG', 0.0031317768152803183)","('NON-ESG', 0.003119934583082795)"
Line 432,Increase the representation and development of Black and Hispanic people in executive director and above roles .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9747123122215271)","('Human_Rights_And_Community_Relations', 0.0020671153906732798)","('Employee_Health_And_Safety', 0.0019648554734885693)","(['Talent Attraction & Retention'], 0.9747123122215271)","('NON-ESG', 0.0020671153906732798)","('NON-ESG', 0.0019648554734885693)"
Line 433,"VALUE CREATION We believe that an environment of diversity, inclusion, and belonging fosters innovation, strengthens our global workforce, and drives our ability to serve patients.","('Employee_Engagement_Inclusion_And_Diversity', 0.9761226773262024)","('Employee_Health_And_Safety', 0.001844193204306066)","('Human_Rights_And_Community_Relations', 0.0014658821746706963)","(['Talent Attraction & Retention'], 0.9761226773262024)","('NON-ESG', 0.001844193204306066)","('NON-ESG', 0.0014658821746706963)"
Line 434,We believe that our global presence is strengthened by having a workforce that reflects the diversity of the patients we serve and maintaining an environment in which such diversity contributes to our mission .,"('Employee_Engagement_Inclusion_And_Diversity', 0.973000168800354)","('Employee_Health_And_Safety', 0.0020400891080498695)","('Business_Model_Resilience', 0.0017738754395395517)","(['Talent Attraction & Retention'], 0.973000168800354)","('NON-ESG', 0.0020400891080498695)","('NON-ESG', 0.0017738754395395517)"
Line 435,"OUR PRIORITIESHealthy Society 28 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix DIVERSITY , INCLUSION & BELONGING After introducing Managing Unconscious Bias training, which was completed by 100% of our employees in the United States, Puerto Rico, and Canada in 2020, we expanded the required online course to staff around the world in 2021 .16 We also embedded unconscious bias scenarios in our annual Code of Conduct training .","('Employee_Engagement_Inclusion_And_Diversity', 0.9407078623771667)","('Employee_Health_And_Safety', 0.00871911272406578)","('Business_Ethics', 0.005230347625911236)","(['Talent Attraction & Retention'], 0.9407078623771667)","('NON-ESG', 0.00871911272406578)","('NON-ESG', 0.005230347625911236)"
Line 436,"OUR PRIORITIESHealthy Society 28 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix DIVERSITY , INCLUSION & BELONGING After introducing Managing Unconscious Bias training, which was completed by 100% of our employees in the United States, Puerto Rico, and Canada in 2020, we expanded the required online course to staff around the world in 2021 .16 We also embedded unconscious bias scenarios in our annual Code of Conduct training .","('Competitive_Behavior', 0.11062721908092499)","('Waste_And_Hazardous_Materials_Management', 0.07818640768527985)","('Business_Model_Resilience', 0.0678633600473404)","('NON-ESG', 0.11062721908092499)","('NON-ESG', 0.07818640768527985)","('NON-ESG', 0.0678633600473404)"
Line 437,"In 2021, as part of our Company-wide goals under our annual incentive compensation program, we introduced an ESG goal focused on environmental sustainability and diversity, inclusion and belonging (DI&B) .","('Employee_Engagement_Inclusion_And_Diversity', 0.9720068573951721)","('Human_Rights_And_Community_Relations', 0.002596816746518016)","('Employee_Health_And_Safety', 0.0023652100935578346)","(['Talent Attraction & Retention'], 0.9720068573951721)","('NON-ESG', 0.002596816746518016)","('NON-ESG', 0.0023652100935578346)"
Line 438,"The DI&B portion of this ESG goal focused on the establishment and completion of DI&B action plans by our executives, with a target goal of 75% participation, which we exceeded .","('Business_Model_Resilience', 0.3397325873374939)","('Management_Of_Legal_And_Regulatory_Framework', 0.1714838743209839)","('Human_Rights_And_Community_Relations', 0.09103034436702728)","('NON-ESG', 0.3397325873374939)","('NON-ESG', 0.1714838743209839)","('NON-ESG', 0.09103034436702728)"
Line 439,"Hiring, Developing, and Retaining Diverse Talent Amgen is a founding member of OneTen, a coalition of many of the worlds largest companies that aims collectively to hire one million Black Americans into family-sustaining jobs over the next 10 years, with a focus on those without a four-year college degree .","('Employee_Engagement_Inclusion_And_Diversity', 0.9704129099845886)","('Employee_Health_And_Safety', 0.0023423677776008844)","('Customer_Welfare', 0.0020741585176438093)","(['Talent Attraction & Retention'], 0.9704129099845886)","('NON-ESG', 0.0023423677776008844)","('NON-ESG', 0.0020741585176438093)"
Line 440,"Near our global headquarters, we participated in the launch of the Los Angeles OneTen partnership .","('Business_Model_Resilience', 0.6111617088317871)","('Product_Design_And_Lifecycle_Management', 0.060866665095090866)","('Employee_Engagement_Inclusion_And_Diversity', 0.05107506364583969)","(['Human Capital Development', 'Innovation Management'], 0.6111617088317871)","('NON-ESG', 0.060866665095090866)","('NON-ESG', 0.05107506364583969)"
Line 441,"Amgen CEO Bob Bradway is serving as the CEO leader for the Los Angeles partnership, working to bring other like-minded organizations into the coalition .","('Management_Of_Legal_And_Regulatory_Framework', 0.2600196301937103)","('Human_Rights_And_Community_Relations', 0.23248662054538727)","('Employee_Engagement_Inclusion_And_Diversity', 0.05987776815891266)","('NON-ESG', 0.2600196301937103)","('NON-ESG', 0.23248662054538727)","('NON-ESG', 0.05987776815891266)"
Line 442,"We expect that the hiring of 750 people from a diverse talent pool in two new sites approved in 2021, Ohio and North Carolina, will help support our OneTen commitment .","('Employee_Engagement_Inclusion_And_Diversity', 0.9688082933425903)","('Employee_Health_And_Safety', 0.0027222316712141037)","('Customer_Welfare', 0.001954249572008848)","(['Talent Attraction & Retention'], 0.9688082933425903)","('NON-ESG', 0.0027222316712141037)","('NON-ESG', 0.001954249572008848)"
Line 443,We also expanded our work with Historically Black Colleges and Universities (HBCUs) by broadening our partnership with Howard University on a new educational and research fellowship (See page 32) .,"('Employee_Engagement_Inclusion_And_Diversity', 0.7902927994728088)","('Access_And_Affordability', 0.029054995626211166)","('Management_Of_Legal_And_Regulatory_Framework', 0.01754428818821907)","(['Talent Attraction & Retention'], 0.7902927994728088)","('NON-ESG', 0.029054995626211166)","('NON-ESG', 0.01754428818821907)"
Line 444,"In an effort to increase women and minorities in leadership positions, our recruitment providers are expected to provide us with diverse candidate slates for all executive-level positions and we monitor their performance on this commitment .","('Employee_Engagement_Inclusion_And_Diversity', 0.9776637554168701)","('Employee_Health_And_Safety', 0.0015564486384391785)","('Human_Rights_And_Community_Relations', 0.0015429730992764235)","(['Talent Attraction & Retention'], 0.9776637554168701)","('NON-ESG', 0.0015564486384391785)","('NON-ESG', 0.0015429730992764235)"
Line 445,"Within our workforce, we support the development of diverse talent through several initiatives, including a formal 1:1 executive mentoring program, function-specific leadership development programs, and peer mentoring networks through our 11 Employee Resource Groups (ERGs) .","('Employee_Engagement_Inclusion_And_Diversity', 0.9656448364257812)","('Employee_Health_And_Safety', 0.0034954813309013844)","('Business_Model_Resilience', 0.002274435944855213)","(['Talent Attraction & Retention'], 0.9656448364257812)","('NON-ESG', 0.0034954813309013844)","('NON-ESG', 0.002274435944855213)"
Line 446,"Since its inception in 2003, WE2 has grown to be Amgens largest ERG with 24 chapters and thousands of members around the globe .","('Employee_Engagement_Inclusion_And_Diversity', 0.2020302712917328)","('Director_Removal', 0.1434323489665985)","('Business_Model_Resilience', 0.13001805543899536)","('NON-ESG', 0.2020302712917328)","('NON-ESG', 0.1434323489665985)","('NON-ESG', 0.13001805543899536)"
Line 447,"In 2021, WE2 launched a mentoring program designed specifically to help connect high-performing women of color with senior leadership and provide opportunities for advocacy and sponsorship .","('Employee_Engagement_Inclusion_And_Diversity', 0.9612425565719604)","('Human_Rights_And_Community_Relations', 0.0034031537361443043)","('Access_And_Affordability', 0.002783035160973668)","(['Talent Attraction & Retention'], 0.9612425565719604)","('NON-ESG', 0.0034031537361443043)","('NON-ESG', 0.002783035160973668)"
Line 448,Read more about our ERGs below .,"('Systemic_Risk_Management', 0.251995325088501)","('Business_Model_Resilience', 0.20127826929092407)","('Management_Of_Legal_And_Regulatory_Framework', 0.0665016621351242)","('NON-ESG', 0.251995325088501)","('NON-ESG', 0.20127826929092407)","('NON-ESG', 0.0665016621351242)"
Line 449,"We analyze performance ratings, promotions, base pay, and total compensation of our staff as part of our efforts to drive equity in our workplace .","('Labor_Practices', 0.9534122347831726)","('Employee_Engagement_Inclusion_And_Diversity', 0.0054345810785889626)","('Business_Ethics', 0.005200821440666914)","([], 0.9534122347831726)","('NON-ESG', 0.0054345810785889626)","('NON-ESG', 0.005200821440666914)"
Line 450,"Activating a Culture of Inclusion and Belonging Our focus remains on building a more diverse, inclusive Amgen, where our workforce feels a sense of belonging and can achieve their full potential .","('Employee_Engagement_Inclusion_And_Diversity', 0.969738245010376)","('Human_Rights_And_Community_Relations', 0.0027112544048577547)","('Employee_Health_And_Safety', 0.002313094912096858)","(['Talent Attraction & Retention'], 0.969738245010376)","('NON-ESG', 0.0027112544048577547)","('NON-ESG', 0.002313094912096858)"
Line 451,"16 As of December 31, 2021, 98% of staff worldwide completed Managing Unconscious Bias training, which is now mandatory for all new hires .","('Employee_Engagement_Inclusion_And_Diversity', 0.7902626991271973)","('Labor_Practices', 0.03417379409074783)","('Employee_Health_And_Safety', 0.018808824941515923)","(['Talent Attraction & Retention'], 0.7902626991271973)","('NON-ESG', 0.03417379409074783)","('NON-ESG', 0.018808824941515923)"
Line 452,"Unconscious Bias training is recommended, but not required, for staff members in Spain, the Netherlands, Italy, France, and Germany per guidance from the EU Works Council .","('Management_Of_Legal_And_Regulatory_Framework', 0.30526110529899597)","('Employee_Engagement_Inclusion_And_Diversity', 0.1766122281551361)","('Product_Quality_And_Safety', 0.08195071667432785)","('NON-ESG', 0.30526110529899597)","('NON-ESG', 0.1766122281551361)","('NON-ESG', 0.08195071667432785)"
Line 453,"More than 1,000 WOMEN have been mentored through our Women Empowered to Be Exceptional (WE2) ERG peer mentoring program.","('Employee_Engagement_Inclusion_And_Diversity', 0.42056870460510254)","('Access_And_Affordability', 0.3058682084083557)","('Human_Rights_And_Community_Relations', 0.06811212748289108)","('NON-ESG', 0.42056870460510254)","('NON-ESG', 0.3058682084083557)","('NON-ESG', 0.06811212748289108)"
Line 454,"In our year-end employee listening survey, 77% OF STAFF SURVEYED indicated that top leaders demonstrate a visible commitment to diversity.","('Employee_Engagement_Inclusion_And_Diversity', 0.9745557904243469)","('Employee_Health_And_Safety', 0.0019786793272942305)","('Human_Rights_And_Community_Relations', 0.0016276740934699774)","(['Talent Attraction & Retention'], 0.9745557904243469)","('NON-ESG', 0.0019786793272942305)","('NON-ESG', 0.0016276740934699774)"
Line 455,"We also continued to make new learning resources available on our DI&B learning portal, focused on key behaviors needed to create an environment in which diverse teams can flourish and deliver for the patients we serve .","('Employee_Engagement_Inclusion_And_Diversity', 0.7593636512756348)","('Access_And_Affordability', 0.08408476412296295)","('Customer_Welfare', 0.01915343664586544)","(['Talent Attraction & Retention'], 0.7593636512756348)","('NON-ESG', 0.08408476412296295)","('NON-ESG', 0.01915343664586544)"
Line 456,"Healthy Society 29 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix DIVERSITY , INCLUSION & BELONGING Embracing Connectivity and Diverse Points of View Through Our ERGs In 2021, membership in our 11 ERGs increased 41% from a year earlier, and employees formed nine new global ERG chapters .","('Employee_Engagement_Inclusion_And_Diversity', 0.9599824547767639)","('Human_Rights_And_Community_Relations', 0.005924525670707226)","('Employee_Health_And_Safety', 0.00314282882027328)","(['Talent Attraction & Retention'], 0.9599824547767639)","('NON-ESG', 0.005924525670707226)","('NON-ESG', 0.00314282882027328)"
Line 457,"In total, there are more than 60 Amgen ERG chapters around the world .","('Management_Of_Legal_And_Regulatory_Framework', 0.3022134602069855)","('Competitive_Behavior', 0.06679850071668625)","('Business_Model_Resilience', 0.06471727788448334)","('NON-ESG', 0.3022134602069855)","('NON-ESG', 0.06679850071668625)","('NON-ESG', 0.06471727788448334)"
Line 458,"During 2021, ERGs hosted events to address relevant issues, such as parenting during the pandemic, and created resources such as a new podcast, The Brain Trust, developed by the Amgen Black Employee Network (ABEN) to build staff understanding and empower conversations about race in the workplace .","('Employee_Engagement_Inclusion_And_Diversity', 0.9651018381118774)","('Employee_Health_And_Safety', 0.004756868816912174)","('Human_Rights_And_Community_Relations', 0.003964579198509455)","(['Talent Attraction & Retention'], 0.9651018381118774)","('NON-ESG', 0.004756868816912174)","('NON-ESG', 0.003964579198509455)"
Line 459,ERGs also provide cultural perspectives that are helping to inform Amgen leadership and our strategic initiatives .,"('Human_Rights_And_Community_Relations', 0.4143815040588379)","('Employee_Engagement_Inclusion_And_Diversity', 0.1341487020254135)","('Business_Model_Resilience', 0.09130366891622543)","('NON-ESG', 0.4143815040588379)","('NON-ESG', 0.1341487020254135)","('NON-ESG', 0.09130366891622543)"
Line 460,"In 2021, ABEN leaders met bimonthly with senior leadership to support recruitment efforts, report on Amgen actions and advocacy in local communities, and provide insight and support for the Amgen Foundations social justice grant making (see page 30) .","('Human_Rights_And_Community_Relations', 0.9436100125312805)","('Access_And_Affordability', 0.010231751948595047)","('Management_Of_Legal_And_Regulatory_Framework', 0.004013862460851669)","([], 0.9436100125312805)","('NON-ESG', 0.010231751948595047)","('NON-ESG', 0.004013862460851669)"
Line 461,"ERGs are also supporting Amgens efforts to address healthcare equity; in 2021, the Amgen Asian Association joined ABENs ongoing collaboration with the RISE Team to increase diverse representation in clinical trials .","('Employee_Engagement_Inclusion_And_Diversity', 0.9397236108779907)","('Competitive_Behavior', 0.006739004515111446)","('Customer_Welfare', 0.00539255328476429)","(['Talent Attraction & Retention'], 0.9397236108779907)","('NON-ESG', 0.006739004515111446)","('NON-ESG', 0.00539255328476429)"
Line 462,See page 21 for more information .,"('Management_Of_Legal_And_Regulatory_Framework', 0.15811307728290558)","('GHG_Emissions', 0.08137824386358261)","('Ecological_Impacts', 0.06878712773323059)","('NON-ESG', 0.15811307728290558)","('NON-ESG', 0.08137824386358261)","('NON-ESG', 0.06878712773323059)"
Line 463,"ANA ARANTES, ABEN Brazil LeaderI am proud to see the great work the Amgen Black Employee Network Brazil team has been doing to raise awareness of racial inequalities in our country and taking actions to change it .","('Employee_Engagement_Inclusion_And_Diversity', 0.9597733616828918)","('Labor_Practices', 0.00667212950065732)","('Employee_Health_And_Safety', 0.004657135345041752)","(['Talent Attraction & Retention'], 0.9597733616828918)","('NON-ESG', 0.00667212950065732)","('NON-ESG', 0.004657135345041752)"
Line 464,Dealing with racism and other types of discriminations and prejudices are urgent tasks and critical in creating a diverse and inclusive environment where people feel they belong .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9554680585861206)","('Human_Rights_And_Community_Relations', 0.005294813308864832)","('Employee_Health_And_Safety', 0.004227770958095789)","(['Talent Attraction & Retention'], 0.9554680585861206)","('NON-ESG', 0.005294813308864832)","('NON-ESG', 0.004227770958095789)"
Line 465,DI&B strategies are also essential for us to accomplish our mission to serve patients .,"('Access_And_Affordability', 0.5149093866348267)","('Customer_Welfare', 0.06465882807970047)","('Employee_Engagement_Inclusion_And_Diversity', 0.06051374226808548)","(['Access to Healthcare'], 0.5149093866348267)","('NON-ESG', 0.06465882807970047)","('NON-ESG', 0.06051374226808548)"
Line 466,"Supporting Mental Health The pandemic and ongoing racial and social justice protests led us to reimagine and amplify mental health support for our staff, as many were mentally exhausted by the increase in racial hate incidents, particularly in the United States, said Derek Miller, Senior Vice President, Human Resources .","('Employee_Engagement_Inclusion_And_Diversity', 0.6022627949714661)","('Employee_Health_And_Safety', 0.15384092926979065)","('Human_Rights_And_Community_Relations', 0.041878800839185715)","(['Talent Attraction & Retention'], 0.6022627949714661)","('NON-ESG', 0.15384092926979065)","('NON-ESG', 0.041878800839185715)"
Line 467,"In response to ongoing racial and social injustices experienced by staff members in 2021, we created a DI&B online wellness portal where staff could find more than 20 well-being and mental health resources .","('Employee_Engagement_Inclusion_And_Diversity', 0.3365510106086731)","('Human_Rights_And_Community_Relations', 0.26341909170150757)","('Employee_Health_And_Safety', 0.1498776525259018)","('NON-ESG', 0.3365510106086731)","('NON-ESG', 0.26341909170150757)","('NON-ESG', 0.1498776525259018)"
Line 468,"Healthy Society 30 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix structures that sustain racial inequity in medicine, education, and STEM fields in the United States .","('Human_Rights_And_Community_Relations', 0.4071981608867645)","('Employee_Engagement_Inclusion_And_Diversity', 0.12722744047641754)","('Business_Model_Resilience', 0.08992229402065277)","('NON-ESG', 0.4071981608867645)","('NON-ESG', 0.12722744047641754)","('NON-ESG', 0.08992229402065277)"
Line 469,"For more information on this and other initiatives we support that seek to remove barriers to access to science education, see page 37 .","('Access_And_Affordability', 0.9021648168563843)","('Product_Quality_And_Safety', 0.011829804629087448)","('Management_Of_Legal_And_Regulatory_Framework', 0.007420070935040712)","(['Access to Healthcare'], 0.9021648168563843)","('NON-ESG', 0.011829804629087448)","('NON-ESG', 0.007420070935040712)"
Line 470,"DIVERSITY , INCLUSION & BELONGING Our Scholars are the type of students best positioned to diversify the leadership of the STEM industry, said Steve Stein, Thrive Scholars CEO .","('Employee_Engagement_Inclusion_And_Diversity', 0.9709713459014893)","('Employee_Health_And_Safety', 0.0022899762261658907)","('Business_Model_Resilience', 0.002026030793786049)","(['Talent Attraction & Retention'], 0.9709713459014893)","('NON-ESG', 0.0022899762261658907)","('NON-ESG', 0.002026030793786049)"
Line 471,But without a program like oursand partners like the Amgen Foundationmany will not .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8083215355873108)","('Business_Ethics', 0.021589534357190132)","('Ecological_Impacts', 0.02067953534424305)","([], 0.8083215355873108)","('NON-ESG', 0.021589534357190132)","('NON-ESG', 0.02067953534424305)"
Line 472,"Through our new model, Scholars receive tailored college admission guidance for STEM college programs, STEM-specific academic preparation prior to college, social-emotional and academic support geared to the rigors of STEM majors, and STEM-focused career trainingsetting them on a course for success not only in college but in life .","('Employee_Engagement_Inclusion_And_Diversity', 0.5505355596542358)","('Access_And_Affordability', 0.18074525892734528)","('Customer_Welfare', 0.026872731745243073)","(['Talent Attraction & Retention'], 0.5505355596542358)","('NON-ESG', 0.18074525892734528)","('NON-ESG', 0.026872731745243073)"
Line 473,"STEVE STEIN, Thrive Scholars CEOHelping to Build a More Just and Equitable Society In 2021, the Amgen Foundation provided grants totaling $3 million to nearly 40 U .","('Management_Of_Legal_And_Regulatory_Framework', 0.27493295073509216)","('Human_Rights_And_Community_Relations', 0.15504352748394012)","('Access_And_Affordability', 0.10573156923055649)","('NON-ESG', 0.27493295073509216)","('NON-ESG', 0.15504352748394012)","('NON-ESG', 0.10573156923055649)"
Line 474,"S .-based nonprofits in support of racial and social justice initiatives, economic empowerment, and equal opportunity in education .","('Employee_Engagement_Inclusion_And_Diversity', 0.6125661134719849)","('Human_Rights_And_Community_Relations', 0.22249864041805267)","('Access_And_Affordability', 0.0402526780962944)","(['Talent Attraction & Retention'], 0.6125661134719849)","('NON-ESG', 0.22249864041805267)","('NON-ESG', 0.0402526780962944)"
Line 475,"This included support to National Urban League, which works to elevate the standard of living in historically underserved urban communities .","('Access_And_Affordability', 0.9428118467330933)","('Product_Quality_And_Safety', 0.005654009524732828)","('Human_Rights_And_Community_Relations', 0.005466378293931484)","(['Access to Healthcare'], 0.9428118467330933)","('NON-ESG', 0.005654009524732828)","('NON-ESG', 0.005466378293931484)"
Line 476,"Supporting Future Leaders As part of our support of social justice and equal opportunity, in 2020 the Amgen Foundation provided $7 .5 million in grants to support social justice and equal opportunity to national organizations and local organizations in U .","('Employee_Engagement_Inclusion_And_Diversity', 0.34993976354599)","('Human_Rights_And_Community_Relations', 0.33926546573638916)","('Access_And_Affordability', 0.06657043099403381)","('NON-ESG', 0.34993976354599)","('NON-ESG', 0.33926546573638916)","('NON-ESG', 0.06657043099403381)"
Line 477,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 478,communities where Amgen operates .,"('Human_Rights_And_Community_Relations', 0.36593392491340637)","('Business_Model_Resilience', 0.10264647006988525)","('Access_And_Affordability', 0.10171961784362793)","('NON-ESG', 0.36593392491340637)","('NON-ESG', 0.10264647006988525)","('NON-ESG', 0.10171961784362793)"
Line 479,"One of the recipients was Thrive Scholars, which provides high-achieving, low- income students of color with six years of academic and mentoring support from high school to early career .","('Employee_Engagement_Inclusion_And_Diversity', 0.6456842422485352)","('Access_And_Affordability', 0.17721733450889587)","('Human_Rights_And_Community_Relations', 0.017513953149318695)","(['Talent Attraction & Retention'], 0.6456842422485352)","('NON-ESG', 0.17721733450889587)","('NON-ESG', 0.017513953149318695)"
Line 480,"With this 2021 grant from the Amgen Foundation, Thrive Scholars provided additional support to students interested in the life sciences, technology, and engineering, and also piloted a STEM Capstone project .","('Employee_Engagement_Inclusion_And_Diversity', 0.3178962469100952)","('Access_And_Affordability', 0.22479581832885742)","('Ecological_Impacts', 0.05966394022107124)","('NON-ESG', 0.3178962469100952)","('NON-ESG', 0.22479581832885742)","('NON-ESG', 0.05966394022107124)"
Line 481,"Through the project, 80 incoming high school seniors in a variety of locations participated in real-world consulting projects, helping to nurture their interests and skills in STEM .","('Employee_Engagement_Inclusion_And_Diversity', 0.8492141366004944)","('Access_And_Affordability', 0.04600148648023605)","('Human_Rights_And_Community_Relations', 0.008906688541173935)","(['Talent Attraction & Retention'], 0.8492141366004944)","('NON-ESG', 0.04600148648023605)","('NON-ESG', 0.008906688541173935)"
Line 482,The organization also kickstarted a program with STEM companies to provide mentorship opportunities to Thrive Scholars as well as potential internships .,"('Employee_Engagement_Inclusion_And_Diversity', 0.6965276598930359)","('Access_And_Affordability', 0.09012536704540253)","('Management_Of_Legal_And_Regulatory_Framework', 0.01744380220770836)","(['Talent Attraction & Retention'], 0.6965276598930359)","('NON-ESG', 0.09012536704540253)","('NON-ESG', 0.01744380220770836)"
Line 483,"In 2021, the Amgen Foundation also came together with leading scholars to support the launch of a new collaborative effort with LabXchange, a free online science education platform supported by the Amgen Foundation and Harvard University .","('Access_And_Affordability', 0.5405383110046387)","('Management_Of_Legal_And_Regulatory_Framework', 0.1113835871219635)","('Ecological_Impacts', 0.05514034256339073)","(['Access to Healthcare'], 0.5405383110046387)","('NON-ESG', 0.1113835871219635)","('NON-ESG', 0.05514034256339073)"
Line 484,"This latest effort is designed to empower science learners and educators to recognize and help rectify the Stop AAPI (Asian American and Pacific Islander) Hate, a reporting and resource center .","('Employee_Engagement_Inclusion_And_Diversity', 0.9715307950973511)","('Human_Rights_And_Community_Relations', 0.002584845293313265)","('Employee_Health_And_Safety', 0.0019893446005880833)","(['Talent Attraction & Retention'], 0.9715307950973511)","('NON-ESG', 0.002584845293313265)","('NON-ESG', 0.0019893446005880833)"
Line 485,"This center tracks and responds to incidents of hate, violence, harassment, discrimination, shunning, and child bullying against Asian Americans and Pacific Islanders in the United States .","('Employee_Engagement_Inclusion_And_Diversity', 0.792293906211853)","('Employee_Health_And_Safety', 0.05570635944604874)","('Labor_Practices', 0.02221847139298916)","(['Talent Attraction & Retention'], 0.792293906211853)","('NON-ESG', 0.05570635944604874)","('NON-ESG', 0.02221847139298916)"
Line 486,"Thurgood Marshall College Fund, which is dedicated to transforming the lives of students at HBCUs and Predominantly Black Institutions .","('Employee_Engagement_Inclusion_And_Diversity', 0.8474169373512268)","('Access_And_Affordability', 0.037321992218494415)","('Human_Rights_And_Community_Relations', 0.017019499093294144)","(['Talent Attraction & Retention'], 0.8474169373512268)","('NON-ESG', 0.037321992218494415)","('NON-ESG', 0.017019499093294144)"
Line 487,Education Trust to help highlight racial disparities in participation in advanced placement (AP) science courses in U .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9732316732406616)","('Access_And_Affordability', 0.0017515295185148716)","('Labor_Practices', 0.0017243375768885016)","(['Talent Attraction & Retention'], 0.9732316732406616)","('NON-ESG', 0.0017515295185148716)","('NON-ESG', 0.0017243375768885016)"
Line 488,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 489,"high schools, and identify opportunities to build foundational skills in middle school that will prepare students for success in AP-level biology, life sciences, and other STEM disciplines .","('Employee_Engagement_Inclusion_And_Diversity', 0.5540002584457397)","('Access_And_Affordability', 0.19270722568035126)","('Customer_Welfare', 0.026923025026917458)","(['Talent Attraction & Retention'], 0.5540002584457397)","('NON-ESG', 0.19270722568035126)","('NON-ESG', 0.026923025026917458)"
Line 490,"Healthy Society 31 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix 2021 DI&B DATA17 Women in total workforce18Ethnic minority in workforce (U .","('Employee_Engagement_Inclusion_And_Diversity', 0.9470722079277039)","('Human_Rights_And_Community_Relations', 0.009900009259581566)","('Employee_Health_And_Safety', 0.004779820330440998)","(['Talent Attraction & Retention'], 0.9470722079277039)","('NON-ESG', 0.009900009259581566)","('NON-ESG', 0.004779820330440998)"
Line 491,S ./P .,"('Management_Of_Legal_And_Regulatory_Framework', 0.16893349587917328)","('Systemic_Risk_Management', 0.09899919480085373)","('Waste_And_Hazardous_Materials_Management', 0.06692611426115036)","('NON-ESG', 0.16893349587917328)","('NON-ESG', 0.09899919480085373)","('NON-ESG', 0.06692611426115036)"
Line 492,R .,"('Management_Of_Legal_And_Regulatory_Framework', 0.16864672303199768)","('Human_Rights_And_Community_Relations', 0.08567094802856445)","('Ecological_Impacts', 0.06714435666799545)","('NON-ESG', 0.16864672303199768)","('NON-ESG', 0.08567094802856445)","('NON-ESG', 0.06714435666799545)"
Line 493,)Ethnic minority in workforce (U .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9659966826438904)","('Human_Rights_And_Community_Relations', 0.0027383361011743546)","('Customer_Privacy', 0.002545171184465289)","(['Talent Attraction & Retention'], 0.9659966826438904)","('NON-ESG', 0.0027383361011743546)","('NON-ESG', 0.002545171184465289)"
Line 494,S ./P .,"('Management_Of_Legal_And_Regulatory_Framework', 0.16893349587917328)","('Systemic_Risk_Management', 0.09899919480085373)","('Waste_And_Hazardous_Materials_Management', 0.06692611426115036)","('NON-ESG', 0.16893349587917328)","('NON-ESG', 0.09899919480085373)","('NON-ESG', 0.06692611426115036)"
Line 495,R .),"('Management_Of_Legal_And_Regulatory_Framework', 0.31386688351631165)","('Ecological_Impacts', 0.10419274866580963)","('Competitive_Behavior', 0.07130784541368484)","('NON-ESG', 0.31386688351631165)","('NON-ESG', 0.10419274866580963)","('NON-ESG', 0.07130784541368484)"
Line 496,"20% 20% 20%40% 40% 40%60% 60% 60%80% 80% 80%100% 100% 100%52% WOMEN18 Management level19Management level19Executive level20Executive level2049%44% 32%44% 20%25% 4% 2%DIVERSITY , INCLUSION & BELONGING Stamping Out Unconscious Bias Unconscious bias in the workplace disproportionately impacts underrepresented or underserved groups and reduces workplace productivity .","('Employee_Engagement_Inclusion_And_Diversity', 0.9634737968444824)","('Employee_Health_And_Safety', 0.0030582682229578495)","('Access_And_Affordability', 0.0028808636125177145)","(['Talent Attraction & Retention'], 0.9634737968444824)","('NON-ESG', 0.0030582682229578495)","('NON-ESG', 0.0028808636125177145)"
Line 497,"Such biases create barriers that not only prevent people from working together effectively, but also damage the trust and respect in relationships that help foster creativity and innovation .","('Business_Ethics', 0.46820029616355896)","('Human_Rights_And_Community_Relations', 0.12644928693771362)","('Employee_Engagement_Inclusion_And_Diversity', 0.08582871407270432)","('NON-ESG', 0.46820029616355896)","('NON-ESG', 0.12644928693771362)","('NON-ESG', 0.08582871407270432)"
Line 498,"Excerpt from scenario in Amgen Code of Conduct employee training module Asian Black/ African AmericanHispanic/ LatinoOther21 MORE INFORMATION Amgens Commitment to Diversity, Inclusion and Belonging 17 Data as of December 2021 .","('Employee_Engagement_Inclusion_And_Diversity', 0.9760010242462158)","('Employee_Health_And_Safety', 0.0017765138763934374)","('Human_Rights_And_Community_Relations', 0.001489694812335074)","(['Talent Attraction & Retention'], 0.9760010242462158)","('NON-ESG', 0.0017765138763934374)","('NON-ESG', 0.001489694812335074)"
Line 499,To align with U .,"('Product_Design_And_Lifecycle_Management', 0.1661994308233261)","('Business_Model_Resilience', 0.15775853395462036)","('Employee_Engagement_Inclusion_And_Diversity', 0.12257901579141617)","('NON-ESG', 0.1661994308233261)","('NON-ESG', 0.15775853395462036)","('NON-ESG', 0.12257901579141617)"
Line 500,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 501,"government reporting requirements, data in this document use the traditional gender categories of male and female .","('Employee_Engagement_Inclusion_And_Diversity', 0.8526014685630798)","('Labor_Practices', 0.05245722830295563)","('Customer_Privacy', 0.012999639846384525)","(['Talent Attraction & Retention'], 0.8526014685630798)","('NON-ESG', 0.05245722830295563)","('NON-ESG', 0.012999639846384525)"
Line 502,We deeply respect that gender is not binary; reporting in this manner should not represent our position on the issue .,"('Employee_Engagement_Inclusion_And_Diversity', 0.969722330570221)","('Labor_Practices', 0.0027313928585499525)","('Employee_Health_And_Safety', 0.002396285766735673)","(['Talent Attraction & Retention'], 0.969722330570221)","('NON-ESG', 0.0027313928585499525)","('NON-ESG', 0.002396285766735673)"
Line 503,Totals may not add up to 100% due to rounding or employees who have not reported their gender and/or race/ethnicity .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9694464206695557)","('Customer_Privacy', 0.0027000606060028076)","('Employee_Health_And_Safety', 0.002403479302302003)","(['Talent Attraction & Retention'], 0.9694464206695557)","('NON-ESG', 0.0027000606060028076)","('NON-ESG', 0.002403479302302003)"
Line 504,"18 Data based on total headcount as reported in our Form 10-K for the year ended December 31, 2021, modified to reflect active employee headcount, which, among other things, excludes co-ops and interns .","('Employee_Engagement_Inclusion_And_Diversity', 0.4961145222187042)","('Labor_Practices', 0.12541992962360382)","('Director_Removal', 0.06437677145004272)","('NON-ESG', 0.4961145222187042)","('NON-ESG', 0.12541992962360382)","('NON-ESG', 0.06437677145004272)"
Line 505,Also excludes Gensenta Pharmaceuticals and deCode Genetics .,"('Competitive_Behavior', 0.1897391974925995)","('Systemic_Risk_Management', 0.11011549830436707)","('Business_Model_Resilience', 0.08192653954029083)","('NON-ESG', 0.1897391974925995)","('NON-ESG', 0.11011549830436707)","('NON-ESG', 0.08192653954029083)"
Line 506,19 Management: Senior managers and directors .,"('Director_Removal', 0.5360201001167297)","('Employee_Engagement_Inclusion_And_Diversity', 0.11605685204267502)","('Business_Model_Resilience', 0.04466041922569275)","(['Business Ethics'], 0.5360201001167297)","('NON-ESG', 0.11605685204267502)","('NON-ESG', 0.04466041922569275)"
Line 507,20 Executive level: Executive directors and above .,"('Director_Removal', 0.7276946902275085)","('Employee_Engagement_Inclusion_And_Diversity', 0.026580382138490677)","('Data_Security', 0.025149742141366005)","(['Business Ethics'], 0.7276946902275085)","('NON-ESG', 0.026580382138490677)","('NON-ESG', 0.025149742141366005)"
Line 508,"21 Other: American Indian/Alaska Native, Native Hawaiian or Pacific Islander, two or more races, or not specified .","('Employee_Engagement_Inclusion_And_Diversity', 0.9657649397850037)","('Human_Rights_And_Community_Relations', 0.0036753122694790363)","('Labor_Practices', 0.0024697950575500727)","(['Talent Attraction & Retention'], 0.9657649397850037)","('NON-ESG', 0.0036753122694790363)","('NON-ESG', 0.0024697950575500727)"
Line 509,"Although we do not use our Federal Employer Information Report EEO-1 to measure progress, we make our most recent filing publicly available .","('Customer_Privacy', 0.7270581126213074)","('Employee_Engagement_Inclusion_And_Diversity', 0.06933639943599701)","('Access_And_Affordability', 0.024161646142601967)","([], 0.7270581126213074)","('NON-ESG', 0.06933639943599701)","('NON-ESG', 0.024161646142601967)"
Line 510,"For more information around the composition of our workforce, please go to our 2021 Workforce Diversity Report .51% MINORITY (U .","('Employee_Engagement_Inclusion_And_Diversity', 0.9732093214988708)","('Business_Model_Resilience', 0.0017061737598851323)","('Employee_Health_And_Safety', 0.0017036722274497151)","(['Talent Attraction & Retention'], 0.9732093214988708)","('NON-ESG', 0.0017061737598851323)","('NON-ESG', 0.0017036722274497151)"
Line 511,S ./P .,"('Management_Of_Legal_And_Regulatory_Framework', 0.16893349587917328)","('Systemic_Risk_Management', 0.09899919480085373)","('Waste_And_Hazardous_Materials_Management', 0.06692611426115036)","('NON-ESG', 0.16893349587917328)","('NON-ESG', 0.09899919480085373)","('NON-ESG', 0.06692611426115036)"
Line 512,R .,"('Management_Of_Legal_And_Regulatory_Framework', 0.16864672303199768)","('Human_Rights_And_Community_Relations', 0.08567094802856445)","('Ecological_Impacts', 0.06714435666799545)","('NON-ESG', 0.16864672303199768)","('NON-ESG', 0.08567094802856445)","('NON-ESG', 0.06714435666799545)"
Line 513,")Healthy Society Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix NEW FELLOWSHIP PROGRAM BETWEEN AMGEN AND HOWARD UNIVERSITY AIMS TO EXPAND TALENT POOL Her passion was fueled by a mother who held a math degree and made sure ONeal took advanced classes, enrolled her in summer camps centered on science and took trips to Dr .","('Access_And_Affordability', 0.4255343973636627)","('Employee_Engagement_Inclusion_And_Diversity', 0.20849674940109253)","('Employee_Health_And_Safety', 0.07941318303346634)","('NON-ESG', 0.4255343973636627)","('NON-ESG', 0.20849674940109253)","('NON-ESG', 0.07941318303346634)"
Line 514,Johnsons house .,"('Waste_And_Hazardous_Materials_Management', 0.13297341763973236)","('Product_Design_And_Lifecycle_Management', 0.08654339611530304)","('Ecological_Impacts', 0.0835377648472786)","('NON-ESG', 0.13297341763973236)","('NON-ESG', 0.08654339611530304)","('NON-ESG', 0.0835377648472786)"
Line 515,Dr .,"('Management_Of_Legal_And_Regulatory_Framework', 0.124688521027565)","('Competitive_Behavior', 0.11675971746444702)","('Product_Quality_And_Safety', 0.09105435758829117)","('NON-ESG', 0.124688521027565)","('NON-ESG', 0.11675971746444702)","('NON-ESG', 0.09105435758829117)"
Line 516,"Johnson, a family friend, often let her come to a lab to see chemistry experiments in action and it thrilled her .","('Access_And_Affordability', 0.1679934859275818)","('Waste_And_Hazardous_Materials_Management', 0.12214979529380798)","('Employee_Engagement_Inclusion_And_Diversity', 0.11831428855657578)","('NON-ESG', 0.1679934859275818)","('NON-ESG', 0.12214979529380798)","('NON-ESG', 0.11831428855657578)"
Line 517,That path was solidified through high school and college as ONeal earned scholarships and science awards and obtained her bachelors degree in chemical engineering from Howard University .,"('Access_And_Affordability', 0.5151719450950623)","('Employee_Engagement_Inclusion_And_Diversity', 0.13933663070201874)","('Management_Of_Legal_And_Regulatory_Framework', 0.03648293390870094)","(['Access to Healthcare'], 0.5151719450950623)","('NON-ESG', 0.13933663070201874)","('NON-ESG', 0.03648293390870094)"
Line 518,"In 2021, she took another step working towards a masters degree and joining Amgen as a part of the Amgen Educational Fellowship at Howard University in its inaugural year .","('Access_And_Affordability', 0.34558823704719543)","('Employee_Engagement_Inclusion_And_Diversity', 0.16927549242973328)","('Management_Of_Legal_And_Regulatory_Framework', 0.08602886646986008)","('NON-ESG', 0.34558823704719543)","('NON-ESG', 0.16927549242973328)","('NON-ESG', 0.08602886646986008)"
Line 519,"The program provides its fellows further insights into a career in science, including what a career at Amgen looks like and understanding the Companys interest in adding diversity to its research ranks .","('Employee_Engagement_Inclusion_And_Diversity', 0.9660577774047852)","('Employee_Health_And_Safety', 0.0027958485297858715)","('Business_Model_Resilience', 0.0022223955020308495)","(['Talent Attraction & Retention'], 0.9660577774047852)","('NON-ESG', 0.0027958485297858715)","('NON-ESG', 0.0022223955020308495)"
Line 520,"It was the excitement of connecting science to the real world, ONeal says.","('Access_And_Affordability', 0.10957616567611694)","('Business_Model_Resilience', 0.08312880992889404)","('Product_Design_And_Lifecycle_Management', 0.07925225049257278)","('NON-ESG', 0.10957616567611694)","('NON-ESG', 0.08312880992889404)","('NON-ESG', 0.07925225049257278)"
Line 521,It wasnt magic or ambiguous.,"('Business_Ethics', 0.3089144229888916)","('Competitive_Behavior', 0.17851774394512177)","('Management_Of_Legal_And_Regulatory_Framework', 0.04519078508019447)","('NON-ESG', 0.3089144229888916)","('NON-ESG', 0.17851774394512177)","('NON-ESG', 0.04519078508019447)"
Line 522,It was relatable to everything.,"('Business_Ethics', 0.2449118196964264)","('Competitive_Behavior', 0.21826347708702087)","('Labor_Practices', 0.04599462077021599)","('NON-ESG', 0.2449118196964264)","('NON-ESG', 0.21826347708702087)","('NON-ESG', 0.04599462077021599)"
Line 523,"PILAR ONEAL loved science from an early age, doing dissections or investigating the ingredients in everyday household items to understand the chemistry that made them what they were .","('Selling_Practices_And_Product_Labeling', 0.9167774319648743)","('Customer_Welfare', 0.015310562215745449)","('Product_Design_And_Lifecycle_Management', 0.009904425591230392)","(['Business Ethics'], 0.9167774319648743)","('NON-ESG', 0.015310562215745449)","('NON-ESG', 0.009904425591230392)"
Line 524,"This program exemplifies our commitment to improving diversity and inclusion throughout Amgen and our Research & Development organization, said Alan Russell, Vice President, Research at Amgen .","('Employee_Engagement_Inclusion_And_Diversity', 0.9708043932914734)","('Employee_Health_And_Safety', 0.0024396581575274467)","('Human_Rights_And_Community_Relations', 0.0023856221232563257)","(['Talent Attraction & Retention'], 0.9708043932914734)","('NON-ESG', 0.0024396581575274467)","('NON-ESG', 0.0023856221232563257)"
Line 525,We hope it will serve as a flagship to expand to other departments at Howard University and other HBCUs .,"('Employee_Engagement_Inclusion_And_Diversity', 0.2830619513988495)","('Access_And_Affordability', 0.17245522141456604)","('Ecological_Impacts', 0.07114596664905548)","('NON-ESG', 0.2830619513988495)","('NON-ESG', 0.17245522141456604)","('NON-ESG', 0.07114596664905548)"
Line 526,"During the first year of the program, students will be at Howard working with mentors from the Howard University Department of Chemical Engineering .","('Employee_Engagement_Inclusion_And_Diversity', 0.3740301728248596)","('Access_And_Affordability', 0.17458321154117584)","('Product_Design_And_Lifecycle_Management', 0.05135750770568848)","('NON-ESG', 0.3740301728248596)","('NON-ESG', 0.17458321154117584)","('NON-ESG', 0.05135750770568848)"
Line 527,"During the second year, they will be onsite at an Amgen location for six months working on research projects .","('Access_And_Affordability', 0.251516729593277)","('Supply_Chain_Management', 0.10348160564899445)","('GHG_Emissions', 0.07189703732728958)","('NON-ESG', 0.251516729593277)","('NON-ESG', 0.10348160564899445)","('NON-ESG', 0.07189703732728958)"
Line 528,"Bram Estes, a senior scientist in biologics at Amgen, is ONeals mentor, working with her on a project connected to DNA protein co-delivery into cells and intracellular routing and uptake of biologics .","('Customer_Welfare', 0.361126571893692)","('Access_And_Affordability', 0.09405762702226639)","('Business_Model_Resilience', 0.05278848111629486)","('NON-ESG', 0.361126571893692)","('NON-ESG', 0.09405762702226639)","('NON-ESG', 0.05278848111629486)"
Line 529,He has high hopes for both the project and ONeal .,"('Business_Model_Resilience', 0.15167981386184692)","('Business_Ethics', 0.11099106073379517)","('Management_Of_Legal_And_Regulatory_Framework', 0.10048390179872513)","('NON-ESG', 0.15167981386184692)","('NON-ESG', 0.11099106073379517)","('NON-ESG', 0.10048390179872513)"
Line 530,"I would like her to publish her research in the Amgen-Howard collaboration, both to advance science and to establish her reputation in the scientific community, Estes said .","('Ecological_Impacts', 0.23528939485549927)","('Management_Of_Legal_And_Regulatory_Framework', 0.11364865303039551)","('GHG_Emissions', 0.09827705472707748)","('NON-ESG', 0.23528939485549927)","('NON-ESG', 0.11364865303039551)","('NON-ESG', 0.09827705472707748)"
Line 531,This project is the beginning of what I hope will be a great career .,"('Employee_Engagement_Inclusion_And_Diversity', 0.28617656230926514)","('Business_Model_Resilience', 0.15658830106258392)","('Director_Removal', 0.06318365037441254)","('NON-ESG', 0.28617656230926514)","('NON-ESG', 0.15658830106258392)","('NON-ESG', 0.06318365037441254)"
Line 532,ONeal agrees .,"('Business_Ethics', 0.23348310589790344)","('Management_Of_Legal_And_Regulatory_Framework', 0.22630535066127777)","('Competitive_Behavior', 0.10265248268842697)","('NON-ESG', 0.23348310589790344)","('NON-ESG', 0.22630535066127777)","('NON-ESG', 0.10265248268842697)"
Line 533,"When she completes the program in two years, she will have her graduate degree and, she hopes, a chance to fulfill a lifelong dream to contribute to the world of science .","('Employee_Engagement_Inclusion_And_Diversity', 0.33647140860557556)","('Access_And_Affordability', 0.11384553462266922)","('Management_Of_Legal_And_Regulatory_Framework', 0.06518933922052383)","('NON-ESG', 0.33647140860557556)","('NON-ESG', 0.11384553462266922)","('NON-ESG', 0.06518933922052383)"
Line 534,"My goal is to help my community and to help humanity, ONeal says .","('Human_Rights_And_Community_Relations', 0.8658521175384521)","('Access_And_Affordability', 0.017157316207885742)","('Employee_Engagement_Inclusion_And_Diversity', 0.015082046389579773)","([], 0.8658521175384521)","('NON-ESG', 0.017157316207885742)","('NON-ESG', 0.015082046389579773)"
Line 535,"So maybe one day, even if I help just a few people, Ill have made a positive impact on the world .","('Human_Rights_And_Community_Relations', 0.46593496203422546)","('Access_And_Affordability', 0.10658842325210571)","('Employee_Health_And_Safety', 0.05428773909807205)","('NON-ESG', 0.46593496203422546)","('NON-ESG', 0.10658842325210571)","('NON-ESG', 0.05428773909807205)"
Line 536,"32 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021Healthy Society 33 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix We seek to recruit, develop, and retain the best and the brightest from an array of fields and diverse backgrounds .","('Employee_Engagement_Inclusion_And_Diversity', 0.7122696042060852)","('Human_Rights_And_Community_Relations', 0.052272994071245193)","('Business_Model_Resilience', 0.03085189126431942)","(['Talent Attraction & Retention'], 0.7122696042060852)","('NON-ESG', 0.052272994071245193)","('NON-ESG', 0.03085189126431942)"
Line 537,We work to provide our employees the skills and career development they need to build meaningful careers and tools to support their total wellness .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9005413055419922)","('Employee_Health_And_Safety', 0.015553548000752926)","('Access_And_Affordability', 0.008961026556789875)","(['Talent Attraction & Retention'], 0.9005413055419922)","('NON-ESG', 0.015553548000752926)","('NON-ESG', 0.008961026556789875)"
Line 538,We also invest in the safety of our staff and work to help ensure compliance with all applicable international human rights standards within both our own operations and those of our suppliers .,"('Human_Rights_And_Community_Relations', 0.17540857195854187)","('Employee_Health_And_Safety', 0.17217756807804108)","('Labor_Practices', 0.15354909002780914)","('NON-ESG', 0.17540857195854187)","('NON-ESG', 0.17217756807804108)","('NON-ESG', 0.15354909002780914)"
Line 539,"TALENT MANAGEMENT AND DEVELOPMENT We help our employees at every level build and strengthen skills required to meet the evolving needs of our business, as well as advance into new roles .","('Employee_Engagement_Inclusion_And_Diversity', 0.964944064617157)","('Employee_Health_And_Safety', 0.00368765601888299)","('Business_Model_Resilience', 0.002389178378507495)","(['Talent Attraction & Retention'], 0.964944064617157)","('NON-ESG', 0.00368765601888299)","('NON-ESG', 0.002389178378507495)"
Line 540,"Our online learning hub is accessible to all staff globally and includes resources for skills development, playlists based on topic areas such as manager effectiveness and time management, podcasts, and articles .","('Employee_Engagement_Inclusion_And_Diversity', 0.7943130731582642)","('Access_And_Affordability', 0.04711247980594635)","('Employee_Health_And_Safety', 0.024396175518631935)","(['Talent Attraction & Retention'], 0.7943130731582642)","('NON-ESG', 0.04711247980594635)","('NON-ESG', 0.024396175518631935)"
Line 541,"Within the United States, Canada, and Puerto Rico, we offer a tuition reimbursement program, which reimburses participating full- and part-time staff members for college tuition, books, and specified exam and registration fees (up to plan limits) .","('Management_Of_Legal_And_Regulatory_Framework', 0.26273107528686523)","('Access_And_Affordability', 0.21419720351696014)","('Labor_Practices', 0.18965575098991394)","('NON-ESG', 0.26273107528686523)","('NON-ESG', 0.21419720351696014)","('NON-ESG', 0.18965575098991394)"
Line 542,We also offer a manager training curriculum to prepare new managers to lead and inspire their teams .,"('Employee_Engagement_Inclusion_And_Diversity', 0.30412524938583374)","('Human_Rights_And_Community_Relations', 0.244449183344841)","('Access_And_Affordability', 0.07361958920955658)","('NON-ESG', 0.30412524938583374)","('NON-ESG', 0.244449183344841)","('NON-ESG', 0.07361958920955658)"
Line 543,"At leadership levels, we have an annual process to help identify and develop talent and prepare future leaders .","('Employee_Engagement_Inclusion_And_Diversity', 0.9418317079544067)","('Business_Model_Resilience', 0.005266046151518822)","('Employee_Health_And_Safety', 0.0037171277217566967)","(['Talent Attraction & Retention'], 0.9418317079544067)","('NON-ESG', 0.005266046151518822)","('NON-ESG', 0.0037171277217566967)"
Line 544,Our consistent process has resulted in a strong internal pipeline of leadership talent that we draw on when hiring or replacing key leadership roles .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9299695491790771)","('Director_Removal', 0.007454766426235437)","('Business_Model_Resilience', 0.0061989896930754185)","(['Talent Attraction & Retention'], 0.9299695491790771)","('NON-ESG', 0.007454766426235437)","('NON-ESG', 0.0061989896930754185)"
Line 545,"VALUE CREATION Our global presence is strengthened by our ability to attract, retain, and promote a diverse workforce of talented and engaged employees who believe in our mission and values.","('Employee_Engagement_Inclusion_And_Diversity', 0.9702665209770203)","('Business_Model_Resilience', 0.0022063341457396746)","('Employee_Health_And_Safety', 0.002192786429077387)","(['Talent Attraction & Retention'], 0.9702665209770203)","('NON-ESG', 0.0022063341457396746)","('NON-ESG', 0.002192786429077387)"
Line 546,"At Amgen, it is our staff that bring innovation to life and make us who we are a leader in serving patients.","('Access_And_Affordability', 0.3699398338794708)","('Product_Design_And_Lifecycle_Management', 0.12098176777362823)","('Customer_Welfare', 0.11008363217115402)","('NON-ESG', 0.3699398338794708)","('NON-ESG', 0.12098176777362823)","('NON-ESG', 0.11008363217115402)"
Line 547,HUMAN CAPITAL MANAGEMENT BUILDING OUR DIGITAL MUSCLE Accelerating digital innovation is an Amgen priority .,"('Business_Model_Resilience', 0.5717810392379761)","('Competitive_Behavior', 0.09627421200275421)","('Systemic_Risk_Management', 0.07685188949108124)","(['Human Capital Development', 'Innovation Management'], 0.5717810392379761)","('NON-ESG', 0.09627421200275421)","('NON-ESG', 0.07685188949108124)"
Line 548,"Critical to the programs success is having highly skilled Amgen staff equipped with capabilities in data science, software and data engineering, automation, information security, and other areas requiring complex problem-solving skills .","('Data_Security', 0.9279558658599854)","('Systemic_Risk_Management', 0.009526252746582031)","('Business_Ethics', 0.00939007569104433)","([], 0.9279558658599854)","('NON-ESG', 0.009526252746582031)","('NON-ESG', 0.00939007569104433)"
Line 549,"We are investing to help our current employees strengthen their digital skills through fully reimbursed certification programs, as well as online courses .","('Employee_Engagement_Inclusion_And_Diversity', 0.7570775151252747)","('Product_Quality_And_Safety', 0.03581638261675835)","('Access_And_Affordability', 0.02930539660155773)","(['Talent Attraction & Retention'], 0.7570775151252747)","('NON-ESG', 0.03581638261675835)","('NON-ESG', 0.02930539660155773)"
Line 550,And we are accelerating our recruitment of candidates with this highly sought-after digital expertise .,"('Employee_Engagement_Inclusion_And_Diversity', 0.8873457312583923)","('Business_Model_Resilience', 0.015077454037964344)","('Customer_Welfare', 0.00940912589430809)","(['Talent Attraction & Retention'], 0.8873457312583923)","('NON-ESG', 0.015077454037964344)","('NON-ESG', 0.00940912589430809)"
Line 551,"To help in our outreach to new candidates, we asked our current staff working in digital to talk about their experience and what life is like at Amgen .","('Employee_Engagement_Inclusion_And_Diversity', 0.7408379912376404)","('Business_Model_Resilience', 0.036643680185079575)","('Access_And_Affordability', 0.027714552357792854)","(['Talent Attraction & Retention'], 0.7408379912376404)","('NON-ESG', 0.036643680185079575)","('NON-ESG', 0.027714552357792854)"
Line 552,You can hear their stories here .,"('Employee_Engagement_Inclusion_And_Diversity', 0.1731603592634201)","('Human_Rights_And_Community_Relations', 0.11886616796255112)","('Access_And_Affordability', 0.08527512848377228)","('NON-ESG', 0.1731603592634201)","('NON-ESG', 0.11886616796255112)","('NON-ESG', 0.08527512848377228)"
Line 553,"Healthy Society 34 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix HUMAN CAPITAL MANAGEMENT EMPLOYEE HEAL TH AND WELL-BEING From our competitive compensation programs to our progressive benefits and wellness programs, we work hard to support the health and well-being of our employees and their families .","('Employee_Health_And_Safety', 0.4165920615196228)","('Employee_Engagement_Inclusion_And_Diversity', 0.17008669674396515)","('Human_Rights_And_Community_Relations', 0.14602553844451904)","('NON-ESG', 0.4165920615196228)","('NON-ESG', 0.17008669674396515)","('NON-ESG', 0.14602553844451904)"
Line 554,"Our approach to employee compensation and benefits is designed to deliver cash, equity, and benefit programs that are competitive with those offered by leading companies in the biotechnology and pharmaceutical industries to attract, motivate, and retain talent .","('Employee_Engagement_Inclusion_And_Diversity', 0.8714733123779297)","('Labor_Practices', 0.0494859404861927)","('Employee_Health_And_Safety', 0.020223764702677727)","(['Talent Attraction & Retention'], 0.8714733123779297)","('NON-ESG', 0.0494859404861927)","('NON-ESG', 0.020223764702677727)"
Line 555,All regular U .,"('Employee_Engagement_Inclusion_And_Diversity', 0.1477479338645935)","('Labor_Practices', 0.07187385857105255)","('Data_Security', 0.06135021150112152)","('NON-ESG', 0.1477479338645935)","('NON-ESG', 0.07187385857105255)","('NON-ESG', 0.06135021150112152)"
Line 556,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 557,staff members are eligible to participate in the same core health and welfare and retirement savings plans .,"('Labor_Practices', 0.30306804180145264)","('Employee_Engagement_Inclusion_And_Diversity', 0.23940211534500122)","('Management_Of_Legal_And_Regulatory_Framework', 0.0669284388422966)","('NON-ESG', 0.30306804180145264)","('NON-ESG', 0.23940211534500122)","('NON-ESG', 0.0669284388422966)"
Line 558,U .,"('Management_Of_Legal_And_Regulatory_Framework', 0.14571937918663025)","('Product_Design_And_Lifecycle_Management', 0.12332227826118469)","('Employee_Engagement_Inclusion_And_Diversity', 0.06306221336126328)","('NON-ESG', 0.14571937918663025)","('NON-ESG', 0.12332227826118469)","('NON-ESG', 0.06306221336126328)"
Line 559,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 560,"employee benefits include medical, dental and vision care plans, retirement savings plans, employee assistance programs, adoption assistance, paid parental leave programs, access to childcare, an employee stock purchase plan, healthcare and dependent care flexible spending accounts, business travel accident insurance, short- and long-term disability benefits, wellness programs, and work-life resources and referrals .","('Access_And_Affordability', 0.28231221437454224)","('Employee_Health_And_Safety', 0.2170395702123642)","('Employee_Engagement_Inclusion_And_Diversity', 0.1719784289598465)","('NON-ESG', 0.28231221437454224)","('NON-ESG', 0.2170395702123642)","('NON-ESG', 0.1719784289598465)"
Line 561,"Globally, comparable benefit programs are offered with the same health and well-being goals, while also designed to comply with local statutory requirements .","('Access_And_Affordability', 0.6526577472686768)","('Employee_Health_And_Safety', 0.126266211271286)","('Human_Rights_And_Community_Relations', 0.03971128165721893)","(['Access to Healthcare'], 0.6526577472686768)","('NON-ESG', 0.126266211271286)","('NON-ESG', 0.03971128165721893)"
Line 562,"To learn more, visit our website .","('Employee_Engagement_Inclusion_And_Diversity', 0.23569506406784058)","('Supply_Chain_Management', 0.09630031883716583)","('Business_Model_Resilience', 0.06169185787439346)","('NON-ESG', 0.23569506406784058)","('NON-ESG', 0.09630031883716583)","('NON-ESG', 0.06169185787439346)"
Line 563,Support for Employees Emotional Well-being All U .,"('Access_And_Affordability', 0.2431689202785492)","('Human_Rights_And_Community_Relations', 0.22073052823543549)","('Employee_Health_And_Safety', 0.17538635432720184)","('NON-ESG', 0.2431689202785492)","('NON-ESG', 0.22073052823543549)","('NON-ESG', 0.17538635432720184)"
Line 564,S .-based Amgen employees have access to an enhanced behavioral health program that provides employees and their dependents with mental health care .,"('Access_And_Affordability', 0.5049424171447754)","('Employee_Health_And_Safety', 0.1808386892080307)","('Employee_Engagement_Inclusion_And_Diversity', 0.093451589345932)","(['Access to Healthcare'], 0.5049424171447754)","('NON-ESG', 0.1808386892080307)","('NON-ESG', 0.093451589345932)"
Line 565,Staff outside the United States are eligible for behavioral health support consistent with national health programs in their respective local country and/or via a supplemental program sponsored by Amgen .,"('Access_And_Affordability', 0.6469728350639343)","('Employee_Health_And_Safety', 0.056257463991642)","('Product_Quality_And_Safety', 0.044136252254247665)","(['Access to Healthcare'], 0.6469728350639343)","('NON-ESG', 0.056257463991642)","('NON-ESG', 0.044136252254247665)"
Line 566,"Employees can use the program for a wide range of outpatient behavioral health conditions, including stress, anxiety, postpartum and other types of depression, relationship concerns, and sleep disorders .","('Employee_Health_And_Safety', 0.2478686273097992)","('Employee_Engagement_Inclusion_And_Diversity', 0.13185718655586243)","('Access_And_Affordability', 0.10580425709486008)","('NON-ESG', 0.2478686273097992)","('NON-ESG', 0.13185718655586243)","('NON-ESG', 0.10580425709486008)"
Line 567,"Globally, we also offer mental health training and education to Amgen managers to help them notice and respond to staff possibly in need .","('Employee_Health_And_Safety', 0.41760048270225525)","('Access_And_Affordability', 0.3389416038990021)","('Product_Quality_And_Safety', 0.03665774688124657)","('NON-ESG', 0.41760048270225525)","('NON-ESG', 0.3389416038990021)","('NON-ESG', 0.03665774688124657)"
Line 568,"In addition, we make available to our general workforce meditation and mindfulness programming, resilience training, mental and behavioral health workshops, and parenting support resources .","('Business_Model_Resilience', 0.32197293639183044)","('Employee_Engagement_Inclusion_And_Diversity', 0.2825133204460144)","('Human_Rights_And_Community_Relations', 0.07900772243738174)","('NON-ESG', 0.32197293639183044)","('NON-ESG', 0.2825133204460144)","('NON-ESG', 0.07900772243738174)"
Line 569,Employee-Centered Health Programs We offer a variety of programs to help our employees better manage a range of health conditions from breast cancer to migraines .,"('Employee_Health_And_Safety', 0.8489105701446533)","('Access_And_Affordability', 0.02751799114048481)","('Employee_Engagement_Inclusion_And_Diversity', 0.023301122710108757)","(['Health Outcome Contribution'], 0.8489105701446533)","('NON-ESG', 0.02751799114048481)","('NON-ESG', 0.023301122710108757)"
Line 570,Many offer convenient ways for employees to manage their care .,"('Access_And_Affordability', 0.5640023946762085)","('Employee_Health_And_Safety', 0.24281945824623108)","('Employee_Engagement_Inclusion_And_Diversity', 0.02695988491177559)","(['Access to Healthcare'], 0.5640023946762085)","('NON-ESG', 0.24281945824623108)","('NON-ESG', 0.02695988491177559)"
Line 571,"For example, employees with high blood pressure can track, manage, and improve their heart health from their phone with an app-based program and blood pressure monitor available at no cost to eligible health plan members .","('Employee_Health_And_Safety', 0.771822452545166)","('Critical_Incident_Risk_Management', 0.030799830332398415)","('Water_And_Wastewater_Management', 0.01899382844567299)","(['Health Outcome Contribution'], 0.771822452545166)","('NON-ESG', 0.030799830332398415)","('NON-ESG', 0.01899382844567299)"
Line 572,WORK-LIFE BALANCE The COVID-19 pandemic has brought employees need and desire for flexibility and support for work-life balance to the forefront like never before .,"('Employee_Health_And_Safety', 0.3285481035709381)","('Employee_Engagement_Inclusion_And_Diversity', 0.13189610838890076)","('Labor_Practices', 0.07253608852624893)","('NON-ESG', 0.3285481035709381)","('NON-ESG', 0.13189610838890076)","('NON-ESG', 0.07253608852624893)"
Line 573,Companies like Amgen that realize this will be on the leading edge in talent recruitment and retention .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9646462202072144)","('Employee_Health_And_Safety', 0.003470628522336483)","('Human_Rights_And_Community_Relations', 0.00243634101934731)","(['Talent Attraction & Retention'], 0.9646462202072144)","('NON-ESG', 0.003470628522336483)","('NON-ESG', 0.00243634101934731)"
Line 574,"As pandemic restrictions eased around the world in 2021, we announced a new, more flexible workplace approach, based on lessons learned during the pandemic and employee feedback .","('Critical_Incident_Risk_Management', 0.18590405583381653)","('Physical_Impacts_Of_Climate_Change', 0.1848667412996292)","('Air_Quality', 0.13281410932540894)","('NON-ESG', 0.18590405583381653)","('NON-ESG', 0.1848667412996292)","('NON-ESG', 0.13281410932540894)"
Line 575,"Our new, global approach encourages eligible employees to choose the workplace best suited to their work, while coming to an Amgen site for activities that benefit from face-to-face collaboration, networking, and recognition events .","('Employee_Engagement_Inclusion_And_Diversity', 0.6258813142776489)","('Employee_Health_And_Safety', 0.11578895896673203)","('Human_Rights_And_Community_Relations', 0.04150941222906113)","(['Talent Attraction & Retention'], 0.6258813142776489)","('NON-ESG', 0.11578895896673203)","('NON-ESG', 0.04150941222906113)"
Line 576,"Many of our employees can also choose, with manager approval, to work fully remote from anywhere within their existing assigned country .","('Labor_Practices', 0.24935872852802277)","('Employee_Engagement_Inclusion_And_Diversity', 0.2347957342863083)","('Employee_Health_And_Safety', 0.1725609302520752)","('NON-ESG', 0.24935872852802277)","('NON-ESG', 0.2347957342863083)","('NON-ESG', 0.1725609302520752)"
Line 577,"This was a pivotal moment, an opportunity to reimagine the future of working at Amgen, said Bob Bradway, Amgen CEO .","('Business_Model_Resilience', 0.6027145981788635)","('Supply_Chain_Management', 0.05800678953528404)","('Product_Design_And_Lifecycle_Management', 0.049320369958877563)","(['Human Capital Development', 'Innovation Management'], 0.6027145981788635)","('NON-ESG', 0.05800678953528404)","('NON-ESG', 0.049320369958877563)"
Line 578,"Our goal is to empower our global workforce to work when and where they are most productive, while also providing the flexibility to achieve work-life balance .","('Employee_Engagement_Inclusion_And_Diversity', 0.40142393112182617)","('Labor_Practices', 0.1490587741136551)","('Employee_Health_And_Safety', 0.14198137819766998)","('NON-ESG', 0.40142393112182617)","('NON-ESG', 0.1490587741136551)","('NON-ESG', 0.14198137819766998)"
Line 579,"For many years, Amgen has supported the need for staff flexibility, including the times surrounding life events such as the birth or adoption of a child .","('Access_And_Affordability', 0.3530418872833252)","('Employee_Engagement_Inclusion_And_Diversity', 0.2425118237733841)","('Employee_Health_And_Safety', 0.06360341608524323)","('NON-ESG', 0.3530418872833252)","('NON-ESG', 0.2425118237733841)","('NON-ESG', 0.06360341608524323)"
Line 580,We heightened our support for working parents during the pandemic by offering additional access to resources for tutoring and childcare services .,"('Access_And_Affordability', 0.9258716106414795)","('Product_Quality_And_Safety', 0.0071718948893249035)","('Critical_Incident_Risk_Management', 0.006576755084097385)","(['Access to Healthcare'], 0.9258716106414795)","('NON-ESG', 0.0071718948893249035)","('NON-ESG', 0.006576755084097385)"
Line 581,"We also offer staff members access to college Healthy Society 35 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix HUMAN CAPITAL MANAGEMENT advisory services, as well as resources to assist staff with elder care responsibilities .","('Human_Rights_And_Community_Relations', 0.3670292794704437)","('Access_And_Affordability', 0.17995746433734894)","('Employee_Engagement_Inclusion_And_Diversity', 0.10905148833990097)","('NON-ESG', 0.3670292794704437)","('NON-ESG', 0.17995746433734894)","('NON-ESG', 0.10905148833990097)"
Line 582,"Amgen continues to offer subsidized, onsite childcare at our larger Company locations .","('Access_And_Affordability', 0.8479071259498596)","('Employee_Health_And_Safety', 0.026630470529198647)","('Employee_Engagement_Inclusion_And_Diversity', 0.013137852773070335)","(['Access to Healthcare'], 0.8479071259498596)","('NON-ESG', 0.026630470529198647)","('NON-ESG', 0.013137852773070335)"
Line 583,"HUMAN RIGHTS Amgen believes in the inherent dignity of every human being, regardless of where they live or were born, their economic status, their religious beliefs, their race, their sexual orientation or expression, their disability status, or their gender identity .","('Employee_Engagement_Inclusion_And_Diversity', 0.8771655559539795)","('Human_Rights_And_Community_Relations', 0.049699075520038605)","('Employee_Health_And_Safety', 0.00867513194680214)","(['Talent Attraction & Retention'], 0.8771655559539795)","('NON-ESG', 0.049699075520038605)","('NON-ESG', 0.00867513194680214)"
Line 584,Amgen grounds this belief in its mission to serve patients and in its support of the key tenets of the United Nations Universal Declaration of Human Rights .,"('Human_Rights_And_Community_Relations', 0.9454666972160339)","('Access_And_Affordability', 0.0081767737865448)","('Labor_Practices', 0.005489136558026075)","([], 0.9454666972160339)","('NON-ESG', 0.0081767737865448)","('NON-ESG', 0.005489136558026075)"
Line 585,We expect our suppliers to uphold the same human rights of their workers .,"('Human_Rights_And_Community_Relations', 0.5873895883560181)","('Labor_Practices', 0.2794080376625061)","('Employee_Health_And_Safety', 0.025803040713071823)","([], 0.5873895883560181)","('NON-ESG', 0.2794080376625061)","('NON-ESG', 0.025803040713071823)"
Line 586,"Through our supplier assessment program (see page 42), we monitor our suppliers compliance with our Supplier Code of Conduct and internationally recognized human rights standards, including those that seek to prevent forced and child labor, support fair pay based on applicable wage laws, and allow for freedom of association .","('Labor_Practices', 0.9780681729316711)","('Director_Removal', 0.0017634161049500108)","('Human_Rights_And_Community_Relations', 0.0016364186303690076)","([], 0.9780681729316711)","('NON-ESG', 0.0017634161049500108)","('NON-ESG', 0.0016364186303690076)"
Line 587,"For more information, see our Human Rights Commitment statement .","('Human_Rights_And_Community_Relations', 0.9556612372398376)","('Access_And_Affordability', 0.0041189175099134445)","('Labor_Practices', 0.00323043717071414)","([], 0.9556612372398376)","('NON-ESG', 0.0041189175099134445)","('NON-ESG', 0.00323043717071414)"
Line 588,EMPLOYEE SAFETY Our aspiration is for an accident-free workplace .,"('Employee_Health_And_Safety', 0.9557437896728516)","('Critical_Incident_Risk_Management', 0.020644577220082283)","('Air_Quality', 0.002027019625529647)","(['Health Outcome Contribution'], 0.9557437896728516)","('NON-ESG', 0.020644577220082283)","('NON-ESG', 0.002027019625529647)"
Line 589,"Through comprehensive safety programs and ongoing education and training, we strive to maintain a robust safety culture for all employees and minimize work-related injuries, illnesses, and incidents .","('Employee_Health_And_Safety', 0.9851616621017456)","('Critical_Incident_Risk_Management', 0.002185429446399212)","('Employee_Engagement_Inclusion_And_Diversity', 0.0013080677017569542)","(['Health Outcome Contribution'], 0.9851616621017456)","('NON-ESG', 0.002185429446399212)","('NON-ESG', 0.0013080677017569542)"
Line 590,Our safety policies are based on the U .,"('Employee_Health_And_Safety', 0.5858571529388428)","('Product_Quality_And_Safety', 0.2820681035518646)","('Product_Design_And_Lifecycle_Management', 0.023345855996012688)","(['Health Outcome Contribution'], 0.5858571529388428)","('NON-ESG', 0.2820681035518646)","('NON-ESG', 0.023345855996012688)"
Line 591,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 592,Occupational Safety and Health Administration standards .,"('Employee_Health_And_Safety', 0.9698376655578613)","('Product_Quality_And_Safety', 0.005251522175967693)","('Employee_Engagement_Inclusion_And_Diversity', 0.0024784253910183907)","(['Health Outcome Contribution'], 0.9698376655578613)","('NON-ESG', 0.005251522175967693)","('NON-ESG', 0.0024784253910183907)"
Line 593,"Being able to be with my newborn daughter for several weeks after she was born in 2021 not only provided invaluable bonding time, it also helped me support my wife and my other children, all of whom were home due to the pandemic .","('Access_And_Affordability', 0.45696520805358887)","('Employee_Health_And_Safety', 0.20911014080047607)","('Critical_Incident_Risk_Management', 0.05035388842225075)","('NON-ESG', 0.45696520805358887)","('NON-ESG', 0.20911014080047607)","('NON-ESG', 0.05035388842225075)"
Line 594,It allowed me to unplug and be in the moment .,"('Product_Design_And_Lifecycle_Management', 0.44825857877731323)","('Competitive_Behavior', 0.11083052307367325)","('Business_Model_Resilience', 0.04112505540251732)","('NON-ESG', 0.44825857877731323)","('NON-ESG', 0.11083052307367325)","('NON-ESG', 0.04112505540251732)"
Line 595,"As my children continue to grow, it is reassuring to know that I have the ongoing support of my management and colleagues during this busy life stage .","('Access_And_Affordability', 0.1853983998298645)","('Human_Rights_And_Community_Relations', 0.15079310536384583)","('Employee_Engagement_Inclusion_And_Diversity', 0.1335698515176773)","('NON-ESG', 0.1853983998298645)","('NON-ESG', 0.15079310536384583)","('NON-ESG', 0.1335698515176773)"
Line 596,"For me, family-friendly policies like parental leave are important factors for why I work at Amgen .","('Access_And_Affordability', 0.271318644285202)","('Labor_Practices', 0.22039954364299774)","('Human_Rights_And_Community_Relations', 0.09556852281093597)","('NON-ESG', 0.271318644285202)","('NON-ESG', 0.22039954364299774)","('NON-ESG', 0.09556852281093597)"
Line 597,"DENNIS YAI, Senior Cousel at Amgen All employees undergo safety training during new-hire orientation and annually through our required Code of Conduct training .","('Employee_Health_And_Safety', 0.9369219541549683)","('Employee_Engagement_Inclusion_And_Diversity', 0.020307796075940132)","('Product_Quality_And_Safety', 0.008225482888519764)","(['Health Outcome Contribution'], 0.9369219541549683)","('NON-ESG', 0.020307796075940132)","('NON-ESG', 0.008225482888519764)"
Line 598,We also conduct regular safety engagement discussions between supervisors and frontline workers in our manufacturing and research facilities where expectations and feedback are exchanged .,"('Employee_Health_And_Safety', 0.9693121910095215)","('Labor_Practices', 0.006743330508470535)","('Employee_Engagement_Inclusion_And_Diversity', 0.0035845350939780474)","(['Health Outcome Contribution'], 0.9693121910095215)","('NON-ESG', 0.006743330508470535)","('NON-ESG', 0.0035845350939780474)"
Line 599,We encourage employees to offer safety observations and improvement suggestions during these discussions or through a Safety Event Evaluation (SEE) card .,"('Employee_Health_And_Safety', 0.9778444766998291)","('Product_Quality_And_Safety', 0.0028481234330683947)","('Employee_Engagement_Inclusion_And_Diversity', 0.0023373537696897984)","(['Health Outcome Contribution'], 0.9778444766998291)","('NON-ESG', 0.0028481234330683947)","('NON-ESG', 0.0023373537696897984)"
Line 600,We track injuries and near-miss incidents in an online incident tracking system .,"('Employee_Health_And_Safety', 0.926325798034668)","('Critical_Incident_Risk_Management', 0.04662204906344414)","('Air_Quality', 0.0021503535099327564)","(['Health Outcome Contribution'], 0.926325798034668)","('NON-ESG', 0.04662204906344414)","('NON-ESG', 0.0021503535099327564)"
Line 601,"In addition, we conduct a formal executive management review of functional safety performance for our Operations, Global Commercial Operations, and Research and Development facilities on a quarterly basis with a focus on identifying early signals and taking action to drive continuous improvement .","('Employee_Health_And_Safety', 0.5234185457229614)","('Product_Quality_And_Safety', 0.3450976610183716)","('Product_Design_And_Lifecycle_Management', 0.012761657126247883)","(['Health Outcome Contribution'], 0.5234185457229614)","('NON-ESG', 0.3450976610183716)","('NON-ESG', 0.012761657126247883)"
Line 602,"While many Amgen staff continued to work from home in 2021, safety did not take a back seat .","('Employee_Health_And_Safety', 0.9319150447845459)","('Product_Quality_And_Safety', 0.010366689413785934)","('Employee_Engagement_Inclusion_And_Diversity', 0.007985364645719528)","(['Health Outcome Contribution'], 0.9319150447845459)","('NON-ESG', 0.010366689413785934)","('NON-ESG', 0.007985364645719528)"
Line 603,"We conducted home ergonomic assessments for many staff, identifying equipment such as ergonomic chairs, standup desks, and external monitors to help staff work safely and comfortably .","('Employee_Health_And_Safety', 0.7552526593208313)","('Labor_Practices', 0.028684724122285843)","('Employee_Engagement_Inclusion_And_Diversity', 0.028549062088131905)","(['Health Outcome Contribution'], 0.7552526593208313)","('NON-ESG', 0.028684724122285843)","('NON-ESG', 0.028549062088131905)"
Line 604,Amgen purchased identified equipment at no cost to our employees .,"('Energy_Management', 0.36379361152648926)","('Product_Design_And_Lifecycle_Management', 0.22740158438682556)","('Employee_Health_And_Safety', 0.05171063914895058)","('NON-ESG', 0.36379361152648926)","('NON-ESG', 0.22740158438682556)","('NON-ESG', 0.05171063914895058)"
Line 605,We also implemented telematics tracking for our U .,"('Energy_Management', 0.32112327218055725)","('Product_Design_And_Lifecycle_Management', 0.20985877513885498)","('Data_Security', 0.0933244526386261)","('NON-ESG', 0.32112327218055725)","('NON-ESG', 0.20985877513885498)","('NON-ESG', 0.0933244526386261)"
Line 606,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 607,sales fleet as part of our driver safety program .,"('Employee_Health_And_Safety', 0.7746558785438538)","('Critical_Incident_Risk_Management', 0.05907711759209633)","('Product_Quality_And_Safety', 0.04532487317919731)","(['Health Outcome Contribution'], 0.7746558785438538)","('NON-ESG', 0.05907711759209633)","('NON-ESG', 0.04532487317919731)"
Line 608,Telematics helps us detect certain driving behaviors such as speeding and harsh braking .,"('Employee_Health_And_Safety', 0.2417013794183731)","('Critical_Incident_Risk_Management', 0.10265681892633438)","('Competitive_Behavior', 0.07065533846616745)","('NON-ESG', 0.2417013794183731)","('NON-ESG', 0.10265681892633438)","('NON-ESG', 0.07065533846616745)"
Line 609,"In 2021, our collision rate declined (an improvement of 8% year over year) .","('Systemic_Risk_Management', 0.5660817623138428)","('Management_Of_Legal_And_Regulatory_Framework', 0.0742257684469223)","('Physical_Impacts_Of_Climate_Change', 0.04054771736264229)","([], 0.5660817623138428)","('NON-ESG', 0.0742257684469223)","('NON-ESG', 0.04054771736264229)"
Line 610,"In addition, better driving habits typically translate into reduced fuel use, which is better for Healthy Society 36 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix HUMAN CAPITAL MANAGEMENT the environment .","('Human_Rights_And_Community_Relations', 0.47591105103492737)","('Product_Design_And_Lifecycle_Management', 0.06136604771018028)","('Access_And_Affordability', 0.06034498289227486)","('NON-ESG', 0.47591105103492737)","('NON-ESG', 0.06136604771018028)","('NON-ESG', 0.06034498289227486)"
Line 611,"With the help of telematics and other fleet safety investments in previous years, we have reduced our collision rate by 37% over the past five years .","('Employee_Health_And_Safety', 0.6186490058898926)","('Critical_Incident_Risk_Management', 0.15423744916915894)","('Product_Quality_And_Safety', 0.07260937988758087)","(['Health Outcome Contribution'], 0.6186490058898926)","('NON-ESG', 0.15423744916915894)","('NON-ESG', 0.07260937988758087)"
Line 612,"Within our manufacturing operations, we implemented human error prevention training to help facilitate our actively caring culture .","('Employee_Health_And_Safety', 0.7525617480278015)","('Business_Ethics', 0.06736989319324493)","('Critical_Incident_Risk_Management', 0.04183834046125412)","(['Health Outcome Contribution'], 0.7525617480278015)","('NON-ESG', 0.06736989319324493)","('NON-ESG', 0.04183834046125412)"
Line 613,These tools are used by staff and management to openly discuss concerns and eliminate barriers to safe performance through a raise your hand mindset .,"('Business_Ethics', 0.2347782403230667)","('Human_Rights_And_Community_Relations', 0.13690784573554993)","('Systemic_Risk_Management', 0.12672963738441467)","('NON-ESG', 0.2347782403230667)","('NON-ESG', 0.13690784573554993)","('NON-ESG', 0.12672963738441467)"
Line 614,These discussions allow teams to systematically identify and resolve small issues before they become larger problems .,"('Systemic_Risk_Management', 0.4076729416847229)","('Human_Rights_And_Community_Relations', 0.1371029168367386)","('Business_Ethics', 0.07773697376251221)","('NON-ESG', 0.4076729416847229)","('NON-ESG', 0.1371029168367386)","('NON-ESG', 0.07773697376251221)"
Line 615,"MORE INFORMATION Wellness at Amgen Safety at Amgen Environment, Health, and Safety Policy2021 PERFORMANCE DATA Amgen StaffAmgen Staff Target (0 .27)ContractorsContractors Target (0 .40) 2021 2020 2019Recordable Incident Rate 0.62 0.5 Amgen hosts an annual safety summit for employees, and 2021 was no different.","('Employee_Health_And_Safety', 0.9802533388137817)","('Critical_Incident_Risk_Management', 0.0030485421884804964)","('Employee_Engagement_Inclusion_And_Diversity', 0.0018496188567951322)","(['Health Outcome Contribution'], 0.9802533388137817)","('NON-ESG', 0.0030485421884804964)","('NON-ESG', 0.0018496188567951322)"
Line 616,What was different was the increased focus on nurturing a psychologically safe environment.,"('Access_And_Affordability', 0.5551804900169373)","('Employee_Health_And_Safety', 0.1611938178539276)","('Human_Rights_And_Community_Relations', 0.07434901595115662)","(['Access to Healthcare'], 0.5551804900169373)","('NON-ESG', 0.1611938178539276)","('NON-ESG', 0.07434901595115662)"
Line 617,"Through discussions, Amgen leaders explored ways to incorporate psychological safety within their teams.","('Employee_Health_And_Safety', 0.42451274394989014)","('Human_Rights_And_Community_Relations', 0.10509345680475235)","('Employee_Engagement_Inclusion_And_Diversity', 0.09693483263254166)","('NON-ESG', 0.42451274394989014)","('NON-ESG', 0.10509345680475235)","('NON-ESG', 0.09693483263254166)"
Line 618,"Lost Day Case Rate Amgen Staff 0 .12 0 .08 0 .09 Contractors 0 .27 0 .17 0 .25 Fatalities Amgen Staff 0 1 0 Contractors 0 0 0 Motor Vehicle Safety (collisions per million miles) Fleet 4 .40 3 .38 3 .092021 2020 20190.31 0.31 0.190.4Healthy Society 37 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix The Amgen Foundation is guided by the belief that everyone needs science, and science needs everyone .","('Employee_Health_And_Safety', 0.7465792298316956)","('Access_And_Affordability', 0.046200793236494064)","('Product_Quality_And_Safety', 0.03546144440770149)","(['Health Outcome Contribution'], 0.7465792298316956)","('NON-ESG', 0.046200793236494064)","('NON-ESG', 0.03546144440770149)"
Line 619,"By broadening access to engaging and inspiring science programs, we are working to equip future generations with the essential skills needed to thrive in our increasingly complex world .","('Access_And_Affordability', 0.7448744773864746)","('Employee_Engagement_Inclusion_And_Diversity', 0.043769411742687225)","('Product_Quality_And_Safety', 0.029573895037174225)","(['Access to Healthcare'], 0.7448744773864746)","('NON-ESG', 0.043769411742687225)","('NON-ESG', 0.029573895037174225)"
Line 620,"Working with trusted local and global partners, our aim is to Inspire the next generation of scientists and foster future problem solverswherever they are .","('Access_And_Affordability', 0.15820619463920593)","('Physical_Impacts_Of_Climate_Change', 0.12134131789207458)","('Human_Rights_And_Community_Relations', 0.08938466012477875)","('NON-ESG', 0.15820619463920593)","('NON-ESG', 0.12134131789207458)","('NON-ESG', 0.08938466012477875)"
Line 621,Engage students with diverse perspectives and backgrounds by helping to remove barriers to access to quality science education .,"('Employee_Engagement_Inclusion_And_Diversity', 0.8941940665245056)","('Access_And_Affordability', 0.03123844414949417)","('Human_Rights_And_Community_Relations', 0.008635235950350761)","(['Talent Attraction & Retention'], 0.8941940665245056)","('NON-ESG', 0.03123844414949417)","('NON-ESG', 0.008635235950350761)"
Line 622,"Support the development of best-in-class science education resources at no cost to teachers and students, particularly low-income and disadvantaged learners .","('Access_And_Affordability', 0.7735913395881653)","('Employee_Engagement_Inclusion_And_Diversity', 0.04953077435493469)","('Human_Rights_And_Community_Relations', 0.027547692880034447)","(['Access to Healthcare'], 0.7735913395881653)","('NON-ESG', 0.04953077435493469)","('NON-ESG', 0.027547692880034447)"
Line 623,"We are doing this through our four signature science education programs, described below .","('Access_And_Affordability', 0.8311001658439636)","('Product_Quality_And_Safety', 0.019219815731048584)","('Employee_Engagement_Inclusion_And_Diversity', 0.017446119338274002)","(['Access to Healthcare'], 0.8311001658439636)","('NON-ESG', 0.019219815731048584)","('NON-ESG', 0.017446119338274002)"
Line 624,"Since 1991, the Amgen Foundation has committed more than $200 million to advancing science education programming globally, reaching tens of millions of students and teachers .","('Access_And_Affordability', 0.6904746294021606)","('Employee_Engagement_Inclusion_And_Diversity', 0.06221906095743179)","('Ecological_Impacts', 0.022196928039193153)","(['Access to Healthcare'], 0.6904746294021606)","('NON-ESG', 0.06221906095743179)","('NON-ESG', 0.022196928039193153)"
Line 625,"In 2021 alone, the Amgen Foundation reached over 27 million students and educators worldwide through its four core science education programs .","('Access_And_Affordability', 0.797989010810852)","('Employee_Engagement_Inclusion_And_Diversity', 0.0330890454351902)","('Product_Quality_And_Safety', 0.017928561195731163)","(['Access to Healthcare'], 0.797989010810852)","('NON-ESG', 0.0330890454351902)","('NON-ESG', 0.017928561195731163)"
Line 626,"Through the Amgen Foundation, we are reimagining science education to improve science literacy and empower diverse thinkers to develop solutions to humanitys biggest challenges.","('Employee_Engagement_Inclusion_And_Diversity', 0.7913877367973328)","('Access_And_Affordability', 0.061780620366334915)","('Customer_Welfare', 0.01929534040391445)","(['Talent Attraction & Retention'], 0.7913877367973328)","('NON-ESG', 0.061780620366334915)","('NON-ESG', 0.01929534040391445)"
Line 627,"COMMUNITY INVESTMENT VALUE CREATION Investment in science education helps build the future pipeline of innovators and scientists the world will need to tackle global challenges, from climate change to pandemics.","('Physical_Impacts_Of_Climate_Change', 0.9460289478302002)","('Business_Model_Resilience', 0.012507008388638496)","('GHG_Emissions', 0.006039887201040983)","([], 0.9460289478302002)","('NON-ESG', 0.012507008388638496)","('NON-ESG', 0.006039887201040983)"
Line 628,"It also helps to build scientific literacy, which is critical to our industry, society, and public health .","('Access_And_Affordability', 0.39915797114372253)","('Management_Of_Legal_And_Regulatory_Framework', 0.12140849232673645)","('Ecological_Impacts', 0.09705793857574463)","('NON-ESG', 0.39915797114372253)","('NON-ESG', 0.12140849232673645)","('NON-ESG', 0.09705793857574463)"
Line 629,"Healthy Society 38 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix COMMUNITY INVESTMENT LABXCHANGE Launched by the Amgen Foundation and Harvard University in 2020, LabXchange is a free online science education platform that provides users with access to personalized instruction, virtual lab experiences, and networking opportunities across the global scientific community .","('Human_Rights_And_Community_Relations', 0.28919270634651184)","('Access_And_Affordability', 0.1447416990995407)","('Employee_Engagement_Inclusion_And_Diversity', 0.10213211923837662)","('NON-ESG', 0.28919270634651184)","('NON-ESG', 0.1447416990995407)","('NON-ESG', 0.10213211923837662)"
Line 630,"Through $13 million in grants to date from the Amgen Foundation, LabXchange reached over 12 million users in 2021, of which more than 80% were in low- or lower- middle-income countries .","('Access_And_Affordability', 0.4947219789028168)","('Management_Of_Legal_And_Regulatory_Framework', 0.13110601902008057)","('Human_Rights_And_Community_Relations', 0.0729607492685318)","('NON-ESG', 0.4947219789028168)","('NON-ESG', 0.13110601902008057)","('NON-ESG', 0.0729607492685318)"
Line 631,"LabXchange offers more than 13,000 learning experiences from over 140 different collaborating organizations .","('Access_And_Affordability', 0.3780118227005005)","('Employee_Engagement_Inclusion_And_Diversity', 0.15320685505867004)","('Customer_Welfare', 0.04376727715134621)","('NON-ESG', 0.3780118227005005)","('NON-ESG', 0.15320685505867004)","('NON-ESG', 0.04376727715134621)"
Line 632,"LabXchange has helped teachers remain connected, especially during the pandemic .","('Access_And_Affordability', 0.5405263304710388)","('Critical_Incident_Risk_Management', 0.11529971659183502)","('Employee_Health_And_Safety', 0.06329510360956192)","(['Access to Healthcare'], 0.5405263304710388)","('NON-ESG', 0.11529971659183502)","('NON-ESG', 0.06329510360956192)"
Line 633,"Uma Mahajan, a secondary educator, notes how COVID-19 has really pushed teachers to rethink their teaching strategies .","('Access_And_Affordability', 0.29577749967575073)","('Employee_Engagement_Inclusion_And_Diversity', 0.1902409791946411)","('Human_Rights_And_Community_Relations', 0.05033896490931511)","('NON-ESG', 0.29577749967575073)","('NON-ESG', 0.1902409791946411)","('NON-ESG', 0.05033896490931511)"
Line 634,"A top priority for me was to make my classroom resources equitable for all students, she says .","('Access_And_Affordability', 0.6478214859962463)","('Employee_Engagement_Inclusion_And_Diversity', 0.10827499628067017)","('Human_Rights_And_Community_Relations', 0.053852301090955734)","(['Access to Healthcare'], 0.6478214859962463)","('NON-ESG', 0.10827499628067017)","('NON-ESG', 0.053852301090955734)"
Line 635,LabXchange allows students to progress at their own pace .,"('Access_And_Affordability', 0.23526859283447266)","('Employee_Engagement_Inclusion_And_Diversity', 0.2062155306339264)","('Product_Quality_And_Safety', 0.04984361305832863)","('NON-ESG', 0.23526859283447266)","('NON-ESG', 0.2062155306339264)","('NON-ESG', 0.04984361305832863)"
Line 636,"And because I can tailor my lessons to fit my classes, it is an outstanding differentiation tool .","('Employee_Engagement_Inclusion_And_Diversity', 0.3540915846824646)","('Access_And_Affordability', 0.12678836286067963)","('Business_Model_Resilience', 0.049889031797647476)","('NON-ESG', 0.3540915846824646)","('NON-ESG', 0.12678836286067963)","('NON-ESG', 0.049889031797647476)"
Line 637,"LabXchange Provides Resources to Examine Racism in Public Health, Science, and Education With the support of a $1 .2 million grant from the Amgen Foundation in 2021, LabXchange launched a groundbreaking project designed to explore and address the structures that have perpetuated racial inequity in healthcare, education, and STEM fields in the United States .","('Employee_Engagement_Inclusion_And_Diversity', 0.9160616993904114)","('Human_Rights_And_Community_Relations', 0.012514590285718441)","('Access_And_Affordability', 0.010468813590705395)","(['Talent Attraction & Retention'], 0.9160616993904114)","('NON-ESG', 0.012514590285718441)","('NON-ESG', 0.010468813590705395)"
Line 638,"Under the guidance of an expert faculty steering committee, graduate student fellows from HBCUs and other institutions are authoring new digital learning resources for high school and college educators .","('Access_And_Affordability', 0.4337049722671509)","('Employee_Engagement_Inclusion_And_Diversity', 0.22100377082824707)","('Ecological_Impacts', 0.03379859775304794)","('NON-ESG', 0.4337049722671509)","('NON-ESG', 0.22100377082824707)","('NON-ESG', 0.03379859775304794)"
Line 639,"Resources, which will be made freely available in English and Spanish, will focus on Racism as a Public Health Crisis: Increasing public awareness of racial health disparities and teaching critical thinking skills needed to dismantle structures that perpetuate inequities .","('Employee_Engagement_Inclusion_And_Diversity', 0.5792137384414673)","('Employee_Health_And_Safety', 0.11959033459424973)","('Access_And_Affordability', 0.0456777922809124)","(['Talent Attraction & Retention'], 0.5792137384414673)","('NON-ESG', 0.11959033459424973)","('NON-ESG', 0.0456777922809124)"
Line 640,"Inclusive and Antiracist Teaching Strategies: Providing evidence-based practices to support Black students sense of belonging, identity, and success in science; and culturally responsive teaching, as well as strategies to increase participation and leadership in science from historically underrepresented and underserved groups .","('Access_And_Affordability', 0.5314252972602844)","('Employee_Engagement_Inclusion_And_Diversity', 0.2598377764225006)","('Human_Rights_And_Community_Relations', 0.045449815690517426)","(['Access to Healthcare'], 0.5314252972602844)","('NON-ESG', 0.2598377764225006)","('NON-ESG', 0.045449815690517426)"
Line 641,"Twenty years ago in my essay Why We Should Teach Our Students About Race, I opined about the completely ineffective K-12 approach concerning human biological diversity .","('Employee_Engagement_Inclusion_And_Diversity', 0.9726699590682983)","('Human_Rights_And_Community_Relations', 0.0022315653041005135)","('Employee_Health_And_Safety', 0.0019281561253592372)","(['Talent Attraction & Retention'], 0.9726699590682983)","('NON-ESG', 0.0022315653041005135)","('NON-ESG', 0.0019281561253592372)"
Line 642,"Thanks to LabXchange and the Amgen Foundation, we now have a plan to rectify this .","('Management_Of_Legal_And_Regulatory_Framework', 0.26915013790130615)","('Business_Model_Resilience', 0.20780745148658752)","('Systemic_Risk_Management', 0.07884553074836731)","('NON-ESG', 0.26915013790130615)","('NON-ESG', 0.20780745148658752)","('NON-ESG', 0.07884553074836731)"
Line 643,DR.,"('Management_Of_Legal_And_Regulatory_Framework', 0.124688521027565)","('Competitive_Behavior', 0.11675971746444702)","('Product_Quality_And_Safety', 0.09105435758829117)","('NON-ESG', 0.124688521027565)","('NON-ESG', 0.11675971746444702)","('NON-ESG', 0.09105435758829117)"
Line 644,JOSEPH L.,"('Employee_Engagement_Inclusion_And_Diversity', 0.13969582319259644)","('Business_Ethics', 0.0746745616197586)","('Management_Of_Legal_And_Regulatory_Framework', 0.07409217208623886)","('NON-ESG', 0.13969582319259644)","('NON-ESG', 0.0746745616197586)","('NON-ESG', 0.07409217208623886)"
Line 645,"GRAVES JR., renowned evolutionary geneticist, and faculty steering committee member for the Racial Diversity LabXchange project LABXCHANGE IMPACT Users WorldwideCollaboratorsHours of Engagement 2021 2021 2021 2020 2020 20203.8M12.4M 59 133,487191,31781 For more information, visit the Racial Diversity, Equity and Inclusion in Science Education project on LabXchange .","('Employee_Engagement_Inclusion_And_Diversity', 0.9765692949295044)","('Employee_Health_And_Safety', 0.0018235913012176752)","('Business_Model_Resilience', 0.0016220926772803068)","(['Talent Attraction & Retention'], 0.9765692949295044)","('NON-ESG', 0.0018235913012176752)","('NON-ESG', 0.0016220926772803068)"
Line 646,"Healthy Society 39 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix COMMUNITY INVESTMENT KHAN ACADEMY The Amgen Foundation is the exclusive sponsor of Khan Academys biology resources, which range from ninth-grade biology content to Advanced Placement (AP) biology .","('Human_Rights_And_Community_Relations', 0.27419614791870117)","('Employee_Engagement_Inclusion_And_Diversity', 0.22236603498458862)","('Access_And_Affordability', 0.1311524510383606)","('NON-ESG', 0.27419614791870117)","('NON-ESG', 0.22236603498458862)","('NON-ESG', 0.1311524510383606)"
Line 647,These biology resources reached 15 million students and educators worldwide in 2021 .,"('Access_And_Affordability', 0.7247599363327026)","('Employee_Engagement_Inclusion_And_Diversity', 0.053241413086652756)","('Product_Quality_And_Safety', 0.024188216775655746)","(['Access to Healthcare'], 0.7247599363327026)","('NON-ESG', 0.053241413086652756)","('NON-ESG', 0.024188216775655746)"
Line 648,"Khan Academy offers a free, high-quality virtual classroom for students and teachers around the world .","('Access_And_Affordability', 0.8013663291931152)","('Employee_Engagement_Inclusion_And_Diversity', 0.02241652086377144)","('Product_Quality_And_Safety', 0.018764745444059372)","(['Access to Healthcare'], 0.8013663291931152)","('NON-ESG', 0.02241652086377144)","('NON-ESG', 0.018764745444059372)"
Line 649,"Since 2015, the Amgen Foundation has committed nearly $7 million to Khan Academy, including to support school district partnerships during the COVID-19 pandemic .","('Access_And_Affordability', 0.6388350129127502)","('Critical_Incident_Risk_Management', 0.06087838113307953)","('Employee_Health_And_Safety', 0.0338359959423542)","(['Access to Healthcare'], 0.6388350129127502)","('NON-ESG', 0.06087838113307953)","('NON-ESG', 0.0338359959423542)"
Line 650,"As of the end of 2021, Khan Academy has more than 130 million registered users around the world .","('Data_Security', 0.36150145530700684)","('Product_Design_And_Lifecycle_Management', 0.06331510841846466)","('Management_Of_Legal_And_Regulatory_Framework', 0.061866991221904755)","('NON-ESG', 0.36150145530700684)","('NON-ESG', 0.06331510841846466)","('NON-ESG', 0.061866991221904755)"
Line 651,"One of the schools supported by Khan Academy is Hueneme Elementary, in Port Hueneme, Calif ., where 84% of students qualify for free and reduced lunch, and 44% are English language learners .","('Employee_Engagement_Inclusion_And_Diversity', 0.3613095283508301)","('Access_And_Affordability', 0.3602830469608307)","('Customer_Welfare', 0.028650952503085136)","('NON-ESG', 0.3613095283508301)","('NON-ESG', 0.3602830469608307)","('NON-ESG', 0.028650952503085136)"
Line 652,The district worked with Khan Academy to set goals and train teachers to help strengthen learning outcomes through encouraging increased student use of Khan Academy resources .,"('Access_And_Affordability', 0.8117110133171082)","('Employee_Engagement_Inclusion_And_Diversity', 0.03289905562996864)","('Product_Quality_And_Safety', 0.017676474526524544)","(['Access to Healthcare'], 0.8117110133171082)","('NON-ESG', 0.03289905562996864)","('NON-ESG', 0.017676474526524544)"
Line 653,"I started to use Khan Academy on a daily basis a few weeks into lockdown, says one Khan Academy student .","('Data_Security', 0.2797999680042267)","('Labor_Practices', 0.10341800004243851)","('Systemic_Risk_Management', 0.08854326605796814)","('NON-ESG', 0.2797999680042267)","('NON-ESG', 0.10341800004243851)","('NON-ESG', 0.08854326605796814)"
Line 654,I had used it before but I started to use it a lot more in quarantine .,"('Waste_And_Hazardous_Materials_Management', 0.19569435715675354)","('Critical_Incident_Risk_Management', 0.15795384347438812)","('Air_Quality', 0.13547015190124512)","('NON-ESG', 0.19569435715675354)","('NON-ESG', 0.15795384347438812)","('NON-ESG', 0.13547015190124512)"
Line 655,"While I liked science before, now I really enjoy learning about things that are alive .","('Product_Design_And_Lifecycle_Management', 0.1696048080921173)","('Ecological_Impacts', 0.09990648925304413)","('Business_Model_Resilience', 0.09282099455595016)","('NON-ESG', 0.1696048080921173)","('NON-ESG', 0.09990648925304413)","('NON-ESG', 0.09282099455595016)"
Line 656,I have gained a greater appreciation of the importance of science and can easily grasp what Im learning in school .,"('Access_And_Affordability', 0.6276593804359436)","('Employee_Engagement_Inclusion_And_Diversity', 0.07321291416883469)","('Ecological_Impacts', 0.02985612489283085)","(['Access to Healthcare'], 0.6276593804359436)","('NON-ESG', 0.07321291416883469)","('NON-ESG', 0.02985612489283085)"
Line 657,90% of teachers and students who have used Khan Academy report it is an effective learning resource .,"('Access_And_Affordability', 0.8380505442619324)","('Employee_Engagement_Inclusion_And_Diversity', 0.024882590398192406)","('Product_Quality_And_Safety', 0.012448273599147797)","(['Access to Healthcare'], 0.8380505442619324)","('NON-ESG', 0.024882590398192406)","('NON-ESG', 0.012448273599147797)"
Line 658,"AMGEN BIOTECH EXPERIENCE With leadership from university and other partners, the Amgen Biotech Experience (ABE) is a lab initiative that provides professional development for science teachers, teaching materials, and research-grade lab equipment to high schools around the world .","('Access_And_Affordability', 0.4237557649612427)","('Employee_Engagement_Inclusion_And_Diversity', 0.17329587042331696)","('Customer_Welfare', 0.047878820449113846)","('NON-ESG', 0.4237557649612427)","('NON-ESG', 0.17329587042331696)","('NON-ESG', 0.047878820449113846)"
Line 659,Not having the ability to conduct hands-on laboratories has been a significant challenge for ABE teachers during the pandemic .,"('Access_And_Affordability', 0.6540901064872742)","('Employee_Health_And_Safety', 0.06296567618846893)","('Product_Quality_And_Safety', 0.0371117927134037)","(['Access to Healthcare'], 0.6540901064872742)","('NON-ESG', 0.06296567618846893)","('NON-ESG', 0.0371117927134037)"
Line 660,"Through LabXchange, launched in January 2020 shortly before the pandemic began, ABE teachers were able to utilize the Foundational Concepts and Techniques in Biotechnology, a collection of resources including laboratory simulations built around the core lab techniques of the ABE program curriculum .","('Access_And_Affordability', 0.3837552070617676)","('Employee_Engagement_Inclusion_And_Diversity', 0.09792434424161911)","('Product_Quality_And_Safety', 0.058813437819480896)","('NON-ESG', 0.3837552070617676)","('NON-ESG', 0.09792434424161911)","('NON-ESG', 0.058813437819480896)"
Line 661,"The biotechnology resources, available in 13 languages as of December 2021, are available here .","('Access_And_Affordability', 0.3020066022872925)","('Management_Of_Legal_And_Regulatory_Framework', 0.1133136972784996)","('Employee_Engagement_Inclusion_And_Diversity', 0.09271451085805893)","('NON-ESG', 0.3020066022872925)","('NON-ESG', 0.1133136972784996)","('NON-ESG', 0.09271451085805893)"
Line 662,"As the COVID-19 pandemic stretched into 2021, ABE teachers persisted, adapted, and innovatedfinding new ways to engage their students and developing new best practices .","('Access_And_Affordability', 0.2615605294704437)","('Systemic_Risk_Management', 0.14915001392364502)","('Product_Quality_And_Safety', 0.0637781172990799)","('NON-ESG', 0.2615605294704437)","('NON-ESG', 0.14915001392364502)","('NON-ESG', 0.0637781172990799)"
Line 663,"The Amgen Foundation celebrated their resilience and shared their unique stories in a blog series, which you can read here .","('Business_Model_Resilience', 0.8909138441085815)","('Physical_Impacts_Of_Climate_Change', 0.012955007143318653)","('Supply_Chain_Management', 0.012211992405354977)","(['Human Capital Development', 'Innovation Management'], 0.8909138441085815)","('NON-ESG', 0.012955007143318653)","('NON-ESG', 0.012211992405354977)"
Line 664,"Amidst a year of chaos and uncertainty, we are finding ways to engage, teach, and learn .","('Employee_Engagement_Inclusion_And_Diversity', 0.22889754176139832)","('Access_And_Affordability', 0.1529291570186615)","('Systemic_Risk_Management', 0.10005523264408112)","('NON-ESG', 0.22889754176139832)","('NON-ESG', 0.1529291570186615)","('NON-ESG', 0.10005523264408112)"
Line 665,My students have banded together to create a safe haven of hope for their future .,"('Access_And_Affordability', 0.47428151965141296)","('Employee_Health_And_Safety', 0.14911527931690216)","('Human_Rights_And_Community_Relations', 0.07014381885528564)","('NON-ESG', 0.47428151965141296)","('NON-ESG', 0.14911527931690216)","('NON-ESG', 0.07014381885528564)"
Line 666,"KATHERINE SUTTON, ABE Rhode Island Teacher Healthy Society 40 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix COMMUNITY INVESTMENT ABE Launches Master Teacher Fellowship In early 2021, based on the feedback of ABE teachers looking for an opportunity to further their own science learning, the Amgen Foundation and the ABE program launched the ABE Master Teacher Fellowship .","('Human_Rights_And_Community_Relations', 0.3268069326877594)","('Employee_Engagement_Inclusion_And_Diversity', 0.15071621537208557)","('Access_And_Affordability', 0.13772393763065338)","('NON-ESG', 0.3268069326877594)","('NON-ESG', 0.15071621537208557)","('NON-ESG', 0.13772393763065338)"
Line 667,An inaugural cohort of 12 fellows was selected from 10 countries .,"('Employee_Engagement_Inclusion_And_Diversity', 0.3363356590270996)","('Management_Of_Legal_And_Regulatory_Framework', 0.12707297503948212)","('Director_Removal', 0.05900558456778526)","('NON-ESG', 0.3363356590270996)","('NON-ESG', 0.12707297503948212)","('NON-ESG', 0.05900558456778526)"
Line 668,"Over the yearlong fellowship, with financial support from the Amgen Foundation and access to Amgen scientists and experts at other STEM-focused organizations, each fellow developed their own biotech curriculum passion project .","('Access_And_Affordability', 0.3437550365924835)","('Management_Of_Legal_And_Regulatory_Framework', 0.12631037831306458)","('Employee_Engagement_Inclusion_And_Diversity', 0.09552047401666641)","('NON-ESG', 0.3437550365924835)","('NON-ESG', 0.12631037831306458)","('NON-ESG', 0.09552047401666641)"
Line 669,"Once final, this resulting curriculum will be available on the ABE website for use in classrooms everywhere .","('Access_And_Affordability', 0.5880556702613831)","('Employee_Engagement_Inclusion_And_Diversity', 0.06247111037373543)","('Management_Of_Legal_And_Regulatory_Framework', 0.03709457069635391)","(['Access to Healthcare'], 0.5880556702613831)","('NON-ESG', 0.06247111037373543)","('NON-ESG', 0.03709457069635391)"
Line 670,Select members of the inaugural cohort will continue their Master Teacher engagement by supporting the second cohort of fellows in 2022 .,"('Employee_Engagement_Inclusion_And_Diversity', 0.7437201738357544)","('Director_Removal', 0.029366854578256607)","('Management_Of_Legal_And_Regulatory_Framework', 0.022409718483686447)","(['Talent Attraction & Retention'], 0.7437201738357544)","('NON-ESG', 0.029366854578256607)","('NON-ESG', 0.022409718483686447)"
Line 671,Learn more here .,"('Access_And_Affordability', 0.17906130850315094)","('Employee_Engagement_Inclusion_And_Diversity', 0.13617536425590515)","('Supply_Chain_Management', 0.05700230225920677)","('NON-ESG', 0.17906130850315094)","('NON-ESG', 0.13617536425590515)","('NON-ESG', 0.05700230225920677)"
Line 672,ABE Volunteers The ABE Volunteer Program matches Amgen staff with high-need ABE high schools to share their career journeys and describe what they do professionally .,"('Employee_Health_And_Safety', 0.30725622177124023)","('Employee_Engagement_Inclusion_And_Diversity', 0.26573678851127625)","('Access_And_Affordability', 0.09116657823324203)","('NON-ESG', 0.30725622177124023)","('NON-ESG', 0.26573678851127625)","('NON-ESG', 0.09116657823324203)"
Line 673,"Despite the impact of COVID-19, more than 70 Amgen staff volunteers reached nearly 1,000 students across 32 schools in six Amgen U .","('Access_And_Affordability', 0.47852393984794617)","('Employee_Engagement_Inclusion_And_Diversity', 0.19391489028930664)","('Management_Of_Legal_And_Regulatory_Framework', 0.036730822175741196)","('NON-ESG', 0.47852393984794617)","('NON-ESG', 0.19391489028930664)","('NON-ESG', 0.036730822175741196)"
Line 674,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 675,communities through virtual classroom visits in 2021 .,"('Access_And_Affordability', 0.6275324821472168)","('Human_Rights_And_Community_Relations', 0.10470538586378098)","('Employee_Engagement_Inclusion_And_Diversity', 0.05796513706445694)","(['Access to Healthcare'], 0.6275324821472168)","('NON-ESG', 0.10470538586378098)","('NON-ESG', 0.05796513706445694)"
Line 676,"For students, the program provides diverse role models for a range of biotech careers, as well as real-world context for science content in the classroom .","('Employee_Engagement_Inclusion_And_Diversity', 0.8656815886497498)","('Access_And_Affordability', 0.026317154988646507)","('Customer_Welfare', 0.011930345557630062)","(['Talent Attraction & Retention'], 0.8656815886497498)","('NON-ESG', 0.026317154988646507)","('NON-ESG', 0.011930345557630062)"
Line 677,"For Amgen volunteers, it provides a rewarding and motivating experience .","('Access_And_Affordability', 0.175216406583786)","('Employee_Engagement_Inclusion_And_Diversity', 0.1723576933145523)","('Employee_Health_And_Safety', 0.1600642055273056)","('NON-ESG', 0.175216406583786)","('NON-ESG', 0.1723576933145523)","('NON-ESG', 0.1600642055273056)"
Line 678,"Diversity in STEM needs to be increased by planting the seeds of what is possible as early as possible, says Krista Dong, Amgen Scientist and ABE Volunteer .","('Employee_Engagement_Inclusion_And_Diversity', 0.9544690251350403)","('Employee_Health_And_Safety', 0.003580827498808503)","('Ecological_Impacts', 0.0033859198447316885)","(['Talent Attraction & Retention'], 0.9544690251350403)","('NON-ESG', 0.003580827498808503)","('NON-ESG', 0.0033859198447316885)"
Line 679,"Ive also been generous with their time, thoughts, opinions and feedback .","('Management_Of_Legal_And_Regulatory_Framework', 0.3749200105667114)","('Business_Ethics', 0.09068608283996582)","('Access_And_Affordability', 0.05730845034122467)","('NON-ESG', 0.3749200105667114)","('NON-ESG', 0.09068608283996582)","('NON-ESG', 0.05730845034122467)"
Line 680,They have been instrumental in my development as a scientist and I know that I would not be where I am today without their support .,"('Management_Of_Legal_And_Regulatory_Framework', 0.2911853790283203)","('Access_And_Affordability', 0.19151298701763153)","('Ecological_Impacts', 0.08929148316383362)","('NON-ESG', 0.2911853790283203)","('NON-ESG', 0.19151298701763153)","('NON-ESG', 0.08929148316383362)"
Line 681,That is why I choose to volunteer with ABE .,"('Employee_Health_And_Safety', 0.2390078902244568)","('Access_And_Affordability', 0.19272392988204956)","('Employee_Engagement_Inclusion_And_Diversity', 0.19107109308242798)","('NON-ESG', 0.2390078902244568)","('NON-ESG', 0.19272392988204956)","('NON-ESG', 0.19107109308242798)"
Line 682,"AMGEN SCHOLARS Amgen Scholars is an annual summer program that pairs over 350 undergraduate students from around the globe with research opportunities at more than 20 world-class institutions in the United States, Europe, Asia, Australia, and Canada .","('Employee_Engagement_Inclusion_And_Diversity', 0.28037235140800476)","('Access_And_Affordability', 0.1333722323179245)","('Management_Of_Legal_And_Regulatory_Framework', 0.07840783894062042)","('NON-ESG', 0.28037235140800476)","('NON-ESG', 0.1333722323179245)","('NON-ESG', 0.07840783894062042)"
Line 683,"Since 2006, Amgen Scholars has supported nearly 4,500 undergraduates from more than 825 colleges and universities globally, with many alumni now pursuing advanced scientific degrees and careers .","('Employee_Engagement_Inclusion_And_Diversity', 0.4662702679634094)","('Access_And_Affordability', 0.058460526168346405)","('Ecological_Impacts', 0.04837118834257126)","('NON-ESG', 0.4662702679634094)","('NON-ESG', 0.058460526168346405)","('NON-ESG', 0.04837118834257126)"
Line 684,"Prior to COVID-19, Amgen Scholars supported undergraduates from over 200 colleges and universities annually to conduct research in-person at 24 academic institutions around the globe .","('Access_And_Affordability', 0.3252648115158081)","('Management_Of_Legal_And_Regulatory_Framework', 0.13423627614974976)","('Employee_Engagement_Inclusion_And_Diversity', 0.10284161567687988)","('NON-ESG', 0.3252648115158081)","('NON-ESG', 0.13423627614974976)","('NON-ESG', 0.10284161567687988)"
Line 685,"While the program has had to pivot during the pandemic, in 2021, we supported 170 Amgen Scholars, the majority through a virtual experience .","('Physical_Impacts_Of_Climate_Change', 0.2671951651573181)","('Systemic_Risk_Management', 0.14520485699176788)","('Critical_Incident_Risk_Management', 0.10424250364303589)","('NON-ESG', 0.2671951651573181)","('NON-ESG', 0.14520485699176788)","('NON-ESG', 0.10424250364303589)"
Line 686,"This included a four-day virtual global symposium with alumni, biotech professionals, and academics who discussed various aspects of the biosciences with Amgen Scholars, including life as a PhD candidate, science communication, career opportunities in academia and industry, and more .","('Employee_Engagement_Inclusion_And_Diversity', 0.6118862628936768)","('Ecological_Impacts', 0.035614293068647385)","('Access_And_Affordability', 0.03348223492503166)","(['Talent Attraction & Retention'], 0.6118862628936768)","('NON-ESG', 0.035614293068647385)","('NON-ESG', 0.03348223492503166)"
Line 687,"Healthy Society 41 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix COMMUNITY INVESTMENT COMMUNITY-FOCUSED GIVING In addition to science education, the Amgen Foundation supports local organizations where Amgen employees live and work, as well as employee-driven philanthropy with matching gifts and volunteer service programs .","('Human_Rights_And_Community_Relations', 0.6906872987747192)","('Access_And_Affordability', 0.07563701272010803)","('Employee_Engagement_Inclusion_And_Diversity', 0.0454968698322773)","([], 0.6906872987747192)","('NON-ESG', 0.07563701272010803)","('NON-ESG', 0.0454968698322773)"
Line 688,The Foundation also works with partners to support disaster relief efforts .,"('Critical_Incident_Risk_Management', 0.9661865830421448)","('Air_Quality', 0.003758668899536133)","('Physical_Impacts_Of_Climate_Change', 0.0035416383761912584)","([], 0.9661865830421448)","('NON-ESG', 0.003758668899536133)","('NON-ESG', 0.0035416383761912584)"
Line 689,Disaster Relief The Amgen Foundation provides assistance to significant humanitarian disasters in communities where Amgen staff live and work .,"('Critical_Incident_Risk_Management', 0.9687734246253967)","('Access_And_Affordability', 0.00312182423658669)","('Physical_Impacts_Of_Climate_Change', 0.0030782283283770084)","([], 0.9687734246253967)","('NON-ESG', 0.00312182423658669)","('NON-ESG', 0.0030782283283770084)"
Line 690,"In 2021, this included support in response to historic flooding in Europe and devastating tornados in the United States .","('Physical_Impacts_Of_Climate_Change', 0.5172005891799927)","('Critical_Incident_Risk_Management', 0.3262687027454376)","('Air_Quality', 0.031716104596853256)","([], 0.5172005891799927)","('NON-ESG', 0.3262687027454376)","('NON-ESG', 0.031716104596853256)"
Line 691,"In the aftermath of the devastation caused by Hurricane Maria in Puerto Rico in 2017, the Amgen Foundation pledged $3 million to support Hurricane Maria relief efforts and $2 million for longer-term rebuilding efforts .","('Physical_Impacts_Of_Climate_Change', 0.8775145411491394)","('Critical_Incident_Risk_Management', 0.047290731221437454)","('Business_Model_Resilience', 0.012063000351190567)","([], 0.8775145411491394)","('NON-ESG', 0.047290731221437454)","('NON-ESG', 0.012063000351190567)"
Line 692,"In 2021, the rebuilding efforts were completed .","('Critical_Incident_Risk_Management', 0.14631932973861694)","('Ecological_Impacts', 0.09936926513910294)","('Business_Model_Resilience', 0.07835672050714493)","('NON-ESG', 0.14631932973861694)","('NON-ESG', 0.09936926513910294)","('NON-ESG', 0.07835672050714493)"
Line 693,"Included in these efforts, the Amgen Foundation along with local communities, government, and nonprofit partners helped rebuild eight schools and two universities on the island that is home to more than 2,000 Amgen employees .","('Human_Rights_And_Community_Relations', 0.41260838508605957)","('Access_And_Affordability', 0.27069076895713806)","('Employee_Engagement_Inclusion_And_Diversity', 0.052139364182949066)","('NON-ESG', 0.41260838508605957)","('NON-ESG', 0.27069076895713806)","('NON-ESG', 0.052139364182949066)"
Line 694,"Giving Tuesday In 2021, the Amgen Foundation observed Giving Tuesday by offering a 2:1 match for every $1 donated by Amgen U .","('Management_Of_Legal_And_Regulatory_Framework', 0.34737005829811096)","('Access_And_Affordability', 0.10177382826805115)","('Human_Rights_And_Community_Relations', 0.054813485592603683)","('NON-ESG', 0.34737005829811096)","('NON-ESG', 0.10177382826805115)","('NON-ESG', 0.054813485592603683)"
Line 695,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 696,and Puerto Rico staff members to eligible nonprofit organizations .,"('Employee_Engagement_Inclusion_And_Diversity', 0.4723512530326843)","('Management_Of_Legal_And_Regulatory_Framework', 0.10426244139671326)","('Labor_Practices', 0.05603421479463577)","('NON-ESG', 0.4723512530326843)","('NON-ESG', 0.10426244139671326)","('NON-ESG', 0.05603421479463577)"
Line 697,The response from across the organization was very enthusiastic as ERG members and local teams helped amplify the event and highlighted worthy charities within their own teams .,"('Management_Of_Legal_And_Regulatory_Framework', 0.3721100986003876)","('Human_Rights_And_Community_Relations', 0.2882988750934601)","('Access_And_Affordability', 0.1485321819782257)","('NON-ESG', 0.3721100986003876)","('NON-ESG', 0.2882988750934601)","('NON-ESG', 0.1485321819782257)"
Line 698,"At the end of the day, nearly 750 Amgen employees donated almost $900K to over 900 unique nonprofit organizations .","('Management_Of_Legal_And_Regulatory_Framework', 0.3819502592086792)","('Access_And_Affordability', 0.17393168807029724)","('Human_Rights_And_Community_Relations', 0.07439630478620529)","('NON-ESG', 0.3819502592086792)","('NON-ESG', 0.17393168807029724)","('NON-ESG', 0.07439630478620529)"
Line 699,"With the Amgen Foundation match, a total of $2 .6 million was donated to nonprofit organizations .","('Management_Of_Legal_And_Regulatory_Framework', 0.5625196695327759)","('Access_And_Affordability', 0.08634565025568008)","('Ecological_Impacts', 0.04810447245836258)","([], 0.5625196695327759)","('NON-ESG', 0.08634565025568008)","('NON-ESG', 0.04810447245836258)"
Line 700,"AMGEN FOUNDATION GIVIN G22 2018 2019 2020 2021$21M$31M$32M $23M 22 Since its inception, the Amgen Foundation has contributed in aggregate more than $375 million .","('Management_Of_Legal_And_Regulatory_Framework', 0.6951057314872742)","('Ecological_Impacts', 0.04204856604337692)","('Access_And_Affordability', 0.028550133109092712)","([], 0.6951057314872742)","('NON-ESG', 0.04204856604337692)","('NON-ESG', 0.028550133109092712)"
Line 701,"AMGEN FOUNDATION HELPS ADDRESS HUNGER In 2021, the Amgen Foundation provided critical operating support to the San FranciscoMarin County Food Bank, which continued to experience heightened demand for its services due to the impact of COVID-19 .","('Access_And_Affordability', 0.39851734042167664)","('Human_Rights_And_Community_Relations', 0.0838739424943924)","('Employee_Health_And_Safety', 0.08069687336683273)","('NON-ESG', 0.39851734042167664)","('NON-ESG', 0.0838739424943924)","('NON-ESG', 0.08069687336683273)"
Line 702,The California nonprofit addresses hunger head-on by focusing on the immediate distribution of food while simultaneously working on long-term strategies to end hunger and empower neighbors in need .,"('Critical_Incident_Risk_Management', 0.141880601644516)","('Water_And_Wastewater_Management', 0.09660650789737701)","('Access_And_Affordability', 0.0896637886762619)","('NON-ESG', 0.141880601644516)","('NON-ESG', 0.09660650789737701)","('NON-ESG', 0.0896637886762619)"
Line 703,"Every week, over 50,000 local households count on this food bank for food assistance .","('Access_And_Affordability', 0.8134424090385437)","('Energy_Management', 0.02755625545978546)","('Critical_Incident_Risk_Management', 0.01671217568218708)","(['Access to Healthcare'], 0.8134424090385437)","('NON-ESG', 0.02755625545978546)","('NON-ESG', 0.01671217568218708)"
Line 704,"MORE INFORMATION Amgen Foundation Amgen Biotech ExperienceLabXchange Amgen Scholars Khan AcademyHealthy Society 42 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix SUPPLIER SUSTAINABILITY Our Supplier Sustainability Program aims to help ensure that suppliers address not only quality, cost, and reliability requirements, but also ethical, environmental, and social considerations, including business ethics, labor, human rights, and environmental impact .","('Supply_Chain_Management', 0.71108078956604)","('Labor_Practices', 0.060811955481767654)","('Business_Ethics', 0.031271521002054214)","([], 0.71108078956604)","('NON-ESG', 0.060811955481767654)","('NON-ESG', 0.031271521002054214)"
Line 705,"MORE INFORMATION Amgen Foundation Amgen Biotech ExperienceLabXchange Amgen Scholars Khan AcademyHealthy Society 42 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix SUPPLIER SUSTAINABILITY Our Supplier Sustainability Program aims to help ensure that suppliers address not only quality, cost, and reliability requirements, but also ethical, environmental, and social considerations, including business ethics, labor, human rights, and environmental impact .","('Business_Model_Resilience', 0.2689560055732727)","('Physical_Impacts_Of_Climate_Change', 0.1476774364709854)","('Ecological_Impacts', 0.13506707549095154)","('NON-ESG', 0.2689560055732727)","('NON-ESG', 0.1476774364709854)","('NON-ESG', 0.13506707549095154)"
Line 706,Our Supplier Code of Conduct sets our fundamental expectations of our suppliers and is aligned with our core values .,"('Supply_Chain_Management', 0.9221099019050598)","('Labor_Practices', 0.011078310199081898)","('Product_Design_And_Lifecycle_Management', 0.008563060313463211)","([], 0.9221099019050598)","('NON-ESG', 0.011078310199081898)","('NON-ESG', 0.008563060313463211)"
Line 707,"In 2021, we continued our participation in the Pharmaceutical Supply Chain Initiative, which seeks to promote responsible supply chain management and better business conditions across the industry .","('Supply_Chain_Management', 0.9519338607788086)","('Product_Design_And_Lifecycle_Management', 0.004238896071910858)","('Physical_Impacts_Of_Climate_Change', 0.004126323387026787)","([], 0.9519338607788086)","('NON-ESG', 0.004238896071910858)","('NON-ESG', 0.004126323387026787)"
Line 708,"We also continued our involvement in a life science-specific forum established by EcoVadis, a leading provider of business sustainability ratings, to strengthen the sectors approach to supply chain management with a specific focus on environmental and social sustainability .","('Supply_Chain_Management', 0.9360730051994324)","('Product_Design_And_Lifecycle_Management', 0.013293555937707424)","('Business_Model_Resilience', 0.0050696199759840965)","([], 0.9360730051994324)","('NON-ESG', 0.013293555937707424)","('NON-ESG', 0.0050696199759840965)"
Line 709,VALUE CREATION Our ability to deliver lifesaving medicines depends on a resilient supply chain.,"('Supply_Chain_Management', 0.7179977893829346)","('Business_Model_Resilience', 0.1095166951417923)","('Product_Design_And_Lifecycle_Management', 0.04583218693733215)","([], 0.7179977893829346)","('NON-ESG', 0.1095166951417923)","('NON-ESG', 0.04583218693733215)"
Line 710,"By strengthening the sustainability performance of our suppliers, we can reduce our collective environmental footprint and help ensure business continuity through improved supply chain conditions .","('Supply_Chain_Management', 0.9499630928039551)","('Product_Design_And_Lifecycle_Management', 0.0054916576482355595)","('Labor_Practices', 0.00397843960672617)","([], 0.9499630928039551)","('NON-ESG', 0.0054916576482355595)","('NON-ESG', 0.00397843960672617)"
Line 711,"Engaging small and diverse suppliers not only benefits these suppliers and Amgen, but also uplifts the communities in which they operate through job creation and potential for better wages .","('Supply_Chain_Management', 0.2541005611419678)","('Employee_Engagement_Inclusion_And_Diversity', 0.1672080010175705)","('Human_Rights_And_Community_Relations', 0.16443757712841034)","('NON-ESG', 0.2541005611419678)","('NON-ESG', 0.1672080010175705)","('NON-ESG', 0.16443757712841034)"
Line 712,Amgen procures goods and services from thousands of suppliers each year.,"('Product_Design_And_Lifecycle_Management', 0.7374730706214905)","('Supply_Chain_Management', 0.13015323877334595)","('Energy_Management', 0.020532194525003433)","([], 0.7374730706214905)","('NON-ESG', 0.13015323877334595)","('NON-ESG', 0.020532194525003433)"
Line 713,We recognize that our suppliers are an important part of our value chain that impacts our business and the communities in which we live and operate.,"('Supply_Chain_Management', 0.9146678447723389)","('Product_Design_And_Lifecycle_Management', 0.017794424667954445)","('Water_And_Wastewater_Management', 0.005739899352192879)","([], 0.9146678447723389)","('NON-ESG', 0.017794424667954445)","('NON-ESG', 0.005739899352192879)"
Line 714,"RESPONSIBLE SOURCING 2021 PERFORMANCE DATA We continued to increase the number of suppliers we assessed for ethics, human and labor rights, and environmental impact .","('Labor_Practices', 0.7209455966949463)","('Human_Rights_And_Community_Relations', 0.07992412149906158)","('Supply_Chain_Management', 0.05794021114706993)","([], 0.7209455966949463)","('NON-ESG', 0.07992412149906158)","('NON-ESG', 0.05794021114706993)"
Line 715,* 2020 2021~65%~70% *Suppliers assessed increased from ~65% of our total supplier spend in 2020 to ~70% in 2021 .,"('Supply_Chain_Management', 0.927903950214386)","('Labor_Practices', 0.007886874489486217)","('Product_Design_And_Lifecycle_Management', 0.00710254767909646)","([], 0.927903950214386)","('NON-ESG', 0.007886874489486217)","('NON-ESG', 0.00710254767909646)"
Line 716,"Healthy Society 43 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Planet A Healthy Amgen Appendix RESPONSIBLE SOURCING SUPPLIER DIVERSITY Through our U .","('Supply_Chain_Management', 0.5039204359054565)","('Employee_Engagement_Inclusion_And_Diversity', 0.14792069792747498)","('Product_Design_And_Lifecycle_Management', 0.04714290797710419)","([], 0.5039204359054565)","('NON-ESG', 0.14792069792747498)","('NON-ESG', 0.04714290797710419)"
Line 717,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 718,"Supplier Diversity Program, by 2023 we aim to double our spend with diverse businesses, including minority, women, disadvantaged, veteran, and LGBTQ-owned suppliers and triple our spend with Black-owned businesses .23 In 2021, we participated in numerous external events with diverse suppliers to share opportunities about working with Amgen .","('Employee_Engagement_Inclusion_And_Diversity', 0.9661345481872559)","('Labor_Practices', 0.002884723013266921)","('Employee_Health_And_Safety', 0.0028176431078463793)","(['Talent Attraction & Retention'], 0.9661345481872559)","('NON-ESG', 0.002884723013266921)","('NON-ESG', 0.0028176431078463793)"
Line 719,We also began requiring select key suppliers to report their supplier diversity spend to us quarterly .,"('Supply_Chain_Management', 0.37938398122787476)","('Employee_Engagement_Inclusion_And_Diversity', 0.3329816460609436)","('Labor_Practices', 0.051907915621995926)","('NON-ESG', 0.37938398122787476)","('NON-ESG', 0.3329816460609436)","('NON-ESG', 0.051907915621995926)"
Line 720,We expanded our supplier mentorship program from women-owned suppliers to minority-owned suppliers with a focus on Black-owned businesses .,"('Supply_Chain_Management', 0.7561857104301453)","('Labor_Practices', 0.0702379122376442)","('Employee_Engagement_Inclusion_And_Diversity', 0.024948155507445335)","([], 0.7561857104301453)","('NON-ESG', 0.0702379122376442)","('NON-ESG', 0.024948155507445335)"
Line 721,"Through this program, conducted in partnership with local diversity councils, suppliers engage with senior leaders to learn more about Amgen .","('Employee_Engagement_Inclusion_And_Diversity', 0.9688065052032471)","('Employee_Health_And_Safety', 0.002817402593791485)","('Labor_Practices', 0.0021492198575288057)","(['Talent Attraction & Retention'], 0.9688065052032471)","('NON-ESG', 0.002817402593791485)","('NON-ESG', 0.0021492198575288057)"
Line 722,"Participating in the Amgen Supplier Mentorship Program shed light on what my agency needs to know to do business with large corporations, said Marci Klein, the owner of Klein Creative Media .","('Supply_Chain_Management', 0.9083362817764282)","('Product_Design_And_Lifecycle_Management', 0.018996169790625572)","('Labor_Practices', 0.006924592889845371)","([], 0.9083362817764282)","('NON-ESG', 0.018996169790625572)","('NON-ESG', 0.006924592889845371)"
Line 723,"MORE INFORMATION Supplier Code of Conduct Supplier Sustainability Supplier Diversity2021 PERFORMANCE DATA 35% increase in overall diversity spending more than doubled our spend with Black-owned businesses Shortly after we announced plans to build new manufacturing facilities in Ohio and North Carolina in 2021 we hosted virtual supplier forums for diverse suppliers in both locations, sharing sourcing opportunities and information on Amgens Supplier Diversity Program .","('Supply_Chain_Management', 0.7038833498954773)","('Employee_Engagement_Inclusion_And_Diversity', 0.08075595647096634)","('Labor_Practices', 0.04093772545456886)","([], 0.7038833498954773)","('NON-ESG', 0.08075595647096634)","('NON-ESG', 0.04093772545456886)"
Line 724,"23 Compared to a 2019 baseline .44 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix Healthy Planet HEALTHY PLANET We exceeded our goals for carbon, water, and waste reductions in 2021 and are on track to achieve our 2027 ambition.","('Human_Rights_And_Community_Relations', 0.21973004937171936)","('Ecological_Impacts', 0.19053159654140472)","('Water_And_Wastewater_Management', 0.09355534613132477)","('NON-ESG', 0.21973004937171936)","('NON-ESG', 0.19053159654140472)","('NON-ESG', 0.09355534613132477)"
Line 725,We initiated environmental sustainability IMPACT ASSESSMENTS for all capital funding requests as part of Amgens capital funding program.,"('Business_Model_Resilience', 0.33230066299438477)","('Management_Of_Legal_And_Regulatory_Framework', 0.2596845030784607)","('Physical_Impacts_Of_Climate_Change', 0.08308827131986618)","('NON-ESG', 0.33230066299438477)","('NON-ESG', 0.2596845030784607)","('NON-ESG', 0.08308827131986618)"
Line 726,"We updated Amgens sustainability design standard target for the LEED CERTIFICATION (Leadership in Energy and Environmental Design), the most widely used green building rating system globally, from Silver to Gold.2021 Highlights For the first time, we LINKED OUR EXECUTIVE PAY TO ENVIRONMENTAL SUSTAINABILITY with the addition of an ESG goal in Amgens annual incentive compensation plan .","('Product_Design_And_Lifecycle_Management', 0.5588499903678894)","('Product_Quality_And_Safety', 0.10228554159402847)","('Energy_Management', 0.048891741782426834)","([], 0.5588499903678894)","('NON-ESG', 0.10228554159402847)","('NON-ESG', 0.048891741782426834)"
Line 727,"Healthy Planet 45 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix In 2021, we introduced our latest environmental sustainability program, which we call The Road to Net Zero , and announced a new set of environmental targets .","('Human_Rights_And_Community_Relations', 0.6005498170852661)","('Business_Model_Resilience', 0.08116617053747177)","('Ecological_Impacts', 0.058266781270504)","([], 0.6005498170852661)","('NON-ESG', 0.08116617053747177)","('NON-ESG', 0.058266781270504)"
Line 728,Our 2027 plan includes the following aspirations:24 Achieve carbon neutrality for Amgen-owned and operated facilities and operations .,"('Energy_Management', 0.1791774034500122)","('Management_Of_Legal_And_Regulatory_Framework', 0.127000629901886)","('GHG_Emissions', 0.10485275834798813)","('NON-ESG', 0.1791774034500122)","('NON-ESG', 0.127000629901886)","('NON-ESG', 0.10485275834798813)"
Line 729,Reduce water consumption by 40% from a 2019 baseline .,"('Water_And_Wastewater_Management', 0.9710158705711365)","('Energy_Management', 0.004911939147859812)","('GHG_Emissions', 0.0031801527366042137)","([], 0.9710158705711365)","('NON-ESG', 0.004911939147859812)","('NON-ESG', 0.0031801527366042137)"
Line 730,Reduce waste disposed by 75% from a 2019 baseline .,"('Waste_And_Hazardous_Materials_Management', 0.9831246137619019)","('Water_And_Wastewater_Management', 0.0018226387910544872)","('Air_Quality', 0.0013722743606194854)","([], 0.9831246137619019)","('NON-ESG', 0.0018226387910544872)","('NON-ESG', 0.0013722743606194854)"
Line 731,"To achieve our 2027 goals, Amgen is focusing on the use of innovative approaches and processes, efficiency improvements, and increased sourcing of renewable energy .","('Energy_Management', 0.9748631715774536)","('Product_Design_And_Lifecycle_Management', 0.004118467681109905)","('Management_Of_Legal_And_Regulatory_Framework', 0.0023495208006352186)","(['Operational Eco-Efficiency'], 0.9748631715774536)","('NON-ESG', 0.004118467681109905)","('NON-ESG', 0.0023495208006352186)"
Line 732,"In addition, while our 2027 aspirations do not incorporate Scope 3 emissions, we are evaluating the carbon impact from our value chainincluding suppliers, contract manufacturers, and distributorsto help identify reduction opportunities as we continue to pursue a responsible sourcing strategy .","('Supply_Chain_Management', 0.6320940852165222)","('GHG_Emissions', 0.11598651856184006)","('Product_Design_And_Lifecycle_Management', 0.04170967638492584)","([], 0.6320940852165222)","('NON-ESG', 0.11598651856184006)","('NON-ESG', 0.04170967638492584)"
Line 733,"We exceeded our goals for carbon, water, and waste reductions in 2021and we are on track to achieve our 2027 ambition .","('Waste_And_Hazardous_Materials_Management', 0.8387480974197388)","('Water_And_Wastewater_Management', 0.09448660165071487)","('Air_Quality', 0.0068974848836660385)","([], 0.8387480974197388)","('NON-ESG', 0.09448660165071487)","('NON-ESG', 0.0068974848836660385)"
Line 734,"AMBITION As a Company committed to advancing human health, we have a sense of responsibility to patients, employees and shareholders to have a positive impact on the health of our planet .","('Employee_Health_And_Safety', 0.8301020860671997)","('Access_And_Affordability', 0.03357493504881859)","('Human_Rights_And_Community_Relations', 0.03064190223813057)","(['Health Outcome Contribution'], 0.8301020860671997)","('NON-ESG', 0.03357493504881859)","('NON-ESG', 0.03064190223813057)"
Line 735,"Reducing our impact on the planet is not only part of our role as a corporate citizen, it can also bring added value as energy prices rise and the impact of climate change further strains access to natural resources .","('Physical_Impacts_Of_Climate_Change', 0.9076406359672546)","('Business_Model_Resilience', 0.022874757647514343)","('GHG_Emissions', 0.014581180177628994)","([], 0.9076406359672546)","('NON-ESG', 0.022874757647514343)","('NON-ESG', 0.014581180177628994)"
Line 736,We recognize the close connection between environmental stresses and health and the role we can play through our core business .,"('Employee_Health_And_Safety', 0.49482688307762146)","('Human_Rights_And_Community_Relations', 0.22407127916812897)","('Access_And_Affordability', 0.0604013167321682)","('NON-ESG', 0.49482688307762146)","('NON-ESG', 0.22407127916812897)","('NON-ESG', 0.0604013167321682)"
Line 737,Amgen has a longstanding objective to conduct environmentally responsible operations and regularly sets targets to challenge ourselves to deliver further improvements.,"('Ecological_Impacts', 0.29142993688583374)","('Product_Design_And_Lifecycle_Management', 0.18449044227600098)","('Energy_Management', 0.07765920460224152)","('NON-ESG', 0.29142993688583374)","('NON-ESG', 0.18449044227600098)","('NON-ESG', 0.07765920460224152)"
Line 738,"Since 2007, we have successfully advanced our environmental sustainability program while increasing our global production capacity and expanding our presence to approximately 100 countries.","('Product_Design_And_Lifecycle_Management', 0.46874698996543884)","('Supply_Chain_Management', 0.16408929228782654)","('Energy_Management', 0.13594931364059448)","('NON-ESG', 0.46874698996543884)","('NON-ESG', 0.16408929228782654)","('NON-ESG', 0.13594931364059448)"
Line 739,Investing in sustainable operations also has the potential to improve efficiency and create value.,"('Product_Design_And_Lifecycle_Management', 0.6743142604827881)","('Energy_Management', 0.1499125361442566)","('Business_Model_Resilience', 0.022387204691767693)","([], 0.6743142604827881)","('NON-ESG', 0.1499125361442566)","('NON-ESG', 0.022387204691767693)"
Line 740,HEALTHY PLANET 24 Carbon neutrality goal refers to Scope 1 and 2 emissions .,"('GHG_Emissions', 0.8678205013275146)","('Management_Of_Legal_And_Regulatory_Framework', 0.02734210155904293)","('Air_Quality', 0.01808028295636177)","(['Operational Eco-Efficiency'], 0.8678205013275146)","('NON-ESG', 0.02734210155904293)","('NON-ESG', 0.01808028295636177)"
Line 741,"Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline .","('Systemic_Risk_Management', 0.5973811149597168)","('Business_Model_Resilience', 0.22292457520961761)","('Competitive_Behavior', 0.0244595929980278)","([], 0.5973811149597168)","('NON-ESG', 0.22292457520961761)","('NON-ESG', 0.0244595929980278)"
Line 742,"Healthy Planet 46 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix Our sustainability strategy embraces innovation, efficiency, and renewable energy to achieve our 2027 plan.","('Energy_Management', 0.48770835995674133)","('Product_Design_And_Lifecycle_Management', 0.14105692505836487)","('Access_And_Affordability', 0.05637853965163231)","('NON-ESG', 0.48770835995674133)","('NON-ESG', 0.14105692505836487)","('NON-ESG', 0.05637853965163231)"
Line 743,"VALUE CREATION Our investment in environmental sustainability has not only reduced our impact on the planet but also allowed us to be more efficient, productive, and resilient, resulting in reduced operating costs.","('Business_Model_Resilience', 0.8431010246276855)","('Product_Design_And_Lifecycle_Management', 0.025178436189889908)","('Physical_Impacts_Of_Climate_Change', 0.024417884647846222)","(['Human Capital Development', 'Innovation Management'], 0.8431010246276855)","('NON-ESG', 0.025178436189889908)","('NON-ESG', 0.024417884647846222)"
Line 744,"In addition, as the effects of climate change could be disruptive to business, we are doing our part to decrease carbon emissions, water use, and waste disposed and working to reduce the risks of climate-related events to our operations and to make Amgen a better partner for the communities in which we live and work .","('Physical_Impacts_Of_Climate_Change', 0.9489166140556335)","('Business_Model_Resilience', 0.0091001121327281)","('GHG_Emissions', 0.006712597329169512)","([], 0.9489166140556335)","('NON-ESG', 0.0091001121327281)","('NON-ESG', 0.006712597329169512)"
Line 745,"Drought, wildfires, heat, flooding, and pollution are already creating serious threats to lung health .","('Physical_Impacts_Of_Climate_Change', 0.5108926296234131)","('Ecological_Impacts', 0.1437751054763794)","('Critical_Incident_Risk_Management', 0.0639902725815773)","([], 0.5108926296234131)","('NON-ESG', 0.1437751054763794)","('NON-ESG', 0.0639902725815773)"
Line 746,"According to recent research by public health experts in the United Kingdom, short-term exposure to elevated levels of air pollution from the burning of fossil fuels can exacerbate asthma, affect lung function, and increase respiratory and cardiovascular hospital admissions and deaths .","('Air_Quality', 0.9396793842315674)","('Employee_Health_And_Safety', 0.01003050897270441)","('Critical_Incident_Risk_Management', 0.009966688230633736)","([], 0.9396793842315674)","('NON-ESG', 0.01003050897270441)","('NON-ESG', 0.009966688230633736)"
Line 747,"Research also shows that, far too often, people of color and people living in low-income communities live and work in places in areas with increased risks from climate change and are more likely to have chronic lung disease .25 As a Company focused on improving health and saving lives, Amgen is determined to be part of the solution .","('Physical_Impacts_Of_Climate_Change', 0.8172681927680969)","('Human_Rights_And_Community_Relations', 0.04843106493353844)","('Critical_Incident_Risk_Management', 0.02376081980764866)","([], 0.8172681927680969)","('NON-ESG', 0.04843106493353844)","('NON-ESG', 0.02376081980764866)"
Line 748,"In September 2021, we sponsored a virtual Expert Voices roundtable (hosted by a leading national news outlet Axios) to hear how stakeholders from across disciplines are addressing challenges, and to better understand how Amgen can collaborate to make an impact .","('Business_Model_Resilience', 0.2024334818124771)","('Human_Rights_And_Community_Relations', 0.1764453947544098)","('Employee_Engagement_Inclusion_And_Diversity', 0.08060836791992188)","('NON-ESG', 0.2024334818124771)","('NON-ESG', 0.1764453947544098)","('NON-ESG', 0.08060836791992188)"
Line 749,"Leaders, subject matter experts, and policy makers from various geographies and disciplines gathered virtually to discuss the widening socioeconomic disparities and preventative measures .","('Management_Of_Legal_And_Regulatory_Framework', 0.19716008007526398)","('Business_Model_Resilience', 0.15859562158584595)","('Human_Rights_And_Community_Relations', 0.12919385731220245)","('NON-ESG', 0.19716008007526398)","('NON-ESG', 0.15859562158584595)","('NON-ESG', 0.12919385731220245)"
Line 750,They also shared ideas on how to better prepare for future and long-term effects of climate change on lung health .,"('Physical_Impacts_Of_Climate_Change', 0.9561902284622192)","('Business_Model_Resilience', 0.007807412650436163)","('GHG_Emissions', 0.0036770578008145094)","([], 0.9561902284622192)","('NON-ESG', 0.007807412650436163)","('NON-ESG', 0.0036770578008145094)"
Line 751,"To read more about the conversation, visit Axios' event recap here .","('Business_Model_Resilience', 0.4437057673931122)","('Systemic_Risk_Management', 0.24018594622612)","('Competitive_Behavior', 0.06652332842350006)","('NON-ESG', 0.4437057673931122)","('NON-ESG', 0.24018594622612)","('NON-ESG', 0.06652332842350006)"
Line 752,Amgen is also seeking to support lung health through a new collaboration with the Asthma and Allergy Foundation of America (AAFA) .,"('Employee_Health_And_Safety', 0.5379577875137329)","('Access_And_Affordability', 0.0984654650092125)","('Product_Quality_And_Safety', 0.057663775980472565)","(['Health Outcome Contribution'], 0.5379577875137329)","('NON-ESG', 0.0984654650092125)","('NON-ESG', 0.057663775980472565)"
Line 753,"The collaboration aims to help reduce disparities in asthma prevalence, healthcare utilization and mortality among underserved, high-risk populations through the Health Equity Advancement and Leadership program (HEAL) .","('Access_And_Affordability', 0.9449144005775452)","('Product_Quality_And_Safety', 0.0048715295270085335)","('Human_Rights_And_Community_Relations', 0.0047472016885876656)","(['Access to Healthcare'], 0.9449144005775452)","('NON-ESG', 0.0048715295270085335)","('NON-ESG', 0.0047472016885876656)"
Line 754,"AAFA will work in 2022 with community-based partners to increase patient knowledge, strengthen patient and physician communications, and help address asthma symptoms .","('Access_And_Affordability', 0.6759759187698364)","('Employee_Health_And_Safety', 0.04969128966331482)","('Human_Rights_And_Community_Relations', 0.03710760176181793)","(['Access to Healthcare'], 0.6759759187698364)","('NON-ESG', 0.04969128966331482)","('NON-ESG', 0.03710760176181793)"
Line 755,25 American Lung Association .,"('Employee_Health_And_Safety', 0.19415411353111267)","('Ecological_Impacts', 0.08586802333593369)","('Product_Quality_And_Safety', 0.07544735819101334)","('NON-ESG', 0.19415411353111267)","('NON-ESG', 0.08586802333593369)","('NON-ESG', 0.07544735819101334)"
Line 756,"EXPLORING CLIMATE CHANGE AND LUNG HEAL THENVIRONMENTAL SUSTAINABILITY Healthy Planet 47 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix CARBON NEUTRALITY Manufacturing Through innovative manufacturing technologies implemented at our manufacturing facility in Singapore , we reduced carbon emissions by 69% and water use by 54%, as compared to conventional biotechnology manufacturing .26 In January 2022, we received FDA approval for a new manufacturing facility in Rhode Island utilizing the same technologies as our facility in Singapore .","('Physical_Impacts_Of_Climate_Change', 0.9084491729736328)","('GHG_Emissions', 0.018740151077508926)","('Business_Model_Resilience', 0.012277104891836643)","([], 0.9084491729736328)","('NON-ESG', 0.018740151077508926)","('NON-ESG', 0.012277104891836643)"
Line 757,"EXPLORING CLIMATE CHANGE AND LUNG HEAL THENVIRONMENTAL SUSTAINABILITY Healthy Planet 47 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix CARBON NEUTRALITY Manufacturing Through innovative manufacturing technologies implemented at our manufacturing facility in Singapore , we reduced carbon emissions by 69% and water use by 54%, as compared to conventional biotechnology manufacturing .26 In January 2022, we received FDA approval for a new manufacturing facility in Rhode Island utilizing the same technologies as our facility in Singapore .","('Product_Design_And_Lifecycle_Management', 0.667394757270813)","('Supply_Chain_Management', 0.08507328480482101)","('Customer_Welfare', 0.03577030822634697)","([], 0.667394757270813)","('NON-ESG', 0.08507328480482101)","('NON-ESG', 0.03577030822634697)"
Line 758,"In addition, in 2021, we announced plans for the construction of new facilities in Ohio and North Carolina .","('Access_And_Affordability', 0.19625362753868103)","('Employee_Engagement_Inclusion_And_Diversity', 0.13136638700962067)","('Management_Of_Legal_And_Regulatory_Framework', 0.08984541893005371)","('NON-ESG', 0.19625362753868103)","('NON-ESG', 0.13136638700962067)","('NON-ESG', 0.08984541893005371)"
Line 759,"At both, we are embedding environmental sustainability into upfront project design, development, and execution .","('Product_Design_And_Lifecycle_Management', 0.5624271035194397)","('Business_Model_Resilience', 0.102566659450531)","('Ecological_Impacts', 0.0451577790081501)","([], 0.5624271035194397)","('NON-ESG', 0.102566659450531)","('NON-ESG', 0.0451577790081501)"
Line 760,"For example, at our new multiproduct drug substance manufacturing facility in North Carolina, we expect our carbon footprint and water usage to be substantially lower than at a traditional drug substance manufacturing plant due to deployment of innovative technologies and resource conservation .","('Water_And_Wastewater_Management', 0.9425226449966431)","('Energy_Management', 0.007528285495936871)","('Waste_And_Hazardous_Materials_Management', 0.007194362115114927)","([], 0.9425226449966431)","('NON-ESG', 0.007528285495936871)","('NON-ESG', 0.007194362115114927)"
Line 761,The site will use traditional drug substance technologies and Amgens latest innovations to create a facility called FleXBatch .,"('Customer_Welfare', 0.3211838901042938)","('Competitive_Behavior', 0.142252579331398)","('Product_Design_And_Lifecycle_Management', 0.09448462724685669)","('NON-ESG', 0.3211838901042938)","('NON-ESG', 0.142252579331398)","('NON-ESG', 0.09448462724685669)"
Line 762,"This new FleXBatch plant exemplifies Amgens approach to innovative and sustainable biomanufacturing, which Im pleased to announce we are now calling Amgen EcovationTM, said Bob Bradway, Amgen CEO .","('Product_Design_And_Lifecycle_Management', 0.8593506217002869)","('Customer_Welfare', 0.02004265785217285)","('Business_Model_Resilience', 0.0195330698043108)","([], 0.8593506217002869)","('NON-ESG', 0.02004265785217285)","('NON-ESG', 0.0195330698043108)"
Line 763,"This new name underscores what is today and has always been distinctive about biomanufacturing at Amgen: It is highly innovative, efficient, safe, and environmentally sustainable all in the service of benefiting patients with medicines manufactured according to the highest quality standards .","('Product_Design_And_Lifecycle_Management', 0.687110185623169)","('Product_Quality_And_Safety', 0.07813335955142975)","('Customer_Welfare', 0.07791634649038315)","([], 0.687110185623169)","('NON-ESG', 0.07813335955142975)","('NON-ESG', 0.07791634649038315)"
Line 764,"In Ohio, we are building our new final product advanced assembly and packaging plant to LEED27 standards to maximize energy efficiency and waste reduction .","('Product_Design_And_Lifecycle_Management', 0.5692319869995117)","('Energy_Management', 0.31307175755500793)","('Waste_And_Hazardous_Materials_Management', 0.017358388751745224)","([], 0.5692319869995117)","('NON-ESG', 0.31307175755500793)","('NON-ESG', 0.017358388751745224)"
Line 765,"Electric Vehicles By 2027, we plan to convert 30% of our sales fleet vehicles to electric vehicles (EV) .28 In 2021, we launched an EV pilot program in the United States, the Netherlands and South Korea, enabling sales representatives and medical liaisons to upgrade their traditional fuel-operated vehicle to a new electric vehicle .","('Energy_Management', 0.7945011258125305)","('Product_Design_And_Lifecycle_Management', 0.0857829600572586)","('Management_Of_Legal_And_Regulatory_Framework', 0.013254988938570023)","(['Operational Eco-Efficiency'], 0.7945011258125305)","('NON-ESG', 0.0857829600572586)","('NON-ESG', 0.013254988938570023)"
Line 766,Our program also includes EV charging infrastructure improvements in the EV marketplace .,"('Energy_Management', 0.7754643559455872)","('Management_Of_Legal_And_Regulatory_Framework', 0.042234890162944794)","('Data_Security', 0.024279432371258736)","(['Operational Eco-Efficiency'], 0.7754643559455872)","('NON-ESG', 0.042234890162944794)","('NON-ESG', 0.024279432371258736)"
Line 767,"Renewable Energy The generation and procurement of clean, renewable energy is an important component of achieving our 2027 carbon neutrality target .29 Across our network, each Amgen facility has a portfolio of renewable energy projects .","('Energy_Management', 0.9761674404144287)","('Management_Of_Legal_And_Regulatory_Framework', 0.0044059292413294315)","('Product_Design_And_Lifecycle_Management', 0.0018936486449092627)","(['Operational Eco-Efficiency'], 0.9761674404144287)","('NON-ESG', 0.0044059292413294315)","('NON-ESG', 0.0018936486449092627)"
Line 768,"Projects range from installing innovative renewable energy technologies, such as onsite solar arrays, to purchasing electricity from renewable sources .","('Energy_Management', 0.9784677028656006)","('Management_Of_Legal_And_Regulatory_Framework', 0.0029963788110762835)","('Critical_Incident_Risk_Management', 0.0017111736815422773)","(['Operational Eco-Efficiency'], 0.9784677028656006)","('NON-ESG', 0.0029963788110762835)","('NON-ESG', 0.0017111736815422773)"
Line 769,"In 2021, we increased the number of facilities sourcing renewable energy, including our major North American sites in Rhode Island and our headquarters in California; our aim is for all Amgen facilities, wherever feasible, to procure 100% renewable electricity by 2027 .","('Energy_Management', 0.9772405028343201)","('Management_Of_Legal_And_Regulatory_Framework', 0.0030100736767053604)","('Product_Design_And_Lifecycle_Management', 0.002073832554742694)","(['Operational Eco-Efficiency'], 0.9772405028343201)","('NON-ESG', 0.0030100736767053604)","('NON-ESG', 0.002073832554742694)"
Line 770,Our carbon neutrality target applies to Amgen-owned and -operated facilities and operations .,"('Management_Of_Legal_And_Regulatory_Framework', 0.29277071356773376)","('GHG_Emissions', 0.09900226444005966)","('Competitive_Behavior', 0.09161791950464249)","('NON-ESG', 0.29277071356773376)","('NON-ESG', 0.09900226444005966)","('NON-ESG', 0.09161791950464249)"
Line 771,"At the end of 2021, renewable electricity accounted for 79% of our total electricity consumption, compared to 41% in 2020 .","('Energy_Management', 0.9751832485198975)","('Management_Of_Legal_And_Regulatory_Framework', 0.003794044256210327)","('Water_And_Wastewater_Management', 0.0020318322349339724)","(['Operational Eco-Efficiency'], 0.9751832485198975)","('NON-ESG', 0.003794044256210327)","('NON-ESG', 0.0020318322349339724)"
Line 772,We achieved this increase in renewable electricity through the purchase of renewable energy certificates for electricity consumption at our North American facilities .,"('Energy_Management', 0.9770197868347168)","('Management_Of_Legal_And_Regulatory_Framework', 0.004206138662993908)","('Air_Quality', 0.0016087889671325684)","(['Operational Eco-Efficiency'], 0.9770197868347168)","('NON-ESG', 0.004206138662993908)","('NON-ESG', 0.0016087889671325684)"
Line 773,WATER We plan to achieve our water reduction target30 of 40% by emphasizing water treatment and recycling as well as reduced primary usage .,"('Water_And_Wastewater_Management', 0.9766684174537659)","('Energy_Management', 0.0023284992203116417)","('GHG_Emissions', 0.0023129910696297884)","([], 0.9766684174537659)","('NON-ESG', 0.0023284992203116417)","('NON-ESG', 0.0023129910696297884)"
Line 774,"While our strategy is global, we work with different Amgen sites particularly in water-stressed regions .","('Water_And_Wastewater_Management', 0.9740801453590393)","('GHG_Emissions', 0.0030105917248874903)","('Ecological_Impacts', 0.00241506053134799)","([], 0.9740801453590393)","('NON-ESG', 0.0030105917248874903)","('NON-ESG', 0.00241506053134799)"
Line 775,Amgen completed externally validated water studies at each of our major manufacturing sites in 2021 to identify additional reduction opportunities .,"('Water_And_Wastewater_Management', 0.9733921885490417)","('GHG_Emissions', 0.003300121985375881)","('Waste_And_Hazardous_Materials_Management', 0.002391204470768571)","([], 0.9733921885490417)","('NON-ESG', 0.003300121985375881)","('NON-ESG', 0.002391204470768571)"
Line 776,We also established a cross-functional water sustainability team to share projects and best practices globally .,"('Water_And_Wastewater_Management', 0.9497407674789429)","('Supply_Chain_Management', 0.005181087646633387)","('GHG_Emissions', 0.005148027092218399)","([], 0.9497407674789429)","('NON-ESG', 0.005181087646633387)","('NON-ESG', 0.005148027092218399)"
Line 777,"By the end of 2021, Amgen had identified more than 90 potential water reduction projects .","('Water_And_Wastewater_Management', 0.9748966097831726)","('GHG_Emissions', 0.002807839773595333)","('Energy_Management', 0.002625888679176569)","([], 0.9748966097831726)","('NON-ESG', 0.002807839773595333)","('NON-ESG', 0.002625888679176569)"
Line 778,"These are being reviewed for viability and prioritization, including some key projects involving large utility systems such as reverse osmosis skids and cooling towers .","('Energy_Management', 0.9204744100570679)","('Product_Design_And_Lifecycle_Management', 0.008442201651632786)","('Air_Quality', 0.00743828946724534)","(['Operational Eco-Efficiency'], 0.9204744100570679)","('NON-ESG', 0.008442201651632786)","('NON-ESG', 0.00743828946724534)"
Line 779,"In 2021, Amgen developed water reduction pipeline proposals with the potential for high impact at facilities in water-stressed regions .","('Water_And_Wastewater_Management', 0.9769243597984314)","('GHG_Emissions', 0.0025896842125803232)","('Energy_Management', 0.0018804722931236029)","([], 0.9769243597984314)","('NON-ESG', 0.0025896842125803232)","('NON-ESG', 0.0018804722931236029)"
Line 780,"26 As of September 30, 2021 .","('Business_Model_Resilience', 0.13943028450012207)","('Systemic_Risk_Management', 0.11921058595180511)","('Customer_Privacy', 0.07965734601020813)","('NON-ESG', 0.13943028450012207)","('NON-ESG', 0.11921058595180511)","('NON-ESG', 0.07965734601020813)"
Line 781,27 Developed by the U .,"('Management_Of_Legal_And_Regulatory_Framework', 0.7207158803939819)","('Human_Rights_And_Community_Relations', 0.033343177288770676)","('Ecological_Impacts', 0.0332365520298481)","([], 0.7207158803939819)","('NON-ESG', 0.033343177288770676)","('NON-ESG', 0.0332365520298481)"
Line 782,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 783,"Green Building Council, LEED is a set of rating systems for the design, construction, operation, and maintenance of green buildings, homes and neighborhoods .","('Energy_Management', 0.24455179274082184)","('Product_Design_And_Lifecycle_Management', 0.16905885934829712)","('Ecological_Impacts', 0.09033173322677612)","('NON-ESG', 0.24455179274082184)","('NON-ESG', 0.16905885934829712)","('NON-ESG', 0.09033173322677612)"
Line 784,28 Based on a 2019 baseline .,"('Management_Of_Legal_And_Regulatory_Framework', 0.39048969745635986)","('GHG_Emissions', 0.10767267644405365)","('Ecological_Impacts', 0.09250131249427795)","('NON-ESG', 0.39048969745635986)","('NON-ESG', 0.10767267644405365)","('NON-ESG', 0.09250131249427795)"
Line 785,29 Carbon neutrality goal refers to Scope 1 and 2 emissions .,"('GHG_Emissions', 0.7967841625213623)","('Management_Of_Legal_And_Regulatory_Framework', 0.05683667212724686)","('Ecological_Impacts', 0.0186614990234375)","(['Operational Eco-Efficiency'], 0.7967841625213623)","('NON-ESG', 0.05683667212724686)","('NON-ESG', 0.0186614990234375)"
Line 786,"30 Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline .","('Systemic_Risk_Management', 0.5490548610687256)","('Business_Model_Resilience', 0.2518865168094635)","('Competitive_Behavior', 0.026711398735642433)","([], 0.5490548610687256)","('NON-ESG', 0.2518865168094635)","('NON-ESG', 0.026711398735642433)"
Line 787,"ENVIRONMENTAL SUSTAINABILITY Healthy Planet 48 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix SUSTAINABILITY BY DESIGN We are growing with the future in mind by integrating sustainability into our expansion efforts .","('Human_Rights_And_Community_Relations', 0.4138477146625519)","('Business_Model_Resilience', 0.10667552798986435)","('Ecological_Impacts', 0.080470010638237)","('NON-ESG', 0.4138477146625519)","('NON-ESG', 0.10667552798986435)","('NON-ESG', 0.080470010638237)"
Line 788,"In 2021, we upgraded our LEED design and construction standards from Sliver to Gold certification for all new buildings and major renovations .","('Product_Quality_And_Safety', 0.38446834683418274)","('Product_Design_And_Lifecycle_Management', 0.10839974880218506)","('Management_Of_Legal_And_Regulatory_Framework', 0.08591801673173904)","('NON-ESG', 0.38446834683418274)","('NON-ESG', 0.10839974880218506)","('NON-ESG', 0.08591801673173904)"
Line 789,"This includes the design, construction, and operation of our planned new facilities in Ohio and North Carolina .","('Business_Model_Resilience', 0.22201932966709137)","('Product_Design_And_Lifecycle_Management', 0.1615380048751831)","('Customer_Welfare', 0.06377644091844559)","('NON-ESG', 0.22201932966709137)","('NON-ESG', 0.1615380048751831)","('NON-ESG', 0.06377644091844559)"
Line 790,LEED is the most widely used green building rating system in the world .,"('Energy_Management', 0.26656025648117065)","('Management_Of_Legal_And_Regulatory_Framework', 0.16031180322170258)","('Product_Quality_And_Safety', 0.14088395237922668)","('NON-ESG', 0.26656025648117065)","('NON-ESG', 0.16031180322170258)","('NON-ESG', 0.14088395237922668)"
Line 791,"We also initiated an internal carbon fee as part of our investment lifecycle management (ILM) process, which includes capital projects and building leases .","('Business_Model_Resilience', 0.7996354103088379)","('Physical_Impacts_Of_Climate_Change', 0.025120439007878304)","('Product_Design_And_Lifecycle_Management', 0.023460736498236656)","(['Human Capital Development', 'Innovation Management'], 0.7996354103088379)","('NON-ESG', 0.025120439007878304)","('NON-ESG', 0.023460736498236656)"
Line 792,"Beginning in 2021, this process now requires project-specific sustainability plans and assigns an internal price to carbon emissions, water intake, and waste generation .","('Waste_And_Hazardous_Materials_Management', 0.51308274269104)","('Water_And_Wastewater_Management', 0.2862103283405304)","('Energy_Management', 0.0357821062207222)","([], 0.51308274269104)","('NON-ESG', 0.2862103283405304)","('NON-ESG', 0.0357821062207222)"
Line 793,"For example, projects that increase carbon emissions above an established threshold are charged an internal carbon fee to help ensure that the impact to the environment is accounted for in our decision-making as we consider alternative options with lower environmental footprints .","('GHG_Emissions', 0.7624637484550476)","('Ecological_Impacts', 0.05709889531135559)","('Management_Of_Legal_And_Regulatory_Framework', 0.053475700318813324)","(['Operational Eco-Efficiency'], 0.7624637484550476)","('NON-ESG', 0.05709889531135559)","('NON-ESG', 0.053475700318813324)"
Line 794,WASTE We plan to reduce 75% of waste disposed31 through recycling and reuse of waste materials sent to landfills or disposed via combustion or incineration without energy recovery .,"('Waste_And_Hazardous_Materials_Management', 0.9845018982887268)","('Data_Security', 0.0013365563936531544)","('Water_And_Wastewater_Management', 0.0012487616622820497)","([], 0.9845018982887268)","('NON-ESG', 0.0013365563936531544)","('NON-ESG', 0.0012487616622820497)"
Line 795,"In 2021, three Amgen sites did not send any waste to landfills .","('Waste_And_Hazardous_Materials_Management', 0.9834179282188416)","('Data_Security', 0.0014204410836100578)","('Water_And_Wastewater_Management', 0.0013974913163110614)","([], 0.9834179282188416)","('NON-ESG', 0.0014204410836100578)","('NON-ESG', 0.0013974913163110614)"
Line 796,"While our strategy prioritizes innovation and efficiency to reduce waste before its generated, for 2021 Amgen Rhode Island transferred the majority of the landfill waste it did generate to a neighboring state for energy recovery .","('Waste_And_Hazardous_Materials_Management', 0.98473060131073)","('Water_And_Wastewater_Management', 0.0013686370803043246)","('Data_Security', 0.0012123220367357135)","([], 0.98473060131073)","('NON-ESG', 0.0013686370803043246)","('NON-ESG', 0.0012123220367357135)"
Line 797,"The change was made, in part, because the Rhode Island Central Landfill, which provides disposal for 97% of Rhode Island residents, is projected to reach its capacity in the next decade .","('Waste_And_Hazardous_Materials_Management', 0.7795995473861694)","('Water_And_Wastewater_Management', 0.10489898175001144)","('Ecological_Impacts', 0.027424614876508713)","([], 0.7795995473861694)","('NON-ESG', 0.10489898175001144)","('NON-ESG', 0.027424614876508713)"
Line 798,Waste-to-energy incineration is a better alternative to landfills for waste disposal and actually reduces the amount of greenhouse gas emissions in the atmosphere .,"('Waste_And_Hazardous_Materials_Management', 0.9820175766944885)","('Water_And_Wastewater_Management', 0.001714247395284474)","('Product_Design_And_Lifecycle_Management', 0.0013125971890985966)","([], 0.9820175766944885)","('NON-ESG', 0.001714247395284474)","('NON-ESG', 0.0013125971890985966)"
Line 799,"JIM RAWLEY , Environmental Healthy & Safety Manager at Amgen Rhode Island Mask Recycling A Silver Lining of the COVID Cloud The emergence of COVID-19 in 2020 brought with it the need for our employees to wear personal protective equipment (PPE), including masks, and in some cases gloves at Amgen facilities .","('Employee_Health_And_Safety', 0.9386234283447266)","('Product_Design_And_Lifecycle_Management', 0.00860259123146534)","('Employee_Engagement_Inclusion_And_Diversity', 0.008549111895263195)","(['Health Outcome Contribution'], 0.9386234283447266)","('NON-ESG', 0.00860259123146534)","('NON-ESG', 0.008549111895263195)"
Line 800,"However, while helping protect the safety of employees and contractors at our sites, we also wanted to mitigate unnecessary waste .","('Waste_And_Hazardous_Materials_Management', 0.9707480669021606)","('Employee_Health_And_Safety', 0.005909886211156845)","('Labor_Practices', 0.001871846616268158)","([], 0.9707480669021606)","('NON-ESG', 0.005909886211156845)","('NON-ESG', 0.001871846616268158)"
Line 801,"Beginning in July 2020, we partnered with a global leader in recycling hard-to-recycle materials to help .","('Product_Design_And_Lifecycle_Management', 0.9044861793518066)","('Supply_Chain_Management', 0.018502971157431602)","('Energy_Management', 0.010475900955498219)","([], 0.9044861793518066)","('NON-ESG', 0.018502971157431602)","('NON-ESG', 0.010475900955498219)"
Line 802,"Through our partnership, our employees can dispose of used PPE in onsite collection boxes .","('Waste_And_Hazardous_Materials_Management', 0.9069191813468933)","('Product_Design_And_Lifecycle_Management', 0.015210810117423534)","('Water_And_Wastewater_Management', 0.011412062682211399)","([], 0.9069191813468933)","('NON-ESG', 0.015210810117423534)","('NON-ESG', 0.011412062682211399)"
Line 803,"Our third-party vendor then breaks down the used PPE into its component fibers and plastics, which can be used to create new products such as plastic lumber for park benches .","('Product_Design_And_Lifecycle_Management', 0.9082103967666626)","('Waste_And_Hazardous_Materials_Management', 0.01760712079703808)","('Energy_Management', 0.010494295507669449)","([], 0.9082103967666626)","('NON-ESG', 0.01760712079703808)","('NON-ESG', 0.010494295507669449)"
Line 804,"Through 2021 we recycledand diverted from landfillsapproximately one metric ton of masks at our corporate headquarters in Thousand Oaks, California .","('Waste_And_Hazardous_Materials_Management', 0.9114871025085449)","('Water_And_Wastewater_Management', 0.03267551586031914)","('Air_Quality', 0.006072452757507563)","([], 0.9114871025085449)","('NON-ESG', 0.03267551586031914)","('NON-ESG', 0.006072452757507563)"
Line 805,"31 Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline .","('Systemic_Risk_Management', 0.5582717657089233)","('Business_Model_Resilience', 0.24591094255447388)","('Physical_Impacts_Of_Climate_Change', 0.025320183485746384)","([], 0.5582717657089233)","('NON-ESG', 0.24591094255447388)","('NON-ESG', 0.025320183485746384)"
Line 806,"ENVIRONMENTAL SUSTAINABILITY Healthy Planet 49 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix ENVIRONMENTAL SUSTAINABILITY While the program is currently only in the United States, we are exploring expansion to other Amgen sites in Europe .","('Human_Rights_And_Community_Relations', 0.5064992904663086)","('Business_Model_Resilience', 0.08029475063085556)","('Employee_Engagement_Inclusion_And_Diversity', 0.06967006623744965)","([], 0.5064992904663086)","('NON-ESG', 0.08029475063085556)","('NON-ESG', 0.06967006623744965)"
Line 807,"University of Massachusetts Lowell was one SAM recipient in 2021, receiving donated pipettes and other lab equipment for use in its Cell and Tissue Engineering teaching labs .","('Energy_Management', 0.19501632452011108)","('Management_Of_Legal_And_Regulatory_Framework', 0.13139812648296356)","('Access_And_Affordability', 0.1308504045009613)","('NON-ESG', 0.19501632452011108)","('NON-ESG', 0.13139812648296356)","('NON-ESG', 0.1308504045009613)"
Line 808,"Of this amount, 123 metric tons has been donated to educational programs and nonprofit organizations .","('Management_Of_Legal_And_Regulatory_Framework', 0.4992240071296692)","('Access_And_Affordability', 0.11267903447151184)","('Ecological_Impacts', 0.06658881902694702)","('NON-ESG', 0.4992240071296692)","('NON-ESG', 0.11267903447151184)","('NON-ESG', 0.06658881902694702)"
Line 809,"Since the program began in 2012, we diverted approximately 1,950 metric tons of materials from the landfill through SAM .","('Waste_And_Hazardous_Materials_Management', 0.9562031030654907)","('Water_And_Wastewater_Management', 0.006988196168094873)","('Supply_Chain_Management', 0.003595613408833742)","([], 0.9562031030654907)","('NON-ESG', 0.006988196168094873)","('NON-ESG', 0.003595613408833742)"
Line 810,"In 2021, we diverted approximately 82 metric tons of materials from landfills through SAM .","('Waste_And_Hazardous_Materials_Management', 0.9417123794555664)","('Water_And_Wastewater_Management', 0.007724890951067209)","('Supply_Chain_Management', 0.005795588716864586)","([], 0.9417123794555664)","('NON-ESG', 0.007724890951067209)","('NON-ESG', 0.005795588716864586)"
Line 811,"For assets not able to be repurposed, SAM responsibly recycled approximately 17 metric tons of material .","('Product_Design_And_Lifecycle_Management', 0.46115800738334656)","('Energy_Management', 0.1665559858083725)","('Waste_And_Hazardous_Materials_Management', 0.09888746589422226)","('NON-ESG', 0.46115800738334656)","('NON-ESG', 0.1665559858083725)","('NON-ESG', 0.09888746589422226)"
Line 812,SUSTAINABLE PACKAGING Amgen is on a journey to reduce the environmental impacts of its packaging through its Global Packaging Sustainability program .,"('Product_Design_And_Lifecycle_Management', 0.957707405090332)","('Energy_Management', 0.00425929669290781)","('Product_Quality_And_Safety', 0.0039907293394207954)","([], 0.957707405090332)","('NON-ESG', 0.00425929669290781)","('NON-ESG', 0.0039907293394207954)"
Line 813,"In 2021, we enhanced our Green Packaging Assessment process, showing its impact on our carbon footprint .","('Product_Design_And_Lifecycle_Management', 0.36554890871047974)","('Supply_Chain_Management', 0.12207766622304916)","('Energy_Management', 0.09660103172063828)","('NON-ESG', 0.36554890871047974)","('NON-ESG', 0.12207766622304916)","('NON-ESG', 0.09660103172063828)"
Line 814,"Moving forward, we plan to conduct life-cycle assessments on existing packaging to inform new, more sustainable designs for Amgen products that reduce adverse impacts on the variety of life in the world, or biodiversity .","('Product_Design_And_Lifecycle_Management', 0.9673810601234436)","('Selling_Practices_And_Product_Labeling', 0.0029533926863223314)","('Product_Quality_And_Safety', 0.0029278434813022614)","([], 0.9673810601234436)","('NON-ESG', 0.0029533926863223314)","('NON-ESG', 0.0029278434813022614)"
Line 815,"We also started to phase out use of PVC in secondary packaging, an accomplishment our manufacturing sites in Ireland and the Netherlands were the first to achieve in 2021 .","('Energy_Management', 0.5322719216346741)","('Product_Design_And_Lifecycle_Management', 0.3130865693092346)","('Supply_Chain_Management', 0.019995128735899925)","(['Operational Eco-Efficiency'], 0.5322719216346741)","('NON-ESG', 0.3130865693092346)","('NON-ESG', 0.019995128735899925)"
Line 816,"Moreover, in addition to efforts to promote biodiversity, we remain committed to using fully recyclable paperboard from certified sustainable forests in the packaging of all Amgen products and, where regulation allows, to shift to electronic leaflets .","('Product_Design_And_Lifecycle_Management', 0.9561957716941833)","('Product_Quality_And_Safety', 0.006604747846722603)","('Selling_Practices_And_Product_Labeling', 0.0052131363190710545)","([], 0.9561957716941833)","('NON-ESG', 0.006604747846722603)","('NON-ESG', 0.0052131363190710545)"
Line 817,"In 2021, the Australian Packaging Covenant Organisation honored Amgen with its Healthcare and Scientific Award .","('Management_Of_Legal_And_Regulatory_Framework', 0.2569199204444885)","('Customer_Welfare', 0.09816520661115646)","('Access_And_Affordability', 0.08605879545211792)","('NON-ESG', 0.2569199204444885)","('NON-ESG', 0.09816520661115646)","('NON-ESG', 0.08605879545211792)"
Line 818,"The award showcases Australian industrys commitment to meeting the nations 2025 packaging targets and building a regenerative, or circular, economy approach to packaging .","('Product_Design_And_Lifecycle_Management', 0.8912200927734375)","('Energy_Management', 0.016841115429997444)","('Business_Model_Resilience', 0.01212872564792633)","([], 0.8912200927734375)","('NON-ESG', 0.016841115429997444)","('NON-ESG', 0.01212872564792633)"
Line 819,"Among its efforts, Amgen is participating in the reusable Cool Green Shipper collaboration with the logistics company DHL and also examining recyclable and renewable alternatives to PVC in packaging trays for several products packaged in Australia .","('Product_Design_And_Lifecycle_Management', 0.9508109092712402)","('Energy_Management', 0.01091713272035122)","('Customer_Welfare', 0.004083725623786449)","([], 0.9508109092712402)","('NON-ESG', 0.01091713272035122)","('NON-ESG', 0.004083725623786449)"
Line 820,"FINDING NEW HOMES FOR SURPLUS ASSETS To conserve financial resources and reduce environmental impact, Amgen maintains a robust Surplus Asset Management (SAM) program, where staff can repurpose or donate equipment for reuse .","('Energy_Management', 0.18808981776237488)","('Access_And_Affordability', 0.12540937960147858)","('Management_Of_Legal_And_Regulatory_Framework', 0.11291658878326416)","('NON-ESG', 0.18808981776237488)","('NON-ESG', 0.12540937960147858)","('NON-ESG', 0.11291658878326416)"
Line 821,"This includes items such as laboratory, manufacturing, and facilities equipment; office furniture and supplies; and carts, glassware, and spare parts .","('Waste_And_Hazardous_Materials_Management', 0.46532246470451355)","('Product_Design_And_Lifecycle_Management', 0.1742548793554306)","('Employee_Health_And_Safety', 0.060193512588739395)","('NON-ESG', 0.46532246470451355)","('NON-ESG', 0.1742548793554306)","('NON-ESG', 0.060193512588739395)"
Line 822,"SAM also auctions equipment and donates to nonprofit organizations, educational institutions, and programs like the Amgen Biotech Experience (see page 39), an innovative science education program that empowers teachers to bring biotechnology into their classrooms .","('Access_And_Affordability', 0.6247209310531616)","('Employee_Engagement_Inclusion_And_Diversity', 0.059322539716959)","('Customer_Welfare', 0.039214301854372025)","(['Access to Healthcare'], 0.6247209310531616)","('NON-ESG', 0.059322539716959)","('NON-ESG', 0.039214301854372025)"
Line 823,Healthy Planet Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix Brent Meeks spends most of his workdays at Amgen behind the wheel of a car .,"('Access_And_Affordability', 0.22092923521995544)","('Employee_Health_And_Safety', 0.13230352103710175)","('Employee_Engagement_Inclusion_And_Diversity', 0.13098418712615967)","('NON-ESG', 0.22092923521995544)","('NON-ESG', 0.13230352103710175)","('NON-ESG', 0.13098418712615967)"
Line 824,"As a Senior Specialty Sales Representative in Northern California, he visits physicians as much as two hours away from his home across a large rural territory that stretches from Yreka to Davis, California .","('Customer_Welfare', 0.15998554229736328)","('Product_Design_And_Lifecycle_Management', 0.07733619213104248)","('Energy_Management', 0.0718763917684555)","('NON-ESG', 0.15998554229736328)","('NON-ESG', 0.07733619213104248)","('NON-ESG', 0.0718763917684555)"
Line 825,When he received an email asking for volunteers to join a new electric vehicle pilot program for Amgens U .,"('Management_Of_Legal_And_Regulatory_Framework', 0.3318340480327606)","('Energy_Management', 0.0937923789024353)","('Access_And_Affordability', 0.0749526396393776)","('NON-ESG', 0.3318340480327606)","('NON-ESG', 0.0937923789024353)","('NON-ESG', 0.0749526396393776)"
Line 826,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 827,"field fleet, the self-described car and technology nerd jumped at the chance to take part .","('Competitive_Behavior', 0.3653798997402191)","('Management_Of_Legal_And_Regulatory_Framework', 0.12752947211265564)","('Product_Design_And_Lifecycle_Management', 0.07333666831254959)","('NON-ESG', 0.3653798997402191)","('NON-ESG', 0.12752947211265564)","('NON-ESG', 0.07333666831254959)"
Line 828,"I was excited to join the pilot program because I know electric vehicles are the future, said Meeks.","('Energy_Management', 0.6338191628456116)","('Product_Design_And_Lifecycle_Management', 0.1372247040271759)","('Management_Of_Legal_And_Regulatory_Framework', 0.05095778778195381)","(['Operational Eco-Efficiency'], 0.6338191628456116)","('NON-ESG', 0.1372247040271759)","('NON-ESG', 0.05095778778195381)"
Line 829,"Along with the sustainability benefits, theyre fun to drive!","('Product_Design_And_Lifecycle_Management', 0.7979658246040344)","('Product_Quality_And_Safety', 0.024888284504413605)","('Employee_Health_And_Safety', 0.020975178107619286)","([], 0.7979658246040344)","('NON-ESG', 0.024888284504413605)","('NON-ESG', 0.020975178107619286)"
Line 830,"Globally, Amgens field fleet represents around 15% of the Companys overall carbon footprint, making it the third largest contributor of carbon emissions, behind Amgens manufacturing facilities in Juncos, Puerto Rico, and Thousand Oaks, Calif .","('GHG_Emissions', 0.759804904460907)","('Air_Quality', 0.04603690281510353)","('Energy_Management', 0.04256901144981384)","(['Operational Eco-Efficiency'], 0.759804904460907)","('NON-ESG', 0.04603690281510353)","('NON-ESG', 0.04256901144981384)"
Line 831,"The goal of the pilot program is to capture lessons learned in preparation for launching a minimum of 1,800 electric vehicles on the road globally by 2027 .","('Energy_Management', 0.828635573387146)","('Product_Design_And_Lifecycle_Management', 0.03252186253666878)","('Management_Of_Legal_And_Regulatory_Framework', 0.017451275140047073)","(['Operational Eco-Efficiency'], 0.828635573387146)","('NON-ESG', 0.03252186253666878)","('NON-ESG', 0.017451275140047073)"
Line 832,"It will take global participation to help Amgen reach carbon neutrality32 by 2027, said Yanina Barrera, Ph .","('Management_Of_Legal_And_Regulatory_Framework', 0.7151145935058594)","('GHG_Emissions', 0.05539632961153984)","('Competitive_Behavior', 0.02421646937727928)","([], 0.7151145935058594)","('NON-ESG', 0.05539632961153984)","('NON-ESG', 0.02421646937727928)"
Line 833,"D ., Principal Engineer, Engineering Technical Authority, who leads Amgens sustainability efforts to increase electrification33 of the field fleet to at least 30%, and electrifying our fleet in countries that are ready is critical to making that happen .","('Energy_Management', 0.4437640309333801)","('Management_Of_Legal_And_Regulatory_Framework', 0.10386932641267776)","('Product_Design_And_Lifecycle_Management', 0.053330112248659134)","('NON-ESG', 0.4437640309333801)","('NON-ESG', 0.10386932641267776)","('NON-ESG', 0.053330112248659134)"
Line 834,"The pilot has not been without challenges, ranging from the lower mileage range of electric vehicles paired with limited charging infrastructure availability in some territories, and the lack of available vehicles due to supply chain issues .","('Supply_Chain_Management', 0.9363132119178772)","('Energy_Management', 0.0071299998089671135)","('Labor_Practices', 0.005740368738770485)","([], 0.9363132119178772)","('NON-ESG', 0.0071299998089671135)","('NON-ESG', 0.005740368738770485)"
Line 835,"Nevertheless, as of January 1, 2022, Barreras team has placed orders for 195 electric vehicles, which have been assigned to field staff .","('Energy_Management', 0.5682311058044434)","('Product_Design_And_Lifecycle_Management', 0.1489858776330948)","('Management_Of_Legal_And_Regulatory_Framework', 0.03334994986653328)","(['Operational Eco-Efficiency'], 0.5682311058044434)","('NON-ESG', 0.1489858776330948)","('NON-ESG', 0.03334994986653328)"
Line 836,"Planning is also underway for deployment of all-electric vehicles in other geographies, and we have launched the program in the Netherlands and South Korea .","('Energy_Management', 0.7097875475883484)","('Product_Design_And_Lifecycle_Management', 0.06901378929615021)","('Management_Of_Legal_And_Regulatory_Framework', 0.05631738156080246)","(['Operational Eco-Efficiency'], 0.7097875475883484)","('NON-ESG', 0.06901378929615021)","('NON-ESG', 0.05631738156080246)"
Line 837,"To support the transition, Amgen is providing home charger installation and hosting driver workshops to educate on issues such as public charging stations and reimbursement processes for electricity usage .","('Energy_Management', 0.8319993019104004)","('Management_Of_Legal_And_Regulatory_Framework', 0.09677616506814957)","('Air_Quality', 0.008141083642840385)","(['Operational Eco-Efficiency'], 0.8319993019104004)","('NON-ESG', 0.09677616506814957)","('NON-ESG', 0.008141083642840385)"
Line 838,"For Meeks, its an experience he has been glad to be part of .","('Human_Rights_And_Community_Relations', 0.18404130637645721)","('Employee_Engagement_Inclusion_And_Diversity', 0.16091665625572205)","('Management_Of_Legal_And_Regulatory_Framework', 0.12804333865642548)","('NON-ESG', 0.18404130637645721)","('NON-ESG', 0.16091665625572205)","('NON-ESG', 0.12804333865642548)"
Line 839,"I look forward to driving the car -- Its fun, its high tech, and it puts a smile on my face every time .","('Product_Design_And_Lifecycle_Management', 0.19315771758556366)","('Employee_Engagement_Inclusion_And_Diversity', 0.09252122044563293)","('Business_Model_Resilience', 0.08775179088115692)","('NON-ESG', 0.19315771758556366)","('NON-ESG', 0.09252122044563293)","('NON-ESG', 0.08775179088115692)"
Line 840,ELECTRIC VEHICLE PILOT PROGRAM ADVANCES CARBON NEUTRALITY GOAL32 32 Carbon neutrality goal refers to Scope 1 and 2 emissions .,"('GHG_Emissions', 0.8399530649185181)","('Management_Of_Legal_And_Regulatory_Framework', 0.04226478561758995)","('Air_Quality', 0.01966232620179653)","(['Operational Eco-Efficiency'], 0.8399530649185181)","('NON-ESG', 0.04226478561758995)","('NON-ESG', 0.01966232620179653)"
Line 841,33 Based on a 2019 baseline .,"('Management_Of_Legal_And_Regulatory_Framework', 0.26829656958580017)","('GHG_Emissions', 0.15823204815387726)","('Ecological_Impacts', 0.11545930802822113)","('NON-ESG', 0.26829656958580017)","('NON-ESG', 0.15823204815387726)","('NON-ESG', 0.11545930802822113)"
Line 842,"50 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021Healthy Planet 51 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix ENVIRONMENTAL SUSTAINABILITY OTHER REPORTS The CDP is an international nonprofit organization and reporting platform that helps companies and cities disclose their environmental impacts .","('Human_Rights_And_Community_Relations', 0.6559181213378906)","('Business_Model_Resilience', 0.06161540746688843)","('Ecological_Impacts', 0.04638597369194031)","([], 0.6559181213378906)","('NON-ESG', 0.06161540746688843)","('NON-ESG', 0.04638597369194031)"
Line 843,"Since 2010, Amgen has reported to the CDP and you can find our most recent CDP reports for Climate Change and Water here .","('Water_And_Wastewater_Management', 0.8069353699684143)","('Physical_Impacts_Of_Climate_Change', 0.046962205320596695)","('GHG_Emissions', 0.034242164343595505)","([], 0.8069353699684143)","('NON-ESG', 0.046962205320596695)","('NON-ESG', 0.034242164343595505)"
Line 844,"Our reports provide additional details about Amgens governance, strategy, risk management, metrics, and targets related to climate change and water .","('Physical_Impacts_Of_Climate_Change', 0.8974969983100891)","('Business_Model_Resilience', 0.019839271903038025)","('GHG_Emissions', 0.010633120313286781)","([], 0.8974969983100891)","('NON-ESG', 0.019839271903038025)","('NON-ESG', 0.010633120313286781)"
Line 845,"Over time, CDPs disclosure platform for climate change has evolved to contain over 25 questions (within its governance, risks and opportunities, strategy, targets and emissions modules) that are aligned with the recommendations of the Task Force on Climate-related Financial Disclosures, or TCFD; this platform is now nearly in full alignment with the TCFD .","('Physical_Impacts_Of_Climate_Change', 0.9494585990905762)","('Business_Model_Resilience', 0.011143092066049576)","('GHG_Emissions', 0.0055214883759617805)","([], 0.9494585990905762)","('NON-ESG', 0.011143092066049576)","('NON-ESG', 0.0055214883759617805)"
Line 846,"We continue to report to the CDP as completely as possible and, in 2022, we are undertaking a TCFD-aligned scenario analysis assessment to improve our understanding of the physical and transitional effects of climate change as well as to inform our future reporting .","('Physical_Impacts_Of_Climate_Change', 0.9458468556404114)","('Business_Model_Resilience', 0.012009031139314175)","('GHG_Emissions', 0.007952419109642506)","([], 0.9458468556404114)","('NON-ESG', 0.012009031139314175)","('NON-ESG', 0.007952419109642506)"
Line 847,"Additionally, while the Companys 2027 environmental sustainability targets do not incorporate Scope 3 emissions, we continue exploring approaches to better understand this area, including identifying potential emissions reduction opportunities in our value chain .2021 PERFORMANCE DATA We measure and report on our overall carbon emissions, energy, water use, and waste disposed .","('GHG_Emissions', 0.6667723655700684)","('Air_Quality', 0.1404031217098236)","('Energy_Management', 0.06464272737503052)","(['Operational Eco-Efficiency'], 0.6667723655700684)","('NON-ESG', 0.1404031217098236)","('NON-ESG', 0.06464272737503052)"
Line 848,"We include data gathered from 16 manufacturing, R&D, and distribution facilities located in North America, South America, Asia, and Europe, representing (based on square footage) approximately 88% of our operations .","('Supply_Chain_Management', 0.2260054647922516)","('Business_Model_Resilience', 0.16898857057094574)","('Product_Design_And_Lifecycle_Management', 0.1083613708615303)","('NON-ESG', 0.2260054647922516)","('NON-ESG', 0.16898857057094574)","('NON-ESG', 0.1083613708615303)"
Line 849,"For the remaining 12% of square footage, primarily administrative offices, we estimate energy usage to calculate carbon emissions .","('Energy_Management', 0.9716588854789734)","('Air_Quality', 0.004337064456194639)","('Management_Of_Legal_And_Regulatory_Framework', 0.004030624404549599)","(['Operational Eco-Efficiency'], 0.9716588854789734)","('NON-ESG', 0.004337064456194639)","('NON-ESG', 0.004030624404549599)"
Line 850,We measure progress toward our targets by quantifying results independent of growth or contraction of our business .,"('Business_Model_Resilience', 0.5930237770080566)","('Systemic_Risk_Management', 0.25557005405426025)","('Competitive_Behavior', 0.01728007197380066)","(['Human Capital Development', 'Innovation Management'], 0.5930237770080566)","('NON-ESG', 0.25557005405426025)","('NON-ESG', 0.01728007197380066)"
Line 851,We do not include facility or building closures or recently acquired facilities in our target progress .,"('Supply_Chain_Management', 0.24859032034873962)","('Business_Model_Resilience', 0.09398063272237778)","('Waste_And_Hazardous_Materials_Management', 0.06858192384243011)","('NON-ESG', 0.24859032034873962)","('NON-ESG', 0.09398063272237778)","('NON-ESG', 0.06858192384243011)"
Line 852,Our 2021 environmental data have undergone a reasonable assurance audit .,"('Management_Of_Legal_And_Regulatory_Framework', 0.2558410167694092)","('Customer_Privacy', 0.1725131869316101)","('Data_Security', 0.12353817373514175)","('NON-ESG', 0.2558410167694092)","('NON-ESG', 0.1725131869316101)","('NON-ESG', 0.12353817373514175)"
Line 853,Highlights of our environmental performance are presented below; more detailed data can be found here .,"('Business_Model_Resilience', 0.4971420466899872)","('Systemic_Risk_Management', 0.11333581060171127)","('Human_Rights_And_Community_Relations', 0.06832712888717651)","('NON-ESG', 0.4971420466899872)","('NON-ESG', 0.11333581060171127)","('NON-ESG', 0.06832712888717651)"
Line 854,"ENERGY In 2021, we increased the amount of renewable energy in our purchased electricity to 79% compared to 41% in 2020 .","('Energy_Management', 0.9785005450248718)","('Management_Of_Legal_And_Regulatory_Framework', 0.0037022638134658337)","('Water_And_Wastewater_Management', 0.001513343071565032)","(['Operational Eco-Efficiency'], 0.9785005450248718)","('NON-ESG', 0.0037022638134658337)","('NON-ESG', 0.001513343071565032)"
Line 855,"We purchased in-country renewable energy certificates to make our facilities in Thousand Oaks, CA; West Greenwich, RI; Louisville, KY; Cambridge, MA; Breda, Netherlands; and Singapore use 100% renewable electricity .","('Energy_Management', 0.9762054681777954)","('Management_Of_Legal_And_Regulatory_Framework', 0.0029691033996641636)","('Air_Quality', 0.0022363760508596897)","(['Operational Eco-Efficiency'], 0.9762054681777954)","('NON-ESG', 0.0029691033996641636)","('NON-ESG', 0.0022363760508596897)"
Line 856,This is in addition to our GreenPower Purchase Plans with local utilities at our facility in Ireland and our two locations in Great Britain .,"('Management_Of_Legal_And_Regulatory_Framework', 0.4682005047798157)","('Energy_Management', 0.2468918114900589)","('Physical_Impacts_Of_Climate_Change', 0.033915940672159195)","('NON-ESG', 0.4682005047798157)","('NON-ESG', 0.2468918114900589)","('NON-ESG', 0.033915940672159195)"
Line 857,"2021 Energy Use by Source (1,000 GJ) 7 3831,131 16091,0607 3831,131 16091,060 Renewables Fossil FuelNuclear Natural Gas Diesel PropaneHealthy Planet 52 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society A Healthy Amgen Appendix CARBON Carbon emissions from onsite combustion of fuel and purchased energy in 2021 decreased by 88,000 metric tons (MT) from 2020 .","('Energy_Management', 0.9631262421607971)","('GHG_Emissions', 0.0070444331504404545)","('Air_Quality', 0.004219889175146818)","(['Operational Eco-Efficiency'], 0.9631262421607971)","('NON-ESG', 0.0070444331504404545)","('NON-ESG', 0.004219889175146818)"
Line 858,"This represents a 36% reduction from the previous year and was primarily achieved through the increased procurement of renewable electricity, as discussed above, for our North American facilities .","('Energy_Management', 0.9614058136940002)","('Management_Of_Legal_And_Regulatory_Framework', 0.011312992312014103)","('GHG_Emissions', 0.0031591204460710287)","(['Operational Eco-Efficiency'], 0.9614058136940002)","('NON-ESG', 0.011312992312014103)","('NON-ESG', 0.0031591204460710287)"
Line 859,"Carbon Emissions From Onsite Combustion of Fuel and Purchased Energy (1,000 MT)Water Intake (1,000 CM)Waste Generation (MT) 1001000 50020002002500 2000 15006000 400030030001000 8000400350012000 2007*2007*2007*2019**2019**2019**2020 2020 2020 2021 2021 2021133977 2,2387,466129 155 2,823416 3,286 6,6043,542133 977 6,329133 977 6,678 249 2,146 3,490243 2,355 3,163 Carbon EmissionsWater IntakeWaste DisposedAnnual Carbon Emissions Avoided 2007-2019Annual Water Intake Avoided 2007-2019Waste Recycled, Composted, Incinerated With Energy Recovery 2007-2019Annual Carbon Emissions Avoided 2020-PresentAnnual Water Intake Avoided 2020-PresentReductions in Waste Disposed 2020-Present64 55183884WATER Our total water usage in 2021 decreased by 117,000 cubic meters (CM) from 2020 .","('Water_And_Wastewater_Management', 0.38933056592941284)","('Air_Quality', 0.19935287535190582)","('GHG_Emissions', 0.13385967910289764)","('NON-ESG', 0.38933056592941284)","('NON-ESG', 0.19935287535190582)","('NON-ESG', 0.13385967910289764)"
Line 860,"Carbon Emissions From Onsite Combustion of Fuel and Purchased Energy (1,000 MT)Water Intake (1,000 CM)Waste Generation (MT) 1001000 50020002002500 2000 15006000 400030030001000 8000400350012000 2007*2007*2007*2019**2019**2019**2020 2020 2020 2021 2021 2021133977 2,2387,466129 155 2,823416 3,286 6,6043,542133 977 6,329133 977 6,678 249 2,146 3,490243 2,355 3,163 Carbon EmissionsWater IntakeWaste DisposedAnnual Carbon Emissions Avoided 2007-2019Annual Water Intake Avoided 2007-2019Waste Recycled, Composted, Incinerated With Energy Recovery 2007-2019Annual Carbon Emissions Avoided 2020-PresentAnnual Water Intake Avoided 2020-PresentReductions in Waste Disposed 2020-Present64 55183884WATER Our total water usage in 2021 decreased by 117,000 cubic meters (CM) from 2020 .","('Water_And_Wastewater_Management', 0.9730392098426819)","('Energy_Management', 0.0038003798108547926)","('Waste_And_Hazardous_Materials_Management', 0.002529008314013481)","([], 0.9730392098426819)","('NON-ESG', 0.0038003798108547926)","('NON-ESG', 0.002529008314013481)"
Line 861,"Water usage decreases are a result of water reclamation projects, irrigation control enhancements and completion of equipment commissioning (which temporarily increased water usage in 2020) .","('Water_And_Wastewater_Management', 0.9764404892921448)","('GHG_Emissions', 0.002310275798663497)","('Energy_Management', 0.002308969385921955)","([], 0.9764404892921448)","('NON-ESG', 0.002310275798663497)","('NON-ESG', 0.002308969385921955)"
Line 862,"Since 2007, we have avoided the usage of 1 million CM annually through the implementation of water innovation and efficiency projects .","('Water_And_Wastewater_Management', 0.9178385138511658)","('Energy_Management', 0.03766955807805061)","('GHG_Emissions', 0.004909837618470192)","([], 0.9178385138511658)","('NON-ESG', 0.03766955807805061)","('NON-ESG', 0.004909837618470192)"
Line 863,WASTE Waste disposed decreased in 2021 primarily due to an increase in the Amgen Rhode Island waste-to-energy conversion at a nearby facility .,"('Waste_And_Hazardous_Materials_Management', 0.9843367338180542)","('Data_Security', 0.0014332733117043972)","('Water_And_Wastewater_Management', 0.00130361202172935)","([], 0.9843367338180542)","('NON-ESG', 0.0014332733117043972)","('NON-ESG', 0.00130361202172935)"
Line 864,The Amgen Rhode Island manufacturing facilities now divert 80% of landfill waste to the waste-to-energy facility .,"('Waste_And_Hazardous_Materials_Management', 0.9845399260520935)","('Water_And_Wastewater_Management', 0.0013316822005435824)","('Data_Security', 0.0012537090806290507)","([], 0.9845399260520935)","('NON-ESG', 0.0013316822005435824)","('NON-ESG', 0.0012537090806290507)"
Line 865,* Amgen Sustainability program base year .,"('Business_Model_Resilience', 0.3287371098995209)","('Product_Design_And_Lifecycle_Management', 0.19250145554542542)","('Supply_Chain_Management', 0.14110703766345978)","('NON-ESG', 0.3287371098995209)","('NON-ESG', 0.19250145554542542)","('NON-ESG', 0.14110703766345978)"
Line 866,** 2027 Plan base year .,"('Business_Model_Resilience', 0.18413323163986206)","('Physical_Impacts_Of_Climate_Change', 0.15707498788833618)","('Management_Of_Legal_And_Regulatory_Framework', 0.1362544447183609)","('NON-ESG', 0.18413323163986206)","('NON-ESG', 0.15707498788833618)","('NON-ESG', 0.1362544447183609)"
Line 867,"ENVIRONMENTAL SUSTAINABILITY 53 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix A Healthy Amgen A HEALTHY AMGEN We hold ourselves to high standards in our operationsworking to ensure that our actions and culture reflect Amgens values.","('Human_Rights_And_Community_Relations', 0.6281135082244873)","('Business_Model_Resilience', 0.07168617099523544)","('Employee_Engagement_Inclusion_And_Diversity', 0.05002543702721596)","([], 0.6281135082244873)","('NON-ESG', 0.07168617099523544)","('NON-ESG', 0.05002543702721596)"
Line 868,"ZERO class 1 or 2 product recalls*800+ Amgen employees served as cybersecurity ambassadors, representing 34 countries and every function within the Company100% of employees trained on the Code of Conduct * A Class 1 recall recall is defined by the U .","('Product_Quality_And_Safety', 0.5660446286201477)","('Employee_Health_And_Safety', 0.06673470139503479)","('Selling_Practices_And_Product_Labeling', 0.05627894401550293)","(['Product Quality & Recall Management'], 0.5660446286201477)","('NON-ESG', 0.06673470139503479)","('NON-ESG', 0.05627894401550293)"
Line 869,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 870,Food and Drug Administration (FDA) as a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death .,"('Product_Quality_And_Safety', 0.7169400453567505)","('Selling_Practices_And_Product_Labeling', 0.08990643173456192)","('Customer_Welfare', 0.038326866924762726)","(['Product Quality & Recall Management'], 0.7169400453567505)","('NON-ESG', 0.08990643173456192)","('NON-ESG', 0.038326866924762726)"
Line 871,"A Class 2 recall is defined by the FDA as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote .2021 HighlightsA Healthy Amgen 54 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix AMBITION We seek to strengthen and maintain the trust of the stakeholders we serve .","('Product_Quality_And_Safety', 0.5460052490234375)","('Employee_Health_And_Safety', 0.14163969457149506)","('Product_Design_And_Lifecycle_Management', 0.061791907995939255)","(['Product Quality & Recall Management'], 0.5460052490234375)","('NON-ESG', 0.14163969457149506)","('NON-ESG', 0.061791907995939255)"
Line 872,"This is not only the right thing to do, but also essential for the long-term health of Amgen and all we serve .","('Access_And_Affordability', 0.20664946734905243)","('Business_Model_Resilience', 0.14234042167663574)","('Product_Design_And_Lifecycle_Management', 0.10966934263706207)","('NON-ESG', 0.20664946734905243)","('NON-ESG', 0.14234042167663574)","('NON-ESG', 0.10966934263706207)"
Line 873,"CORPORATE GOVERNANCE BUSINESS ETHICS ETHICAL RESEARCH PATIENT SAFETY & PRODUCT QUALITY CYBERSECURITY & DATA PRIVACY GOVERNMENT AFFAIRS & PUBLIC POLICY Our business is built on an unwavering commitment to integrity and compliance, which is demonstrated by our staff members every day through their words, decisions and actions.","('Business_Ethics', 0.9654468894004822)","('Management_Of_Legal_And_Regulatory_Framework', 0.0033965534530580044)","('Data_Security', 0.0031365538015961647)","(['Business Ethics'], 0.9654468894004822)","('NON-ESG', 0.0033965534530580044)","('NON-ESG', 0.0031365538015961647)"
Line 874,"A HEALTHY AMGEN Our commitment to integrity and compliance requires preserving our heritage of high ethical values and standards, ensuring accountability for our actions, and putting the patient first .","('Business_Ethics', 0.9502936601638794)","('Human_Rights_And_Community_Relations', 0.003831219393759966)","('Management_Of_Legal_And_Regulatory_Framework', 0.0037603448145091534)","(['Business Ethics'], 0.9502936601638794)","('NON-ESG', 0.003831219393759966)","('NON-ESG', 0.0037603448145091534)"
Line 875,"Quite simply, it requires doing things right and doing the right things .","('Director_Removal', 0.15311011672019958)","('Business_Ethics', 0.09495404362678528)","('Business_Model_Resilience', 0.08507335186004639)","('NON-ESG', 0.15311011672019958)","('NON-ESG', 0.09495404362678528)","('NON-ESG', 0.08507335186004639)"
Line 876,"This approach is woven through all facets of our organization by robust governance practices, global policies, performance management systems, training, and ongoing monitoring and remediation .","('Management_Of_Legal_And_Regulatory_Framework', 0.8582080006599426)","('Human_Rights_And_Community_Relations', 0.030309529975056648)","('Business_Ethics', 0.021903855726122856)","([], 0.8582080006599426)","('NON-ESG', 0.030309529975056648)","('NON-ESG', 0.021903855726122856)"
Line 877,It is also built on a culture of transparency and engagement with stakeholders .,"('Business_Ethics', 0.9633662700653076)","('Management_Of_Legal_And_Regulatory_Framework', 0.005124510731548071)","('Data_Security', 0.002992821391671896)","(['Business Ethics'], 0.9633662700653076)","('NON-ESG', 0.005124510731548071)","('NON-ESG', 0.002992821391671896)"
Line 878,"This section includes: A Healthy Amgen 55 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix CORPORATE GOVERNANCEBoard of Director composition is an area of focus for the Board .","('Human_Rights_And_Community_Relations', 0.19156992435455322)","('Director_Removal', 0.18853656947612762)","('Business_Model_Resilience', 0.12930354475975037)","('NON-ESG', 0.19156992435455322)","('NON-ESG', 0.18853656947612762)","('NON-ESG', 0.12930354475975037)"
Line 879,"Reflecting our Boards commitment to refreshment, the Board has appointed seven new directors since 2015, including women as well as those from underrepresented communities, adding critical skills and experience to our Board in furtherance of our strategic priorities .","('Employee_Engagement_Inclusion_And_Diversity', 0.3485506474971771)","('Director_Removal', 0.30047354102134705)","('Business_Model_Resilience', 0.09307822585105896)","('NON-ESG', 0.3485506474971771)","('NON-ESG', 0.30047354102134705)","('NON-ESG', 0.09307822585105896)"
Line 880,"Our Governance and Nominating Committee regularly screens and recommends candidates for nomination by the full Board and, among other things, considers feedback received during the annual Board and committee evaluation process, investor feedback, our qualification guidelines and skills matrix, director commitment levels (with consideration given to public company leadership roles and outside commitments) and diversity .","('Employee_Engagement_Inclusion_And_Diversity', 0.7263513803482056)","('Director_Removal', 0.09873649477958679)","('Business_Model_Resilience', 0.02016480639576912)","(['Talent Attraction & Retention'], 0.7263513803482056)","('NON-ESG', 0.09873649477958679)","('NON-ESG', 0.02016480639576912)"
Line 881,"The Governance and Nominating Committee and the Board of Directors view diversity as a priority, consider diversity in its determinations, and seek representation across a range of attributes .","('Employee_Engagement_Inclusion_And_Diversity', 0.9335845112800598)","('Director_Removal', 0.008728527463972569)","('Labor_Practices', 0.004299575928598642)","(['Talent Attraction & Retention'], 0.9335845112800598)","('NON-ESG', 0.008728527463972569)","('NON-ESG', 0.004299575928598642)"
Line 882,"Diversity includes race, ethnicity, age, and gender and is also broadly construed to take into consideration many other factors, including industry knowledge, operational experience, scientific and academic expertise, geography, and personal background .","('Employee_Engagement_Inclusion_And_Diversity', 0.972968578338623)","('Customer_Privacy', 0.0019462330965325236)","('Employee_Health_And_Safety', 0.001850958913564682)","(['Talent Attraction & Retention'], 0.972968578338623)","('NON-ESG', 0.0019462330965325236)","('NON-ESG', 0.001850958913564682)"
Line 883,"In an effort to best support maintaining and expanding the diversity of our Board, our Governance and Nominating Committee actively seeks diverse candidates, including women and minority candidates, as part of its search for new directors .","('Employee_Engagement_Inclusion_And_Diversity', 0.9672397375106812)","('Director_Removal', 0.0025586660485714674)","('Business_Model_Resilience', 0.0021760547533631325)","(['Talent Attraction & Retention'], 0.9672397375106812)","('NON-ESG', 0.0025586660485714674)","('NON-ESG', 0.0021760547533631325)"
Line 884,CORPORATE GOVERNANCE Effective corporate governance is critical for both our long-term performance and maintaining stakeholder trust.,"('Management_Of_Legal_And_Regulatory_Framework', 0.3852776288986206)","('Competitive_Behavior', 0.21088898181915283)","('Business_Ethics', 0.12372897565364838)","('NON-ESG', 0.3852776288986206)","('NON-ESG', 0.21088898181915283)","('NON-ESG', 0.12372897565364838)"
Line 885,"Amgen has a highly independent Board of Directors elected annually by a majority of our stockholders, with a lead independent director with robust responsibilities .","('Director_Removal', 0.7825717329978943)","('Management_Of_Legal_And_Regulatory_Framework', 0.02786874771118164)","('Data_Security', 0.01755683124065399)","(['Business Ethics'], 0.7825717329978943)","('NON-ESG', 0.02786874771118164)","('NON-ESG', 0.01755683124065399)"
Line 886,Only independent Board members serve on key standing committees .,"('Director_Removal', 0.6371855735778809)","('Management_Of_Legal_And_Regulatory_Framework', 0.10130628198385239)","('Employee_Engagement_Inclusion_And_Diversity', 0.023464443162083626)","(['Business Ethics'], 0.6371855735778809)","('NON-ESG', 0.10130628198385239)","('NON-ESG', 0.023464443162083626)"
Line 887,"Key standing committees of our Board include the Audit, Compensation and Management Development, Corporate Responsibility and Compliance, and the Governance and Nominating Committees .","('Management_Of_Legal_And_Regulatory_Framework', 0.7878634929656982)","('Business_Ethics', 0.08950872719287872)","('Director_Removal', 0.03371521085500717)","([], 0.7878634929656982)","('NON-ESG', 0.08950872719287872)","('NON-ESG', 0.03371521085500717)"
Line 888,Our Board of Directors is guided by our Amgen Board of Directors Corporate Governance Principles that are amended from time to time to incorporate certain current best practices in corporate governance .,"('Director_Removal', 0.46794798970222473)","('Management_Of_Legal_And_Regulatory_Framework', 0.1543995440006256)","('Business_Ethics', 0.07716266065835953)","('NON-ESG', 0.46794798970222473)","('NON-ESG', 0.1543995440006256)","('NON-ESG', 0.07716266065835953)"
Line 889,"Our Board operates in alignment with two codes of business conductthe Amgen Board of Directors Code of Conduct that applies to our Board and a global Code of Conduct that applies to our Board, all our staff, and others conducting business on our behalf .","('Director_Removal', 0.6813459396362305)","('Management_Of_Legal_And_Regulatory_Framework', 0.06628879904747009)","('Business_Ethics', 0.055368389934301376)","(['Business Ethics'], 0.6813459396362305)","('NON-ESG', 0.06628879904747009)","('NON-ESG', 0.055368389934301376)"
Line 890,Annual training on the global Code of Conduct is required and our Board participates in such training .,"('Management_Of_Legal_And_Regulatory_Framework', 0.5172829031944275)","('Business_Ethics', 0.17376069724559784)","('Product_Quality_And_Safety', 0.05047264322638512)","([], 0.5172829031944275)","('NON-ESG', 0.17376069724559784)","('NON-ESG', 0.05047264322638512)"
Line 891,Our Corporate Governance Principles and codes of conduct may be found on our website .,"('Business_Ethics', 0.6072282791137695)","('Management_Of_Legal_And_Regulatory_Framework', 0.23772065341472626)","('Director_Removal', 0.0274349395185709)","(['Business Ethics'], 0.6072282791137695)","('NON-ESG', 0.23772065341472626)","('NON-ESG', 0.0274349395185709)"
Line 892,"25% FEMALE DIRECTORS GENDER DIVERSITY3 92 1017% DIVERSE DIRECTORS RACIAL/ETHNIC DIVERSITYAs part of its oversight of the Company, our Board of Directors oversees an enterprise-wide approach to risk management, which is designed to support the achievement of the Companys objectives, including its strategic priorities to improve long-term operational and financial performance and deliver stockholder value .","('Employee_Engagement_Inclusion_And_Diversity', 0.9734205007553101)","('Business_Model_Resilience', 0.002014986937865615)","('Employee_Health_And_Safety', 0.001887961640022695)","(['Talent Attraction & Retention'], 0.9734205007553101)","('NON-ESG', 0.002014986937865615)","('NON-ESG', 0.001887961640022695)"
Line 893,"Our Board believes that a fundamental part of risk management is understanding the risks that we face, adopting appropriate controls and mitigation activities for such risks, monitoring these risks, and responding to emerging developments for such risks .","('Systemic_Risk_Management', 0.9347606897354126)","('Business_Model_Resilience', 0.014098240062594414)","('Physical_Impacts_Of_Climate_Change', 0.011235986836254597)","([], 0.9347606897354126)","('NON-ESG', 0.014098240062594414)","('NON-ESG', 0.011235986836254597)"
Line 894,"For more information on our Board and our corporate governance practices, please visit our website and our 2022 Proxy Statement .","('Management_Of_Legal_And_Regulatory_Framework', 0.2827005982398987)","('Director_Removal', 0.27282240986824036)","('Business_Ethics', 0.07429472357034683)","('NON-ESG', 0.2827005982398987)","('NON-ESG', 0.27282240986824036)","('NON-ESG', 0.07429472357034683)"
Line 895,"A Healthy Amgen 56 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix Together, the Amgen Values and Code of Conduct serve as principles that guide the way we conduct business .","('Human_Rights_And_Community_Relations', 0.66119384765625)","('Business_Model_Resilience', 0.06096111983060837)","('Employee_Engagement_Inclusion_And_Diversity', 0.0502530001103878)","([], 0.66119384765625)","('NON-ESG', 0.06096111983060837)","('NON-ESG', 0.0502530001103878)"
Line 896,The Amgen Values define the day-to-day behavioral expectations of every Amgen staff member around the world .,"('Human_Rights_And_Community_Relations', 0.19088426232337952)","('Employee_Engagement_Inclusion_And_Diversity', 0.16332580149173737)","('Business_Model_Resilience', 0.14570750296115875)","('NON-ESG', 0.19088426232337952)","('NON-ESG', 0.16332580149173737)","('NON-ESG', 0.14570750296115875)"
Line 897,The Code of Conduct is our guide to doing the right thing .,"('Business_Ethics', 0.6637536883354187)","('Management_Of_Legal_And_Regulatory_Framework', 0.06302638351917267)","('Human_Rights_And_Community_Relations', 0.05819758400321007)","(['Business Ethics'], 0.6637536883354187)","('NON-ESG', 0.06302638351917267)","('NON-ESG', 0.05819758400321007)"
Line 898,"Including demonstrating high ethical standards, good judgment, and accountability for our actions .","('Business_Ethics', 0.9415314197540283)","('Competitive_Behavior', 0.00578701077029109)","('Director_Removal', 0.004282303154468536)","(['Business Ethics'], 0.9415314197540283)","('NON-ESG', 0.00578701077029109)","('NON-ESG', 0.004282303154468536)"
Line 899,"Our Code of Conduct applies to every person who does business on behalf of our Company worldwideincluding our Board, all employees and all levels of management, as well as consultants, contract workers, and temporary workers (as applicable by law) .","('Labor_Practices', 0.9612545371055603)","('Employee_Health_And_Safety', 0.005765099078416824)","('Director_Removal', 0.004421641584485769)","([], 0.9612545371055603)","('NON-ESG', 0.005765099078416824)","('NON-ESG', 0.004421641584485769)"
Line 900,We require all employees to take Code of Conduct training annually; our Code is available in 24 languages to support global understanding .,"('Management_Of_Legal_And_Regulatory_Framework', 0.19787998497486115)","('Employee_Engagement_Inclusion_And_Diversity', 0.1583893895149231)","('Product_Quality_And_Safety', 0.14019867777824402)","('NON-ESG', 0.19787998497486115)","('NON-ESG', 0.1583893895149231)","('NON-ESG', 0.14019867777824402)"
Line 901,Our staff and anyone external to the Company can report suspected misconduct or ask a question by phone or via the Internet using Amgens Business Conduct Hotline .,"('Business_Ethics', 0.959234356880188)","('Customer_Privacy', 0.003436822909861803)","('Employee_Health_And_Safety', 0.0032790498808026314)","(['Business Ethics'], 0.959234356880188)","('NON-ESG', 0.003436822909861803)","('NON-ESG', 0.0032790498808026314)"
Line 902,We provide regular updates on the number and types of reports received through the Business Conduct Hotline to the Corporate Responsibility and Compliance Committee of our Board of Directors .,"('Management_Of_Legal_And_Regulatory_Framework', 0.6866167783737183)","('Director_Removal', 0.11403380334377289)","('Business_Ethics', 0.05199374258518219)","([], 0.6866167783737183)","('NON-ESG', 0.11403380334377289)","('NON-ESG', 0.05199374258518219)"
Line 903,Amgens nonretaliation policy prohibits any form of retaliation or intimidation against Amgen employees for reporting a concern in good faith .,"('Business_Ethics', 0.9212630987167358)","('Labor_Practices', 0.012805378995835781)","('Employee_Engagement_Inclusion_And_Diversity', 0.009477680549025536)","(['Business Ethics'], 0.9212630987167358)","('NON-ESG', 0.012805378995835781)","('NON-ESG', 0.009477680549025536)"
Line 904,VALUE CREATION We operate within a highly regulated and increasingly complex environment.,"('Competitive_Behavior', 0.3917539119720459)","('Management_Of_Legal_And_Regulatory_Framework', 0.2520056366920471)","('Systemic_Risk_Management', 0.1278741955757141)","('NON-ESG', 0.3917539119720459)","('NON-ESG', 0.2520056366920471)","('NON-ESG', 0.1278741955757141)"
Line 905,Our Worldwide Compliance and Business Ethics organization is charged with navigating these requirements and anticipating emerging issues .,"('Business_Ethics', 0.9679917693138123)","('Management_Of_Legal_And_Regulatory_Framework', 0.0065458472818136215)","('Product_Quality_And_Safety', 0.003133349819108844)","(['Business Ethics'], 0.9679917693138123)","('NON-ESG', 0.0065458472818136215)","('NON-ESG', 0.003133349819108844)"
Line 906,We do this through our annual Global Risk Assessment and by developing proactive plans to mitigate the risk of unethical business practices .,"('Business_Ethics', 0.9548712372779846)","('Systemic_Risk_Management', 0.006178481504321098)","('Competitive_Behavior', 0.00555062759667635)","(['Business Ethics'], 0.9548712372779846)","('NON-ESG', 0.006178481504321098)","('NON-ESG', 0.00555062759667635)"
Line 907,We disclose policies that govern how we operate and our efforts to help ensure enterprise-wide compliance with them to further increase the trust and support of our stakeholders .,"('Management_Of_Legal_And_Regulatory_Framework', 0.941982626914978)","('Business_Ethics', 0.00951596349477768)","('Human_Rights_And_Community_Relations', 0.006999922916293144)","([], 0.941982626914978)","('NON-ESG', 0.00951596349477768)","('NON-ESG', 0.006999922916293144)"
Line 908,BUSINESS ETHICS Amgen staff are privileged to be part of a Company that develops and delivers medicines to treat seriously ill patients.,"('Access_And_Affordability', 0.3302040100097656)","('Employee_Health_And_Safety', 0.1787794828414917)","('Product_Quality_And_Safety', 0.10298115015029907)","('NON-ESG', 0.3302040100097656)","('NON-ESG', 0.1787794828414917)","('NON-ESG', 0.10298115015029907)"
Line 909,That privilege comes with important ethical and legal considerations.,"('Business_Ethics', 0.4495857357978821)","('Management_Of_Legal_And_Regulatory_Framework', 0.19322150945663452)","('Competitive_Behavior', 0.19233880937099457)","('NON-ESG', 0.4495857357978821)","('NON-ESG', 0.19322150945663452)","('NON-ESG', 0.19233880937099457)"
Line 910,"To deliver on our mission, we must conduct business ethically and with integrity, and also effectively comply with the laws and regulations that govern our business and industry.","('Business_Ethics', 0.8483778238296509)","('Management_Of_Legal_And_Regulatory_Framework', 0.06575287878513336)","('Human_Rights_And_Community_Relations', 0.013171730563044548)","(['Business Ethics'], 0.8483778238296509)","('NON-ESG', 0.06575287878513336)","('NON-ESG', 0.013171730563044548)"
Line 911,"A Healthy Amgen 57 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix Tone at the Top Our leaders play a critical role in creating an ethical culture .","('Human_Rights_And_Community_Relations', 0.646895170211792)","('Employee_Engagement_Inclusion_And_Diversity', 0.05848478525876999)","('Business_Model_Resilience', 0.0394245870411396)","([], 0.646895170211792)","('NON-ESG', 0.05848478525876999)","('NON-ESG', 0.0394245870411396)"
Line 912,"At Amgen, all managers are responsible for maintaining a work environment that encourages asking questions and reporting concerns regarding business conduct .","('Business_Ethics', 0.3928529918193817)","('Systemic_Risk_Management', 0.12767532467842102)","('Management_Of_Legal_And_Regulatory_Framework', 0.09273229539394379)","('NON-ESG', 0.3928529918193817)","('NON-ESG', 0.12767532467842102)","('NON-ESG', 0.09273229539394379)"
Line 913,"All Amgen leaders (vice president and above, plus other select roles) must participate in our annual Global Ethics and Compliance Declaration Program, which provides them with a framework and resources to demonstrate their commitment to ethics and compliance .","('Business_Ethics', 0.9679577350616455)","('Product_Quality_And_Safety', 0.0035171196796000004)","('Management_Of_Legal_And_Regulatory_Framework', 0.003237375058233738)","(['Business Ethics'], 0.9679577350616455)","('NON-ESG', 0.0035171196796000004)","('NON-ESG', 0.003237375058233738)"
Line 914,Leaders are required to execute an ethics and compliance engagement plan and sign a declaration form confirming that they have executed against their plan and have reported any potential noncompliance incidents to Human Resources or the Business Conduct Hotline (including any violations of our Conflict of Interest policy) .,"('Business_Ethics', 0.9644700884819031)","('Management_Of_Legal_And_Regulatory_Framework', 0.005393664818257093)","('Product_Quality_And_Safety', 0.003106798278167844)","(['Business Ethics'], 0.9644700884819031)","('NON-ESG', 0.005393664818257093)","('NON-ESG', 0.003106798278167844)"
Line 915,"Strengthening Our Safe-to-Speak-Up Culture In 2020, we found through employee survey responses that our employees wanted to better understand Amgens Business Conduct Hotline .","('Employee_Engagement_Inclusion_And_Diversity', 0.6291811466217041)","('Business_Ethics', 0.046380456537008286)","('Business_Model_Resilience', 0.03268402814865112)","(['Talent Attraction & Retention'], 0.6291811466217041)","('NON-ESG', 0.046380456537008286)","('NON-ESG', 0.03268402814865112)"
Line 916,"This led to efforts in 2021 to strengthen Amgens speak-up culture and raise awareness of Amgens report handling and investigative process, as well as our nonretaliation policy .","('Business_Ethics', 0.27400603890419006)","('Management_Of_Legal_And_Regulatory_Framework', 0.25694382190704346)","('Human_Rights_And_Community_Relations', 0.10716773569583893)","('NON-ESG', 0.27400603890419006)","('NON-ESG', 0.25694382190704346)","('NON-ESG', 0.10716773569583893)"
Line 917,Our goal is for 100% of Amgen employees to be aware of how to report concerns or ask questions and feel comfortable doing so .,"('Employee_Health_And_Safety', 0.7652878165245056)","('Business_Ethics', 0.03077830746769905)","('Product_Quality_And_Safety', 0.028441794216632843)","(['Health Outcome Contribution'], 0.7652878165245056)","('NON-ESG', 0.03077830746769905)","('NON-ESG', 0.028441794216632843)"
Line 918,"During the first half of 2021, we created and disseminated awareness materials through multiple channels, including our leaders, to help set the correct ethical tone at the top .","('Business_Ethics', 0.5755977034568787)","('Human_Rights_And_Community_Relations', 0.09459135681390762)","('Product_Quality_And_Safety', 0.05692632496356964)","(['Business Ethics'], 0.5755977034568787)","('NON-ESG', 0.09459135681390762)","('NON-ESG', 0.05692632496356964)"
Line 919,BUSINESS ETHICS Robust Anti-Bribery/Anti-Corruption Compliance Program We are committed to competing lawfully and ethically in the marketplaces across the geographies in which we operate .,"('Business_Ethics', 0.9763254523277283)","('Management_Of_Legal_And_Regulatory_Framework', 0.0022375043481588364)","('Competitive_Behavior', 0.002175138331949711)","(['Business Ethics'], 0.9763254523277283)","('NON-ESG', 0.0022375043481588364)","('NON-ESG', 0.002175138331949711)"
Line 920,"We have a robust anti-bribery/anti-corruption program, which includes a global policy that states our expectation that all employees conduct all aspects of Amgen business lawfully and with integrity .","('Business_Ethics', 0.9754434823989868)","('Competitive_Behavior', 0.002114952076226473)","('Management_Of_Legal_And_Regulatory_Framework', 0.002024915302172303)","(['Business Ethics'], 0.9754434823989868)","('NON-ESG', 0.002114952076226473)","('NON-ESG', 0.002024915302172303)"
Line 921,All employees are trained on this policy as part of our annual Code of Conduct training .,"('Labor_Practices', 0.2122797966003418)","('Employee_Engagement_Inclusion_And_Diversity', 0.19873039424419403)","('Business_Ethics', 0.11397343873977661)","('NON-ESG', 0.2122797966003418)","('NON-ESG', 0.19873039424419403)","('NON-ESG', 0.11397343873977661)"
Line 922,"Tailored, function-centric training is also assigned to select groups such as Global Commercial Operations, Research and Development, and Operations .","('Business_Model_Resilience', 0.31092965602874756)","('Employee_Engagement_Inclusion_And_Diversity', 0.24916930496692657)","('Customer_Welfare', 0.04955656826496124)","('NON-ESG', 0.31092965602874756)","('NON-ESG', 0.24916930496692657)","('NON-ESG', 0.04955656826496124)"
Line 923,"In addition, we perform periodic risk assessments to support programmatic improvement opportunities, as well as ongoing audit and monitoring activities .","('Systemic_Risk_Management', 0.3853316307067871)","('Management_Of_Legal_And_Regulatory_Framework', 0.3260732889175415)","('Business_Ethics', 0.09421753138303757)","('NON-ESG', 0.3853316307067871)","('NON-ESG', 0.3260732889175415)","('NON-ESG', 0.09421753138303757)"
Line 924,"Our anti-bribery/anti-corruption program also extends to third parties and intermediaries doing business on behalf of Amgen and includes periodic auditing, training, and due diligence .","('Business_Ethics', 0.9756019711494446)","('Management_Of_Legal_And_Regulatory_Framework', 0.0024768689181655645)","('Competitive_Behavior', 0.0023437656927853823)","(['Business Ethics'], 0.9756019711494446)","('NON-ESG', 0.0024768689181655645)","('NON-ESG', 0.0023437656927853823)"
Line 925,"2021 PERFORMANCE DATA 83% of Global Pulse Survey respondents stated they are aware of the various ways to seek guidance on ethical matters 100% of employees trained on the Code of Conduct Making Compliance Easier Than Ever In 2021, we made it easier for employees to be compliant by streamlining and consolidating policies around the globe and making information easier to find .","('Business_Ethics', 0.9524718523025513)","('Management_Of_Legal_And_Regulatory_Framework', 0.009505371563136578)","('Product_Quality_And_Safety', 0.00591249531134963)","(['Business Ethics'], 0.9524718523025513)","('NON-ESG', 0.009505371563136578)","('NON-ESG', 0.00591249531134963)"
Line 926,"In the United States, this included the introduction of the Amgen BlueBook, which combines our U .","('Management_Of_Legal_And_Regulatory_Framework', 0.23904526233673096)","('Business_Model_Resilience', 0.1332198679447174)","('Competitive_Behavior', 0.0907161608338356)","('NON-ESG', 0.23904526233673096)","('NON-ESG', 0.1332198679447174)","('NON-ESG', 0.0907161608338356)"
Line 927,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 928,"Healthcare Compliance requirements into one comprehensive document to better enable employees to find the compliance information they need to do their jobs in an intuitive, flexible, and responsive way .","('Management_Of_Legal_And_Regulatory_Framework', 0.5904287099838257)","('Business_Ethics', 0.2665327489376068)","('Product_Quality_And_Safety', 0.02339095249772072)","([], 0.5904287099838257)","('NON-ESG', 0.2665327489376068)","('NON-ESG', 0.02339095249772072)"
Line 929,We also introduced several just-in-time microlearning courses to employees based on their roles and daily activities to increase engagement and knowledge retention .,"('Employee_Engagement_Inclusion_And_Diversity', 0.905463695526123)","('Employee_Health_And_Safety', 0.009089767932891846)","('Product_Design_And_Lifecycle_Management', 0.008478325791656971)","(['Talent Attraction & Retention'], 0.905463695526123)","('NON-ESG', 0.009089767932891846)","('NON-ESG', 0.008478325791656971)"
Line 930,"MORE INFORMATION Business Ethics and Compliance Staff Code of Conduct Board of Directors Code of Conduct Code of Ethics for CEO and Senior Financial Officers Corporate Compliance Policies Reporting a Concern at AmgenA Healthy Amgen 58 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix VALUE CREATION Conducting our R&D activities in accordance with our internal policies and external standards helps to ensure the integrity of and confidence in our trial results and, ultimately, in medicines approved for use.","('Business_Ethics', 0.9631983637809753)","('Management_Of_Legal_And_Regulatory_Framework', 0.004163606557995081)","('Director_Removal', 0.0033975092228502035)","(['Business Ethics'], 0.9631983637809753)","('NON-ESG', 0.004163606557995081)","('NON-ESG', 0.0033975092228502035)"
Line 931,"MORE INFORMATION Business Ethics and Compliance Staff Code of Conduct Board of Directors Code of Conduct Code of Ethics for CEO and Senior Financial Officers Corporate Compliance Policies Reporting a Concern at AmgenA Healthy Amgen 58 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix VALUE CREATION Conducting our R&D activities in accordance with our internal policies and external standards helps to ensure the integrity of and confidence in our trial results and, ultimately, in medicines approved for use.","('Selling_Practices_And_Product_Labeling', 0.3350498378276825)","('Customer_Welfare', 0.1856088638305664)","('Competitive_Behavior', 0.06756485253572464)","('NON-ESG', 0.3350498378276825)","('NON-ESG', 0.1856088638305664)","('NON-ESG', 0.06756485253572464)"
Line 932,"It also helps inspire confidence among potential clinical trial participants, increasing the likelihood of their enrollment in studies .","('Access_And_Affordability', 0.17530111968517303)","('Competitive_Behavior', 0.16684415936470032)","('Employee_Engagement_Inclusion_And_Diversity', 0.13046494126319885)","('NON-ESG', 0.17530111968517303)","('NON-ESG', 0.16684415936470032)","('NON-ESG', 0.13046494126319885)"
Line 933,"Amgen aims to discover, develop, and deliver transformative medicines to address some of the leading causes of death and disability worldwide, working to meet the needs of as many patients as possible.","('Employee_Health_And_Safety', 0.9114323258399963)","('Access_And_Affordability', 0.018654746934771538)","('Product_Quality_And_Safety', 0.009140418842434883)","(['Health Outcome Contribution'], 0.9114323258399963)","('NON-ESG', 0.018654746934771538)","('NON-ESG', 0.009140418842434883)"
Line 934,"ETHICAL RESEARCH CLINICAL RESEARCH AND DEVELOPMENT At any given time, Amgen may conduct or is conducting hundreds of clinical trials involving many thousands of patients .","('Competitive_Behavior', 0.3315979838371277)","('Management_Of_Legal_And_Regulatory_Framework', 0.09594965726137161)","('Customer_Welfare', 0.0886320248246193)","('NON-ESG', 0.3315979838371277)","('NON-ESG', 0.09594965726137161)","('NON-ESG', 0.0886320248246193)"
Line 935,"The rights, dignity, safety, and well-being of trial participants are critical to the effective conduct of Amgen clinical trials .","('Product_Quality_And_Safety', 0.5251898765563965)","('Customer_Welfare', 0.08825766295194626)","('Selling_Practices_And_Product_Labeling', 0.0772218406200409)","(['Product Quality & Recall Management'], 0.5251898765563965)","('NON-ESG', 0.08825766295194626)","('NON-ESG', 0.0772218406200409)"
Line 936,"To that end, our Global Code of Ethics governs the design and conduct of Amgen-sponsored clinical trials .","('Business_Ethics', 0.9340217113494873)","('Competitive_Behavior', 0.010475900024175644)","('Management_Of_Legal_And_Regulatory_Framework', 0.00979821290820837)","(['Business Ethics'], 0.9340217113494873)","('NON-ESG', 0.010475900024175644)","('NON-ESG', 0.00979821290820837)"
Line 937,Our high standards meet or exceed applicable local laws as well as widely accepted international regulatory standards .,"('Management_Of_Legal_And_Regulatory_Framework', 0.9424293637275696)","('Business_Ethics', 0.012384881265461445)","('Product_Quality_And_Safety', 0.006508342456072569)","([], 0.9424293637275696)","('NON-ESG', 0.012384881265461445)","('NON-ESG', 0.006508342456072569)"
Line 938,"Amgen is committed to the timely registration of clinical trials, communication of research results, and routine publi- cation of Amgen-sponsored trials and observational studies .","('Competitive_Behavior', 0.22089360654354095)","('Management_Of_Legal_And_Regulatory_Framework', 0.0977323055267334)","('GHG_Emissions', 0.09010268747806549)","('NON-ESG', 0.22089360654354095)","('NON-ESG', 0.0977323055267334)","('NON-ESG', 0.09010268747806549)"
Line 939,"We support the data-sharing initiatives and principles adopt- ed by leading industry organizations, including the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) .","('Management_Of_Legal_And_Regulatory_Framework', 0.18493784964084625)","('Competitive_Behavior', 0.1792176216840744)","('Supply_Chain_Management', 0.09027962386608124)","('NON-ESG', 0.18493784964084625)","('NON-ESG', 0.1792176216840744)","('NON-ESG', 0.09027962386608124)"
Line 940,"Amgen is committed to providing scientifically accurate, truthful, nonmisleading, and well-balanced results to the scientific community regardless of trial outcome or regulatory approval .","('Management_Of_Legal_And_Regulatory_Framework', 0.5425406098365784)","('GHG_Emissions', 0.07861290127038956)","('Competitive_Behavior', 0.06723573803901672)","([], 0.5425406098365784)","('NON-ESG', 0.07861290127038956)","('NON-ESG', 0.06723573803901672)"
Line 941,We aim to submit the results of the primary analysis of all completed Amgen-sponsored phase 2 and phase 3 studies (and some phase 1 studies) to medical congresses or peer-reviewed journals within 18 months of trial completion .,"('GHG_Emissions', 0.13652609288692474)","('Customer_Welfare', 0.12766218185424805)","('Access_And_Affordability', 0.0985426977276802)","('NON-ESG', 0.13652609288692474)","('NON-ESG', 0.12766218185424805)","('NON-ESG', 0.0985426977276802)"
Line 942,"In addition, we post technical summary results on the registries in which the study was registered .","('Management_Of_Legal_And_Regulatory_Framework', 0.8833686113357544)","('Ecological_Impacts', 0.012731660157442093)","('Director_Removal', 0.009543642401695251)","([], 0.8833686113357544)","('NON-ESG', 0.012731660157442093)","('NON-ESG', 0.009543642401695251)"
Line 943,"We also register certain Amgen-sponsored noninterventional studies on the EU PAS Register before the start of data collection, including post-authorization safety studies .","('Product_Quality_And_Safety', 0.8311488032341003)","('Customer_Welfare', 0.017232658341526985)","('Competitive_Behavior', 0.016053583472967148)","(['Product Quality & Recall Management'], 0.8311488032341003)","('NON-ESG', 0.017232658341526985)","('NON-ESG', 0.016053583472967148)"
Line 944,"other noninterventional studies when requested by our protocol governance committees, such as non- interventional studies planned for submission to health authorities in a marketing application .","('Management_Of_Legal_And_Regulatory_Framework', 0.2969062626361847)","('Access_And_Affordability', 0.15868234634399414)","('GHG_Emissions', 0.09751085937023163)","('NON-ESG', 0.2969062626361847)","('NON-ESG', 0.15868234634399414)","('NON-ESG', 0.09751085937023163)"
Line 945,"In 2021, in compliance with the EU Clinical Trial Regulation, we began providing plain-language summaries of trial results for all new interventional clinical trials that include sites in the EU .","('Competitive_Behavior', 0.34166473150253296)","('Management_Of_Legal_And_Regulatory_Framework', 0.27672040462493896)","('Access_And_Affordability', 0.05395280942320824)","('NON-ESG', 0.34166473150253296)","('NON-ESG', 0.27672040462493896)","('NON-ESG', 0.05395280942320824)"
Line 946,"Summaries are publicly available in every language used during the clinical trial on the Amgen Trials webpage, Trial Results Summaries portal, and, as applicable, on the EU Clinical Trials Information System .","('Competitive_Behavior', 0.2613023519515991)","('Management_Of_Legal_And_Regulatory_Framework', 0.1726040095090866)","('Access_And_Affordability', 0.07125677913427353)","('NON-ESG', 0.2613023519515991)","('NON-ESG', 0.1726040095090866)","('NON-ESG', 0.07125677913427353)"
Line 947,We continue to advance our work to improve diversity and representation of racial and ethnic minority populations in clinical trial research at Amgen by advancing solutions and advancing dialogue across the industry .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9762816429138184)","('Employee_Health_And_Safety', 0.0020124721340835094)","('Human_Rights_And_Community_Relations', 0.0016022425843402743)","(['Talent Attraction & Retention'], 0.9762816429138184)","('NON-ESG', 0.0020124721340835094)","('NON-ESG', 0.0016022425843402743)"
Line 948,We have developed a framework to embed inclusive research principles across our clinical trial lifecycle process .,"('Competitive_Behavior', 0.2747773230075836)","('Business_Model_Resilience', 0.11851194500923157)","('Customer_Welfare', 0.10163401067256927)","('NON-ESG', 0.2747773230075836)","('NON-ESG', 0.11851194500923157)","('NON-ESG', 0.10163401067256927)"
Line 949,"We are also working to A Healthy Amgen 59 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix ETHICAL RESEARCH develop relationships with community organizations, HBCUs and Hispanic-serving institutions, government officials, and healthcare providers and patients from underserved and underrepresented communities to raise awareness of clinical trials and build trust .","('Access_And_Affordability', 0.9172093868255615)","('Human_Rights_And_Community_Relations', 0.017212172970175743)","('Product_Quality_And_Safety', 0.006026856601238251)","(['Access to Healthcare'], 0.9172093868255615)","('NON-ESG', 0.017212172970175743)","('NON-ESG', 0.006026856601238251)"
Line 950,"Moving forward, we will continue to evolve how we capture, analyze, and report demographic data for our clinical trials .","('Customer_Privacy', 0.15134170651435852)","('Customer_Welfare', 0.13753339648246765)","('Employee_Engagement_Inclusion_And_Diversity', 0.1180412694811821)","('NON-ESG', 0.15134170651435852)","('NON-ESG', 0.13753339648246765)","('NON-ESG', 0.1180412694811821)"
Line 951,"To learn more, visit page 21 .","('Management_Of_Legal_And_Regulatory_Framework', 0.11526022851467133)","('Data_Security', 0.11190062016248703)","('Customer_Privacy', 0.10545077919960022)","('NON-ESG', 0.11526022851467133)","('NON-ESG', 0.11190062016248703)","('NON-ESG', 0.10545077919960022)"
Line 952,USE OF ANIMALS IN RESEARCH We are committed to the ethical and responsible treatment of animals required to be used in the discovery and development of our medicines .,"('Ecological_Impacts', 0.1866321563720703)","('Selling_Practices_And_Product_Labeling', 0.12959174811840057)","('Customer_Welfare', 0.08932878822088242)","('NON-ESG', 0.1866321563720703)","('NON-ESG', 0.12959174811840057)","('NON-ESG', 0.08932878822088242)"
Line 953,"Amgen is a longtime proponent of the principles of Reduction, Refinement, and Replacement (the 3 Rs) in the required use of animals in research .","('Customer_Welfare', 0.16880929470062256)","('Ecological_Impacts', 0.13843581080436707)","('Access_And_Affordability', 0.1370653361082077)","('NON-ESG', 0.16880929470062256)","('NON-ESG', 0.13843581080436707)","('NON-ESG', 0.1370653361082077)"
Line 954,Amgen is fully committed to the development and use of scientifically validated alternative testing methods that are acceptable to regulatory authorities and do not compromise patient safety .,"('Product_Quality_And_Safety', 0.8655202984809875)","('Customer_Welfare', 0.015781555324792862)","('Selling_Practices_And_Product_Labeling', 0.012865564785897732)","(['Product Quality & Recall Management'], 0.8655202984809875)","('NON-ESG', 0.015781555324792862)","('NON-ESG', 0.012865564785897732)"
Line 955,We are engaged internally and in cross-industry efforts aimed at developing and refining new in-vitro testing and predictive systems that hold promise for future reduction of animal usage .,"('Customer_Welfare', 0.1710221767425537)","('GHG_Emissions', 0.13569635152816772)","('Access_And_Affordability', 0.09248621761798859)","('NON-ESG', 0.1710221767425537)","('NON-ESG', 0.13569635152816772)","('NON-ESG', 0.09248621761798859)"
Line 956,"As part of these activities, Amgen works directly with global regulatory authorities to increase the recognition and acceptance of alternative models where such methods can be used appropriately .","('Management_Of_Legal_And_Regulatory_Framework', 0.9707722663879395)","('Business_Ethics', 0.0023067714646458626)","('Competitive_Behavior', 0.002278219908475876)","([], 0.9707722663879395)","('NON-ESG', 0.0023067714646458626)","('NON-ESG', 0.002278219908475876)"
Line 957,"Amgen works to comply with all applicable global laws and regulations, including the gold standards of accrediting bodies .","('Management_Of_Legal_And_Regulatory_Framework', 0.9305668473243713)","('Business_Ethics', 0.012377957813441753)","('Product_Quality_And_Safety', 0.011444071307778358)","([], 0.9305668473243713)","('NON-ESG', 0.012377957813441753)","('NON-ESG', 0.011444071307778358)"
Line 958,"We hold our external business partners, including contract research organizations, academic institutions, and animal vendors, accountable to the same regulations, standards, and guidelines that govern our internal animal care and use programs .","('Management_Of_Legal_And_Regulatory_Framework', 0.2730640769004822)","('Selling_Practices_And_Product_Labeling', 0.08944328874349594)","('Ecological_Impacts', 0.07865238934755325)","('NON-ESG', 0.2730640769004822)","('NON-ESG', 0.08944328874349594)","('NON-ESG', 0.07865238934755325)"
Line 959,"We have a robust, proactive process to monitor their compliance with our standards .","('Management_Of_Legal_And_Regulatory_Framework', 0.4202239513397217)","('Business_Ethics', 0.20792953670024872)","('Product_Quality_And_Safety', 0.1587372124195099)","('NON-ESG', 0.4202239513397217)","('NON-ESG', 0.20792953670024872)","('NON-ESG', 0.1587372124195099)"
Line 960,"In 2021, we updated our Commitment to the Ethical Use of Animals in Research policy statement to make our oversight process more transparent .","('Business_Ethics', 0.5965026021003723)","('Management_Of_Legal_And_Regulatory_Framework', 0.2155572474002838)","('Competitive_Behavior', 0.02428480237722397)","(['Business Ethics'], 0.5965026021003723)","('NON-ESG', 0.2155572474002838)","('NON-ESG', 0.02428480237722397)"
Line 961,"USE OF STEM CELLS Amgen uses a wide variety of research tools and technologies to help discover and develop new therapeutics, including animal or adult cells in preclinical research to help unlock new scientific insights, model complex diseases, screen new compounds, and identify novel medicines .","('Customer_Welfare', 0.30726343393325806)","('Competitive_Behavior', 0.1739034801721573)","('Selling_Practices_And_Product_Labeling', 0.07716743648052216)","('NON-ESG', 0.30726343393325806)","('NON-ESG', 0.1739034801721573)","('NON-ESG', 0.07716743648052216)"
Line 962,Amgen also uses a small set of commercially available industry standard immortalized cell lines acquired over several decades for specific research-only purposes .,"('Customer_Welfare', 0.1931123435497284)","('Supply_Chain_Management', 0.16435499489307404)","('Energy_Management', 0.09966516494750977)","('NON-ESG', 0.1931123435497284)","('NON-ESG', 0.16435499489307404)","('NON-ESG', 0.09966516494750977)"
Line 963,"Amgen has not, and does not, perform or fund research in the area of human embryonic or fetal stem cells .","('Access_And_Affordability', 0.23980705440044403)","('Ecological_Impacts', 0.13814324140548706)","('Employee_Engagement_Inclusion_And_Diversity', 0.08798854053020477)","('NON-ESG', 0.23980705440044403)","('NON-ESG', 0.13814324140548706)","('NON-ESG', 0.08798854053020477)"
Line 964,"In 2021, we published a policy position statement on our use of fetal stem cells, which is available here .","('Access_And_Affordability', 0.13282838463783264)","('Ecological_Impacts', 0.11004947870969772)","('Customer_Welfare', 0.09785113483667374)","('NON-ESG', 0.13282838463783264)","('NON-ESG', 0.11004947870969772)","('NON-ESG', 0.09785113483667374)"
Line 965,"MORE INFORMATION Global Code of Ethics for Clinical Trials Clinical Trial Transparency, Data Sharing and Disclosure Practices Guidelines for Publications Commitment to the Ethical Use of Animals in Research Position Statement on Stem Cell Research Position Statement on Biobanking of Human SamplesBIOBANKING OF HUMAN SAMPLES Human samples play a vital role in Amgens research, including helping to predict the safety and effectiveness of potential new therapies and identify people most or least likely to benefit from these therapies .","('Business_Ethics', 0.9450832605361938)","('Product_Quality_And_Safety', 0.007773230317980051)","('Management_Of_Legal_And_Regulatory_Framework', 0.005294357426464558)","(['Business Ethics'], 0.9450832605361938)","('NON-ESG', 0.007773230317980051)","('NON-ESG', 0.005294357426464558)"
Line 966,"MORE INFORMATION Global Code of Ethics for Clinical Trials Clinical Trial Transparency, Data Sharing and Disclosure Practices Guidelines for Publications Commitment to the Ethical Use of Animals in Research Position Statement on Stem Cell Research Position Statement on Biobanking of Human SamplesBIOBANKING OF HUMAN SAMPLES Human samples play a vital role in Amgens research, including helping to predict the safety and effectiveness of potential new therapies and identify people most or least likely to benefit from these therapies .","('Access_And_Affordability', 0.2235804796218872)","('Competitive_Behavior', 0.09271810203790665)","('Product_Quality_And_Safety', 0.08495964109897614)","('NON-ESG', 0.2235804796218872)","('NON-ESG', 0.09271810203790665)","('NON-ESG', 0.08495964109897614)"
Line 967,"Samples are collected, used, stored, and disposed in accordance with the informed consent of the patient and all applicable laws and regulations, including those related to privacy and the use of human specimens in research .","('Waste_And_Hazardous_Materials_Management', 0.45302388072013855)","('Selling_Practices_And_Product_Labeling', 0.09612715989351273)","('Ecological_Impacts', 0.06780825555324554)","('NON-ESG', 0.45302388072013855)","('NON-ESG', 0.09612715989351273)","('NON-ESG', 0.06780825555324554)"
Line 968,"A Healthy Amgen 60 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix VALUE CREATION To remain a leader in our sector, we must continue to provide healthcare professionals and patients with confidence in our products and the information they need to prescribe and use them appropriately.","('Product_Design_And_Lifecycle_Management', 0.7635418176651001)","('Customer_Welfare', 0.054470255970954895)","('Product_Quality_And_Safety', 0.034569982439279556)","([], 0.7635418176651001)","('NON-ESG', 0.054470255970954895)","('NON-ESG', 0.034569982439279556)"
Line 969,We must also maintain the trust of worldwide regulatory authorities through our commitment to product safety and quality .,"('Product_Quality_And_Safety', 0.9235131740570068)","('Business_Ethics', 0.007578131277114153)","('Product_Design_And_Lifecycle_Management', 0.007009337656199932)","(['Product Quality & Recall Management'], 0.9235131740570068)","('NON-ESG', 0.007578131277114153)","('NON-ESG', 0.007009337656199932)"
Line 970,"With more than four decades of experience in biotechnology and a record of reliably supplying high-quality medicines to patients, Amgen is a worldwide leader in research, development, and manufacturing of complex biologic therapies focused on the safety of patients and the safe and effective use of our products.","('Product_Quality_And_Safety', 0.537149965763092)","('Selling_Practices_And_Product_Labeling', 0.14861814677715302)","('Customer_Welfare', 0.09855237603187561)","(['Product Quality & Recall Management'], 0.537149965763092)","('NON-ESG', 0.14861814677715302)","('NON-ESG', 0.09855237603187561)"
Line 971,"PATIENT SAFETY & PRODUCT QUALITY PATIENT SAFETY Patient safety is overseen by Amgens Global Patient Safety organization, whose work begins at the earliest stage of the drug development journey, when a new product development team is formed .","('Product_Quality_And_Safety', 0.8455257415771484)","('Product_Design_And_Lifecycle_Management', 0.02961730770766735)","('Employee_Health_And_Safety', 0.02956480346620083)","(['Product Quality & Recall Management'], 0.8455257415771484)","('NON-ESG', 0.02961730770766735)","('NON-ESG', 0.02956480346620083)"
Line 972,All potential new Amgen medicines undergo years of preclinical and clinical testing to establish their safety and efficacy profiles .,"('Product_Quality_And_Safety', 0.49723416566848755)","('Selling_Practices_And_Product_Labeling', 0.2101428061723709)","('Customer_Welfare', 0.07548908144235611)","('NON-ESG', 0.49723416566848755)","('NON-ESG', 0.2101428061723709)","('NON-ESG', 0.07548908144235611)"
Line 973,This includes appropriate dosing levels and acceptable benefit-risk profiles .,"('Systemic_Risk_Management', 0.25647446513175964)","('Customer_Welfare', 0.17326416075229645)","('Product_Quality_And_Safety', 0.09340748190879822)","('NON-ESG', 0.25647446513175964)","('NON-ESG', 0.17326416075229645)","('NON-ESG', 0.09340748190879822)"
Line 974,"Once a product receives marketing approval from health authorities, safety data collection continues through multiple channels .","('Product_Quality_And_Safety', 0.8883222937583923)","('Selling_Practices_And_Product_Labeling', 0.024888845160603523)","('Employee_Health_And_Safety', 0.00945244450122118)","(['Product Quality & Recall Management'], 0.8883222937583923)","('NON-ESG', 0.024888845160603523)","('NON-ESG', 0.00945244450122118)"
Line 975,"This includes additional clinical and post-marketing studies, reports by patients and healthcare professionals, registries, and scientific literature .","('Access_And_Affordability', 0.1858774721622467)","('Management_Of_Legal_And_Regulatory_Framework', 0.13484548032283783)","('Selling_Practices_And_Product_Labeling', 0.12255338579416275)","('NON-ESG', 0.1858774721622467)","('NON-ESG', 0.13484548032283783)","('NON-ESG', 0.12255338579416275)"
Line 976,Our Global Patient Safety organization includes Amgen colleagues in 46 countries .,"('Product_Quality_And_Safety', 0.521358847618103)","('Employee_Health_And_Safety', 0.2708178758621216)","('Access_And_Affordability', 0.02341596782207489)","(['Product Quality & Recall Management'], 0.521358847618103)","('NON-ESG', 0.2708178758621216)","('NON-ESG', 0.02341596782207489)"
Line 977,"Amgens Global Patient Safety team executes pharmacovigilance activities in collaboration with our worldwide team members, including Local Safety Officers (LSOs) who provide expertise and oversight regarding regional and country-specific regulatory requirements .","('Product_Quality_And_Safety', 0.7806462049484253)","('Employee_Health_And_Safety', 0.06703496724367142)","('Access_And_Affordability', 0.018960269168019295)","(['Product Quality & Recall Management'], 0.7806462049484253)","('NON-ESG', 0.06703496724367142)","('NON-ESG', 0.018960269168019295)"
Line 978,"Through our pharmacovigilance system, we capture, document, and evaluate adverse events and other safety reports regarding the use of our therapies .","('Product_Quality_And_Safety', 0.854541003704071)","('Employee_Health_And_Safety', 0.029452232643961906)","('Selling_Practices_And_Product_Labeling', 0.01804543100297451)","(['Product Quality & Recall Management'], 0.854541003704071)","('NON-ESG', 0.029452232643961906)","('NON-ESG', 0.01804543100297451)"
Line 979,"Data collected are processed and analyzed centrally by our pharmacovigilance team, in compliance with global and local regulatory requirements .","('Management_Of_Legal_And_Regulatory_Framework', 0.9682230353355408)","('Business_Ethics', 0.0028402588795870543)","('Access_And_Affordability', 0.0020101391710340977)","([], 0.9682230353355408)","('NON-ESG', 0.0028402588795870543)","('NON-ESG', 0.0020101391710340977)"
Line 980,"Our Global Patient Safety team maintains oversight of all pharmacovigilance-related activities and collaborates with colleagues across Amgen to communicate product information in a timely, transparent, and accurate manner to patients, prescribers and regulatory agencies around the globe .","('Product_Quality_And_Safety', 0.8681961894035339)","('Selling_Practices_And_Product_Labeling', 0.03211769461631775)","('Customer_Welfare', 0.010522299446165562)","(['Product Quality & Recall Management'], 0.8681961894035339)","('NON-ESG', 0.03211769461631775)","('NON-ESG', 0.010522299446165562)"
Line 981,"In Global Patient Safety, we see ourselves as the voice of the patient, for every patient using Amgen products throughout that products lifecycle .","('Product_Design_And_Lifecycle_Management', 0.8332882523536682)","('Product_Quality_And_Safety', 0.07920479029417038)","('Customer_Welfare', 0.01199344638735056)","([], 0.8332882523536682)","('NON-ESG', 0.07920479029417038)","('NON-ESG', 0.01199344638735056)"
Line 982,"FATIMA BHAYAT, Vice President and Head of Global Patient Safety A Healthy Amgen 61 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix All Amgen staff complete annual training on adverse events and product complaint reporting .","('Product_Quality_And_Safety', 0.8835045695304871)","('Employee_Health_And_Safety', 0.018437089398503304)","('Product_Design_And_Lifecycle_Management', 0.017453504726290703)","(['Product Quality & Recall Management'], 0.8835045695304871)","('NON-ESG', 0.018437089398503304)","('NON-ESG', 0.017453504726290703)"
Line 983,"Amgen staff who learn of potential adverse events, product complaints, and other safety findings are required to report the information to our Global Patient Safety team in accordance with our corporate policies and Code of Conduct .","('Product_Quality_And_Safety', 0.9074620008468628)","('Employee_Health_And_Safety', 0.016825009137392044)","('Selling_Practices_And_Product_Labeling', 0.010007526725530624)","(['Product Quality & Recall Management'], 0.9074620008468628)","('NON-ESG', 0.016825009137392044)","('NON-ESG', 0.010007526725530624)"
Line 984,"Investing in Technology to Increase Safety, Efficiency, and Compliance In recent years, there have been major changes in the pharmacovigilance regulatory landscape .","('Management_Of_Legal_And_Regulatory_Framework', 0.747285008430481)","('Product_Quality_And_Safety', 0.09345714002847672)","('Business_Ethics', 0.02554258517920971)","([], 0.747285008430481)","('NON-ESG', 0.09345714002847672)","('NON-ESG', 0.02554258517920971)"
Line 985,"At the same time, our product portfolio and development pipeline have continued to expand, as has the number of countries in which we market our products .","('Product_Design_And_Lifecycle_Management', 0.9557467103004456)","('Product_Quality_And_Safety', 0.006365539971739054)","('Selling_Practices_And_Product_Labeling', 0.005503449589014053)","([], 0.9557467103004456)","('NON-ESG', 0.006365539971739054)","('NON-ESG', 0.005503449589014053)"
Line 986,"We continuously implement improvements as appropriate to increase the efficiency of our pharmacovigilance system, enhance the quality of our data, strengthen compliance with regulations, and help promote patient safety .","('Product_Quality_And_Safety', 0.887475848197937)","('Employee_Health_And_Safety', 0.022147975862026215)","('Selling_Practices_And_Product_Labeling', 0.009027454070746899)","(['Product Quality & Recall Management'], 0.887475848197937)","('NON-ESG', 0.022147975862026215)","('NON-ESG', 0.009027454070746899)"
Line 987,"As part of our efforts, we continue to enhance our use of technology to further automate capabilities for adverse event and other safety reports coming from Amgens U .","('Product_Quality_And_Safety', 0.4667823910713196)","('Employee_Health_And_Safety', 0.40012675523757935)","('Product_Design_And_Lifecycle_Management', 0.014609329402446747)","('NON-ESG', 0.4667823910713196)","('NON-ESG', 0.40012675523757935)","('NON-ESG', 0.014609329402446747)"
Line 988,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 989,Medical Information Call Center and other companies that market our medicines in different countries .,"('Selling_Practices_And_Product_Labeling', 0.5928626656532288)","('Customer_Welfare', 0.06960329413414001)","('Access_And_Affordability', 0.04629141092300415)","(['Business Ethics'], 0.5928626656532288)","('NON-ESG', 0.06960329413414001)","('NON-ESG', 0.04629141092300415)"
Line 990,We are also using artificial intelligence to expedite and enhance our processes to produce higher-quality data insights .,"('Competitive_Behavior', 0.2159160077571869)","('Business_Model_Resilience', 0.16407440602779388)","('Data_Security', 0.12573108077049255)","('NON-ESG', 0.2159160077571869)","('NON-ESG', 0.16407440602779388)","('NON-ESG', 0.12573108077049255)"
Line 991,"With these insights, we use analytical tools to conduct root cause analyses to better understand and proactively address product safety and quality concerns with the objective to enhance patient experiences with Amgen products .","('Product_Quality_And_Safety', 0.8810955882072449)","('Selling_Practices_And_Product_Labeling', 0.024465786293148994)","('Product_Design_And_Lifecycle_Management', 0.018739428371191025)","(['Product Quality & Recall Management'], 0.8810955882072449)","('NON-ESG', 0.024465786293148994)","('NON-ESG', 0.018739428371191025)"
Line 992,"PRODUCT QUALITY We employ an enterprise-wide Quality Management System (QMS) composed of processes that work together to translate customer, quality, and regulatory requirements into Amgen products to help ensure a favorable safety and effectiveness profile through each stage of a products lifecycle .","('Product_Quality_And_Safety', 0.5058192014694214)","('Product_Design_And_Lifecycle_Management', 0.3544429838657379)","('Selling_Practices_And_Product_Labeling', 0.020753297954797745)","(['Product Quality & Recall Management'], 0.5058192014694214)","('NON-ESG', 0.3544429838657379)","('NON-ESG', 0.020753297954797745)"
Line 993,This supports our ability to reliably supply high-quality medicines to patients on time every time .,"('Access_And_Affordability', 0.30792292952537537)","('Customer_Welfare', 0.17134124040603638)","('Selling_Practices_And_Product_Labeling', 0.08995096385478973)","('NON-ESG', 0.30792292952537537)","('NON-ESG', 0.17134124040603638)","('NON-ESG', 0.08995096385478973)"
Line 994,The system includes numerous quality checks and is based on a set of global Quality by Design principles .,"('Product_Quality_And_Safety', 0.3009343147277832)","('Product_Design_And_Lifecycle_Management', 0.11547945439815521)","('Supply_Chain_Management', 0.11417459696531296)","('NON-ESG', 0.3009343147277832)","('NON-ESG', 0.11547945439815521)","('NON-ESG', 0.11417459696531296)"
Line 995,"It is built in accordance with more than 150 country, regional, and international standards and regulations covering pharmaceuticals, medical devices, and combination products including ISO 13485, current Good Manufacturing Practices (cGMP), and ICH guidelines .","('Product_Quality_And_Safety', 0.7227479815483093)","('Selling_Practices_And_Product_Labeling', 0.05877026170492172)","('Product_Design_And_Lifecycle_Management', 0.057443320751190186)","(['Product Quality & Recall Management'], 0.7227479815483093)","('NON-ESG', 0.05877026170492172)","('NON-ESG', 0.057443320751190186)"
Line 996,"We hold the required clinical, commercial, manufacturing, wholesale and distribution licenses, as well as necessary GxP certificates issued by governing health and regulatory authorities .","('Management_Of_Legal_And_Regulatory_Framework', 0.8310835957527161)","('Competitive_Behavior', 0.034752313047647476)","('Selling_Practices_And_Product_Labeling', 0.01723613403737545)","([], 0.8310835957527161)","('NON-ESG', 0.034752313047647476)","('NON-ESG', 0.01723613403737545)"
Line 997,We conduct investigations when deviations to our specifications or quality standards occur .,"('Product_Quality_And_Safety', 0.48241642117500305)","('Business_Ethics', 0.08340682089328766)","('Product_Design_And_Lifecycle_Management', 0.051198605448007584)","('NON-ESG', 0.48241642117500305)","('NON-ESG', 0.08340682089328766)","('NON-ESG', 0.051198605448007584)"
Line 998,We determine the root cause and implement corrective actions to ensure that we maintain high levels of compliance and quality .,"('Management_Of_Legal_And_Regulatory_Framework', 0.7413845658302307)","('Business_Ethics', 0.0697803795337677)","('Product_Quality_And_Safety', 0.029406115412712097)","([], 0.7413845658302307)","('NON-ESG', 0.0697803795337677)","('NON-ESG', 0.029406115412712097)"
Line 999,Amgen has a robust QMS training program for all of our employees and many third parties .,"('Employee_Engagement_Inclusion_And_Diversity', 0.48212552070617676)","('Employee_Health_And_Safety', 0.07974421977996826)","('Product_Quality_And_Safety', 0.0796094760298729)","('NON-ESG', 0.48212552070617676)","('NON-ESG', 0.07974421977996826)","('NON-ESG', 0.0796094760298729)"
Line 1000,All third parties providing services or products manufactured to GxP standards are required by regulation to have their own quality assurance department and a formal training process .,"('Product_Quality_And_Safety', 0.7117084264755249)","('Management_Of_Legal_And_Regulatory_Framework', 0.07195544242858887)","('Business_Ethics', 0.04106969013810158)","(['Product Quality & Recall Management'], 0.7117084264755249)","('NON-ESG', 0.07195544242858887)","('NON-ESG', 0.04106969013810158)"
Line 1001,Our training program is rigorously examined during internal and external audits .,"('Business_Ethics', 0.7867942452430725)","('Management_Of_Legal_And_Regulatory_Framework', 0.09392654150724411)","('Systemic_Risk_Management', 0.02615755796432495)","(['Business Ethics'], 0.7867942452430725)","('NON-ESG', 0.09392654150724411)","('NON-ESG', 0.02615755796432495)"
Line 1002,"New employees receive training on cGMP , other regulatory requirements and emerging trends .","('Management_Of_Legal_And_Regulatory_Framework', 0.9669150710105896)","('Business_Ethics', 0.0030160988681018353)","('Product_Quality_And_Safety', 0.002774496329948306)","([], 0.9669150710105896)","('NON-ESG', 0.0030160988681018353)","('NON-ESG', 0.002774496329948306)"
Line 1003,Existing employees receive this training on an annual basis .,"('Employee_Engagement_Inclusion_And_Diversity', 0.32547757029533386)","('Labor_Practices', 0.14124976098537445)","('Access_And_Affordability', 0.0903804749250412)","('NON-ESG', 0.32547757029533386)","('NON-ESG', 0.14124976098537445)","('NON-ESG', 0.0903804749250412)"
Line 1004,We assess compliance with our QMS and global regulations through audits conducted by our internal audit teams .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8153472542762756)","('Business_Ethics', 0.1131482645869255)","('Product_Quality_And_Safety', 0.006908018607646227)","([], 0.8153472542762756)","('NON-ESG', 0.1131482645869255)","('NON-ESG', 0.006908018607646227)"
Line 1005,Our audit plans are risk-based and assess operations or activities with a higher potential to affect product quality and/or patient safety .,"('Product_Quality_And_Safety', 0.8873274326324463)","('Product_Design_And_Lifecycle_Management', 0.028763659298419952)","('Selling_Practices_And_Product_Labeling', 0.013228857889771461)","(['Product Quality & Recall Management'], 0.8873274326324463)","('NON-ESG', 0.028763659298419952)","('NON-ESG', 0.013228857889771461)"
Line 1006,"PATIENT SAFETY & PRODUCT QUALITYA Healthy Amgen 62 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix GUARDING AGAINST COUNTERFEIT MEDICINES Amgen takes the issue of counterfeit drugs very seriously and applies significant efforts to deter, detect, and disrupt criminal counterfeiting of our medicines, includingSUPPLIER COMPLIANCE External service providers, component suppliers, and contract manufacturers play an increasingly important part in Amgens manufacturing strategy .","('Business_Ethics', 0.47591346502304077)","('Product_Quality_And_Safety', 0.20840197801589966)","('Data_Security', 0.06489654630422592)","('NON-ESG', 0.47591346502304077)","('NON-ESG', 0.20840197801589966)","('NON-ESG', 0.06489654630422592)"
Line 1007,"PATIENT SAFETY & PRODUCT QUALITYA Healthy Amgen 62 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix GUARDING AGAINST COUNTERFEIT MEDICINES Amgen takes the issue of counterfeit drugs very seriously and applies significant efforts to deter, detect, and disrupt criminal counterfeiting of our medicines, includingSUPPLIER COMPLIANCE External service providers, component suppliers, and contract manufacturers play an increasingly important part in Amgens manufacturing strategy .","('Product_Design_And_Lifecycle_Management', 0.8876367211341858)","('Supply_Chain_Management', 0.024222752079367638)","('Energy_Management', 0.013932405970990658)","([], 0.8876367211341858)","('NON-ESG', 0.024222752079367638)","('NON-ESG', 0.013932405970990658)"
Line 1008,Their operational performance and compliance with applicable regulations have direct impact on the quality of Amgen final drug and combination products .,"('Product_Quality_And_Safety', 0.4389397203922272)","('Product_Design_And_Lifecycle_Management', 0.34331056475639343)","('Customer_Welfare', 0.04570607841014862)","('NON-ESG', 0.4389397203922272)","('NON-ESG', 0.34331056475639343)","('NON-ESG', 0.04570607841014862)"
Line 1009,"Because of this, we audit the operations of our suppliers to help ensure the products they manufacture or services they provide meet Amgens and regulators expectations for quality .","('Product_Design_And_Lifecycle_Management', 0.937088668346405)","('Product_Quality_And_Safety', 0.01296798326075077)","('Supply_Chain_Management', 0.008013669401407242)","([], 0.937088668346405)","('NON-ESG', 0.01296798326075077)","('NON-ESG', 0.008013669401407242)"
Line 1010,We have formal programs to continuously monitor the performance and provide oversight and support for our suppliers .,"('Supply_Chain_Management', 0.8818743824958801)","('GHG_Emissions', 0.015573772601783276)","('Water_And_Wastewater_Management', 0.00966899748891592)","([], 0.8818743824958801)","('NON-ESG', 0.015573772601783276)","('NON-ESG', 0.00966899748891592)"
Line 1011,MORE INFORMATION Global Patient Safety About Amgen Clinical Trials Adverse Event and Product Complaint Reporting Quality Assurance of Our Medicines Employing sophisticated technology to hamper the ability of counterfeiters to create packaging that resembles Amgens packaging .,"('Product_Quality_And_Safety', 0.8072680234909058)","('Selling_Practices_And_Product_Labeling', 0.049572329968214035)","('Product_Design_And_Lifecycle_Management', 0.022428324446082115)","(['Product Quality & Recall Management'], 0.8072680234909058)","('NON-ESG', 0.049572329968214035)","('NON-ESG', 0.022428324446082115)"
Line 1012,"In the United States, requiring wholesalers to buy only directly from Amgen, and auditing compliance with these purchasing practices .","('Competitive_Behavior', 0.3055363595485687)","('Management_Of_Legal_And_Regulatory_Framework', 0.11241574585437775)","('Supply_Chain_Management', 0.0657094269990921)","('NON-ESG', 0.3055363595485687)","('NON-ESG', 0.11241574585437775)","('NON-ESG', 0.0657094269990921)"
Line 1013,"Partnering with federal and state law enforcement agencies to investigate and prosecute those involved in product tampering and counterfeiting, facilitating the arrest and conviction of counterfeiters .","('Business_Ethics', 0.8978574872016907)","('Product_Quality_And_Safety', 0.01747116446495056)","('Data_Security', 0.014795897528529167)","(['Business Ethics'], 0.8978574872016907)","('NON-ESG', 0.01747116446495056)","('NON-ESG', 0.014795897528529167)"
Line 1014,"In addition, Amgen uses industry-leading serialization and traceability technologies where required to advance the security of the supply chain and protect our products and patients .","('Product_Design_And_Lifecycle_Management', 0.4706684648990631)","('Supply_Chain_Management', 0.3799359202384949)","('Customer_Welfare', 0.014231279492378235)","('NON-ESG', 0.4706684648990631)","('NON-ESG', 0.3799359202384949)","('NON-ESG', 0.014231279492378235)"
Line 1015,Amgen products have distinctive security features that allow us to confirm whether a product has been legitimately produced following Amgen quality standards .,"('Product_Quality_And_Safety', 0.788794755935669)","('Product_Design_And_Lifecycle_Management', 0.06125598028302193)","('Business_Ethics', 0.021150963380932808)","(['Product Quality & Recall Management'], 0.788794755935669)","('NON-ESG', 0.06125598028302193)","('NON-ESG', 0.021150963380932808)"
Line 1016,"For more information, see our counterfeit drug statement .","('Business_Ethics', 0.25231245160102844)","('Data_Security', 0.15985019505023956)","('Competitive_Behavior', 0.12424419075250626)","('NON-ESG', 0.25231245160102844)","('NON-ESG', 0.15985019505023956)","('NON-ESG', 0.12424419075250626)"
Line 1017,"PATIENT SAFETY & PRODUCT QUALITYA Healthy Amgen 63 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix We have robust systems and processes in place to support the ethical use, management, and protection of all information and data.","('Product_Quality_And_Safety', 0.7181369662284851)","('Product_Design_And_Lifecycle_Management', 0.1064339131116867)","('Selling_Practices_And_Product_Labeling', 0.05285859480500221)","(['Product Quality & Recall Management'], 0.7181369662284851)","('NON-ESG', 0.1064339131116867)","('NON-ESG', 0.05285859480500221)"
Line 1018,"CYBERSECURITY & DATA PRIVACY Our Chief Information Security Officer oversees our enterprise-wide cybersecurity program, which follows internationally recognized industry standards including ISO/IEC34 27002 .","('Data_Security', 0.963528037071228)","('Business_Ethics', 0.003567937994375825)","('Systemic_Risk_Management', 0.0033802147954702377)","([], 0.963528037071228)","('NON-ESG', 0.003567937994375825)","('NON-ESG', 0.0033802147954702377)"
Line 1019,"Amgen has multiple mechanisms in place designed to guard against cyber threats, including a global team that gathers threat intelligence and conducts ongoing monitoring .","('Data_Security', 0.9548740983009338)","('Physical_Impacts_Of_Climate_Change', 0.004312809091061354)","('Customer_Privacy', 0.004173449706286192)","([], 0.9548740983009338)","('NON-ESG', 0.004312809091061354)","('NON-ESG', 0.004173449706286192)"
Line 1020,"Our Global Privacy Compliance team maintains policies and processes that guide how we collect, maintain, and protect personal information based on the legal and regulatory requirements of the many regions where we do business .","('Customer_Privacy', 0.9525613784790039)","('Data_Security', 0.014195111580193043)","('Waste_And_Hazardous_Materials_Management', 0.0026401507202535868)","([], 0.9525613784790039)","('NON-ESG', 0.014195111580193043)","('NON-ESG', 0.0026401507202535868)"
Line 1021,Examples of the practices we follow to support the integrity of our data protection processes include Collecting and using the minimum amount of personal information necessary to achieve our business purposes .,"('Customer_Privacy', 0.9653920531272888)","('Data_Security', 0.0059202685952186584)","('Selling_Practices_And_Product_Labeling', 0.0025756345130503178)","([], 0.9653920531272888)","('NON-ESG', 0.0059202685952186584)","('NON-ESG', 0.0025756345130503178)"
Line 1022,Sharing personal information only with individuals who have a legitimate need for it and will protect it .,"('Customer_Privacy', 0.9659790992736816)","('Data_Security', 0.004485271871089935)","('Selling_Practices_And_Product_Labeling', 0.0025993320159614086)","([], 0.9659790992736816)","('NON-ESG', 0.004485271871089935)","('NON-ESG', 0.0025993320159614086)"
Line 1023,"Maintaining appropriate administrative, technical, and organizational security measures to protect personal information .","('Customer_Privacy', 0.8825928568840027)","('Data_Security', 0.06427686661481857)","('Waste_And_Hazardous_Materials_Management', 0.005084965843707323)","([], 0.8825928568840027)","('NON-ESG', 0.06427686661481857)","('NON-ESG', 0.005084965843707323)"
Line 1024,Conducting vendor assessments to review third-party applications and technologies that contain personal and sensitive information .,"('Data_Security', 0.4978111684322357)","('Customer_Privacy', 0.3995975852012634)","('Business_Ethics', 0.015222582034766674)","('NON-ESG', 0.4978111684322357)","('NON-ESG', 0.3995975852012634)","('NON-ESG', 0.015222582034766674)"
Line 1025,Continued access to data allows Amgen to develop and deliver products and solutions that provide value to patients worldwide and improve health outcomes .,"('Access_And_Affordability', 0.2697086036205292)","('Product_Design_And_Lifecycle_Management', 0.1995781511068344)","('Product_Quality_And_Safety', 0.12867912650108337)","('NON-ESG', 0.2697086036205292)","('NON-ESG', 0.1995781511068344)","('NON-ESG', 0.12867912650108337)"
Line 1026,"In addition, strong defenses against cyber threats support the Companys business continuity and resilience .","('Business_Model_Resilience', 0.4110584259033203)","('Data_Security', 0.3267628848552704)","('Physical_Impacts_Of_Climate_Change', 0.04856066778302193)","('NON-ESG', 0.4110584259033203)","('NON-ESG', 0.3267628848552704)","('NON-ESG', 0.04856066778302193)"
Line 1027,"VALUE CREATION Amgen relies on information systems to operate its business, including the collection and retention of personal data entrusted to us by patients, customers, employees, and others.","('Customer_Privacy', 0.9677051305770874)","('Data_Security', 0.005049531348049641)","('Selling_Practices_And_Product_Labeling', 0.0022304898593574762)","([], 0.9677051305770874)","('NON-ESG', 0.005049531348049641)","('NON-ESG', 0.0022304898593574762)"
Line 1028,34 The international standard for information security management developed by the International Organization for Standardization and the International Electrotechnical Commission .,"('Data_Security', 0.9509958624839783)","('Customer_Privacy', 0.007257578428834677)","('Director_Removal', 0.0029541305266320705)","([], 0.9509958624839783)","('NON-ESG', 0.007257578428834677)","('NON-ESG', 0.0029541305266320705)"
Line 1029,"Monitoring technical and organizational measures to safeguard the data through appropriate user access management, secure file transfers, and consent management .","('Customer_Privacy', 0.8107404112815857)","('Data_Security', 0.12254759669303894)","('Waste_And_Hazardous_Materials_Management', 0.005731743760406971)","([], 0.8107404112815857)","('NON-ESG', 0.12254759669303894)","('NON-ESG', 0.005731743760406971)"
Line 1030,All Amgen employees receive annual security awareness and compliance training that includes information on applicable data security and privacy laws and regulations including the EU General Data Protection Regulation and the appropriate handling of personal information in the Companys various markets .,"('Customer_Privacy', 0.6252103447914124)","('Data_Security', 0.2890758514404297)","('Business_Ethics', 0.006712628062814474)","([], 0.6252103447914124)","('NON-ESG', 0.2890758514404297)","('NON-ESG', 0.006712628062814474)"
Line 1031,The global training programs are available in 24 languages .,"('Access_And_Affordability', 0.3873240649700165)","('Employee_Engagement_Inclusion_And_Diversity', 0.16171762347221375)","('Human_Rights_And_Community_Relations', 0.06037568300962448)","('NON-ESG', 0.3873240649700165)","('NON-ESG', 0.16171762347221375)","('NON-ESG', 0.06037568300962448)"
Line 1032,"We also host regular employee awareness events and campaigns on topics such as ransomware, identity theft, and mobile security, and conduct internal phishing exercises .","('Data_Security', 0.9617834687232971)","('Business_Ethics', 0.003565063001587987)","('Systemic_Risk_Management', 0.003341848263517022)","([], 0.9617834687232971)","('NON-ESG', 0.003565063001587987)","('NON-ESG', 0.003341848263517022)"
Line 1033,"New in 2021, to keep employees educated and engaged on cybersecurity, we launched a series of virtual cyber escape rooms where teams compete to solve security challenges .","('Data_Security', 0.9558720588684082)","('Systemic_Risk_Management', 0.005968835670500994)","('Physical_Impacts_Of_Climate_Change', 0.0032044078689068556)","([], 0.9558720588684082)","('NON-ESG', 0.005968835670500994)","('NON-ESG', 0.0032044078689068556)"
Line 1034,"Amgen is also a member of the Health Information Sharing and Analysis Center, a community of critical infrastructure owners and operators within the healthcare and public health sector focused on sharing timely, actionable, and relevant information .","('Data_Security', 0.4266732931137085)","('Customer_Privacy', 0.14682307839393616)","('Access_And_Affordability', 0.06822466105222702)","('NON-ESG', 0.4266732931137085)","('NON-ESG', 0.14682307839393616)","('NON-ESG', 0.06822466105222702)"
Line 1035,"MORE INFORMATION Protection of Personal Information PolicyA Healthy Amgen Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix Healthy Society Healthy People Introduction INFORMATION SECURITY IS EVERYONES BUSINESS At Amgen, protecting information is not something that someone else does it is a responsibility everyone shares.","('Data_Security', 0.4941445589065552)","('Customer_Privacy', 0.4009872078895569)","('Business_Ethics', 0.009259226731956005)","('NON-ESG', 0.4941445589065552)","('NON-ESG', 0.4009872078895569)","('NON-ESG', 0.009259226731956005)"
Line 1036,"Increasingly sophisticated threats to our information and data, including the personal information entrusted to us and the records we maintain, is a matter of concern to us all, said Greg Barnes, Global Chief Information Security Officer at Amgen .","('Customer_Privacy', 0.6740077137947083)","('Data_Security', 0.2532525956630707)","('Waste_And_Hazardous_Materials_Management', 0.005993276368826628)","([], 0.6740077137947083)","('NON-ESG', 0.2532525956630707)","('NON-ESG', 0.005993276368826628)"
Line 1037,Information protection is a responsibility we all share to achieve our collective mission of serving patients .,"('Data_Security', 0.3887679874897003)","('Customer_Privacy', 0.3290218114852905)","('Access_And_Affordability', 0.03281553462147713)","('NON-ESG', 0.3887679874897003)","('NON-ESG', 0.3290218114852905)","('NON-ESG', 0.03281553462147713)"
Line 1038,"To encourage employee engagement, the Company created a community of security advocates through its Sentinels Program .","('Employee_Engagement_Inclusion_And_Diversity', 0.6759692430496216)","('Employee_Health_And_Safety', 0.14905770123004913)","('Labor_Practices', 0.021568628028035164)","(['Talent Attraction & Retention'], 0.6759692430496216)","('NON-ESG', 0.14905770123004913)","('NON-ESG', 0.021568628028035164)"
Line 1039,"Now in its seventh year, the program has become one of the largest of its kind in the private sector, with over 800 Amgen employees serving as Chief Sentinels, representing 34 countries and every function within the Company .","('Employee_Engagement_Inclusion_And_Diversity', 0.2537270486354828)","('Director_Removal', 0.1648302674293518)","('Business_Model_Resilience', 0.08603205531835556)","('NON-ESG', 0.2537270486354828)","('NON-ESG', 0.1648302674293518)","('NON-ESG', 0.08603205531835556)"
Line 1040,"Globally, 85% of all security incidents at large enterprises are based on human error,35 such as inadvertently clicking on a phishing email or downloading malicious software .","('Data_Security', 0.9602859616279602)","('Business_Ethics', 0.004262364469468594)","('Systemic_Risk_Management', 0.003127096686512232)","([], 0.9602859616279602)","('NON-ESG', 0.004262364469468594)","('NON-ESG', 0.003127096686512232)"
Line 1041,"Amgens Sentinels Program addresses these human-related risks head-on with robust education and engagement programs on our approach to prevent, defend, detect and respond to cyberthreats .","('Data_Security', 0.8596447110176086)","('Physical_Impacts_Of_Climate_Change', 0.024490918964147568)","('Systemic_Risk_Management', 0.020833449438214302)","([], 0.8596447110176086)","('NON-ESG', 0.024490918964147568)","('NON-ESG', 0.020833449438214302)"
Line 1042,"The program operates like a Neighborhood Watch for information a community of security advocates who, working in partnership with Amgens Global Information Protection (GIP) team, are the Companys information protection eyes and ears on the ground .","('Data_Security', 0.9552951455116272)","('Customer_Privacy', 0.009107790887355804)","('Business_Ethics', 0.0027340000960975885)","([], 0.9552951455116272)","('NON-ESG', 0.009107790887355804)","('NON-ESG', 0.0027340000960975885)"
Line 1043,"They are alert and vigilant at a local level and, with GIPs guidance, help their local business area and team protect itself by keeping staff informed about threats and empowered with tools and knowledge to stay secure .","('Data_Security', 0.8702390193939209)","('Critical_Incident_Risk_Management', 0.022233856841921806)","('Customer_Privacy', 0.014040886424481869)","([], 0.8702390193939209)","('NON-ESG', 0.022233856841921806)","('NON-ESG', 0.014040886424481869)"
Line 1044,"Alix Stahl, who is an Organizational Effectiveness Manager at Amgen and has been a Chief Sentinel since 2014, says there is an important human factor to protecting Amgens information .","('Data_Security', 0.5721808075904846)","('Customer_Privacy', 0.25738033652305603)","('Selling_Practices_And_Product_Labeling', 0.017490297555923462)","([], 0.5721808075904846)","('NON-ESG', 0.25738033652305603)","('NON-ESG', 0.017490297555923462)"
Line 1045,"Stahl helps train new hires on cybersecurity and distributes awareness materials at Amgen headquarters, where she is based .","('Data_Security', 0.9030689001083374)","('Systemic_Risk_Management', 0.018663501366972923)","('Business_Model_Resilience', 0.00806509330868721)","([], 0.9030689001083374)","('NON-ESG', 0.018663501366972923)","('NON-ESG', 0.00806509330868721)"
Line 1046,"With training, any Amgen employee can become a Chief Sentinel .","('Employee_Engagement_Inclusion_And_Diversity', 0.6214005351066589)","('Employee_Health_And_Safety', 0.08332683891057968)","('Product_Quality_And_Safety', 0.04013761505484581)","(['Talent Attraction & Retention'], 0.6214005351066589)","('NON-ESG', 0.08332683891057968)","('NON-ESG', 0.04013761505484581)"
Line 1047,"All Sentinels receive ongoing training, which involves innovative approaches such as cyber escape rooms and gamification where employees earn badges .","('Employee_Engagement_Inclusion_And_Diversity', 0.47033077478408813)","('Business_Ethics', 0.08936066925525665)","('Employee_Health_And_Safety', 0.06586417555809021)","('NON-ESG', 0.47033077478408813)","('NON-ESG', 0.08936066925525665)","('NON-ESG', 0.06586417555809021)"
Line 1048,"A Healthy Amgen A Sentinels role is simple and should be what we do every day as good corporate citizens be alert, respond to issues, and advocate the use of information protection best practices in everything we do.","('Data_Security', 0.23838914930820465)","('Business_Model_Resilience', 0.10914124548435211)","('Human_Rights_And_Community_Relations', 0.07187899947166443)","('NON-ESG', 0.23838914930820465)","('NON-ESG', 0.10914124548435211)","('NON-ESG', 0.07187899947166443)"
Line 1049,The Sentinels Program is about putting our information center stage and ensuring that we all understand the important role we all play in protecting it.,"('Data_Security', 0.7926341891288757)","('Customer_Privacy', 0.050736408680677414)","('Management_Of_Legal_And_Regulatory_Framework', 0.015070834197103977)","([], 0.7926341891288757)","('NON-ESG', 0.050736408680677414)","('NON-ESG', 0.015070834197103977)"
Line 1050,"ALIX STAHL, Organizational Effectiveness Manager at Amgen 35 Verizon 2021 Data Breach & Incident Report (DBIR): https://www .verizon .com/business/resources/reports/dbir/ .","('Data_Security', 0.8861624598503113)","('Business_Ethics', 0.028867259621620178)","('Systemic_Risk_Management', 0.010614161379635334)","([], 0.8861624598503113)","('NON-ESG', 0.028867259621620178)","('NON-ESG', 0.010614161379635334)"
Line 1051,"64 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 A Healthy Amgen 65 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet Appendix Amgen operates in a highly regulated environment and decisions made by elected officials can have a significant impact on our ability to serve patients.","('Human_Rights_And_Community_Relations', 0.5581457018852234)","('Management_Of_Legal_And_Regulatory_Framework', 0.1086757704615593)","('Business_Ethics', 0.03686583414673805)","([], 0.5581457018852234)","('NON-ESG', 0.1086757704615593)","('NON-ESG', 0.03686583414673805)"
Line 1052,GOVERNMENT AFFAIRS & PUBLIC POLICY Amgens Global Government Affairs and Policy (GGA&P) team participates responsibly and constructively in the legislative process .,"('Management_Of_Legal_And_Regulatory_Framework', 0.9193204641342163)","('Human_Rights_And_Community_Relations', 0.01313032116740942)","('Physical_Impacts_Of_Climate_Change', 0.006982794497162104)","([], 0.9193204641342163)","('NON-ESG', 0.01313032116740942)","('NON-ESG', 0.006982794497162104)"
Line 1053,"We work to communicate information to elected officials and other policymakers in Washington, D .","('Management_Of_Legal_And_Regulatory_Framework', 0.9111272096633911)","('Competitive_Behavior', 0.008676765486598015)","('Human_Rights_And_Community_Relations', 0.006629694253206253)","([], 0.9111272096633911)","('NON-ESG', 0.008676765486598015)","('NON-ESG', 0.006629694253206253)"
Line 1054,"C ., and in U .","('Management_Of_Legal_And_Regulatory_Framework', 0.6709387898445129)","('Business_Ethics', 0.049979522824287415)","('Competitive_Behavior', 0.047210175544023514)","([], 0.6709387898445129)","('NON-ESG', 0.049979522824287415)","('NON-ESG', 0.047210175544023514)"
Line 1055,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1056,"state capitols around the country in support of public policies that are consistent with our mission to serve patients promoting access to new and existing medicines, fostering scientific innovation, and protecting intellectual property .","('Management_Of_Legal_And_Regulatory_Framework', 0.28649330139160156)","('Competitive_Behavior', 0.2842366695404053)","('Access_And_Affordability', 0.04492717608809471)","('NON-ESG', 0.28649330139160156)","('NON-ESG', 0.2842366695404053)","('NON-ESG', 0.04492717608809471)"
Line 1057,Amgen supports candidates and organizations who work to advance healthcare innovation and improve patient access .,"('Access_And_Affordability', 0.8574763536453247)","('Critical_Incident_Risk_Management', 0.012232491746544838)","('Customer_Welfare', 0.01191510260105133)","(['Access to Healthcare'], 0.8574763536453247)","('NON-ESG', 0.012232491746544838)","('NON-ESG', 0.01191510260105133)"
Line 1058,We disclose all our political contributions on our website .,"('Management_Of_Legal_And_Regulatory_Framework', 0.2834847569465637)","('Director_Removal', 0.11674857884645462)","('Competitive_Behavior', 0.08465734124183655)","('NON-ESG', 0.2834847569465637)","('NON-ESG', 0.11674857884645462)","('NON-ESG', 0.08465734124183655)"
Line 1059,The Corporate Responsibility and Compliance Committee of the Board of Directors oversees our approach to government affairs .,"('Management_Of_Legal_And_Regulatory_Framework', 0.9424890875816345)","('Director_Removal', 0.007640461437404156)","('Human_Rights_And_Community_Relations', 0.006562419701367617)","([], 0.9424890875816345)","('NON-ESG', 0.007640461437404156)","('NON-ESG', 0.006562419701367617)"
Line 1060,Amgen administers an employee-funded political action committee (PAC) through which direct contributions are made to federal and state candidates for elected office and related committees .,"('Management_Of_Legal_And_Regulatory_Framework', 0.6835045218467712)","('Competitive_Behavior', 0.05241580307483673)","('Director_Removal', 0.04218219965696335)","([], 0.6835045218467712)","('NON-ESG', 0.05241580307483673)","('NON-ESG', 0.04218219965696335)"
Line 1061,The Amgen PAC supports candidates from both parties .,"('Management_Of_Legal_And_Regulatory_Framework', 0.3960809111595154)","('Director_Removal', 0.11245162039995193)","('Competitive_Behavior', 0.0751316174864769)","('NON-ESG', 0.3960809111595154)","('NON-ESG', 0.11245162039995193)","('NON-ESG', 0.0751316174864769)"
Line 1062,"Decisions regarding who the PAC supports are made without regard for the personal political preferences of members of Amgens Board of Directors or PAC Board, executives, or GGA&P staff .","('Director_Removal', 0.5877475738525391)","('Management_Of_Legal_And_Regulatory_Framework', 0.15345081686973572)","('Employee_Engagement_Inclusion_And_Diversity', 0.03065183013677597)","(['Business Ethics'], 0.5877475738525391)","('NON-ESG', 0.15345081686973572)","('NON-ESG', 0.03065183013677597)"
Line 1063,"The Board of the Amgen PAC, currently composed of 10 employees, has oversight of all PAC activities .","('Director_Removal', 0.5957212448120117)","('Management_Of_Legal_And_Regulatory_Framework', 0.13049127161502838)","('Business_Ethics', 0.027379970997571945)","(['Business Ethics'], 0.5957212448120117)","('NON-ESG', 0.13049127161502838)","('NON-ESG', 0.027379970997571945)"
Line 1064,All PAC financial and compliance activities are audited by a third-party firm .,"('Management_Of_Legal_And_Regulatory_Framework', 0.4698695242404938)","('Business_Ethics', 0.3795839846134186)","('Systemic_Risk_Management', 0.022680044174194336)","('NON-ESG', 0.4698695242404938)","('NON-ESG', 0.3795839846134186)","('NON-ESG', 0.022680044174194336)"
Line 1065,"Under certain circumstances, Amgen contributes to other state-level political committees .","('Management_Of_Legal_And_Regulatory_Framework', 0.6396582126617432)","('Director_Removal', 0.0871017649769783)","('Competitive_Behavior', 0.038301095366477966)","([], 0.6396582126617432)","('NON-ESG', 0.0871017649769783)","('NON-ESG', 0.038301095366477966)"
Line 1066,"At this time, Amgen has not made federal independent expenditures on behalf of candidates running for federal office under the 2010 Supreme Court decision in Citizens United.","('Management_Of_Legal_And_Regulatory_Framework', 0.8396032452583313)","('Competitive_Behavior', 0.04820525273680687)","('Business_Ethics', 0.015086958184838295)","([], 0.8396032452583313)","('NON-ESG', 0.04820525273680687)","('NON-ESG', 0.015086958184838295)"
Line 1067,"In addition to the Companys own political and legislative activity, Amgen maintains memberships in trade associations that report lobbying activity to the U .","('Management_Of_Legal_And_Regulatory_Framework', 0.7643078565597534)","('Competitive_Behavior', 0.09398827701807022)","('Director_Removal', 0.016199909150600433)","([], 0.7643078565597534)","('NON-ESG', 0.09398827701807022)","('NON-ESG', 0.016199909150600433)"
Line 1068,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1069,government .,"('Management_Of_Legal_And_Regulatory_Framework', 0.5608922243118286)","('Human_Rights_And_Community_Relations', 0.09637142717838287)","('GHG_Emissions', 0.03728000819683075)","([], 0.5608922243118286)","('NON-ESG', 0.09637142717838287)","('NON-ESG', 0.03728000819683075)"
Line 1070,Amgen supports trade associations that champion scientific innovation and patient access to new and existing therapies .,"('Access_And_Affordability', 0.6273927092552185)","('Customer_Welfare', 0.05708412826061249)","('Product_Quality_And_Safety', 0.033557165414094925)","(['Access to Healthcare'], 0.6273927092552185)","('NON-ESG', 0.05708412826061249)","('NON-ESG', 0.033557165414094925)"
Line 1071,"Outside the United States, rules governing interactions with policymakers vary by country .","('Management_Of_Legal_And_Regulatory_Framework', 0.9210657477378845)","('Competitive_Behavior', 0.012848730199038982)","('Business_Ethics', 0.01014090608805418)","([], 0.9210657477378845)","('NON-ESG', 0.012848730199038982)","('NON-ESG', 0.01014090608805418)"
Line 1072,"Amgen has implemented internal policies regarding compliance with all applicable laws and regulations in countries where relevant interactions with policy makers occur, including the U .","('Management_Of_Legal_And_Regulatory_Framework', 0.9710445404052734)","('Human_Rights_And_Community_Relations', 0.0021972956601530313)","('Energy_Management', 0.0020655810367316008)","([], 0.9710445404052734)","('NON-ESG', 0.0021972956601530313)","('NON-ESG', 0.0020655810367316008)"
Line 1073,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1074,Foreign Corrupt Practices Act .,"('Business_Ethics', 0.9651722311973572)","('Management_Of_Legal_And_Regulatory_Framework', 0.005162456538528204)","('Competitive_Behavior', 0.0028365470934659243)","(['Business Ethics'], 0.9651722311973572)","('NON-ESG', 0.005162456538528204)","('NON-ESG', 0.0028365470934659243)"
Line 1075,"MORE INFORMATION Lobbying Disclosure Act reports Lobbying disclosure by state Political contributions and trade memberships Appendix 66 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen This report serves as Amgens Communication on Progress for the United Nations Global Compact (UNGC) .","('Management_Of_Legal_And_Regulatory_Framework', 0.772264301776886)","('Business_Ethics', 0.07885191589593887)","('Competitive_Behavior', 0.026929594576358795)","([], 0.772264301776886)","('NON-ESG', 0.07885191589593887)","('NON-ESG', 0.026929594576358795)"
Line 1076,"The statement from our CEO and Chairman at the beginning of the report reaffirms our commitment to the principles of the UNGC, and much of the content throughout this report highlights progress in the four key areas of the UNGC: Environment, Labor, Human Rights, and Anti-Corruption .","('Human_Rights_And_Community_Relations', 0.8809909224510193)","('Labor_Practices', 0.02326047793030739)","('Business_Ethics', 0.015178184024989605)","([], 0.8809909224510193)","('NON-ESG', 0.02326047793030739)","('NON-ESG', 0.015178184024989605)"
Line 1077,"Over the past 12 months, we have achieved progress in all four areas a few highlights follow .","('Business_Model_Resilience', 0.3523276746273041)","('Systemic_Risk_Management', 0.12556900084018707)","('Access_And_Affordability', 0.07689327001571655)","('NON-ESG', 0.3523276746273041)","('NON-ESG', 0.12556900084018707)","('NON-ESG', 0.07689327001571655)"
Line 1078,"HUMAN RIGHTS The Amgen Foundation committed $3 million in grants to racial and social justice initiatives, economic empowerment, and equal opportunity in education .","('Human_Rights_And_Community_Relations', 0.8722019195556641)","('Employee_Engagement_Inclusion_And_Diversity', 0.03338106349110603)","('Access_And_Affordability', 0.022511905059218407)","([], 0.8722019195556641)","('NON-ESG', 0.03338106349110603)","('NON-ESG', 0.022511905059218407)"
Line 1079,"Amgen engaged with underserved and underrepresented communities through a series of community health equity advisory boards to help better meet their needs and build long-term, sustainable relationships .","('Access_And_Affordability', 0.9477013349533081)","('Human_Rights_And_Community_Relations', 0.005346253979951143)","('Critical_Incident_Risk_Management', 0.004515416920185089)","(['Access to Healthcare'], 0.9477013349533081)","('NON-ESG', 0.005346253979951143)","('NON-ESG', 0.004515416920185089)"
Line 1080,The Amgen Foundation promoted science education for underserved students throughout the world through innovative virtual initiatives with Khan Academy and Harvard University through LabXchange; these efforts reached over 27 million students and educators globally in 2021 .,"('Access_And_Affordability', 0.9461016058921814)","('Product_Quality_And_Safety', 0.0048194704577326775)","('Critical_Incident_Risk_Management', 0.00466760341078043)","(['Access to Healthcare'], 0.9461016058921814)","('NON-ESG', 0.0048194704577326775)","('NON-ESG', 0.00466760341078043)"
Line 1081,Continued to monitor our suppliers compliance with our Supplier Code of Conduct and internationally recognized human rights standards .,"('Supply_Chain_Management', 0.8628324270248413)","('Labor_Practices', 0.031098291277885437)","('Product_Quality_And_Safety', 0.010828578844666481)","([], 0.8628324270248413)","('NON-ESG', 0.031098291277885437)","('NON-ESG', 0.010828578844666481)"
Line 1082,"LABOR RIGHTS In support of our OneTen pledge,36 we announced investments in two new siteslocated in North Carolina and Ohiothat are expected to create more than 750 jobs drawing from a diverse field of talent .","('Labor_Practices', 0.848861813545227)","('Employee_Engagement_Inclusion_And_Diversity', 0.08565209060907364)","('Human_Rights_And_Community_Relations', 0.009052176028490067)","([], 0.848861813545227)","('NON-ESG', 0.08565209060907364)","('NON-ESG', 0.009052176028490067)"
Line 1083,Ninety-eight percent of staff worldwide completed Managing Unconscious Bias training .,"('Employee_Engagement_Inclusion_And_Diversity', 0.48703733086586)","('Employee_Health_And_Safety', 0.12837354838848114)","('Product_Quality_And_Safety', 0.09702058136463165)","('NON-ESG', 0.48703733086586)","('NON-ESG', 0.12837354838848114)","('NON-ESG', 0.09702058136463165)"
Line 1084,"Increased membership in our 11 Employee Resource Groups by 41 percentmembership now exceeds 11,000 employees in 60 global chapters .","('Employee_Engagement_Inclusion_And_Diversity', 0.8797181844711304)","('Labor_Practices', 0.02268362045288086)","('Employee_Health_And_Safety', 0.01685180328786373)","(['Talent Attraction & Retention'], 0.8797181844711304)","('NON-ESG', 0.02268362045288086)","('NON-ESG', 0.01685180328786373)"
Line 1085,Launched a mentoring program designed specifically to help connect high-performing women of color with senior leadership and provide opportunities for advocacy and sponsorship .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9604715704917908)","('Human_Rights_And_Community_Relations', 0.0033343995455652475)","('Access_And_Affordability', 0.0032584634609520435)","(['Talent Attraction & Retention'], 0.9604715704917908)","('NON-ESG', 0.0033343995455652475)","('NON-ESG', 0.0032584634609520435)"
Line 1086,"Continued to monitor our suppliers compliance with our Supplier Code of Conduct and internationally recognized human rights standards including those that seek to prevent forced and child labor, support fair pay based on applicable wage laws, and allow for freedom of association .","('Labor_Practices', 0.9784693717956543)","('Director_Removal', 0.001801806502044201)","('Human_Rights_And_Community_Relations', 0.0017225855262950063)","([], 0.9784693717956543)","('NON-ESG', 0.001801806502044201)","('NON-ESG', 0.0017225855262950063)"
Line 1087,ENVIRONMENT Increased our total sourcing of renewable electricity to 79% compared to 41% in 2020 .,"('Energy_Management', 0.7789248824119568)","('Supply_Chain_Management', 0.05628787353634834)","('Product_Design_And_Lifecycle_Management', 0.03371270373463631)","(['Operational Eco-Efficiency'], 0.7789248824119568)","('NON-ESG', 0.05628787353634834)","('NON-ESG', 0.03371270373463631)"
Line 1088,"For the first time, we linked our executive pay to environmental sustainability with the addition of an ESG goal in Amgens annual incentive compensation plan .","('Management_Of_Legal_And_Regulatory_Framework', 0.44371917843818665)","('Labor_Practices', 0.3055141866207123)","('Business_Ethics', 0.05010592192411423)","('NON-ESG', 0.44371917843818665)","('NON-ESG', 0.3055141866207123)","('NON-ESG', 0.05010592192411423)"
Line 1089,Initiated environmental sustainability impact assessments for all capital funding requests as part of Amgens capital funding program .,"('Business_Model_Resilience', 0.29460790753364563)","('Management_Of_Legal_And_Regulatory_Framework', 0.28607377409935)","('Physical_Impacts_Of_Climate_Change', 0.08570867776870728)","('NON-ESG', 0.29460790753364563)","('NON-ESG', 0.28607377409935)","('NON-ESG', 0.08570867776870728)"
Line 1090,Updated Amgens sustainability design standard target for the LEED certification .,"('Product_Design_And_Lifecycle_Management', 0.4288783669471741)","('Product_Quality_And_Safety', 0.1557868868112564)","('Energy_Management', 0.0769372507929802)","('NON-ESG', 0.4288783669471741)","('NON-ESG', 0.1557868868112564)","('NON-ESG', 0.0769372507929802)"
Line 1091,ANTI-CORRUPTION Redesigned our U .,"('Business_Ethics', 0.9582873582839966)","('Management_Of_Legal_And_Regulatory_Framework', 0.005501706153154373)","('Competitive_Behavior', 0.00414982158690691)","(['Business Ethics'], 0.9582873582839966)","('NON-ESG', 0.005501706153154373)","('NON-ESG', 0.00414982158690691)"
Line 1092,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1093,Healthcare Compliance training and standardized our global processes and compliance requirements for international staff when interacting with members of the healthcare community .,"('Business_Ethics', 0.49060526490211487)","('Management_Of_Legal_And_Regulatory_Framework', 0.3934137523174286)","('Product_Quality_And_Safety', 0.017873771488666534)","('NON-ESG', 0.49060526490211487)","('NON-ESG', 0.3934137523174286)","('NON-ESG', 0.017873771488666534)"
Line 1094,"Launched an initiative to strengthen Amgens speak-up culture and raise awareness of Amgens report handling and investigative process, as well as our nonretaliation policy .","('Management_Of_Legal_And_Regulatory_Framework', 0.41390639543533325)","('Business_Ethics', 0.2497890144586563)","('Human_Rights_And_Community_Relations', 0.06795701384544373)","('NON-ESG', 0.41390639543533325)","('NON-ESG', 0.2497890144586563)","('NON-ESG', 0.06795701384544373)"
Line 1095,"Introduced the Amgen BlueBook, which combines our U .","('Product_Design_And_Lifecycle_Management', 0.4152221381664276)","('Business_Model_Resilience', 0.14913256466388702)","('Customer_Welfare', 0.04753745719790459)","('NON-ESG', 0.4152221381664276)","('NON-ESG', 0.14913256466388702)","('NON-ESG', 0.04753745719790459)"
Line 1096,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1097,"Healthcare Compliance requirements into one comprehensive document and enables staff to find the compliance information they need to do their jobs in an intuitive, flexible, and responsive way .","('Management_Of_Legal_And_Regulatory_Framework', 0.7108980417251587)","('Business_Ethics', 0.1663113385438919)","('Product_Quality_And_Safety', 0.018417753279209137)","([], 0.7108980417251587)","('NON-ESG', 0.1663113385438919)","('NON-ESG', 0.018417753279209137)"
Line 1098,"In addition to this report, Amgen provides extensive reporting on policies and progress aligned with the UNGC on our website .","('Management_Of_Legal_And_Regulatory_Framework', 0.7150561809539795)","('Human_Rights_And_Community_Relations', 0.15260398387908936)","('Ecological_Impacts', 0.015310079790651798)","([], 0.7150561809539795)","('NON-ESG', 0.15260398387908936)","('NON-ESG', 0.015310079790651798)"
Line 1099,Below is a summary table providing data aligned with the major categories of UNGC principles .,"('Human_Rights_And_Community_Relations', 0.44547584652900696)","('Management_Of_Legal_And_Regulatory_Framework', 0.25348174571990967)","('Business_Ethics', 0.03741928189992905)","('NON-ESG', 0.44547584652900696)","('NON-ESG', 0.25348174571990967)","('NON-ESG', 0.03741928189992905)"
Line 1100,"36 We are a founding member of OneTen, a coalition of many of the worlds largest, best-known companies that aims collectively to hire 1 million Black Americans (with a specific focus on Black Americans without four-year college degrees) into well-paying, family-sustaining jobs over the next 10 years .","('Employee_Engagement_Inclusion_And_Diversity', 0.9371020793914795)","('Labor_Practices', 0.012659060768783092)","('Employee_Health_And_Safety', 0.004477437119930983)","(['Talent Attraction & Retention'], 0.9371020793914795)","('NON-ESG', 0.012659060768783092)","('NON-ESG', 0.004477437119930983)"
Line 1101,"UNITED NATIONS GLOBAL COMMUNICATIONS ON PROGRESSAPPENDIXAppendix 67 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen Type Unit 2017 2018 2019 2020 2021 Total Revenue $ Millions $22,849 $23,747 $23,362 $25,424 $25,979 Product Sales $ Millions $21,795 $22,533 $22,204 $24,240 $24,297 R&D Expenses $ Millions $3,562 $3,737 $4,116 $4,207 $4,819 Total Energy (i) 1,000 GJ 3,709 3,284 3,094 3,286 3,193 Total Carbon From Energy (i) 1,000 MT CO2Eq 278 263 249 243 155 Total Water Withdrawal (i) 2,000 CM 2,320 2,093 2,146 2,355 2,238 Total Routine Waste (i) MT 9,856 9,642 9,818 9,841 10,289 Environmental Notices of Violation (NOVs) (ii) 1 NOV 1 3 2 1 3 Recordable Incident Rate Injuries per 100 workers 0 .36 0 .42 0 .31 0 .31 0 .19 Staff Lost Day Case Rate Injuries per 100 workers 0 .12 0 .14 0 .12 0 .08 0 .09 Staff Fatalities People 1 0 0 1 0 Motor Vehicle Safety Collisions per million miles NA NA 4 .40 3 .38 3 .09 Amgen Employees* People 20,800 21,500 23,400 24,300 24,200 % of Women in Total Workforce** People 51 52 52 52 52 % of Women Management Level (iii)** People 44 45 46 47 49 % of Women Executive Level (iv)** People 37 36 39 42 44 % of Ethnic Minority in Workforce (U .","('Product_Design_And_Lifecycle_Management', 0.5769196152687073)","('Customer_Welfare', 0.10330735892057419)","('Energy_Management', 0.039310600608587265)","([], 0.5769196152687073)","('NON-ESG', 0.10330735892057419)","('NON-ESG', 0.039310600608587265)"
Line 1102,"UNITED NATIONS GLOBAL COMMUNICATIONS ON PROGRESSAPPENDIXAppendix 67 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen Type Unit 2017 2018 2019 2020 2021 Total Revenue $ Millions $22,849 $23,747 $23,362 $25,424 $25,979 Product Sales $ Millions $21,795 $22,533 $22,204 $24,240 $24,297 R&D Expenses $ Millions $3,562 $3,737 $4,116 $4,207 $4,819 Total Energy (i) 1,000 GJ 3,709 3,284 3,094 3,286 3,193 Total Carbon From Energy (i) 1,000 MT CO2Eq 278 263 249 243 155 Total Water Withdrawal (i) 2,000 CM 2,320 2,093 2,146 2,355 2,238 Total Routine Waste (i) MT 9,856 9,642 9,818 9,841 10,289 Environmental Notices of Violation (NOVs) (ii) 1 NOV 1 3 2 1 3 Recordable Incident Rate Injuries per 100 workers 0 .36 0 .42 0 .31 0 .31 0 .19 Staff Lost Day Case Rate Injuries per 100 workers 0 .12 0 .14 0 .12 0 .08 0 .09 Staff Fatalities People 1 0 0 1 0 Motor Vehicle Safety Collisions per million miles NA NA 4 .40 3 .38 3 .09 Amgen Employees* People 20,800 21,500 23,400 24,300 24,200 % of Women in Total Workforce** People 51 52 52 52 52 % of Women Management Level (iii)** People 44 45 46 47 49 % of Women Executive Level (iv)** People 37 36 39 42 44 % of Ethnic Minority in Workforce (U .","('Employee_Health_And_Safety', 0.9830737709999084)","('Critical_Incident_Risk_Management', 0.001794811338186264)","('Employee_Engagement_Inclusion_And_Diversity', 0.001480258535593748)","(['Health Outcome Contribution'], 0.9830737709999084)","('NON-ESG', 0.001794811338186264)","('NON-ESG', 0.001480258535593748)"
Line 1103,"UNITED NATIONS GLOBAL COMMUNICATIONS ON PROGRESSAPPENDIXAppendix 67 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen Type Unit 2017 2018 2019 2020 2021 Total Revenue $ Millions $22,849 $23,747 $23,362 $25,424 $25,979 Product Sales $ Millions $21,795 $22,533 $22,204 $24,240 $24,297 R&D Expenses $ Millions $3,562 $3,737 $4,116 $4,207 $4,819 Total Energy (i) 1,000 GJ 3,709 3,284 3,094 3,286 3,193 Total Carbon From Energy (i) 1,000 MT CO2Eq 278 263 249 243 155 Total Water Withdrawal (i) 2,000 CM 2,320 2,093 2,146 2,355 2,238 Total Routine Waste (i) MT 9,856 9,642 9,818 9,841 10,289 Environmental Notices of Violation (NOVs) (ii) 1 NOV 1 3 2 1 3 Recordable Incident Rate Injuries per 100 workers 0 .36 0 .42 0 .31 0 .31 0 .19 Staff Lost Day Case Rate Injuries per 100 workers 0 .12 0 .14 0 .12 0 .08 0 .09 Staff Fatalities People 1 0 0 1 0 Motor Vehicle Safety Collisions per million miles NA NA 4 .40 3 .38 3 .09 Amgen Employees* People 20,800 21,500 23,400 24,300 24,200 % of Women in Total Workforce** People 51 52 52 52 52 % of Women Management Level (iii)** People 44 45 46 47 49 % of Women Executive Level (iv)** People 37 36 39 42 44 % of Ethnic Minority in Workforce (U .","('Employee_Engagement_Inclusion_And_Diversity', 0.9724771976470947)","('Human_Rights_And_Community_Relations', 0.0022339250426739454)","('Employee_Health_And_Safety', 0.0020329656545072794)","(['Talent Attraction & Retention'], 0.9724771976470947)","('NON-ESG', 0.0022339250426739454)","('NON-ESG', 0.0020329656545072794)"
Line 1104,S .),"('Management_Of_Legal_And_Regulatory_Framework', 0.11190015822649002)","('Competitive_Behavior', 0.10611405968666077)","('Product_Design_And_Lifecycle_Management', 0.08103450387716293)","('NON-ESG', 0.11190015822649002)","('NON-ESG', 0.10611405968666077)","('NON-ESG', 0.08103450387716293)"
Line 1105,People 45 45 47 48 51 % of Ethnic Minority Management Levels (U .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9658295512199402)","('Human_Rights_And_Community_Relations', 0.0029467723798006773)","('Customer_Privacy', 0.0026572777424007654)","(['Talent Attraction & Retention'], 0.9658295512199402)","('NON-ESG', 0.0029467723798006773)","('NON-ESG', 0.0026572777424007654)"
Line 1106,S .),"('Management_Of_Legal_And_Regulatory_Framework', 0.11190015822649002)","('Competitive_Behavior', 0.10611405968666077)","('Product_Design_And_Lifecycle_Management', 0.08103450387716293)","('NON-ESG', 0.11190015822649002)","('NON-ESG', 0.10611405968666077)","('NON-ESG', 0.08103450387716293)"
Line 1107,(iii) People 39 39 41 42 44 % of Ethnic Minority Executive Level (U .,"('Employee_Engagement_Inclusion_And_Diversity', 0.9657909274101257)","('Customer_Privacy', 0.002787564182654023)","('Human_Rights_And_Community_Relations', 0.0026671781670302153)","(['Talent Attraction & Retention'], 0.9657909274101257)","('NON-ESG', 0.002787564182654023)","('NON-ESG', 0.0026671781670302153)"
Line 1108,S .),"('Management_Of_Legal_And_Regulatory_Framework', 0.11190015822649002)","('Competitive_Behavior', 0.10611405968666077)","('Product_Design_And_Lifecycle_Management', 0.08103450387716293)","('NON-ESG', 0.11190015822649002)","('NON-ESG', 0.10611405968666077)","('NON-ESG', 0.08103450387716293)"
Line 1109,"(iv) People 24 25 27 30 32 Value of Medicines provided at no cost in low- and middle-income countries through Direct Relief (v) $ Millions $0 $69+ $0 $73+ $5 Value of medicines provided at no cost to low-income patients in the United States through the Amgen Safety Net Foundation (v)$ Billions $0 .9+ $1 .2+ $1 .4+ $1 .5+ $2 .2+COMPANY PERFORMANCE DATA * As reported in Amgens Form 10-K for the fiscal years ended December 31, 2017 through 2021 .","('Access_And_Affordability', 0.39883601665496826)","('Customer_Welfare', 0.1161162257194519)","('Selling_Practices_And_Product_Labeling', 0.09183640778064728)","('NON-ESG', 0.39883601665496826)","('NON-ESG', 0.1161162257194519)","('NON-ESG', 0.09183640778064728)"
Line 1110,"** Data based on total headcount as reported in our Form 10-K for the year ended December 31, 2021, modified to reflect active employee headcount which, among other things, excludes co-ops and interns .","('Employee_Engagement_Inclusion_And_Diversity', 0.6591470241546631)","('Labor_Practices', 0.07640118151903152)","('Director_Removal', 0.048899680376052856)","(['Talent Attraction & Retention'], 0.6591470241546631)","('NON-ESG', 0.07640118151903152)","('NON-ESG', 0.048899680376052856)"
Line 1111,Also excludes Gensenta Pharmaceuticals and deCode Genetics .,"('Competitive_Behavior', 0.1897391974925995)","('Systemic_Risk_Management', 0.11011549830436707)","('Business_Model_Resilience', 0.08192653954029083)","('NON-ESG', 0.1897391974925995)","('NON-ESG', 0.11011549830436707)","('NON-ESG', 0.08192653954029083)"
Line 1112,DATA NOTES i) Please see Responsibility/Environment on www .amgen .com for an Independent Verification Statement forthis data .,"('Management_Of_Legal_And_Regulatory_Framework', 0.7848330736160278)","('Human_Rights_And_Community_Relations', 0.06898751854896545)","('Access_And_Affordability', 0.018370507284998894)","([], 0.7848330736160278)","('NON-ESG', 0.06898751854896545)","('NON-ESG', 0.018370507284998894)"
Line 1113,"Amgen has included data from 17 facilities covering energy and carbon, water and waste .","('Waste_And_Hazardous_Materials_Management', 0.9655647277832031)","('Water_And_Wastewater_Management', 0.009231367148458958)","('Air_Quality', 0.0024863630533218384)","([], 0.9655647277832031)","('NON-ESG', 0.009231367148458958)","('NON-ESG', 0.0024863630533218384)"
Line 1114,The facilities represent approximately 88 percent of Amgens worldwide facility space based on total square feet .,"('Energy_Management', 0.31120970845222473)","('Customer_Welfare', 0.062033332884311676)","('Water_And_Wastewater_Management', 0.05686609819531441)","('NON-ESG', 0.31120970845222473)","('NON-ESG', 0.062033332884311676)","('NON-ESG', 0.05686609819531441)"
Line 1115,"Included facilities are in Thousand Oaks, California, U .","('Supply_Chain_Management', 0.1625009924173355)","('Product_Design_And_Lifecycle_Management', 0.11077477782964706)","('Customer_Welfare', 0.09555823355913162)","('NON-ESG', 0.1625009924173355)","('NON-ESG', 0.11077477782964706)","('NON-ESG', 0.09555823355913162)"
Line 1116,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1117,"; West Greenwich, Rhode Island, U .","('Ecological_Impacts', 0.28674644231796265)","('Management_Of_Legal_And_Regulatory_Framework', 0.17597696185112)","('Water_And_Wastewater_Management', 0.06569800525903702)","('NON-ESG', 0.28674644231796265)","('NON-ESG', 0.17597696185112)","('NON-ESG', 0.06569800525903702)"
Line 1118,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1119,"; Juncos, Puerto Rico, U .","('Management_Of_Legal_And_Regulatory_Framework', 0.5390446782112122)","('Competitive_Behavior', 0.09350567311048508)","('Ecological_Impacts', 0.03989216312766075)","([], 0.5390446782112122)","('NON-ESG', 0.09350567311048508)","('NON-ESG', 0.03989216312766075)"
Line 1120,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1121,"; Louisville, Kentucky, U .","('Management_Of_Legal_And_Regulatory_Framework', 0.1610567420721054)","('Competitive_Behavior', 0.1391315907239914)","('Employee_Engagement_Inclusion_And_Diversity', 0.07244271785020828)","('NON-ESG', 0.1610567420721054)","('NON-ESG', 0.1391315907239914)","('NON-ESG', 0.07244271785020828)"
Line 1122,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1123,"; South San Francisco, California, U .","('Business_Model_Resilience', 0.20280590653419495)","('Competitive_Behavior', 0.0929507240653038)","('Product_Design_And_Lifecycle_Management', 0.07581299543380737)","('NON-ESG', 0.20280590653419495)","('NON-ESG', 0.0929507240653038)","('NON-ESG', 0.07581299543380737)"
Line 1124,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1125,"; Cambridge and Woburn, Massachusetts, U .","('Employee_Engagement_Inclusion_And_Diversity', 0.1773858368396759)","('Management_Of_Legal_And_Regulatory_Framework', 0.08436895161867142)","('Competitive_Behavior', 0.08137097209692001)","('NON-ESG', 0.1773858368396759)","('NON-ESG', 0.08436895161867142)","('NON-ESG', 0.08137097209692001)"
Line 1126,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1127,"; Burnaby, Canada; Breda, Netherlands; Dun Laoghaire, Ireland; Uxbridge and Cambridge, United Kingdom; Sao Paulo, Brazil; Yenibosna and Sekerpinar, Turkey; Tuas, Singapore; and Shanghai, China .","('Business_Model_Resilience', 0.1618688851594925)","('Management_Of_Legal_And_Regulatory_Framework', 0.1344081312417984)","('Ecological_Impacts', 0.06571216136217117)","('NON-ESG', 0.1618688851594925)","('NON-ESG', 0.1344081312417984)","('NON-ESG', 0.06571216136217117)"
Line 1128,"This includes leased buildings where we have operational control over building infrastructure, including utilities .","('Energy_Management', 0.7423029541969299)","('Water_And_Wastewater_Management', 0.03526819869875908)","('Management_Of_Legal_And_Regulatory_Framework', 0.023909978568553925)","(['Operational Eco-Efficiency'], 0.7423029541969299)","('NON-ESG', 0.03526819869875908)","('NON-ESG', 0.023909978568553925)"
Line 1129,ii) Environmental notices of violation (NOVs) reported that resulted from agency inspections .,"('Business_Ethics', 0.4922613501548767)","('Management_Of_Legal_And_Regulatory_Framework', 0.2205507606267929)","('Critical_Incident_Risk_Management', 0.03453920781612396)","('NON-ESG', 0.4922613501548767)","('NON-ESG', 0.2205507606267929)","('NON-ESG', 0.03453920781612396)"
Line 1130,iiii) Management: Senior managers and directors .,"('Director_Removal', 0.579901397228241)","('Employee_Engagement_Inclusion_And_Diversity', 0.09945101290941238)","('Business_Model_Resilience', 0.03481084108352661)","(['Business Ethics'], 0.579901397228241)","('NON-ESG', 0.09945101290941238)","('NON-ESG', 0.03481084108352661)"
Line 1131,iv) Executive level: Executive directors and above .,"('Director_Removal', 0.7308633327484131)","('Employee_Engagement_Inclusion_And_Diversity', 0.031741365790367126)","('Labor_Practices', 0.02279924601316452)","(['Business Ethics'], 0.7308633327484131)","('NON-ESG', 0.031741365790367126)","('NON-ESG', 0.02279924601316452)"
Line 1132,v) Value calculated at wholesale acquisition cost .,"('Competitive_Behavior', 0.31121522188186646)","('Energy_Management', 0.24099479615688324)","('Management_Of_Legal_And_Regulatory_Framework', 0.10323379933834076)","('NON-ESG', 0.31121522188186646)","('NON-ESG', 0.24099479615688324)","('NON-ESG', 0.10323379933834076)"
Line 1133,"APPENDIXAppendix 68 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen This ESG Report is part of Amgens overall commitment to providing robust reporting on our ESG performance .","('Human_Rights_And_Community_Relations', 0.5216630697250366)","('Business_Model_Resilience', 0.129307821393013)","('Ecological_Impacts', 0.04283083975315094)","([], 0.5216630697250366)","('NON-ESG', 0.129307821393013)","('NON-ESG', 0.04283083975315094)"
Line 1134,"We have also reported information in our Annual Report and 10-K, as well as our Proxy Statement , which may be useful to our investors understanding of our activities that support our ESG efforts .","('Business_Model_Resilience', 0.5068947672843933)","('Systemic_Risk_Management', 0.1552116572856903)","('Management_Of_Legal_And_Regulatory_Framework', 0.0635749027132988)","(['Human Capital Development', 'Innovation Management'], 0.5068947672843933)","('NON-ESG', 0.1552116572856903)","('NON-ESG', 0.0635749027132988)"
Line 1135,"As noted previously, this ESG Report was prepared in alignment with the Biopharma Sustainability Roundtable Investor ESG Communications Guidance , which considers key elements and principles of the Sustainability Accounting Standards Board (SASB) standard for the Biotechnology industry .","('Business_Model_Resilience', 0.23204714059829712)","('Management_Of_Legal_And_Regulatory_Framework', 0.21721406280994415)","('Systemic_Risk_Management', 0.19246003031730652)","('NON-ESG', 0.23204714059829712)","('NON-ESG', 0.21721406280994415)","('NON-ESG', 0.19246003031730652)"
Line 1136,"In the table below we have indicated where Amgen reports on metrics that are included in the SASB standard, including sections of this Report, our website, our proxy statement and our periodic filings with the Securities and Exchange Commission (SEC) .","('Management_Of_Legal_And_Regulatory_Framework', 0.8314226269721985)","('Systemic_Risk_Management', 0.02325959876179695)","('Competitive_Behavior', 0.01750282570719719)","([], 0.8314226269721985)","('NON-ESG', 0.02325959876179695)","('NON-ESG', 0.01750282570719719)"
Line 1137,"Our ESG reporting continues to evolve and expand as a result, where we have indicated that we do not report on a metric at this time, we will continue to evaluate our ability to report on that metric in the future .","('Business_Model_Resilience', 0.322569340467453)","('Systemic_Risk_Management', 0.23093964159488678)","('Management_Of_Legal_And_Regulatory_Framework', 0.06947510689496994)","('NON-ESG', 0.322569340467453)","('NON-ESG', 0.23093964159488678)","('NON-ESG', 0.06947510689496994)"
Line 1138,"SASB INDEX SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Safety of Clinical Trial ParticipantsDiscussion, by world region, management process for ensuring quality and patient safety during clinical trialsn/a HC-BP-210 .a .1 Pertinent reporting can be found in the Product Quality and Patient Safety section of this Report; the Global Code of Ethics for Clinical Trials , Quality and Global Patient Safety sections of our website; and the Business and Risk Factors section in Part I of the 10-K .","('Product_Quality_And_Safety', 0.8733265399932861)","('Employee_Health_And_Safety', 0.02894500456750393)","('Product_Design_And_Lifecycle_Management', 0.01514314766973257)","(['Product Quality & Recall Management'], 0.8733265399932861)","('NON-ESG', 0.02894500456750393)","('NON-ESG', 0.01514314766973257)"
Line 1139,Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)Number HC-BP-210 .a .2 Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .,"('Management_Of_Legal_And_Regulatory_Framework', 0.8986406326293945)","('Competitive_Behavior', 0.014113795943558216)","('Product_Quality_And_Safety', 0.013039734214544296)","([], 0.8986406326293945)","('NON-ESG', 0.014113795943558216)","('NON-ESG', 0.013039734214544296)"
Line 1140,Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countriesReporting currency HC-BP-210 .a .3 Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .,"('Management_Of_Legal_And_Regulatory_Framework', 0.9611232876777649)","('Business_Ethics', 0.004462665878236294)","('Product_Quality_And_Safety', 0.003643282223492861)","([], 0.9611232876777649)","('NON-ESG', 0.004462665878236294)","('NON-ESG', 0.003643282223492861)"
Line 1141,"APPENDIXAppendix 69 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Access to MedicinesDescription of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Indexn/a HC-BP-240a .1 See the Access to Medicines section of this Report, as well as Access to Medicines Initiatives Outside the US section of our website and the Improving Patient Access to Medicines section of our 2022 Proxy Statement (within the Social Responsibility subsection of the heading Our Approach to Environmental Sustainability, Social Responsibility, and Human Capital Management) .","('Access_And_Affordability', 0.6291269659996033)","('Selling_Practices_And_Product_Labeling', 0.053586237132549286)","('Product_Quality_And_Safety', 0.05306440591812134)","(['Access to Healthcare'], 0.6291269659996033)","('NON-ESG', 0.053586237132549286)","('NON-ESG', 0.05306440591812134)"
Line 1142,"APPENDIXAppendix 69 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Access to MedicinesDescription of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Indexn/a HC-BP-240a .1 See the Access to Medicines section of this Report, as well as Access to Medicines Initiatives Outside the US section of our website and the Improving Patient Access to Medicines section of our 2022 Proxy Statement (within the Social Responsibility subsection of the heading Our Approach to Environmental Sustainability, Social Responsibility, and Human Capital Management) .","('Human_Rights_And_Community_Relations', 0.9026861190795898)","('Access_And_Affordability', 0.02522159367799759)","('Management_Of_Legal_And_Regulatory_Framework', 0.007134068291634321)","([], 0.9026861190795898)","('NON-ESG', 0.02522159367799759)","('NON-ESG', 0.007134068291634321)"
Line 1143,List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)n/a HC-BP-240a .2 None to disclose as of December 2021 .,"('Selling_Practices_And_Product_Labeling', 0.4068193733692169)","('Customer_Welfare', 0.1923033893108368)","('Product_Quality_And_Safety', 0.11097504943609238)","('NON-ESG', 0.4068193733692169)","('NON-ESG', 0.1923033893108368)","('NON-ESG', 0.11097504943609238)"
Line 1144,Affordability and PricingNumber of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time periodNumber HC-BP-240b .1 Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .,"('Competitive_Behavior', 0.4426092207431793)","('Management_Of_Legal_And_Regulatory_Framework', 0.17706796526908875)","('Product_Quality_And_Safety', 0.0709795132279396)","('NON-ESG', 0.4426092207431793)","('NON-ESG', 0.17706796526908875)","('NON-ESG', 0.0709795132279396)"
Line 1145,Percentage change in: (1) average list price and (2) average net price across U .,"('Competitive_Behavior', 0.533535361289978)","('Systemic_Risk_Management', 0.06934799253940582)","('Energy_Management', 0.06778504699468613)","([], 0.533535361289978)","('NON-ESG', 0.06934799253940582)","('NON-ESG', 0.06778504699468613)"
Line 1146,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1147,"product portfolio compared to previous yearPercentage (%) HC-BP-240b .2 Pertinent reporting can be found in the Our Approach to Pricing, Access and Affordability and Amgens Approach to Responsible Pricing sections of our website; the Management, Discussion and Analysis and Risk Factors sections of the 10-K and quarterly 10-Qs; and the Approach to Pricing Our Products section of the 2022 Proxy Statement (within the Compensation Discussion and Analysis subsection) .","('Product_Design_And_Lifecycle_Management', 0.7902575135231018)","('Selling_Practices_And_Product_Labeling', 0.0413721427321434)","('Customer_Welfare', 0.04072988033294678)","([], 0.7902575135231018)","('NON-ESG', 0.0413721427321434)","('NON-ESG', 0.04072988033294678)"
Line 1148,"APPENDIXAppendix 70 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous yearPercentage (%) HC-BP-240b .3 Pertinent reporting can be found in the Our Approach to Pricing, Access and Affordability and Amgens Approach to Responsible Pricing sections of our website; the Management, Discussion and Analysis and Risk Factors sections of the 10-K and 10-Qs; and the Approach to Pricing Our Products section of the 2022 Proxy Statement (within the Compensation Discussion and Analysis subsection) .","('Product_Design_And_Lifecycle_Management', 0.3678758144378662)","('Customer_Welfare', 0.183864027261734)","('Competitive_Behavior', 0.13638781011104584)","('NON-ESG', 0.3678758144378662)","('NON-ESG', 0.183864027261734)","('NON-ESG', 0.13638781011104584)"
Line 1149,"APPENDIXAppendix 70 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous yearPercentage (%) HC-BP-240b .3 Pertinent reporting can be found in the Our Approach to Pricing, Access and Affordability and Amgens Approach to Responsible Pricing sections of our website; the Management, Discussion and Analysis and Risk Factors sections of the 10-K and 10-Qs; and the Approach to Pricing Our Products section of the 2022 Proxy Statement (within the Compensation Discussion and Analysis subsection) .","('Product_Design_And_Lifecycle_Management', 0.9148328304290771)","('Selling_Practices_And_Product_Labeling', 0.011387916281819344)","('Customer_Welfare', 0.009674860164523125)","([], 0.9148328304290771)","('NON-ESG', 0.011387916281819344)","('NON-ESG', 0.009674860164523125)"
Line 1150,Drug SafetyList of products listed in the Food and Drug Administrations (FDA) MedWatch Safety Alerts for Human Medical Products databasen/a HC-BP-250a .1 See FDA MedWatch database .,"('Product_Quality_And_Safety', 0.9067302942276001)","('Selling_Practices_And_Product_Labeling', 0.014297625049948692)","('Employee_Health_And_Safety', 0.008557260036468506)","(['Product Quality & Recall Management'], 0.9067302942276001)","('NON-ESG', 0.014297625049948692)","('NON-ESG', 0.008557260036468506)"
Line 1151,Number of fatalities associated with products as reported in the FDA Adverse Event Reporting SystemNumber HC-BP-250a .2 See FDA Adverse Event Reporting System .,"('Product_Quality_And_Safety', 0.37785741686820984)","('Employee_Health_And_Safety', 0.326314777135849)","('Business_Ethics', 0.05788682773709297)","('NON-ESG', 0.37785741686820984)","('NON-ESG', 0.326314777135849)","('NON-ESG', 0.05788682773709297)"
Line 1152,"Number of recalls issued, total units recalled Number HC-BP-250a .3 See the 2021 Highlights in the A Healthy Amgen section of this Report; further, Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .","('Product_Quality_And_Safety', 0.33306899666786194)","('Critical_Incident_Risk_Management', 0.10006611049175262)","('Employee_Health_And_Safety', 0.06436142325401306)","('NON-ESG', 0.33306899666786194)","('NON-ESG', 0.10006611049175262)","('NON-ESG', 0.06436142325401306)"
Line 1153,"Total amount of product accepted for take-back, reuse, or disposalMetric tons (t) HC-BP-250a .4 Data on product accepted through take-back can be found in the Product Sustainability section of our website (see the Product Packaging and Lifecycle section); in addition we provide information about the California Safe Needle Collection and Disposal Plan .","('Product_Design_And_Lifecycle_Management', 0.9223307371139526)","('Selling_Practices_And_Product_Labeling', 0.017087973654270172)","('Product_Quality_And_Safety', 0.012560155242681503)","([], 0.9223307371139526)","('NON-ESG', 0.017087973654270172)","('NON-ESG', 0.012560155242681503)"
Line 1154,"APPENDIXAppendix 71 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by typeNumber HC-BP-250a .5 Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .","('Management_Of_Legal_And_Regulatory_Framework', 0.8006420731544495)","('Business_Ethics', 0.06484086066484451)","('Product_Quality_And_Safety', 0.030857978388667107)","([], 0.8006420731544495)","('NON-ESG', 0.06484086066484451)","('NON-ESG', 0.030857978388667107)"
Line 1155,Counterfeit DrugsDescription of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeitingn/a HC-BP-260a .1 Pertinent reporting can be found in the Counterfeit Drug Statement on our website .,"('Business_Ethics', 0.2640855610370636)","('Data_Security', 0.19967924058437347)","('Product_Quality_And_Safety', 0.07839599996805191)","('NON-ESG', 0.2640855610370636)","('NON-ESG', 0.19967924058437347)","('NON-ESG', 0.07839599996805191)"
Line 1156,Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit productsn/a HC-BP-260a .2 Pertinent reporting can be found in the Counterfeit Drug Statement on our website .,"('Data_Security', 0.15784282982349396)","('Business_Ethics', 0.14978156983852386)","('Selling_Practices_And_Product_Labeling', 0.13333465158939362)","('NON-ESG', 0.15784282982349396)","('NON-ESG', 0.14978156983852386)","('NON-ESG', 0.13333465158939362)"
Line 1157,"Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit productsNumber HC-BP-260a .3 Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .","('Business_Ethics', 0.3303660452365875)","('Product_Quality_And_Safety', 0.16134582459926605)","('Competitive_Behavior', 0.1125326156616211)","('NON-ESG', 0.3303660452365875)","('NON-ESG', 0.16134582459926605)","('NON-ESG', 0.1125326156616211)"
Line 1158,Ethical MarketingTotal amount of monetary losses as a result of legal proceedings associated with false marketing claimsReporting currency HC-BP-270a .1 Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .,"('Business_Ethics', 0.5714635252952576)","('Competitive_Behavior', 0.09146516770124435)","('Selling_Practices_And_Product_Labeling', 0.08009754866361618)","(['Business Ethics'], 0.5714635252952576)","('NON-ESG', 0.09146516770124435)","('NON-ESG', 0.08009754866361618)"
Line 1159,Description of code of ethics governing promotion of off-label use of productsn/a HC-BP-270a .2 Our policy on Communications with Members of the Healthcare Community and the Amgen Code of Conduct prohibit off-label promotion and staff members are trained on these requirements annually as described on the Staff Code Conduct section of our website .,"('Selling_Practices_And_Product_Labeling', 0.5713395476341248)","('Product_Quality_And_Safety', 0.1004251092672348)","('Customer_Welfare', 0.09697814285755157)","(['Business Ethics'], 0.5713395476341248)","('NON-ESG', 0.1004251092672348)","('NON-ESG', 0.09697814285755157)"
Line 1160,"APPENDIXAppendix 72 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Employee Recruitment, Development and RetentionDiscussion of talent recruitment and retention efforts for scientists and research and development personneln/a HC-BP-330a .1 Pertinent reporting can be found on our Careers site, which describes our approach to talent recruitment and retention; also see the Human Capital Resources section (pages 22-24) of our 10-K; and the Human Capital Management section of our 2022 Proxy Statement (pages 34-35) .","('Employee_Engagement_Inclusion_And_Diversity', 0.9687674641609192)","('Employee_Health_And_Safety', 0.003977261949330568)","('Customer_Welfare', 0.0017621621955186129)","(['Talent Attraction & Retention'], 0.9687674641609192)","('NON-ESG', 0.003977261949330568)","('NON-ESG', 0.0017621621955186129)"
Line 1161,"APPENDIXAppendix 72 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen SASB TOPIC ACCOUNTING METRICUNIT OF MEASURECODE REPORTING Employee Recruitment, Development and RetentionDiscussion of talent recruitment and retention efforts for scientists and research and development personneln/a HC-BP-330a .1 Pertinent reporting can be found on our Careers site, which describes our approach to talent recruitment and retention; also see the Human Capital Resources section (pages 22-24) of our 10-K; and the Human Capital Management section of our 2022 Proxy Statement (pages 34-35) .","('Business_Model_Resilience', 0.551446259021759)","('Systemic_Risk_Management', 0.10176309943199158)","('Supply_Chain_Management', 0.08292051404714584)","(['Human Capital Development', 'Innovation Management'], 0.551446259021759)","('NON-ESG', 0.10176309943199158)","('NON-ESG', 0.08292051404714584)"
Line 1162,"(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all othersRate HC-BP-330a .2 Qualitative information about our staff turnover can be found in the Human Capital Resources section of 10-K for the year ended December 31, 2021 and in the Chairman and CEO Letter to Shareholders .","('Employee_Engagement_Inclusion_And_Diversity', 0.2485405057668686)","('Labor_Practices', 0.24748508632183075)","('Director_Removal', 0.1728719025850296)","('NON-ESG', 0.2485405057668686)","('NON-ESG', 0.24748508632183075)","('NON-ESG', 0.1728719025850296)"
Line 1163,Supply Chain ManagementPercentage of (1) entitys facilities and (2) Tier I suppliers facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredientsPercentage (%) HC-BP-430a .1 Amgen applies the requirements of its Quality Management System as described in the Quality section of our website .,"('Supply_Chain_Management', 0.9469577074050903)","('Product_Design_And_Lifecycle_Management', 0.0051224008202552795)","('Labor_Practices', 0.004277592059224844)","([], 0.9469577074050903)","('NON-ESG', 0.0051224008202552795)","('NON-ESG', 0.004277592059224844)"
Line 1164,Business EthicsTotal amount of monetary losses as a result of legal proceedings associated with corruption and briberyReporting Currency HC-BP-510a .1 Amgen discloses material legal and regulatory issues in its annual 10-K and quarterly 10-Qs .,"('Business_Ethics', 0.9764121770858765)","('Management_Of_Legal_And_Regulatory_Framework', 0.002723506186157465)","('Product_Quality_And_Safety', 0.0018743813270702958)","(['Business Ethics'], 0.9764121770858765)","('NON-ESG', 0.002723506186157465)","('NON-ESG', 0.0018743813270702958)"
Line 1165,Description of code of ethics governing interactions with healthcare professionalsn/a HC-BP-510a .2 See the Interactions with Healthcare Providers section of our website; our policy on Communications with Members of the Healthcare Community ; and the Amgen Code of Conduct .,"('Business_Ethics', 0.9553219079971313)","('Customer_Privacy', 0.004995506722480059)","('Management_Of_Legal_And_Regulatory_Framework', 0.0035262166056782007)","(['Business Ethics'], 0.9553219079971313)","('NON-ESG', 0.004995506722480059)","('NON-ESG', 0.0035262166056782007)"
Line 1166,Staff members are trained on these requirements annually as described on the Staff Code Conduct section of our website .,"('Director_Removal', 0.4217362105846405)","('Employee_Engagement_Inclusion_And_Diversity', 0.14792044460773468)","('Labor_Practices', 0.08990227431058884)","('NON-ESG', 0.4217362105846405)","('NON-ESG', 0.14792044460773468)","('NON-ESG', 0.08990227431058884)"
Line 1167,"APPENDIXAppendix 73 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen ACTIVITY METRICUNIT OF MEASURECODE REPORTING Number of patients treated Number HC-BP-000 .","('Human_Rights_And_Community_Relations', 0.3182511329650879)","('Access_And_Affordability', 0.13627777993679047)","('Employee_Health_And_Safety', 0.114069864153862)","('NON-ESG', 0.3182511329650879)","('NON-ESG', 0.13627777993679047)","('NON-ESG', 0.114069864153862)"
Line 1168,A Amgen regularly reports market segment share as part of its earnings calls and in its earnings releases published through Business Wire and furnished on Form 8-K .,"('Systemic_Risk_Management', 0.4265500009059906)","('Business_Model_Resilience', 0.2922615706920624)","('Competitive_Behavior', 0.062362298369407654)","('NON-ESG', 0.4265500009059906)","('NON-ESG', 0.2922615706920624)","('NON-ESG', 0.062362298369407654)"
Line 1169,Number of drugs (1) in portfolio and (2) in research and development (phases 1-3)Number HC-BP-000 .,"('Selling_Practices_And_Product_Labeling', 0.3070075511932373)","('Customer_Welfare', 0.2387767732143402)","('GHG_Emissions', 0.07232815027236938)","('NON-ESG', 0.3070075511932373)","('NON-ESG', 0.2387767732143402)","('NON-ESG', 0.07232815027236938)"
Line 1170,B Pertinent reporting can be found in the Products and Pipeline sections on our website (generally updated quarterly) and the Business section of Part I of our 10-K .,"('Product_Design_And_Lifecycle_Management', 0.9081916213035583)","('Product_Quality_And_Safety', 0.017475495114922523)","('Selling_Practices_And_Product_Labeling', 0.016840273514389992)","([], 0.9081916213035583)","('NON-ESG', 0.017475495114922523)","('NON-ESG', 0.016840273514389992)"
Line 1171,The inclusion of information contained in this disclosure should not be construed as a characterization regarding the materiality or financial impact of that information .,"('Business_Model_Resilience', 0.19782166182994843)","('Management_Of_Legal_And_Regulatory_Framework', 0.1874838024377823)","('Customer_Privacy', 0.10368578881025314)","('NON-ESG', 0.19782166182994843)","('NON-ESG', 0.1874838024377823)","('NON-ESG', 0.10368578881025314)"
Line 1172,"Please also see our filed Form 10-K, and other publicly filed documents available at https://investors .amgen .com/financials/sec-filings .","('Management_Of_Legal_And_Regulatory_Framework', 0.8613680601119995)","('Business_Ethics', 0.013746996410191059)","('Director_Removal', 0.010105705820024014)","([], 0.8613680601119995)","('NON-ESG', 0.013746996410191059)","('NON-ESG', 0.010105705820024014)"
Line 1173,This report contains information about Amgen and may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act .,"('Management_Of_Legal_And_Regulatory_Framework', 0.9439647793769836)","('Business_Ethics', 0.013239698484539986)","('Director_Removal', 0.0038666229229420424)","([], 0.9439647793769836)","('NON-ESG', 0.013239698484539986)","('NON-ESG', 0.0038666229229420424)"
Line 1174,"All statements, other than statements of historical facts, may be forward-looking statements .","('Management_Of_Legal_And_Regulatory_Framework', 0.2466098666191101)","('Business_Ethics', 0.23922321200370789)","('Customer_Privacy', 0.09356050193309784)","('NON-ESG', 0.2466098666191101)","('NON-ESG', 0.23922321200370789)","('NON-ESG', 0.09356050193309784)"
Line 1175,"Amgen cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time .","('Systemic_Risk_Management', 0.9096252918243408)","('Business_Model_Resilience', 0.018290594220161438)","('Business_Ethics', 0.011422614566981792)","([], 0.9096252918243408)","('NON-ESG', 0.018290594220161438)","('NON-ESG', 0.011422614566981792)"
Line 1176,"Forward-looking statements speak only as of the date they are made, and Amgen assumes no duty to and does not undertake to update forward-looking statements .","('Management_Of_Legal_And_Regulatory_Framework', 0.3025364875793457)","('Business_Model_Resilience', 0.11033669114112854)","('Director_Removal', 0.10884485393762589)","('NON-ESG', 0.3025364875793457)","('NON-ESG', 0.11033669114112854)","('NON-ESG', 0.10884485393762589)"
Line 1177,Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance .,"('Business_Model_Resilience', 0.24806077778339386)","('Competitive_Behavior', 0.21158723533153534)","('Management_Of_Legal_And_Regulatory_Framework', 0.13992939889431)","('NON-ESG', 0.24806077778339386)","('NON-ESG', 0.21158723533153534)","('NON-ESG', 0.13992939889431)"
Line 1178,"Factors that can cause results to differ, as well as additional factors that can affect forward-looking statements, are discussed in Amgens Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, accessible on the SECs website at www .sec .gov and on Amgens investor website at https://investors .amgen .com and https://investors .amgen .com/financials/sec-filings .","('Management_Of_Legal_And_Regulatory_Framework', 0.5830399394035339)","('Systemic_Risk_Management', 0.09310225397348404)","('Business_Model_Resilience', 0.07968076318502426)","([], 0.5830399394035339)","('NON-ESG', 0.09310225397348404)","('NON-ESG', 0.07968076318502426)"
Line 1179,"APPENDIXAppendix 74 | ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021 Introduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen This report contains forward-looking statements that are based on the current expectations and beliefs of Amgen .","('Human_Rights_And_Community_Relations', 0.5877367258071899)","('Business_Model_Resilience', 0.08064045011997223)","('Employee_Engagement_Inclusion_And_Diversity', 0.04360144957900047)","([], 0.5877367258071899)","('NON-ESG', 0.08064045011997223)","('NON-ESG', 0.04360144957900047)"
Line 1180,"All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd ., Kyowa-Kirin Co ., Ltd ., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc .","('Competitive_Behavior', 0.5246657133102417)","('Customer_Welfare', 0.12089017778635025)","('Business_Model_Resilience', 0.0556236132979393)","([], 0.5246657133102417)","('NON-ESG', 0.12089017778635025)","('NON-ESG', 0.0556236132979393)"
Line 1181,"All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd ., Kyowa-Kirin Co ., Ltd ., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc .","('Customer_Welfare', 0.2649201452732086)","('Selling_Practices_And_Product_Labeling', 0.12903982400894165)","('Competitive_Behavior', 0.1210983544588089)","('NON-ESG', 0.2649201452732086)","('NON-ESG', 0.12903982400894165)","('NON-ESG', 0.1210983544588089)"
Line 1182,"acquisition, or the Teneobio, Inc .","('Competitive_Behavior', 0.2189641296863556)","('Business_Model_Resilience', 0.20660537481307983)","('Systemic_Risk_Management', 0.13720443844795227)","('NON-ESG', 0.2189641296863556)","('NON-ESG', 0.20660537481307983)","('NON-ESG', 0.13720443844795227)"
Line 1183,"acquisition, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results .","('Systemic_Risk_Management', 0.7071951627731323)","('Physical_Impacts_Of_Climate_Change', 0.07502706348896027)","('Business_Model_Resilience', 0.04912475496530533)","([], 0.7071951627731323)","('NON-ESG', 0.07502706348896027)","('NON-ESG', 0.04912475496530533)"
Line 1184,"Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K .","('Systemic_Risk_Management', 0.912804365158081)","('Business_Ethics', 0.0160733163356781)","('Competitive_Behavior', 0.00834500789642334)","([], 0.912804365158081)","('NON-ESG', 0.0160733163356781)","('NON-ESG', 0.00834500789642334)"
Line 1185,"Unless otherwise noted, Amgen is providing this information as of the date of this report and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise .","('Management_Of_Legal_And_Regulatory_Framework', 0.6741569638252258)","('Business_Model_Resilience', 0.04240690916776657)","('Customer_Privacy', 0.03306521102786064)","([], 0.6741569638252258)","('NON-ESG', 0.04240690916776657)","('NON-ESG', 0.03306521102786064)"
Line 1186,No forward-looking statement can be guaranteed and actual results may differ materially from those we project .,"('Competitive_Behavior', 0.4109910726547241)","('Management_Of_Legal_And_Regulatory_Framework', 0.2041303664445877)","('Systemic_Risk_Management', 0.0704914927482605)","('NON-ESG', 0.4109910726547241)","('NON-ESG', 0.2041303664445877)","('NON-ESG', 0.0704914927482605)"
Line 1187,"Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth FORWARD-LOOKING STATEMENTSof recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions .","('Product_Design_And_Lifecycle_Management', 0.7569261789321899)","('Selling_Practices_And_Product_Labeling', 0.04926072433590889)","('Customer_Welfare', 0.048241276293992996)","([], 0.7569261789321899)","('NON-ESG', 0.04926072433590889)","('NON-ESG', 0.048241276293992996)"
Line 1188,"In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment .","('Management_Of_Legal_And_Regulatory_Framework', 0.9397072792053223)","('Systemic_Risk_Management', 0.007398897781968117)","('Business_Ethics', 0.007029958534985781)","([], 0.9397072792053223)","('NON-ESG', 0.007398897781968117)","('NON-ESG', 0.007029958534985781)"
Line 1189,"Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities .","('Management_Of_Legal_And_Regulatory_Framework', 0.8568360805511475)","('Competitive_Behavior', 0.05309723690152168)","('Business_Ethics', 0.013701618649065495)","([], 0.8568360805511475)","('NON-ESG', 0.05309723690152168)","('NON-ESG', 0.013701618649065495)"
Line 1190,"We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market .","('Product_Quality_And_Safety', 0.8482850193977356)","('Product_Design_And_Lifecycle_Management', 0.03488216549158096)","('Selling_Practices_And_Product_Labeling', 0.027748657390475273)","(['Product Quality & Recall Management'], 0.8482850193977356)","('NON-ESG', 0.03488216549158096)","('NON-ESG', 0.027748657390475273)"
Line 1191,"Our business may be impacted by government investigations, litigation and product liability claims .","('Management_Of_Legal_And_Regulatory_Framework', 0.5352008938789368)","('Business_Ethics', 0.2951006591320038)","('Product_Quality_And_Safety', 0.022900208830833435)","([], 0.5352008938789368)","('NON-ESG', 0.2951006591320038)","('NON-ESG', 0.022900208830833435)"
Line 1192,"In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities .","('Management_Of_Legal_And_Regulatory_Framework', 0.9736495018005371)","('Energy_Management', 0.0033460999839007854)","('Director_Removal', 0.002457590075209737)","([], 0.9736495018005371)","('NON-ESG', 0.0033460999839007854)","('NON-ESG', 0.002457590075209737)"
Line 1193,If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U .,"('Business_Ethics', 0.6803733706474304)","('Management_Of_Legal_And_Regulatory_Framework', 0.2294279783964157)","('Product_Quality_And_Safety', 0.009442094713449478)","(['Business Ethics'], 0.6803733706474304)","('NON-ESG', 0.2294279783964157)","('NON-ESG', 0.009442094713449478)"
Line 1194,S .,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 1195,"government, we could become subject to significant sanctions .","('Management_Of_Legal_And_Regulatory_Framework', 0.453201025724411)","('Business_Ethics', 0.44163766503334045)","('Competitive_Behavior', 0.010774308815598488)","('NON-ESG', 0.453201025724411)","('NON-ESG', 0.44163766503334045)","('NON-ESG', 0.010774308815598488)"
Line 1196,"Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation .","('Competitive_Behavior', 0.9193198680877686)","('Business_Ethics', 0.009759499691426754)","('Product_Quality_And_Safety', 0.008087379857897758)","([], 0.9193198680877686)","('NON-ESG', 0.009759499691426754)","('NON-ESG', 0.008087379857897758)"
Line 1197,"We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development .","('Product_Design_And_Lifecycle_Management', 0.9636968374252319)","('Product_Quality_And_Safety', 0.0039504761807620525)","('Selling_Practices_And_Product_Labeling', 0.0038447107654064894)","([], 0.9636968374252319)","('NON-ESG', 0.0039504761807620525)","('NON-ESG', 0.0038447107654064894)"
Line 1198,"An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations .","('Product_Quality_And_Safety', 0.355288028717041)","('Product_Design_And_Lifecycle_Management', 0.14393331110477448)","('Selling_Practices_And_Product_Labeling', 0.12935416400432587)","('NON-ESG', 0.355288028717041)","('NON-ESG', 0.14393331110477448)","('NON-ESG', 0.12935416400432587)"
Line 1199,"An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations .","('Product_Design_And_Lifecycle_Management', 0.07696884870529175)","('Competitive_Behavior', 0.06801982969045639)","('Energy_Management', 0.06453041732311249)","('NON-ESG', 0.07696884870529175)","('NON-ESG', 0.06801982969045639)","('NON-ESG', 0.06453041732311249)"
Line 1200,We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products .,"('Product_Design_And_Lifecycle_Management', 0.9448821544647217)","('Selling_Practices_And_Product_Labeling', 0.008685150183737278)","('Customer_Welfare', 0.0072788456454873085)","([], 0.9448821544647217)","('NON-ESG', 0.008685150183737278)","('NON-ESG', 0.0072788456454873085)"
Line 1201,"In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products .","('Product_Design_And_Lifecycle_Management', 0.8994156718254089)","('Selling_Practices_And_Product_Labeling', 0.020842667669057846)","('Product_Quality_And_Safety', 0.0179307721555233)","([], 0.8994156718254089)","('NON-ESG', 0.020842667669057846)","('NON-ESG', 0.0179307721555233)"
Line 1202,"Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product .","('Product_Design_And_Lifecycle_Management', 0.701279878616333)","('Selling_Practices_And_Product_Labeling', 0.10304964333772659)","('Customer_Welfare', 0.052546221762895584)","([], 0.701279878616333)","('NON-ESG', 0.10304964333772659)","('NON-ESG', 0.052546221762895584)"
Line 1203,"Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers .","('Product_Design_And_Lifecycle_Management', 0.9382826089859009)","('Supply_Chain_Management', 0.00925006065517664)","('Selling_Practices_And_Product_Labeling', 0.006734355352818966)","([], 0.9382826089859009)","('NON-ESG', 0.00925006065517664)","('NON-ESG', 0.006734355352818966)"
Line 1204,"Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us .","('Competitive_Behavior', 0.8741932511329651)","('Business_Ethics', 0.020313257351517677)","('Management_Of_Legal_And_Regulatory_Framework', 0.01872495375573635)","([], 0.8741932511329651)","('NON-ESG', 0.020313257351517677)","('NON-ESG', 0.01872495375573635)"
Line 1205,The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations .,"('Product_Design_And_Lifecycle_Management', 0.8670198917388916)","('Product_Quality_And_Safety', 0.03872981294989586)","('Selling_Practices_And_Product_Labeling', 0.026341650635004044)","([], 0.8670198917388916)","('NON-ESG', 0.03872981294989586)","('NON-ESG', 0.026341650635004044)"
Line 1206,"Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful .","('Product_Design_And_Lifecycle_Management', 0.9549840688705444)","('Product_Quality_And_Safety', 0.004502188414335251)","('Selling_Practices_And_Product_Labeling', 0.003830746980383992)","([], 0.9549840688705444)","('NON-ESG', 0.004502188414335251)","('NON-ESG', 0.003830746980383992)"
Line 1207,"A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data .","('Data_Security', 0.9624201655387878)","('Business_Ethics', 0.0037631879094988108)","('Customer_Privacy', 0.0035617868416011333)","([], 0.9624201655387878)","('NON-ESG', 0.0037631879094988108)","('NON-ESG', 0.0035617868416011333)"
Line 1208,Our stock price is volatile and may be affected by a number of events .,"('Systemic_Risk_Management', 0.8061410784721375)","('Competitive_Behavior', 0.04891369864344597)","('Business_Model_Resilience', 0.048535026609897614)","([], 0.8061410784721375)","('NON-ESG', 0.04891369864344597)","('NON-ESG', 0.048535026609897614)"
Line 1209,"Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives .","('Human_Rights_And_Community_Relations', 0.5736356973648071)","('Business_Model_Resilience', 0.1304616630077362)","('Management_Of_Legal_And_Regulatory_Framework', 0.04539060965180397)","([], 0.5736356973648071)","('NON-ESG', 0.1304616630077362)","('NON-ESG', 0.04539060965180397)"
Line 1210,The effects of global climate change and related natural disasters could negatively affect our business and operations .,"('Physical_Impacts_Of_Climate_Change', 0.9539950489997864)","('Business_Model_Resilience', 0.009435318410396576)","('Systemic_Risk_Management', 0.003952996339648962)","([], 0.9539950489997864)","('NON-ESG', 0.009435318410396576)","('NON-ESG', 0.003952996339648962)"
Line 1211,Global economic conditions may magnify certain risks that affect our business .,"('Systemic_Risk_Management', 0.9293522834777832)","('Business_Model_Resilience', 0.012857758440077305)","('Physical_Impacts_Of_Climate_Change', 0.008634711615741253)","([], 0.9293522834777832)","('NON-ESG', 0.012857758440077305)","('NON-ESG', 0.008634711615741253)"
Line 1212,Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock .,"('Systemic_Risk_Management', 0.6347249746322632)","('Business_Model_Resilience', 0.07697154581546783)","('Competitive_Behavior', 0.0647614523768425)","([], 0.6347249746322632)","('NON-ESG', 0.07697154581546783)","('NON-ESG', 0.0647614523768425)"
Line 1213,"We may not be able to access the capital and credit markets on terms that are favorable to us, or at all .","('Competitive_Behavior', 0.8363949656486511)","('Management_Of_Legal_And_Regulatory_Framework', 0.03769513964653015)","('Systemic_Risk_Management', 0.03497019410133362)","([], 0.8363949656486511)","('NON-ESG', 0.03769513964653015)","('NON-ESG', 0.03497019410133362)"
Line 1214,"Reference to our website is not intended to function as a hyperlink, and the information contained on our website is not intended to be part of this report .","('Customer_Privacy', 0.5686676502227783)","('Data_Security', 0.09012806415557861)","('Selling_Practices_And_Product_Labeling', 0.04876459389925003)","([], 0.5686676502227783)","('NON-ESG', 0.09012806415557861)","('NON-ESG', 0.04876459389925003)"
Line 1215,APPENDIX,"('Management_Of_Legal_And_Regulatory_Framework', 0.22691978514194489)","('Ecological_Impacts', 0.13352017104625702)","('Director_Removal', 0.060010794550180435)","('NON-ESG', 0.22691978514194489)","('NON-ESG', 0.13352017104625702)","('NON-ESG', 0.060010794550180435)"
